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918-49 Description and Functional Characterization of two 
Novel SNPs in the Promoter of the Human Gene 
GNAQ Encoding the G Protein Gαq Subunit and Their 
Potential Role for Cardiac Hypertrophy
Christoph Naber, Stefanie Klenke, Raimund Erbel, Winfried Siffert, Ulrich Frey, 
Cardiology Clinic, West German Heart Center, Universityhospital, Essen, Germany, 
Institute for Pharmacogenetics, University of Essen, Essen, Germany
Background: GNAQ is a candidate gene for cardiac hypertrophy and heart failure. We have 
recently described a novel polymorphism (Q1) at position -694/-695 of the GNAQ promoter 
which affects transcription factor binding, and is associated with enhanced promoter activity, 
and cardiac hypertrophy. Further sequencing unravelled two additional polymorphisms in 
the promoter (G-168A and G-173A) which are not characterized so far.
Methods: The promoter activity was characterized through reporter essays and 
electrophoretic mobility shift assays (EMSA) in rat aortic smooth muscle cells (A10). 
Genotyping was performed in three healthy Caucasian (N=147), African (N=147), and 
Chinese (n=109) populations.
Results: Investigation in A10 cells revealed signiﬁcant promoter activity of the proximal 
GNAQ promoter construct containing the novel SNPs (>7.5 fold). Serum stimulation 
resulted in a signiﬁcantly different promoter trans-activation between the genotypes (Fig. 
1;p<0.001). In addition, EMSA showed binding of a transcription factor to the respective 
sequence. Genotype distribution was signiﬁcantly different between the ethnicities 
(p<0.01) and -168 and -173 were each in signiﬁcant linkage disequilibrium with Q1 
(p<0.001).
Conclusions: G-168A and G-173A are functional relevant and can signiﬁcantly 
enhance the GNAQ promoter activity in smooth muscle cells. Moreover, they are in 
signiﬁcant linkage disequilibrium with Q1 and may thus be important modiﬁers in cardiac 
hypertrophy.
 
918-50 Association of the Deletion/Insertion Polymorphism 
of the Angiotensin-Converting Enzyme With Cardiac 
Conduction, Repolarization, and Function in A 
Population-based Study
Patricia M. Hobday, Douglas W. Mahoney, Lynn Urban, Steven J. Jacobsen, Margaret M. 
Redﬁeld, Timothy M. Olson, Richard J. Rodeheffer, Michael J. Ackerman, Mayo Clinic 
College of Medicine, Rochester, MN
Background: The deletion/insertion (D/I) polymorphism of the ACE-encoded angiotensin-
converting enzyme is responsible for half of the variance in serum ACE levels. Clinically, 
plasma ACE levels have been associated with prolonged QT intervals, left ventricular 
hypertrophy, myocardial infarction, ischemic and idiopathic dilated cardiomyopathy, and 
sudden cardiac death in hypertrophic cardiomyopathy. In a large, randomized, cross-
sectional, population-based study of predominantly Caucasians in Olmsted County, 
Minnesota, we examined the association between the D/I-ACE polymorphism and cardiac 
conduction, repolarization, and structure/function.
Methods: Using a PCR-based assay and genomic DNA, D/I-ACE was genotyped for 
2042 individuals (1058 females, average age 62 + 11 yrs, range = 45-96 yrs), of which 
1018 were clinically healthy (no cardiovascular medicines, no history of cardiovascular, 
renal or pulmonary disease). Using Spearman correlations, the association between D/I-
ACE genotype and various electro- and echo-cardiographic parameters were analyzed.
Results: The allele frequencies were in Hardy-Weinberg equilibrium with the major D-
ACE-encoding allele frequency being 0.54 (DD genotype in 31.2%, DI in 45.2%, and II 
in 23.6%), independent of sex and health status. There was a sex-speciﬁc association 
between the I-encoding ACE allele and left ventricular mass (LVM) and left ventricular 
wall thickness in diastole. Among females, the mean LVM was 157 + 35 g (DD genotype, 
N = 270), 164 + 42 g (DI genotype, N = 401), and 167 + 42 g (II genotype, N = 216, p 
< 0.02) whereas there was no difference observed in males [213 g (DD), 210 g (DI), 
and 215 g (II), p = NS)]. There was no effect of D/I-ACE genotype and the presence of 
diastolic dysfunction. There was no apparent association between D/I-ACE genotype and 
any electrocardiographic parameters including heart rate, PR, QRS or QT intervals.
Conclusion: In one of the largest population-based studies to analyze the association of 
the D/I-ACE polymorphism with cardiac conduction, repolarization and structure/function, 
we found a sex-speciﬁc association between II-ACE and left ventricular hypertrophy. 
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918-47 Left Ventricular Size and Function and the Common 
Sodium Channel Polymorphism, H558R-SCN5A: A 
Population-Based Association Study
Patricia M. Hobday, Douglas W. Mahoney, Lynn Urban, Steven J. Jacobsen, Jonathan C. 
Makielski, Timothy M. Olson, Richard J. Rodeheffer, Michael J. Ackerman, Mayo Clinic 
College of Medicine, Rochester, MN, University of Wisconsin, Madison, WI
Background: Loss-of-function SCN5A mutations have been identiﬁed in dilated 
cardiomyopathy. H558R is the most common polymorphism in SCN5A. Expression of 
H558R in the context of the minor SCN5A splice variant yields a severe loss-of-function 
phenotype. Extrapolating from this in vitro observation, H558R hosts would have an 
estimated 15% diminution in peak sodium current and individuals homozygous for the 
minor R558-encoding allele would have a 30% reduction. In this study, we sought to 
evaluate the effect of H558R on left ventricular size and function in a large cross-sectional, 
Olmsted County, Minnesota-based study.
Methods: H558R genotype status was determined using restriction fragment length 
polymorphism analysis on genomic DNA derived from 2042 individuals (1024 with 
cardiovascular disease, 1058 females, average age 62 + 11yrs). Spearman’s correlations 
(r) coefﬁcient w as used to measure the association between genotype and left ventricular 
end systolic dimension (LVESD), LV end diastolic dimension (LVEDD), LV mass (LVM), 
and LV ejection fraction (LVEF) as determined by echocardiography. Continuous variables 
are summarized as mean + one standard deviation.
Results: The major H558-encoding allelic frequency was 0.78, was in Hardy-Weinberg 
equilibrium and was independent of sex and health status: 60.4% (HH genotype), 34.5% 
(HR), and 5.1% (RR). Overall, the presence of the minor R558-encoding allele was 
positively associated with LVESD [29 + 5 mm (HH), 30 + 6 mm (HR) and 30 + 7 mm 
(RR), r = 0.05, p < 0.04]. However, this association was restricted to females (r = 0.07, p 
< 0.04) and those classiﬁed with cardiovascular disease (r = 0.1060, p < 0.004). H558R 
also associated with increased LVEDD and LVM among the subset with cardiovascular 
disease (r = 0.10, p = 0.004 and r = 0.08, p = 0.02, respectively). There was a trend 
towards decreased LVEF in females hosting > 1 minor allele (p < 0.06).
Conclusion: Consistent with the in vitro functional phenotype of H558R and the 
cardiomyopathic potential of loss-of-function SCN5A mutations, this common sodium 
channel polymorphism inﬂuences LV size and function, particularly among females and 
those with pre-existing cardiovascular disease.
918-48 Gene Expression Proﬁling of Left Ventricular Tissue 
in Mdx Mice Showing Echocardiographic Evidence of 
Cardiomyopathy
Christopher Spurney, Linda Leatherbury, Andrea De Biase, Susan Knoblach, Gerard 
Martin, Eric Hoffman, Children’s National Medical Center, Washington, DC, Children’s 
Research Institute, Washington, DC
Background: Duchenne muscular dystrophy (DMD) causes dilated cardiomyopathy in 
the second decade of life in affected males and later in life in female carriers. As treatment 
of the muscular and respiratory systems improve, cardiac failure is an increasing cause 
of death in DMD patients.
Methods: Using the dystrophin deﬁcient mdx mouse model, the genetic homologue 
to human dystrophin deﬁciency, we studied the cardiac structure, function and genetic 
expression at 9 months of age. Mdx (n=5) and wild type (n=5) mice were anesthetized 
using inhaled isoﬂorane and echocardiography was performed using a 55 MHz 
transducer. B-mode, M-mode and spectral Doppler images were obtained and function 
was measured. Total RNA extracted from the left ventricles of mdx (n=3) and wild type 
(n=3) mice generated gene expression proﬁles using the Affymetrix GeneChip® Mouse 
Expression Set 430-2.0 with analysis of over 39,000 transcripts. Gene expression data 
analysis was performed using GeneSpring software and three stringent ﬁltering criteria 
including at least one present call for each gene, a Welch ANOVA t-test (p value <0.01) 
and a two-fold difference in gene expression between mdx and wild type mice.
Results: Echocardiography showed a decrease in percent shortening fraction of mdx 
mice (28±4) compared to normals (41±3) (unpaired t-test p<0.05). Gene expression 
proﬁling in mdx mice showed a 2.7-fold increased expression of tenascin C, a gene related 
to cardiac remodeling and ﬁbrosis. We also found a 2.7-fold increase in the expression of 
the epidermal growth factor receptor gene that is implicated in the prevention of dilated 
cardiomyopathy in animal models. The connective tissue growth factor gene, expressed 
in scar tissue resulting from myocardial infarctions, showed a 3.0-fold increase in 
expression.
Conclusions: This is the ﬁrst report of gene expression in cardiac tissue of dystrophic 
mice showing echocardiographic evidence of cardiomyopathy and the pathways 
regulated by these genes may be putative targets for therapeutic interventions to treat 
cardiomyopathy seen in DMD.
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918-51 Cardiac Hypertrophy and Renal Disease in GLUT1-
Overexpressing Mice
James N. Kirkpatrick, Keith A. Collins, Kathleen Heilig, Youli Wang, Georgeanne 
Lammertin, Martin Schlimme, Jennifer Hall, Richard Quigg, Roberto M. Lang, Charles 
Heilig, University of Chicago, Chicago, IL
Background: GLUT1 is a major facilitative glucose transporter of the heart and 
vasculature, and excessive glucose uptake has been implicated in diabetic organ 
damage. However, the effects of excess GLUT1 on the heart and kidneys have not been 
elucidated.
Methods: We overexpressed GLUT1 in C57BL/6 mice (i.e. made GT1S mice) using a 
modiﬁed ß-actin promoter. Effects in heart and kidney were compared to nontransgenics 
(NT). Transthoracic 2-D targeted M-mode echocardiography was performed. We measured 
end-diastolic and systolic diameters and septal and posterior wall thickness. Left 
ventricular (LV) mass, indexed to weight, was calculated by the linear method. Fractional 
shortening was calculated from LV dimensions. Tail cuff blood pressures were measured. 
Kidneys were ﬁxed and stained with PAS and speciﬁc Type IV collagen antibody. Urine 
albumin/Cr ratio was measured with the Exocell Albuwell-M kit. N = 3 - 6 male mice in 
each group, ages 3 - 4 months for heart studies, ages 18 & 26 weeks for kidney studies. 
Data presented as Mean ± SEM.
Results: In GT1S: 7-fold overexpression of GLUT1 in the heart, > 2-fold overexpression 
in the aorta and 3.5-fold overexpression in renal glomeruli. Fasting and nonfasting blood 
glucose levels were unchanged from NT, as were circulating insulin and free fatty acid 
levels. There was no signiﬁcant difference in mean blood pressures. However, LV mass 
was increased 65% in GT1S vs. NT (4.27 ± 0.36 g/kg vs. 2.58 ± 0.36, P < .02). Accordingly, 
mean septal and posterior wall thicknesses were higher in GTIS vs. NT (septal 0.0940+/- 
0.0087cm vs. 0.0823 +/- 0.0056 cm; posterior 0.0913 +/- 0.0077cm vs. 0.0863 +/- 0.0062). 
Mean fractional shortening was 33% higher in GT1S (37.4+/-14.7% vs. 28.1 +/- 0.66%). 
Kidneys: GT1S developed progressive glomerulosclerosis with increased glomerular 
Type IV collagen. Albumin excretion increased progressively to 2-fold control in GT1S by 
age 26 weeks. Conclusions: 1. Overexpression of GLUT1 leads to increased LV mass 
with evidence of elevated LV function, consistent with increased substrate utilization. 
2. Kidneys accumulate glomerular collagen, associated with albuminuria. 3. Increased 
GLUT1 therefore adversely affects both the heart and kidney.
POSTER SESSION
919 
Chronic Heart Failure
Sunday, March 12, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
919-52 Modulation of BNP Release in Relation to Myocardial 
Scarring, Ischemia and Hibernation on PET in Patients 
With Chronic Heart Failure
Drew S. Allen, Mehmet K. Aktas, Wael A. Jaber, Hsuan-Hung Chuang, W. H. Wilson 
Tang, David O. Taylor, Randall C. Starling, Mohamad H. Yamani, Cleveland Clinic 
Foundation, Cleveland, OH, University of Rochester, Rochester, NY
Background: Multiple factors inﬂuence BNP release in patients with heart failure. 
However, the impact of myocardial scarring and hibernation on BNP determination in 
patients with chronic heart failure has not been evaluated before. We hypothesized that 
extensive scarring may result in an attenuated BNP release.
Methods: A total of 115 chronic heart failure patients with ischemic cardiomyopathy were 
evaluated for ischemia, hibernation and myocardial scarring by adenosine-rubidium- PET 
scan with 18C-FDG. Plasma BNP level was determined within 2 weeks of the study. Left 
ventricular dimension and function was evaluated by echocardiography. Patients were 
divided into 2 groups according to the extent of myocardial scarring: Control group (n= 67) 
where 33% or less of the ventricle demonstrated evidence of scarring and the Scar group 
(n= 48) where greater than 33% of the ventricle has evidence of scar. BNP measurements 
were correlated with the amount of myocardial scarring and were evaluated in relation to 
the presence of ischemia and hibernation.
Results: Compared to Control, the Scar group had signiﬁcant diminished BNP release, 
(Average: 317±364 vs 635±852 pg/ml; Median: 212 vs 357 pg/ml, P= 0.016). The Scar 
group tended to have lower LV ejection fraction (23±8 vs 26±9%, P=0.08), increased 
LV end systolic (5.03±1.04 vs 4.65±1.06 mm, P=0.07) and end diastolic dimension 
(6.18±0.85 vs 5.82±0.84 mm, P=0.03). In the overall population, there was a signiﬁcant, 
albeit weak, negative correlation between BNP and extent of myocardial scar (r= -0.24, 
P=0.01). Interestingly, this correlation was negative in the Control group but positive in the 
Scar group. Further, the Control group, where a higher BNP level was noted, had more 
patients expressing ischemia (51% vs 27%, P =0.01) and had a signiﬁcant increased 
amount of myocardial hibernation (22±14% vs 12±7%, P= 0.02) when compared to the 
Scar group.
Conclusions: A diminished BNP response is noted in the presence of extensive 
myocardial scarring, and an enhanced release in the presence of hibernation. Additional 
variables should be examined to determine if this observation is fully explained by 
changes in muscle mass and the relationship to prognosis.
919-53 Comparison and Co-Relation of Invasive and 
Noninvasive Methods of Ejection Fraction 
Measurement
Darshan Godkar, Padmini Sircar, Anil Gupta, Ranju Gupta, Robert Megna, Selva 
Niranjan, Ashok Khanna, Robert Cucco, Coney Island Hospital, Brooklyn, NY
Background: Accurate estimation of ejection fraction (EF) has assumed great signiﬁcance 
in the era of deﬁbrillators (ICD) and a low EF may be one of the sole deciding factor in 
determining ICD implantation in certain patient population.
Aim: There are various methods, invasive and non-invasive which can help calculate 
EF. We sought to conduct a retrospective study comparing EF estimation by invasive 
(angiography) and non-invasive methods (MUGA, ECHO, SPECT) in 5,558 patients in 
our hospital from 1995-2004. Only patients who had all four studies in a span of one 
month from each other were included.
Methods and Results: Values for the four tests in 5,558 patients were as follows: 
angiography mean 46.2, range 20 - 75, SD 13.1; MUGA mean 45.7, range 20 - 70, SD 
11.6; ECHO mean 45.7, range 22 - 70, SD 11.2; and SPECT mean 54.4, range 30 - 
75, SD 11.9. Excellent positive correlations were found between all four tests as follows: 
angiography and MUGA r = 0.97; angiography and ECHO r = 0.96; angiography and 
SPECT r = 0.94; MUGA and ECHO r = 0.97; MUGA and SPECT r = 0.94; and ECHO 
and SPECT r = 0.94. Values for SPECT were signiﬁcantly higher than for angiography, 
ECHO, and MUGA (p < 0.001). In addition, values for angiography were signiﬁcantly 
higher than for MUGA (p < 0.001) and ECHO (p < 0.001). Values for MUGA and ECHO 
were not signiﬁcantly different (p = 0.59). The arithmetic difference between angiography 
and MUGA (mean 0.50, range -5.0 to 5.0) and the arithmetic difference between 
angiography and ECHO (mean 0.52, range -5.0 to 15.0) were similar (p = 0.59). The 
arithmetic difference between SPECT and angiography (mean 8.2, range -15.0 to 20.0) 
was signiﬁcantly larger than the arithmetic difference between angiography and ECHO 
(p < 0.001).
Conclusions: All the four methods used to estimate EF co-relate well with each other. 
However values estimated during stress testing by SPECT overestimate EF and are 
signiﬁcantly higher as compared to MUGA, ECHO and angiography. Estimation of EF 
by MUGA, ECHO or angiography should be preferred over SPECT especially when that 
patient warrants intervention. We conclude that the overestimation of EF by SPECT may 
deprive some medicare medicaid patients of the survival beneﬁt afforded by ICD.
919-54 Physical and Mental Functioning and Health Outcome 
in Patients Enrolled in the Multicenter Automatic 
Deﬁbrillator Implantation Trial-II
Katarzyna Piotrowicz, Katia Noyes, Jeffrey M. Lyness, Scott McNitt, Wojciech Zareba, 
Arthur J. Moss, University of Rochester Medical Center, Rochester, NY
Background: The relation between physical and psychosocial factors in managing 
congestive heart failure (CHF) patients has not been fully explored. In this study, we aim 
to assess health related physical and mental quality of life in postinfarction patients with 
severe heart failure.
Methods: A total of 1,058 patients enrolled in the Multicenter Automatic Deﬁbrillator 
Implantation Trial II (MADIT II) completed the Medical Outcome Trust Short Form (SF-
12) at baseline and 12 months after randomization. Two summary measures: physical 
component (PCS) and mental component (MCS) of SF-12 were analyzed regarding 
survival, hospitalization due to CHF, and ICD therapy during long-term follow-up.
Results: Patients in the conventional group (n=420) had a 36% increase in mortality 
risk and a 30% increase in hospitalization for CHF per 10-unit decrease in PCS and 
MCS, respectively, after adjustment for signiﬁcant clinical covariates (Table).In the ICD 
group (n=638) there was no signiﬁcant association between either PCS or MCS and the 
risk of arrhythmic events deﬁned as ICD therapy. There was a signiﬁcant deterioration of 
PCS from baseline to 12 months, but no change in MCS, in patients who experienced 
appropriate ICD shock.
Conclusions: Lower physical and mental component scores are associated with 
unfavorable outcomes in the conventionally treated MADIT-II patients, but not with ICD 
therapy for ventricular tachyarrhythmias. The mental component score was not adversely 
affected by ICD shocks.
919-55 What Speciﬁc Domains of Cognition Are Impaired in 
Patients With Chronic Heart Failure?
Shaymaa Elkadi, Elsdon Storey, Henry Krum, Monash University, Melbourne, Australia
Background: Chronic heart failure has been associated with generalised cognitive 
decline. However, little is known regarding the impact of this condition on speciﬁc domains 
of cognition. The aim of the present study was therefore to examine the effect of CHF on 
key parameters of cognitive function.
Methods:Patients (pts) with CHF (n=44) were compared with controls (n=22) matched on 
age (56.3 ± 11.7 vs 54.8 ± 10.4 years) and level of education (12.7 ± 3.3 vs 12.9 vs 2.9 
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yrs). Mean EF of CHF was 35.8 ± 12.4% and NT-proBNP was 834 ± 811 pmol/L. Patients 
and controls were administered the Rey Auditory Verbal Learning Test to assess verbal 
memory and the Rey Complex Figure Test to assess visuo-spatial memory as well as 
GDS (15 point) and mini-mental state exam (MMSE).
Results: GDS was 4.32 ± 2.38 in CHF pts vs 1.09 ± 1.63 in controls (p < 0.0001). MMSE 
was 29.5 ± 0.60 in CHF pts vs 29.9 ± 0.29 in controls (p < 0.005). There was signiﬁcantly 
poorer verbal [t(20) = 4.49, p < 0.001] and visuo-spatial [t(16) = 2.19, p < 0.05] short 
term memory in CHF patients. Long term memory scores were also signiﬁcantly lower 
for CHF patients on verbal memory, [t(21) = 3.43, p < 0.01]. Inattention (omissions and 
commissions) was also signiﬁcantly greater in CHF pts vs controls.
Conclusions: CHF is associated with a clinically signiﬁcant adverse impact upon 
cognitive function, particularly in relation to the registration, retention and retrieval of 
information as well as sustained, directed attention. Improvement in speciﬁc domains of 
cognitive function should be a therapeutic goal in the management of CHF.
919-56 Myocardial Heat Production is Invesrely Correlated with 
the Systolic Perfomance of Left Ventricle.
Konstantinos Toutouzas, Maria Drakopoulou, Virginia Markou, John Mitropoulos, Costas 
Gatzoulis, George Zervopoulos, Dimitris Tousoulis, George Latsios, Christodoulos 
Stefanadis, Ippokrateion Hospital, University of Athens, Athens, Greece
Reduced left ventricular systolic performance is associated with increased heat production 
from the myocardium. However, the impact of systolic performance on the produced heat 
is unknown. We investigated whether there is increased CS blood temperature in patients 
(pts) with heart failure (HF) and to compare CS temperature between dilated (DCM) and 
ischemic (ICM) cardiomyopathy.
Methods: We included 54 pts: 19 with DCM, 13 with ICM and 22 control. Temperature 
measurements were performed by a 7F thermography catheter, which can be manipulated 
to enter the CS and right atrium (RA). At the tip of the catheter a thermistor is attached. 
Temperature difference (TD) was the difference between CS and RA blood temperature.
Results: Left ventricular ejection fraction (EF) was lower in DCM or ICM compared to 
controls (DCM: 27.36±7.14%; ICM: 30.53±7.61%; control: 55.22±6.26%, p<0.0001). EF 
was similar between DCM and ICM pts (p=0.24). DT was greater in pts with DCM and 
ICM compared to controls (DCM: 0.25±0.09°C; ICM: 0.20±0.09°C; controls: 0.14±0.07°C, 
p<0.01). DT was similar between DCM and ICM (p=0.17). There was an inverse correlation 
between DT and EF in the whole population (R=0.56, p<0.001).
Conclusions: Pts with systolic HF have increased CS blood temperature compared to 
controls. Myocardial heat production, was inversely related to EF, but was not correlated 
with the etiology of HF.
919-57 Mechanisms of Chronotropic Incompetence in Patients 
With Congestive Heart Failure Taking Beta-blockers
Michael E. Kasper, Ulrich P. Jorde, Alhakam Hudaihed, David Hirsh, Timothy J. Vittorio, 
New York University Medical Center, New York, NY
Background: Heart rate (HR) response to exercise is impaired in subjects with CHF and 
this chronotropic incompetence (CI) can be quantiﬁed as the chronotropic responsiveness 
index (CRI= delta HR/logdeltaNE). The precise mechanism of CI and the contribution of 
beta blockade are unknown. Accordingly, we investigated norepinephrine (NE) and HR 
kinetics in subjects with CHF on chronic beta blockade.
Methods: Subjects underwent symptom limited cardiopulmonary exercise testing and 
were stratiﬁed into 3 groups (VO2 > 20, n=11; VO2 15.1-19.9,n=9; VO2 < 15,n=20). NE 
levels and HR were assessed at baseline (BL) and peak exercise to calculate CRI.
Results: 40 subjects (mean age 53, mean LVEF 25 %) treated with BB for over 3 
months were studied. BL HR, proportion of non-selective BB use, and BB dose were 
not different btw groups. Peak HR and deltaHR were lower in subjects with VO2 < 15 
compared to those with VO2 > 20 (p< 0.01 for both). Peak NE (p 0.08), deltaNE (p=0.03) 
and logdeltaNE (p= 0.02 ) levels were lower in subjects with VO2 < 15 compared to those 
with VO2 > 20. In addition, postsynaptic sensitivity to NE (as evidenced by a lower heart 
rate increase per delta NE) was lower in subjects with VO2 < 15 compared to those with 
VO2 > 20 ( CRI 14.5 vs 21 p < 0.01).
Conclusions: Both attenuated NE release and postsynaptic beta receptor desensitization 
contribute to chronotropic incompetence in CHF. Despite uniform betablockade, these 
ﬁndings are signiﬁcantly more pronounced as CHF advances.
 
919-58 The Incidence of Thromboembolism in Patients With 
NYHA Class II and III Heart Failure: An Analysis From 
the Sudden Cardiac Death in Heart FailureTrial (SCD-
HeFT)
Ronald S. Freudenberger, Anne S. Helkamp, Daniel B. Mark, Kerry L. Lee, Jill Anderson, 
George Johnson, Jeanne E. Poole, Gust H. Bardy, SCD-HeFT Investigators, Robert 
Wood Johnson Medical School, New Brunswick, NJ, Seattle Institute for Cardiovascular 
Research, Seattle, WA
Background: There are no prospective randomized studies of primary or secondary 
prevention of thromboembolism (TE) in systolic dysfunction in the absence of atrial 
ﬁbrillation. Clinical trials of heart failure (HF) treatment have reported clinically apparent 
stroke rates ranging from 1.3 to 3.5 percent per year. SCD-HeFT randomized 2521 
patients with moderately severe HF to receive amiodarone, ICD or placebo. Background 
drug therapy for HF (vasodilators and beta-blockers) was generally excellent.
Methods: We determined the incidence of TE (stroke, TIA, peripheral or pulmonary 
embolism) in patients without a known history of atrial ﬁbrillation at randomization 
(n=2114) and analyzed possible predictors of TE events.
Results; The overall rate of TE was 4.5% over a mean follow-up period of 45.5 months, 
with 3.2% in amiodarone, 3.8% in ICD, and 6.4% in placebo arms. Multivariable analysis 
revealed that only treatment with amiodarone or ICD was a signiﬁcant predictor of TE-free 
survival (p=0.015 for treatment effect; hazard ratio {95% CI} for ICD = 0.58 {0.36, 0.94} 
and for amiodarone = 0.52 {0.32, 0.86} vs. placebo).The addition of new atrial ﬁbrillation 
to the multivariable model did not have an impact on the signiﬁcance of treatment groups 
as a predictor of TE events.
Conclusion: In patients with advanced HF, in the current era of HF treatment TE appears 
at a rate of 1%/ year and those who received amiodarone or ICD had a lower risk of TE 
compared to placebo.
919-59 Difference in Left Ventricular Reverse Remodeling in 
Response to Angiotensin Receptor Blockade Alone or 
in Combination With Spironolactone in Patients With 
Systolic Dsyfunction: Insight From Serial Prospective 
CMR Study
Anna Kin Yin Chan, Yan Zhang, Tina Wang, Maggie Wang, Yat Y Lam, Eugene B Wu, 
John T Wong, Winnye Lam, Nina So, Cheuk M Yu, John E Sanderson, The Chinese 
University of Hong Kong, Hong Kong, Hong Kong
Background: Angiotensin receptor blocker (ARB) might offer more “complete” Renin-
Angiotensin-Aldosterone inhibition and avoid “escape” phenomenon in patients on 
chronic ACE inhibitor. However, the incremental value of aldosterone blockade in heart 
failure patients taking ARB has not been assessed.
Aim: We sought to determine the beneﬁcial effect of candesartan alone or in combination 
with spironolactone on left ventricular remodelling in chronic systolic heart failure 
patients.
Methods: In this double blind study, we enrolled heart failure patients with left ventricular 
ejection fraction (LVEF) <40% who were being treated on ACE inhibitors for more than 6 
months. The patients were randomly assigned to replace ACE inhibitors with candesartan 
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8 mg daily alone (C group, n=25) or candesartan 8 mg daily plus spironolactone 25 mg 
daily (C+S group, n=24) in a double blind manner. The primary end point was changes in 
LV volume index, LVEF, LV mass index measured by cardiac magnetic resonance imaging 
(CMR). Serial CMRs were performed at baseline, 6, and 12 months after randomization.
Results: The baseline demographic data were comparable between the two groups. The 
combination C+S group showed signiﬁcant improvement in LVEF (28% at baseline vs 37% 
at 12 month, p <0.01), reduction of LV end-diastolic (147±15 ml/m2 at baseline vs 120±16 
ml/m2 at 12 month., p =0.001) and end-systolic volume index (112±15 ml/m2 at baseline vs. 
86±17ml/m2 at 12 month, p < 0.0005) and LV mass index (91±6g/m2 at baseline vs 80±7g/
m2 at 12 month, p =0.002) by serial CMR, despite equivalent reduction in blood pressure 
among the 2 treatment groups. Signiﬁcant improvements in LVEF (31%, 51% improvement 
at 6 months and 12 months respectively) were seen compared with baseline. In the C 
group, there were small but insigniﬁcant changes between baseline and 12 months.
Conclusion: The addition of spironolactone to an ARB has important incremental value 
on LV remodelling in patients with chronic systolic heart failure.
919-60 Mortality by Race in Patients With Congestive Heart 
Failure
Jessica Delaney, Evelyn Du, Daniel Spevack, Sanjay Doddamani, Xuan Li, Robert J. 
Ostfeld, Monteﬁore Medical Center, Bronx, NY
Background: Congestive heart failure (CHF) is a growing medical problem with 
approximately 4.9 million Americans suffering from this disease and 550,000 new 
cases diagnosed each year. Data regarding CHF mortality rates by race are limited. We 
examined mortality by race in 16,280 patients with CHF.
Methods: A database, titled Clinical Looking Glass (CLG), was developed at the Albert 
Einstein College of Medicine. All admissions and discharges from April 15, 1997 through 
the present are included. It is updated daily and includes multiple data points including 
ICD-9 codes, self-identiﬁed race and vital status. We queried the CLG database for 
all patients aged 21-85 with the ICD-9 code for congestive heart failure (428.0) who 
were admitted from April 15, 1997 until June 1, 2005. For those subjects with multiple 
admissions, the ﬁrst admission was the index date.
Results: 16,280 subjects of known race were identiﬁed. Mean length of follow-up was 
874 days. There were 5,904 Caucasians (C) age 72.4, (+/- 10.3) years, 5,097 African 
Americans (AA) age 63.8, (+/- 13.8), 5,158 Hispanics (H) age 64.5, (+/- 12.8), and 121 
Asian Paciﬁc islanders (API) age 65.5, (+/- 12.9). When adjusting for age with Cs as the 
reference group, the hazard ratio for mortality for AAs was 0.99, (0.97, 1.05, p=0.78), for 
Hs, 0.89, (0.84, 0.94, p<0.001), and for APIs, 1.06, (0.81, 1.39, p=0.68). On multivariate 
analysis, including age, sex, and multiple co-morbidities, the hazard ratio for mortality for 
AAs was, 0.99, (0.93, 1.05, p=0.67), for Hs, 0.93, (0.87, 0.99, p=0.02), and for APIs, 1.04, 
(0.79, 1.36, p=0.78).
Conclusions: In a tertiary care patient population, after controlling for age, sex and 
multiple co-morbidities, as compared to Cs, AAs and APIs had similar hazards of mortality, 
while Hs had a signiﬁcantly lower hazard of mortality. Further research to explore this 
difference is warranted.
919-89 No Evidence of Detrimental Effects of Doxazosin as an 
Additional Antihypertensive Therapy in Mild/Moderate 
Heart Failure Patients on Full Medical Therapy
Roberto Spoladore, Gabriele Fragasso, Francesco Arioli, Altin Palloshi, Patrizia Puccetti, 
Amarild Cuko, Giorgio Bassanelli, Chiara Montano, Alberto Margonato, San Raffaele 
Institute, Milano, Italy
Background. In the ALLHAT study, the doxazosin arm was stopped earlier because 
of higher prevalence of new onset heart failure. On this ground, a possible speciﬁc 
detrimental effect of doxazosin in patients with heart failure has been hypothesized.
Methods. We retrospectively analyzed the records of 580 NYHA I-III heart failure patients 
(pts) referred to the heart failure clinic of our institution. Because of persistently high 
blood pressure, doxazosin had been added in 51 pts (19 females; age 69±10 yrs; 28 
post-ischemic) already on ACE-inhibitors (44), beta blockers (37), diuretics (45), nitrates 
(14) and digoxin (5).
Results. After doxazosin prescription, patients have been followed for 16±12 months 
(range 1-46). During this period 3 pts died of non-cardiac causes. Average doxazosin 
dose was 4.1±2.0 mg/day. Of 51 pts, 41 continued doxazosin treatment; in 10 pts 
doxazosin was withdrawn after 10±9 months (1 cough, 9 marked hypotension). With 
doxazosin, systolic and diastolic blood pressure signiﬁcantly decreased from 175±22 and 
96±12 to 153±26 and 86±11 mmHg, respectively, p<0.0001 for both, while heart rate 
remained stable (from 71±11 to 71±12 bpm). Ejection fraction increased from 43±9 to 
50±7, p=0.001, and NYHA class decreased not signiﬁcantly from 1.64±0.66 to 1.51±0.60, 
p=0.42. Out of 14 male patients with chronic prostatism, 8 reported a >50% reduction of 
the number of nocturnal micturitions with doxazosin.
Conclusions. Doxazosin administration in mild/moderate heart failure pts, on full speciﬁc 
medical therapy and persistently uncontrolled arterial hypertension, is generally well 
tolerated and successfully reduces blood pressure without yielding speciﬁc detrimental 
effects. Optimization of blood pressure control by the addition of the alfa-blocker might 
partly explain the observed improvement in left ventricular function and functional 
capacity in our patients.
919-90 Effect of False Tendons on Mitral Regurgitation in 
Patients with Severe Left Ventricular Dysfunction
Mehul R. Bhatt, Blake Gardner, Ravikanth Chiravuri, Eduardo De Marchena, Jackson 
Memorial Hospital, Miami, FL
Background: False tendons in the left ventricle (LV) are commonly observed during routine 
2-D echocardiography. Little data is available deﬁning their prevalence and characteristics. 
The purpose of this study was to establish the prevalence and hemodynamic effects of 
LV false tendons.
Methods: Echocardiograms from April 2003 to August 2005 were retrospectively 
examined for LV false tendons. The age, sex, ejection fraction (EF), etiology of LV systolic 
dysfunction, LV internal dimension in diastole (LVIDd), severity of mitral regurgitation 
(none, trace, mild, moderate, or severe), LV posterior wall dimension in diastole 
(LVPWDd), and interventricular septum dimension in diastole (IVSDd) were evaluated. 
The patients with false tendons were compared to a control group.
Results:One hundred seventy-nine patients with false tendons were identiﬁed. A subset 
of patients (n=48) with severe LV systolic dysfunction (average EF = 22%) and false 
tendons that appeared to be tethering the walls together, were compared to a control 
group with similar LV dysfunction and no false tendons (n=62, average EF = 21%; 
p=0.18). The tendons tethered the septum to lateral wall (n=15), apex to apex (n=11), 
papillary muscle to papillary muscle (n=6), apex to ventricular wall (n=4), and anterior 
to inferior wall (n=3); also several patients (n=9) had multiple false tendons. The patients 
with false tendons had similar LVIDd compared to the control group (6.1 and 6.2 cm, 
respectively; p=0.23). Yet, patients with false tendons had lower proportions of moderate 
and severe mitral regurgitation than a control group without false tendons (35% versus 
58%, p=0.0092). Furthermore, there was also a very low incidence of severe mitral 
regurgitation in patients with false tendons and EF ≤ 30% compared to the control group 
(4.2% versus 27%; p=0.0007).
Conclusions: A subset of patients with false tendons and severe LV dysfunction may 
have a tethering effect yielding positive hemodynamic characteristics, speciﬁcally less 
severe mitral regurgitation. In patients with severe LV dysfunction, false tendons or 
potential artiﬁcial tethering techniques may decrease mitral regurgitation and impart an 
improved prognosis.
919-91 Association Between Study Drug Dose and Survival/
Hospitalization in Relation to Initiation of Treatment 
for Chronic Heart Failure With Bisoprolol Followed 
by Additional Enalapril Compared to the Opposite 
Sequence: Results of the Randomized CIBIS-III Trial
Ronnie Willenheimer, Dirk van Veldhuisen, Bernard Silke, Erland Erdmann, Ferenc 
Follath, Henry Krum, Piotr Ponikowski, Allan Skene, Louis van de Ven, Patricia 
Verkenne, Philippe Lechat, on behalf of the CIBIS-III investigators, Lund University, 
Malmö University Hospital, Malmö, Sweden
Background: In CIBIS III, 1010 patients >=65 years old, with stable, mild/moderate 
chronic heart failure (CHF) and left ventricular ejection fraction <=35%, without 
angiotensin converting enzyme inhibitor, betablocker or angiotensin receptor blocker 
therapy, were randomized to monotherapy with either bisoprolol (B) (target dose 10 mg 
o.d., n=505) or enalapril (E) (target dose 10 mg b.i.d., n=505) for 6 months, followed by 
their combination for 6-24 months. The two strategies were similar in terms of mortality, 
hospitalization and safety. We assessed any association between study drug dose and 
survival/hospitalization.
Methods: At the end of the monotherapy phase and at study end, we assessed the dose 
of the respective study drugs as well as mortality/hospitalization.
Results: The last prescribed study drug dose was statistically signiﬁcantly higher for the 
ﬁrst initiated drug in both treatment groups: In the E-ﬁrst group 90% of the patients were 
prescribed >=50% of the target dose of E, versus 82% in the B-ﬁrst group (P<0.001). 
In the B-ﬁrst group 86% of the patients were prescribed >=50% of the target dose of B, 
versus 72% in the E-ﬁrst group (P<0.001).
During the monotherapy phase:
In the B-ﬁrst group, 19% of patients who reached >=50% of the target dose of B had a 
primary endpoint versus 34% of those who reached <50% of the target dose (P=0.002).
In the E-ﬁrst group, 21% of patients who reached >=50% of the target dose of E had a 
primary endpoint versus 35% of those who reached <50% of the target dose (P=0.09).
During the entire study:
In the B-ﬁrst group, 34% of patients who reached >=50% of the target dose of B had a 
primary endpoint versus 40% of those who reached <50% of the target dose (P=0.32).
The corresponding ﬁgures for E were 31% versus 42% (P=0.14).
In the E-ﬁrst group, 36% of patients who reached >=50% of the target dose of E had a 
primary endpoint versus 50% of those who reached <50% of the target dose (P=0.15).
The corresponding ﬁgures for B were 27% versus 49% (P=<0.001).
Conclusions: The vast majority of these elderly patients tolerated >=50% of the respective 
target doses. Combined mortality or hospitalization was associated with achieved doses 
of both B and E, but was particularly evident for B.
919-92 Importance and Signiﬁcance of Baroreﬂex 
Sensitivity(BRS) to Predict Prognosis of Chronic Heart 
Failure With Preserved Systolic Function
Eisaku Nakane, Moriaki Inoko, Nozomi Tanaka, Junji Nakashima, Hitoo Nishi, Tetsuhiko 
Yanazume, Kimisato Nakano, Tetsuya Haruna, Ryohei Hosokawa, Ryuji Nohara, Kitano 
Hospital, Osaka, Japan
Background: About 50% of patients with chronic heart failure (CHF) have preserved 
left ventricular ejection fraction (LVEF). Various neuro-humoral factors and cytokines are 
useful prognostic predictors of chronic heart failure with low LVEF. Moreover, baroreﬂex 
sensitivity (BRS) reﬂecting parasympathetic nerve activity is also a useful prognostic 
predictor, including cardiac sudden death. However, it is still to be unknown whether these 
markers are also useful prognostic predictors in CHF with preserved LVEF. In present 
prospective study, we examined useful predictors of cardiac events or prognosis.
Methods: Plasma brain natriuretic peptide (BNP), interleukin-6 (IL-6), high sensitive 
C-reactive protein (hs-CRP) concentrations and BRS were measured before discharge 
in serial 95 patients with CHF. All patients were under 85 years (mean 64.4+12.6, M 
/ F; 71/ 24) and had a left ventricular ejection fraction (LVEF) >40%. Patients with a 
serum creatinine > 2.0mg/dL were excluded in this study. The end point was death or 
re-admission for decompensated CHF for one year from the date of examination. BRS 
was assessed by phenylephrine injection (2~4µg/kg). Cut off values were determined by 
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analysis of receiver operating characteristic (ROC) curve.
Results: During the follow up period, three patients died, eight patients were re-admitted 
for worsening heart failure. BRS (<1.5ms/mmHg) and BNP (>200 pg/ml) showed higher 
sensitivity and speciﬁcity over a range of different cut off point than other markers (area 
under ROC curve=BRS; 0.91[0.84 to 0.97], BNP; 0.87, IL-6; 0.43, and hs-CRP; 0.57. 
Moreover, BRS and BNP showed higher positive predictive values than other markers 
(BRS; 45%, BNP; 38%, IL-6; 15%, hs-CRP; 7%). BRS and BNP being combined 
(BRS<1.5ms/mmHg and BNP levels>200 pg/ml), the predictive value increased to 75%.
Conclusions: BRS and BNP are useful predictive markers for cardiac events in chronic 
heart failure with preserved left ventricular ejection fraction. Moreover, measurements of 
BRS together with BNP, showing neural and humoral harmonization, allow more powerful 
predictors of cardiac events.
919-93 Loop Diuretic Dose Is Independently Associated With 
Increased Mortality in Advanced Heart Failure
Shervin Eshaghian, Tamara B. Horwich, Gregg C. Fonarow, Cedars Sinai Medical 
Center, Los Angeles, CA, University of California, Los Angeles, Los Angeles, CA
Background: Although loop diuretics are widely used in Heart failure (HF), their effect on 
outcomes has not been well studied.
Methods: We analyzed a cohort of 1,420 patients with advanced HF, referred to a single 
center. Patients were divided into quartiles of equivalent total daily loop diuretic dose: 0-40 
mg; 41-80 mg; 81-160 mg; >160 mg.
Results: The cohort was 75% male, with mean age of 53 ± 13, and ejection fraction (EF) 
of 24 ± 7. Mean diuretic dose equivalence was 107 ± 87 mg. The diuretic quartile groups 
were similar in terms of gender, body mass index (BMI), ischemic etiology, history of 
hypertension, and spironolactone use, but the highest quartile was associated with lower 
EF, serum sodium and hemoglobin, but higher serum blood urea nitrogen and creatinine. 
There was a stepwise decrease in survival with increasing diuretic dose (83%, 79%, 
68%, and 53% for quartiles 1, 2, 3, and 4, respectively). Even after extensive covariate 
adjustment [age, gender, ischemic etiology, EF, BMI, beta-blocker, ACE-I/ARB, and statin, 
serum sodium, BUN, creatinine, hemoglobin, cholesterol, SBP, and smoking history], 
diuretic quartile remained an independent predictor of mortality Q4 vs Q1 HR 2.0 (95% 
CI 1.2-3.1).
Conclusion: In this cohort of patients with advanced HF of multiple etiologies, there is 
an independent, dose dependent association between loop diuretic use and impaired 
survival. Higher loop diuretic dose identiﬁes HF patients at particularly high risk for 
mortality. Prospective studies are needed. 
919-94 Superior Renin-Angiotensin-Aldosterone System 
(RAAS) Inhibiting Properties of a Novel Long-Acting 
ANP Designer Peptide Compared to Native ANP in 
Normal Dogs
Paul M. McKie, Alessandro Cataliotti, Fernando L. Martin, Gail J. Harty, Lynn K. Harstad, 
John C. Burnett, Jr., Mayo Clinic, Rochester, MN, The Stanley J Sarnoff Endowment for 
Cardiovascular Research, Great Falls, VA
Background: We have previously reported a novel 40 AA peptide, termed Long-Acting 
ANP (LA-ANP), whose structure consists of ANP with an additional 12 AA C-terminus. 
At low doses, 2 pmol/kg/min, LA-ANP possesses superior and sustained natriuretic and 
diuretic actions when compared to ANP. Here we report the actions of high dose LA-
ANP.
Methods: Studies were performed in normal dogs comparing equimolar (33 pmol/kg/min) 
intravenous LA-ANP (n=7) and ANP (n=7). Hemodynamic, renal, and humoral data were 
obtained during four 30 minute clearances: 1) baseline; 2) during peptide infusion; 3) 30-
60 minutes post infusion (recovery 1); and 4) 90-120 minutes post infusion (recovery 2). 
*p<0.05 vs. BL, 1-way ANOVA; †p<0.05 vs. ANP, 2-way ANOVA
Results: LA-ANP infusion resulted in an overall greater increase in diuresis†, natriuresis†, 
and RBF† when compared to equimolar ANP. Further, LA-ANP resulted in an overall 
greater decrease in MAP† when compared to ANP. Interestingly, the greater renal and 
hemodynamic actions of LA-ANP were sustained to 120 minutes post-infusion. Despite the 
greater increase in diuresis and natriuresis and decrease in MAP with LA-ANP infusion, 
activation of the RAAS was signiﬁcantly impaired when compared to ANP (Table).
The Effects of Equimolar LA-ANP and ANP Infusion on Plasma 
Angiotensin II Aldosterone, and Renin
Angiotensin II Aldosterone Renin
ANP LA-ANP† ANP LA-ANP† ANP LA-ANP†
Baseline 7.0±1.5 5.0±1.9 11.9±2.6 8.1±1.8 6.0±2.0 4.3±1.5
Infusion 3.7±1.8 1.6±0.5* 8.1±1.9 5.7±1.1* 0.7±0.2* 0.8±0.3*
Recovery 1 11.4±3.5 2.8±0.5 18.1±4.4 7.4±1.8 9.8±2.5 6.5±2.0
Recovery 2 10.3±2.7 4.6±0.9 22.8±6.2* 11.5±3.0 11.4±2.8* 7.6±2.0*
Conclusions: These studies report LA-ANP, despite possessing superior hemodynamic 
and renal actions, results in signiﬁcantly less RAAS activation when compared to ANP. 
LA-ANP may thus serve as a novel saluretic agent and inhibitor of the RAAS in sodium 
retaining syndromes.
919-95 Rhythm Versus Rate Control for Atrial Fibrillation in 
Post-MI Patients With Heart Failure: Results from the 
VALIANT Trial
Sana Al-Khatib, Linda Shaw, Eric J. Velazquez, Harvey White, Christopher B. Granger, 
Marc A. Pfeffer, John J.V. McMurray, Robert M. Califf, Duke Clinical Research Institute, 
Duke University Medical Center, Durham, NC
Background: We compared outcomes of rate-control and rhythm-control strategies in 
1,209 patients with atrial ﬁbrillation (AF) from the VALIANT trial.
Methods: Patients with AF at baseline and at least NYHA class II at discharge or 15-
day follow-up were classiﬁed as treated with a rate-control (n=778) or a rhythm-control 
strategy (n=431), based on reported use of amiodarone or other antiarrhythmics. 
Landmark analyses were used to compare survival and stroke in the groups. Kaplan-
Meier method was used to graph cumulative patient survival. Analyses were adjusted for 
differences in baseline characteristics using Cox proportional hazards models.
Results: Median ejection fraction in both groups was 33% (25th, 75th of 29, 40%). At 30 
days, warfarin use was signiﬁcantly higher in the rhythm-control group; beta-blocker use 
was signiﬁcantly higher in the rate-control group. During follow-up, 319 (26.4%) patients 
died; 200 (25.7%) in the rate-control group and 119 (27.6%) in the rhythm-control group. 
There was no signiﬁcant difference in mortality (HR 1.1; 95% CI 0.9, 1.4; P=0.4) or stroke 
(HR 0.7; 95% CI 0.4, 1.3; P=0.3).
Conclusions: In patients with AF and heart failure, a rhythm-control versus rate-control 
strategy does not appear to be associated with any major difference in mortality. Future 
studies are needed to investigate the impact of each strategy on patients’ quality of life.
 
919-96 The Effects of Antidepressant Therapy on Depression 
and Quality of Life in Patients with Chronic Heart 
Failure
Mark R. Vesely, Nancy Greenberg, Stacey Minshall, Joanne Marshall, Susan Thomas, 
Krishnamurti Rao, Scott Katzen, Melinda Jorge, Debra Chappa, Stephen S. Gottlieb, 
University of Maryland, Baltimore, MD
Background: Using the Beck Depression Index (BDI), the prevalence of depression (dep) 
in patients (pts) with chronic heart failure (CHF) ranges from 24-48%. Since symptoms of 
CHF & dep overlap, it is unclear if dep accounts for a major component of quality of life 
(QOL) measures, such as Minnesota Living with Heart Failure (MLWHF) & SF-36.
Methods: We assessed the correlation of BDI with components of MLWHF (T-total, 
E-emotional, & P-physical) & SF-36 (M-mental, P-physical) in CHF pts with baseline 
(BL) mild to moderate dep (BDI ≥ 10). Pts were then randomized to receive placebo or 
paroxetine-CR for 12 weeks & then reassessed by BDI, MLWHF & SF-36.
Results: 26 pts, 89% male, age 62 ±11, 50% black were enrolled. 65% were NYHA class 
III & 35% were NYHA class II. LVEF was 25% ± 8 (range 10-40%). 85% were on ACE 
inhibitors, 92% beta-blockers & 42% spironolactone. There were no statistical differences 
between treated & placebo groups except for BL MLWHF-E. No QOL measure was highly 
correlated with BDI. BL mean scores & correlations (r) to BDI were: BDI: 21 ± 8; MLWHF-
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T: 53 ± 21(r = 0.38); MLWHF-E: 13 ± 7 (r = 0.46); MLWHF-P: 21 ± 10 (r = 0.34); SF-36-M: 
37 ± 10 (r = -0.41); SF-36-P: 37 ± 8 (r = -0.02). By ANOVA, BDI from BL to 12 weeks 
improved with treatment compared to placebo. However there was no signiﬁcant change 
in any QOL measure
Effect of Paroxetine-CR on Depression and QOL Over Time
∆ BDI ∆ MLWHF-T ∆ MLWHF-E ∆ MLWHF-P ∆ SF-36-M ∆ SF-36-P
Paroxetine-CR -13 ± 9 -9 ± 18 -4 ± 6 -0.3 ± 6 11 ± 13 -3 ± 5
Placebo 0.7 ± 10 -8 ± 20 -3 ± 5 -3 ± 9 2 ± 7 0.2 ± 6
P value 0.004 0.86 0.68 0.50 0.12 0.38
Conclusions: Antidepressant therapy improves mild to moderate depression in CHF pts. 
While SF-36-M trends to improvement, this study suggests that MLWHF does not reﬂect 
the effects of mild to moderate depression.
919-97 Fate of Patients With Reversibile, Non-ischemic Left 
Ventricular Systolic Dysfunction: Is IT Reasonable to 
Continue Anti-Heart Failure Medications?
Jeong Geun Moon, Se-Joong Rim, Sungha Park, Eui-Young Choi, Young-Guk Ko, Jong-
Won Ha, Namsik Chung, Yonsei Cardiovascular Center, Seoul, South Korea, Yonsei 
University College of Medicine, Seoul, South Korea
Background: About 25% of the patients with non ischemic left ventricular (LV) systolic 
dysfunction improve spontaneously. However, little has been known about the fate of 
patients with heart failure after recovery of LV dysfunction. We hypothesized that patients 
who recovered from non-ischemic LV dysfunction have a substantial risk for recurrent 
heart failure.
Methods: Fifty patients (32 male, 54.9±12.4 years) who recovered from systolic 
heart failure (LV ejection fraction (EF) of 28.8±7.2 % at initial presentation) to near-
normal (LVEF >40%, and 10% or more increase in absolute value) were monitored 
for the recurrence of heart failure. Patients with signiﬁcant coronary artery disease 
were excluded. The etiologies of heart failure were idiopathic dilated cardiomyopathy 
(n=39), alcoholic cardiomyopathy (n=7), adriamycin-induced cardiomyopathy (n=2), and 
tachycardia-induced cardiomyopathy (n=2). After recovery of LV dysfunction, the patients 
were followed for 41.0 ± 26.3 months.
Results: In 9 patients (18 %), LV systolic dysfunction recurred during follow-up (LVEF 
32.6±7.3 %). Between patients with and without recurrent heart failure, there was no 
signiﬁcant difference in baseline clinical and echocardiographic variables. However, 
cessation of anti-heart failure medication was more frequently observed in patients with 
recurrent LV systolic dysfunction (55.6% vs 4.9%, p<0.05).
Conclusion: In patients with reversible non-ischemic LV systolic dysfunction, recurrent 
heart failure may ensue. The maintenance of anti-heart failure medication in the patients 
may be a signiﬁcant inﬂuencing factor for the clinical consequences.
919-98 Underuse of ACE Inhibitors, Beta-blockers and 
Spironolactone in Patients With Heart Failure Is 
Primarily Due to Lack of Initiation of Treatment
Gunnar H. Gislason, Jeppe N. Rasmussen, Steen Z. Abildstrom, Pernill Buch, Søren 
Rasmussen, Jens Friberg, Tina K. Schramm, Lars Køber, Mette Madsen, Christian Torp-
Pedersen, Bispebjerg University Hospital, Copenhagen, Denmark, National Institute of 
Public Health, Copenhagen, Denmark
Background: ACE inhibitors, beta-blockers and spironolactone reduce mortality in heart 
failure (HF); however, surveys have reported substantial underuse. We studied initiation of 
treatment, compliance and dosages, to identify likely targets for improvement.
Methods: All patients with ﬁrst admission for HF in Denmark 1995-2002 were identiﬁed 
by linkage of national administrative registers. Patients who claimed a prescription of ACE 
inhibitors, beta-blockers or spironolactone within 90 days after discharge were included 
in the study and subsequent prescription claims were identiﬁed to determine long-term 
compliance.
Results: A total of 96,663 patients were identiﬁed; 43% received ACE inhibitors, 25% 
beta-blockers and 18% spironolactone. After respectively 1, 3 and 5 years from start 
of treatment, 86%, 80% and 76% of survivors were still taking ACE inhibitors; 78%, 
66% and 60% beta-blockers; and 74%, 60% and 52% spironolactone (Fig). Substantial 
underdosing was found for ACE inhibitors and beta-blockers and dosages remained low 
during the observation period. After the ﬁrst 90 days from discharge only additionally 5% 
of patients started treatment.
Conclusions: The results highlight the importance of initiating lifesaving prophylactic 
treatment in adequate dosages in direct relation to discharge after HF. Otherwise the 
probability of starting treatment later or receiving sufﬁcient dosages is low. If started, the 
long-term adherence to treatment is high and continues for many years.
919-99 Chymase Inhibitor Improves Left Ventricular 
Dysfunction Under Long-Term Angiotensin-Converting 
Enzyme Inhibition in Heart Failure
Takehiro Matsumoto, Atuyuki wada, Takayoshi Tsutamoto, Masato Ohnishi, Masanori 
Fujii, Takashi Yamamoto, Tomohiro Dohke, Tomoyuki Takayama, Minoru Horie, Shiga 
University of Medical Science, Ohtsu, Japan
Background: Angiotensin-II (Ang-II) is generated via ACE, however, the alternative 
generating pathway, chymase, which is stored in the mast cells also exist in the heart. 
Moreover, heart chymase directly promotes interstitial ﬁbrosis by affecting collagen 
metabolism via TGF-beta and matrix metalloproteinases in vitro. However, the additional 
therapeutic effects of chymase inhibition on the cardiac function in heart failure (HF) 
under chronic ACE inhibition have not been documented yet.
Methods: HF was induced in beagles by rapid right ventricular pacing (270 beats/min, 
22 days). We evaluated the long-term effects of concomitant therapy of an ACE inhibitor 
(ACEI, Enalapril; 0.3mg/kg; n=7) with a speciﬁc chymase inhibitor (ChyI, TEI-G00471; 
100mg/kg/day; n=7) on cardiac structural changes, and several failing heart related genes 
comparing to a monotherapy of an ACEI. Vehicle dogs were given placebo (n=7).
Results: Our results are shown in the Table. The concomitant inhibition more signiﬁcantly 
upregulated the expression of sarcoplasmic reticlum calcium-ATPase mRNA, suppressed 
collagen accumulation and improved diastolic dysfunction compared to ACE inhibition alone.
Conclusion: Chymase pathway may be critical for cardiac diastolic dysfunction and 
combining the two modes of enzyme inhibition has greater therapeutic potential in the 
prevention of cardiac remodeling than ACE inhibition alone.
*p<0.05 vs normal, #p<0.05 vs vehicle,&p<0.05 vs ACEI
Normal Vehicle ACEI ACEI+ChyI
Mean arterial pressure (mmHg) 122±5.1 87.8±3.9* 98.8±2.3*# 102.2±3.9*#
LV end-daiastolic pressure (mmHg) 6.6±1.1 34.2±3.3* 29.2±0.7*# 19.9±0.3*#&
Tau (msec) 21.2±1.7 49.5±2.6* 36.1±1.7*# 30.9±3.1*#&
Collagen volume fraction (%) 1.6±0.2 10.4±0.4* 6.3±0.3*# 4.0±0.2*#&
ACE mRNA /GAPDH 0.63±0.02 1.86±0.18* 1.32±0.12*# 1.24±0.22*#
Chymase mRNA/GAPDH mRNA/GAPDH 0.24±0.03 2.12±0.09* 1.92±0.16* 0.96±0.19*#&
Sarcoplasmic reticlum calcium-ATPase mRNA/GAPDH 1.92±0.0.11 0.60±0.13* 0.99±0.16*# 1.13±0.08*#&
Collagen type1 mRNA/GAPDH 0.58±0.01 1.59±0.11* 1.12±0.06*# 0.87±0.13*#&
TGF-beta mRNA/GAPDH 0.44±0.02 1.74±0.14* 1.29±0.18*# 1.04±0.12*#&
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920-100 Alcohol Septal Ablation Is Safe and Effective in Patients 
With Left Ventricular Hypertrophy and Outﬂow Tract 
Obstruction
Joanna J. Wykrzykowska, Michael A. Fifer, Kalon KL Ho, Igor Palacios, Laurel Donnell-
Fink, Danita M. Yoerger, Joseph P. Carrozza, Jr., Micheal H. Picard, Patricia A. Lowry, 
Mark E. Josephson, Gus J. Vlahakes, Roger J. Laham, Beth Israel Deaconess Medical 
Center, Boston, MA, Massachusetts General Hospital, Boston, MA
Background: Alcohol septal ablation (ASA) is effective for the management of 
hypertrophic cardiomyopathy (HCM) and symptoms refractory to medical therapy. The 
efﬁcacy and safety of ASA in patients with left ventricular outﬂow tract (LVOT) obstruction 
and left ventricular hypertrophy (LVH) are not established.
Methods: We performed ASA in 26 patients with LVH (septal to inferolateral wall ratio < 
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1.3) and 53 patients with HCM (septal to inferolateral wall ratio ≥ 1.3) at 2 centers. The 
duration of follow-up was 15± 13 (range 1-60) months.
Results: ASA was successful in acutely reducing the LVOT gradient by > 50% in all 
patients. There were no procedural deaths. Patients with LVH were older (69±16 vs. 58±14 
years, p=0.04) and more likely to have hypertension (65% vs. 34%, p<0.01). In patients 
with LVH, NYHA class decreased from 2.4±0.3 to 1.4±0.7 after ASA, which was similar 
to the improvement in patients with HCM (2.6±0.5 to 1.6±0.8). The reduction in LVOT 
gradient in patients with LVH (83±46 to 25±30 mm Hg) was also similar to that in patients 
with HCM (71±33 to 31±40 mm Hg) and mean mitral regurgitation grade decreased by a 
similar amount in both groups.
Conclusions: In short-term follow up, ASA appears efﬁcacious and safe for the 
management of patients with LVH and LVOT obstruction, many of whom are elderly and 
have hypertension. Procedural results are similar to those observed for patients with HCM.
920-101 Impact of Positive Family History on Personal Risk 
of Sudden Death for Patients with Hypertrophic 
Cardiomyopathy
Paul Sorajja, Michael J. Ackerman, Bernard J. Gersh, Win K. Shen, Rick A. Nishimura, 
Steve R. Ommen, Mayo Clinic and Mayo Foundation, Rochester, MN
Background. Prophylactic deﬁbrillator implantation is often recommended to patients 
with hypertrophic cardiomyopathy (HCM) on the basis of a positive family history of 
sudden cardiac death (SCD) involving ﬁrst degree relatives. However, there is a paucity 
of data on the long-term outcome of patients who received an ICD primarily because of 
a positive family history.
Methods and Results. We examined the rates of aborted sudden death in a cohort of 122 
consecutive patients with HCM (mean age, 41 yrs) from a single institution who received 
an ICD for primary prevention of sudden death. A positive family history of SCD in one 
or more ﬁrst-degree relatives was the sole indication for an ICD for 35 (29%) of these 
patients (Group A). Of the remaining 87 patients (Group B), risk factors for SCD were 
syncope (n=13), nonsustained ventricular tachycardia (n=38), abnormal blood pressure 
response to exercise (n=25), and extreme hypertrophy (n=15); multiple risk factors were 
present in 13. Over a mean follow-up of 4.8 yrs, the annual incidences of aborted sudden 
death (i.e., appropriate deﬁbrillator therapy for treatment of lethal arrhythmia) were 1.71% 
and 2.22% in the group A and B patients, respectively (p = 0.69). Five-year survival 
free of aborted sudden death for these two groups were 90.9 ± 9.1% and 85.9 ± 4.6%, 
respectively (p = 0.75).
Conclusions. Patients with HCM who receive an ICD as primary prevention solely due 
to a positive family history of SCD involving a ﬁrst-degree relative experienced rates of 
aborted sudden death that were comparable to that observed in patients who received 
an ICD because of other risk factors. Compared to natural history studies of HCM that 
indicate an annual mortality of ~1%, a positive family history of SCD confers a two-fold 
increase in sudden death risk.
920-102 Usefulness of Arterial Stiffness Evaluation for the 
Differential Diagnosis of Hypertrophic Cardiomyopathy 
From Hypertensive Heart Disease
Takeshi Maruo, Manabu Taniguchi, Satoru Sakuragi, Katsumasa Miyaji, Satoshi Nagase, 
Kazufumi Nakamura, Kengo Fukushima Kusano, Tohru Ohe, Okayama University 
Graduate School of Medicine, Okayama, Japan
Background: Echocardiography is crucial for the diagnosis of hypertrophic 
cardiomyopathy (HCM), while it is difﬁcult to differentiate HCM from hypertensive heart 
disease (HHD). We sought to identify whether ultrasonic evaluation of arterial stiffness 
could used to noninvasively make the differentiation.
Methods: Ninety-eight subjects (74 normal, 12 HCM and 12 HHD) underwent 
echocardiography to assess left ventricular structure and function. Using a wall-tracking 
ultrasound system (E-tracking, Aloka, Japan), stiffness of carotid artery was estimated by 
the pressure-independent stiffness index, β.
Results: Left ventricular mass (276±69 and 248±52 vs. 132±30 g; p<0.001 and p<0.001) 
was higher and early diastolic mitral annulus velocity (5.3±1.2 and 6.0±1.4 vs. 10.8±3.2 
cm/sec; p<0.001 and p<0.001) was lower in HCM and HHD than those in normal, while 
there were no signiﬁcant differences between HCM and HHD (p=0.269 and p=0.228). β in 
HCM showed no signiﬁcant differences from that in normal (6.5±1.1 vs. 6.8±1.8, p=0.638), 
while β in HHD was signiﬁcantly higher than those in HCM and normal (11.7±2.9, p<0.001 
and p<0.001). The optimal cutoff point of β for the diagnosis of HCM was <9, and there 
was 93% sensitivity and 93% speciﬁcity.
Conclusions: Development of left ventricular hypertrophy and concomitant diastolic 
dysfunction showed no signiﬁcant differences between HCM and HHD. Stiffness of 
carotid artery, as the parameter of end-organ damage, in HHD worsened as compared 
with that in HCM. Ultrasonic evaluation of arterial stiffness was useful for the noninvasive 
diagnosis of HCM.
920-103 Abnormal Blood Pressure Response to Exercise and 
Oxygen Consumption in Patients With Hypertrophic 
Cardiomyopathy
Quirino Ciampi, Sandro Betocchi, Maria Angela Losi, Raffaella Lombardi, Bruno Villari, 
Massimo Chiariello, Federico II University, Naples, Italy, Fatebenefratelli Hospital, 
Benevento, Italy
Background. Abnormal blood pressure response to exercise is a risk factor for sudden 
death in patients with hypertrophic cardiomyopathy (HCM). We assess the hemodynamics 
of exercise by ambulatory radionuclide monitoring of LV function (VEST)and exercise 
tolerance by oxygen consumption.
Methods. 21 HCM patients exercised on a treadmill during VEST monitoring and, a few 
days apart, underwent cardiopulmonary exercise test. VEST data were averaged for 1 min 
and analyzed at baseline, at 3 min, and at peak exercise. Stroke volume, cardiac output 
and systemic vascular resistance were expressed as % of baseline. Exercise tolerance 
was assessed as maximal oxygen consumption as % of predicted value (according to 
age, sex, and height).
Results. In 8 HCM patients (38%) with exercise-induced abnormal blood pressure 
response, ejection fraction (-30±16% vs -16±20%, p=.032) and stroke volume fell 
more than in 13 patients with normal blood pressure response (Figure). Cardiac output 
increased less in the former patients (51±41 vs 96±47%, p=.002). Systemic vascular 
resistance decreased similarly irrespective of blood pressure response. Percent of 
maximal predicted oxygen consumption was lower in HCM patients with abnormal blood 
pressure response (Figure).
Conclusions. Exercise-induced abnormal blood pressure response was associated with 
exercise-induced LV systolic dysfunction and impairment in oxygen consumption. This 
may cause hemodynamic instability, associated with a high risk of sudden cardiac death.
 
920-104 Clinical Signiﬁcance of Penetrating Intra-myocardial 
Coronary Arteries in Patients With Apical Hypertrophic 
Cardiomyopathy
Geu-Ru Hong, Hyoung-jun Kim, Hyun-su Cho, Jong-sun Son, Jong-sun Park, Dong-gu 
Shin, Young-jo Kim, Bong-sup Shim, Yeungnam University Hospital, Daegu, South Korea
Background: Patients with apical hypertrophic cardiomyopathy commonly have chest 
pain despite of angiographically normal coronary arteries. But the cause of myocardial 
ischemia has not been clearly deﬁned in these patients. Transthoracic Doppler 
echocardiography with a high frequency transducer can visualize blood ﬂow velocities of 
the penetrating intra-myocardial coronary artery(PICA). However there are no data about 
the pathogenesis of ischemia and role of PICA ﬂows in patients with apical hypertrophic 
cardiomyopathy. The purpose of this study is to evaluate the clinical role of PICA ﬂow in 
patients with apical hypertrophic cardiomyopathy. 
Methods: The study included 42 patients(27 men; mean age 55±13 years) with apical 
hypertrophic cardiomyopathy. Patients were divided into 2 groups according to evidence of 
ischemia: group A comprised 24(57%) patients who have typical chest pain or reversible 
perfusion defects at MIBI scan ; and group B comprised 18(43%) patients who did not 
have chest pain or evidence of ischemia at MIBI scan. In all patients coronary angiogram 
were normal. After routine transthoracic echocardiography, PICA ﬂow were measured 
using high frequency transducer. Real time myocardial contrast echocardiography(MCE) 
was performed and following parameters were compared each group(A;myocardial blood 
volume and β;mean microbubble velocity). 
Results: In group A maximal apical wall thickness(26.5±7mm vs. 19.9±6mm, p<0.01) 
and average PICA ﬂow width(1.7±0.5mm vs. 1.3±0.3mm, p<0.05) were signiﬁcantly 
increased than those of group B. In group A peak diastolic velocity (PDV ; 38.3±19.7cm/s 
vs. 29.7±12.6cm/s, p<0.05) and time velocity integral(TVI ; 15.2±4.4cm vs. 11.3±3.6cm, 
p<0.05) of PICA ﬂow were signiﬁcantly increased. A(1.86±1.16dB vs. 2.15±1.45dB, p<0.05) 
and β value(0.31±0.12 vs. 0.48±0.14, p<0.05) were signiﬁcantly decreased in group A. 
Conclusions: PICA ﬂow may play an important role to elucidate the pathogenesis of 
ischemia in patients with apical hypertrophic cardiomyopathy.
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921-105 Human Menstrual Blood Derived Stem Cell Has a High 
Cardiomyogenic Potential; Possible New Cell Source 
for Cardiac Stem Cell Therapy
Nobuhiro Nishiyama, Shunichiro Miyoshi, Naoko Hida, Yukinori Ikegami, Yoko Hagiwara, 
Kazuma Okamoto, Taro Uyama, Kenji Miyado, Ryohei Yozu, Michiie Sakamoto, Satoshi 
Ogawa, Akihiro Umezawa, Keio Univsersity School of Medicine, Tokyo, Japan, National 
Research Institute for Child Health and Development, Tokyo, Japan
Background: Mesenchymal stem cell (MSC) transplantation slightly improved impaired 
cardiac function but the improvement was insufﬁcient, because the main effect of MSC 
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was attributable to neovascularization, not to cardiomyogenesis (CM). To achieve CM, 
MSC source with a high rate of CM would be required, because not all MSC have the 
potential for CM. Previously, we have reported extremely higher CM potential of human 
endometrial MSC (E-MSC) than marrow-derived MSC. We hypothesized that E-MSC can 
be obtained from menstrual blood (MB) sample, which can be collected more easily.
Method and Results: The MBs were collected from 6 women. Grossly 103 stem cells can 
be obtained from single MB and we named them for E-DOM (EnDOMetrial stem cell). The 
E-DOM reaches senescence or stop cell growth after the average population doubling at 
31. RT-PCR revealed that the E-DOM expressed cardiac speciﬁc gene of hANP, hBNP, Nkx 
2.5, GATA4, before a cardiomyogenic induction. The E-DOM was expanded in number by 
a conventional primary culture then used for the experiment. On day 5 of cardiomyogenic 
induction, about a half of the E-DOM contracted spontaneously, rhythmically, and 
synchronously, suggesting the presence of electrical communication between the E-
DOM (6/6). The membrane potential measured by the standard microelectrode revealed 
that action potential of E-DOM had the cardiac pacemaker potential and cardiomyocyte-
speciﬁc sustained plateau. The E-DOM-derived cardiomyocytes stained positive for cardiac 
troponin-I (with striation pattern) and connexin 43 (diffuse dot-like staining at the margin 
of the cells) by the immunocytochemical method. One week after the cardiomyogenic 
induction, cardiac troponin-I-posivitive E-DOM accounted for 24.6 +- 2.1%.
Conclusion: For the ﬁrst time we showed quite high CM potential of E-DOM. The 
estimated number of the E-DOM-derived cardiomyocytes, which can be obtained from 
single MB was about 5x1011. E-DOM has an extremely higher cardiomyogenic potential 
than human marrow-derived MSC. E-DOM can be repeatedly, painlessly, and easily 
obtained from a younger and large population than marrow-derived MSC.
921-106 Intracoronary Human Bone Marrow Stem Cell 
Transplantation in Acute Myocardial Infarction and 
Ventricular Arrhythmias
Adolfo Villa, Pedro L. Sanchez, J Alberto San Roman, Ricardo Sanz, María Eugenia 
Fernandez, Carolina Hernandez, Francisco Fernández-Avilés, ICICOR. Hospital Clínico 
de Valladolid, Valladolid, Spain
Background: Intracoronary administration of bone marrow progenitors represents 
to date the optimum method for stem cell therapy in patients with acute myocardial 
infarction. Clinical studies have shown an improvement in cardiac function and thus far, 
the incidence of ventricular arrhythmia has never been documented.
Methods and Results: We have intracoronary transplanted 98.0±53.9*106 autologous 
bone marrow mononuclear cells in 69 patients 10.2±4.3 days following ST elevated 
myocardial infarction. Three patients showed delayed episodes of ventricular arrhythmias 
and were implanted with an internal deﬁbrillator. Two presented sustained monomorphic 
ventricular tachycardia within 2 to 3 days following cell transplantation and one patient 
presented several asymptomatic non-sustained ventricular tachycardia on ECG-Holter 
studies 1 month after cell transfer and induction of syncopal sustained ventricular 
tachycardia through programmed ventricular stimulation.
Conclusions: The incidence of malignant ventricular arrhythmias found in our study force 
us to remain extremely cautious until future larger controlled trials allow us to distinguish 
the risk attributable to cell replacement therapy and the myocardial arrhythmogenic 
substrate.
921-107 Human Umbilical Cord Blood Derived Mesenchymal 
Stem Cell Has A Powerful Cardiomyogenic Potential In 
Vitro; A Novel Cell Source For Cardiac Stem Cell Based 
Therapy
Nobuhiro Nishiyama, Shunichiro Miyoshi, Kazuma Okamoto, Naoko Hida, Yukinori 
Ikegami, Taro Uyama, Kenji Miyado, Ryohei Yozu, Michiie Sakamoto, Satoshi Ogawa, 
Akihiro Umezawa, Keio Univsersity School of Medicine, Tokyo, Japan, National 
Research Institute for Child Health and Development, Tokyo, Japan
Background: Both number and function of a stem cell was depressed in a senile patient 
at severe coronary risk factors. Therefore marrow-derived stem cell, obtained from such 
patients, may not work well, as was shown in the experimental animal. Based on this, 
we tested cardiomyogenic (CM) potential of the human umbilical cord blood derived 
mesenchymal stem cell (UCB-MSC), which is a candidate for new stem cell source, since 
it can be obtained from younger population and is a biomaterial for conventional medical 
therapy.
Methods and Results: UCB-MSC was obtained from human. UCB-MSC reaches 
senescence or stop cell growth after average population doubling at 34, therefore in 
some experiments, we prolong the life span of UCB-MSC by infecting them with retrovirus 
encoding teromerase. There was no difference in phenotype between gene-mediated 
UCB-MSC and paternal UCB-MSC. Flow cytometric analysis revealed that UCB-MSC 
was negative for CD34, CD45, CD90, CD177, and CD133 and positive for CD29, CD44, 
and CD59. Before cardiomyogenic induction, mRNA of hANP, hBNP, Nkx 2.5, GATA4 
were detected by the RT-PCR in the UCB-MSC. On day 5 of cardiomyogenic induction, 
almost all of the UCB-MSC contracted rhythmically and synchronously, suggesting the 
presence of electrical communication between the UCB-MSC. The cardiomyocyte-
speciﬁc action potential (AP) with long plateau (AP duration 186 +- 12 msec) was 
recorded with a glass microelectrode. The pacemaker potential was not observed (0/18). 
The fractional shortening of the UCB-MSC was 6.5 +- 0.7 % (n=20). The UCB-MSC-
derived cardiomyocytes stained positive for cardiac troponin-I (clear striation +) and 
connexin 43 (diffuse dot-like staining at the margin of the cell) by the immunocytochemical 
method. One week after the cardiomyogenic induction, cardiac troponin-I positive UCB-
MSC accounted for 45%.
Conclusion: About a half of the human UCB-MSC was successfully transdifferentiated 
to the cardiomyocyte in vitro. We can utilize our own UCB-MSC to repair our own heart 
disease in future, if it has been stored at the birth time. UCB-MSC is superior to marrow-
derived stem cell, because it can be obtained from younger people and has higher 
cardiomyogenic potential.
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941-47 Endogenous Stem Cell Circulation in Patients Suffering 
from Idiopathic Dilated Cardiomyopathy
Hans D. Theiss, Robert David, Markus G. Engelmann, Andreas S. Barth, Michael 
Nabauer, Bruno Reichart, Gerhard Steinbeck, Wolfgang M. Franz, University of Munich, 
Munich, Germany
Background: After myocardial infarction cytokines like SDF-1, which stimulate bone 
marrow, are increased in peripheral blood. Thereafter, CD34+ cell populations are 
released from bone marrow and circulate to ischemic heart tissue attracted by homing 
factors such as HGF, SDF-1 and SCF. Yet, it remains unknown, whether this mechanism 
of regeneration also applies to patients suffering from DCM.
Methods: We determined Cytokines in peripheral blood using ELISA and measured 
circulating CD34+ cell populations (CD34+CD133+, CD34+CD31+, CD34+CXCR-4+) by 
ﬂow cytometry in DCM patients (n=25, NYHA 2.8), ICM patients (n=10, NYHA 2.8) and 
controls (n=10). We analyzed explanted DCM (n=5) and normal hearts (n=5) for the 
expression of several homing factors (HGF, SCF, SDF-1, HIF-1, P-Selectin and VCAM) by 
quantitative real-time PCR and ELISA.
Results: SDF-1 level was signiﬁcantly elevated in peripheral blood of DCM and ICM 
patients showing the same NYHA-class. However, in DCM patients circulating CD34+ 
cell populations were signiﬁcantly increased in comparison to ICM patients and controls. 
mRNA of HGF and SCF related to GAPDH was signiﬁcantly downregulated in DCM 
hearts compared to controls.
Conclusions: A possible explanation for increased circulating CD34+ cells may be a 
deteriorated homing of stem cells in DCM hearts which have a downregulated level of 
myocardial homing factors. These ﬁndings may open a new insight to the pathology and 
treatment of idiopathic dilated cardiomyopathy.
941-48 Bone Marrow-derived Stem Cell Interactions With Adult 
Cardiomyocytes and Skeletal Myoblasts in Culture
Richard Baffour, Rajbabu Pakala, David Hellinga, Michael Joner, Petros Okubagzi, 
Stephen E. Epstein, Ron Waksman, Washigton Hospital Center, Washington, DC, CV 
Path Org, Gaithersburg, MD
Background: Secreted growth factors and cell-to-cell contact are both required for 
eliciting some cellular functions. We tested the hypothesis that bone marrow-derived 
growth factors together with cell-to-cell contact between bone marrow-derived stem 
cells and cardiomyocytes or myoblasts promote proliferation of cardiomyocytes and 
myoblasts.
Methods: Human cardiomyocytes or skeletal myoblasts were cultured for 4 days in 
the presence of low (50%) and high (200%) concentrations of bone marrow-derived 
mononuclear cell or stromal cell conditioned medium (MNCs-CM or MSCs-CM). The 
concentrations of VEGF, MCP-1, HGF and IGF-1, in the respective conditioned medium, 
were assayed by ELISA. Stem cells were mixed with cardiomyocytes or skeletal myoblasts 
at a 1:1 ratio and cultured for 7 days to assess proliferation of these cells. In parallel 
experiments, equal numbers of various cell types were cultured alone.
Results: Concentrations of VEGF, MCP-1, and HGF increased in MNCs-CM and 
MSCs-CM compared with the controls. Both high and low concentrations of MNCs-CM 
tested had no effect on the proliferation of cardiomyocytes. Low concentration of MSCs-
CM increased cardiomyocytes proliferation by 60% (p<0.05) and high concentration of 
MSCs-CM inhibited cardiomyocytes proliferation by ≈41%. Low concentrations of MNCs-
CM or MSCs-CM induced proliferation of myoblasts by ≈90% and ≈47%, whereas high 
concentrations of MNCs-CM had no effect and MSCs-CM inhibited myoblasts proliferation 
by ≈45%. Contact coculture of cardiomyocytes and mononuclear cells had no effect on 
their proliferation, rather there was ≈25% inhibition. Cardiomyocytes or stromal cells 
cultured alone proliferated ≈48% and ≈54%, but in coculture they proliferated at ≈91% 
suggesting an additive effect. Myoblasts in contact coculture with mononuclear or stromal 
cells showed no effect.
Conclusion: These results suggest that the mechanism by which stromal cells are 
beneﬁcial in cardiac therapy may be by their paracrine effect. Mononuclear cells do 
not induce proliferation of cardiomyocytes. Stem cells secreted growth factors induced 
proliferation of myoblasts, which is not inﬂuenced by cell-cell contact.
941-49 Allogeneic and Syngenic Multipotent Adult Progenitor 
Cell Delivery Improves Cardiac Function After 
Myocardial Infarct
Wouter Van’t Hof, Niladri Mal, Zoran Popovic, Farhad Forudi, Robert Deans, Marc Steven 
Penn, Cleveland Clinic Foundation, Cleveland, OH, Athersys, Inc., Cleveland, OH
Background: Multipotent adult progenitor cells (MAPC), a population of bone marrow 
derived progenitor cells are attractive candidates for cell therapy in patients with 
myocardial infarction or heart failure. However, issues related to the host immune 
response to transplanted MAPC in syngenic and allogenic setting is poorly understood. 
We hypothesized that delivery of MAPC in the peri-infarct period could lead to improved 
cardiac function.
Methods: MAPC were isolated from the bone marrow of Sprague-Dawley and Lewis rats 
and stably transfected by using a lentiviral backbone encoding green ﬂuorescent protein 
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(GFP) / beta-galactosidase (�-Gal) reporter gene respectively. In-vitro differentiation 
assays conﬁrmed that the GFP/ �-Gal tagged MAPCs had retained the potential 
for tri-lineage differentiation. Myocardial infarction was induced in Lewis rats by direct 
LAD ligation. Each rat received Sprague-Dawley or Lewis MAPC immediately after 
LAD ligation by directly injecting into the infarct border zone (5 injections of 2,000,000 
cells per injection). Echocardiography was performed to determine if the delivery 
of MAPC to the myocardium at the time of MI led to improvement in cardiac function. 
Immunohistochemistry was performed to identify MAPC (GFP/ �-Gal positive cells) 
within the infarct zone 6 weeks after MI.
Results: At 6 weeks post-MI, we observed a signiﬁcant increase in shortening fraction 
in those animals that received direct injection of Lewis-MAPC or SD-MAPC compared to 
control 21.1 ± 3.3% (n=9) vs. 15.6 ± 4.4 (n=10) vs. 12.9 ± 6.2% (n=5). We identiﬁed MAPC 
in the infarct border zone of all MAPC transplanted rats at 6 weeks post-MI. Conclusion: 
These data show that MAPC delivery to acutely infarcted myocardium may offer signiﬁcant 
beneﬁt and MAPC are capable of surviving in the myocardial tissue in both syngenic and 
allogeneic strategy without inducing a signiﬁcant increase in inﬂammation or rejection.
941-50 Isolation and Characterization Cardiac Progenitor Cells 
from Human Adipose Tissue Derived Stem Cells Using 
Lentiviral Cardiac Promoter/Marker Expression
Xiaowen Bai, Christoph Nabzdyk, Kai Pinkernell, Michael Schwarzer, Susanne 
Freyberg, Jakob Reiser, Edward Newsome, Eckhard Alt, Tulane University, New 
Orleans, LA
Background: Myocardial infarction (MI) leads to a loss in cardiac tissue. Autologous stem 
cells transplantation is a new approach for cardiac repair. In this study we investigated 
the potential of human adipose-derived stem cells (ADSCs) to differentiate into 
cardiomyocytes.
Methods: ADSCs (passage1-5) were cultured under standard conditions in alpha-MEM 
including 20% FBS and transduced with two different lentiviral vectors simultaneously: 1) 
a lentiviral vector expressing eGFP controlled by the Nkx2.5 promoter, and 2) a lentiviral 
vector expressing DsRed2 controlled by the myosin light chain-2v promoter (MLC-2v). 
Nkx2.5-eGFP and MLC-2v-DsRed2 dual positive cells were isolated using FACS. Their 
proliferative potential was measured by cell cycle analysis using ﬂow cytometry and Ki67 
immunoﬂuorescence staining. Gene expression levels and cytoskeleton were investigated 
using RT-PCR and transmission electron microscopy (TEM) seperately.
Results: Between 0.3-2% among regular ADSCs expressed eGFP and DsRed2 
simultaneously. Sorted dual positive cells expressed cardiomyocyte-speciﬁc mRNAs 
including: Nkx2.5, MLC-2v, GATA-4, Troponin I and L-type calcium channel alpha-1c 
subunit (Cav1.2). The skeletal markers MyoD, Myogenin could not be detected. The 
function of Cav1.2 was analyzed through Fura-2 calcium imaging. 15-20% of the dual 
positive cells showed L-type calcium channel speciﬁc response. TEM studies showed 
formation of aligned microﬁlaments in 3-5% of the dual positive cells whereas no 
microﬁlaments could be observed in regular ADSCs. 73% of passage four dual positive 
cells expressed Ki67 and 18% of the cells were in the S-phase of the cell cycle.
Conclusions: Our preliminary studies indicate the existence of cardiac progenitor 
cells among regular ADSCs. They can be isolated from ADSCs in vitro using lentiviral 
ﬂuorescent indicators under the control of Nkx2.5 and MLC-2v promoters. These cells 
show an early cardiac gene expression proﬁle, have proliferative capacity and form 
aligned microﬁlaments. Autologous human cardiac progenitor cells from ADSCs therefore 
can be a source for cell based therapy of MI.
941-51 Human Umbilical Cord Mononuclear Cells (HUCMC) 
Improve Left Ventricular Function and Reduce Infarct 
Size in a Mouse Model of Myocardial Infarction
Joanna J. Wykrzykowska, Alicia Mecklai, Tamer Malik, Guifu Wu, Jian Li, Frank Sellke, 
Roger J. Laham, Beth Israel Deaconess Medical Center, Boston, MA
Background: Irreversible myocyte loss after myocardial infarction leads to left ventricular 
dysfunction and heart failure. Cell-based therapy has been proposed as a novel approach 
to promote cardiac regeneration. This study investigated the therapeutic potential of 
human umbilical cord mononuclear cell (HUCMC) transplantation in a mouse model of 
myocardial infarction.
Methods: Human umbilical cord blood was collected and mononuclear cells were 
extracted using Ficoll gradient centrifugation. Eleven mice were used for the study. 
Myocardial infarct was created by ligation of the left anterior descending (LAD) coronary 
artery. Immediately after LAD ligation, animals were randomized to receive 1x107 
HUCMCs or cell-free medium, injected into the infarcted zone at three sites. One week 
later, hemodynamic assessment was performed using left heart catheterization (Millar 
catheter). Animals were sacriﬁced and hearts were excised for histologic analysis (H&E, 
Trichrome, CD31, CD68, F4/80, and anti-human HLA-B-C) and infarct quantiﬁcation 
(Tetrazolium, TTC staining).
Results: Treated mice (HUCMC) showed higher left ventricular systolic pressures (73.2 ± 
8.6 mmHg vs. 53.1 ± 8.4 mmHg, p=0.004), increased isometric contractility (+dP/dt: 2.1 ± 
0.3 mmHg/s x 103 vs. 1.4 ± 0.3 mmHg/s x 103, p=0.006) and improved isometric relaxation 
(-dP/dt: -1.8 ± 0.6 mmHg/s x 103 vs. -1.0 ± 0.3 mmHg/s x 103, p=0.02). Tetrazolium staining 
showed reduction in infarction size in treated animals (18.9 ± 9.7 % vs. 45.1 ± 13.0 % of 
myocardium, p=0.009). Trichrome and H&E staining revealed no signiﬁcant difference in 
the degree of inﬂammation between groups.
Conclusions: Conclusions: Transplantation of human umbilical cord blood mononuclear 
cells into infarcted myocardium resulted in improved contractility, hemodynamics, and a 
signiﬁcant reduction in infarct size without any evidence of increased inﬂammation at one 
week after treatment.
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942-52 Ventricular Structure and Function in Hypertensive 
Patients with Heart Failure and a Normal Ejection 
Fraction: The Cardiovascular Health Study (CHS)
Mathew S. Maurer, Burkhoff Daniel, Linda P. Fried, Gottdiener John, Donald L. King, 
Dalane Kitzman, Columbia University, New York, NY
Background: Among the elderly with heart failure most have a normal ejection fraction 
(HFNEF) and hypertension. The pathophysiology is usually attributed to left ventricular 
(LV) diastolic dysfunction with normal or reduced LV diastolic chamber size despite 
greater than normal ﬁlling pressures, resulting in reduced stroke volume (SV) and cardiac 
output (CO). However, population-based data regarding LV size and function in HFNEF 
has been lacking.
Methods: CHS is a large population study in 5,888 participants age >65. Demographic/
clinical characteristics and LV structure and function by 2D-echo were compared between 
healthy subjects (Healthy), subjects with hypertension but not heart failure (HTN) and 
subjects with hypertension and heart failure with normal ejection fraction (HFNEF).
Results: Subjects with HFNEF were older, more obese, and more often African American 
than Healthy and HTN subjects, and had a higher prevalence of diabetes, coronary heart 
disease, anemia and chronic renal disease (lower GFR and higher cystatin-C) than 
subjects with HTN alone. The LV size and LV function are shown in the table below. 
Parameter Healthy(n=499) HTN without Heart Failure (n=2184) HTN with HFNEF (n=166)
LVIDd (cm) 4.8±0.6 4.9±0.6 5.2±0.8*†
EDV (ml) 109±29 109±28 124±38*†
LV mass (gms) 134±37 153±48* 176±64*†
EDV/Mass Ratio 0.83±0.16 0.74±0.17* 0.75±0.22*
Stroke volume (ml) 78±20 80±20 89±25*†
Cardiac Output 
(L/min) 4.8±1.3 5.1±1.4* 6.0±2.0*†
* p values < 0.05 versus healthy controls, † p < 0.05 versus HTN without heart failure by 
ANOVA with Bonferroni post hoc correction for multiple comparisons.
Conclusions:HFNEF subjects have increased LV diastolic chamber size, SV and CO 
compared to Healthy and HTN subjects with an increased prevalence of multiple co-
morbidities that can cause volume overload and a high cardiac output. These data suggest 
that extra-cardiac factors leading to volume overload and high basal output contribute to 
the pathophysiology of HFNEF in the elderly
942-53 Effect of Angiotension Receptor Blockade Alone or in 
Combination with Spironolactone on Left Ventricular 
Systolic and Diastolic Function in Chronic Heart Failure
Mei Wang, Tian Wang, Anna Chan, Leata Yeung, Gabriel Yip, Jeffrey Fung, YY Lam, 
CM Yu, John E. Sanderson, Chinese University of Hong Kong, Hong Kong, Hong Kong, 
Keele University Medical School, Stoke-on-Trent, United Kingdom
Background: It is not know if adding spironolactone to an angiotensin receptor blocker in 
heart failure provides additional beneﬁt to LV systolic and diastolic function. Therefore, we 
have investigated the effect of candesartan alone or in combination with spironolactone 
on left ventricular systolic and diastolic function in patients with chronic heart failure.
Methods: Heart failure patients with left ventricular ejection fraction< 40% on standard 
therapy including ACEI for more than six months were randomly assigned to replace ACEI 
with candesartan 8 mg daily plus spironolactone 25 mg daily (C+S group) or candesartan 
8 mg daily alone (C group) for one year. Standard 2D Doppler echocardiography including 
tissue Doppler imaging (TDI) of systolic and diastolic function and cyclic variation of 
integrated backscatter (CVIB) were done at baseline, 6 and 12 months. Quality of Life 
(Qol) score and 6 min. corridor walk were also measured.
Results: 48 pts (23 C+S group and 25 C group) who had comparable demographic data 
at baseline were studied. The C+S group showed signiﬁcant reduction in diastolic ﬁlling 
pressure assessed by TDI (E/Em) from baseline (33.14±0.05) to 12 months (19.94±0.02; 
p<0.01) and a trend towards increased myocardial peak early diastolic annular velocity 
(3.1±0.4 to 3.7±0.4 cm/s) and decreased LA dimensions. LVEF and peak systolic annular 
velocity also signiﬁcantly increased ( both p<0.05). LVmass index was signiﬁcantly 
decreased (236 ±22 to 179±11 g/M2, p<0.05) and CVIB was signiﬁcantly increased with 
C+S therapy (10.3±0.7 to 13.8±1.0 dB, p<0.05). With C alone there was an improvement 
in LVEF but no other signiﬁcant changes although Qol score and 6 min. walk were all 
signiﬁcantly improved in both groups.
Conclusions: Combination therapy with candesartan and spironolactone in chronic heart 
failure signiﬁcantly improves left ventricular systolic and diastolic function with reduction 
of LV mass and ﬁbrosis over 1 year.
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942-54 Exaggerated Alterations in Left ventricular Relaxation 
and Chamber Compliance With Pressure Loading in a 
Model of Left Ventricular Dysfunction With Preserved 
Ejection Fraction
Steven J. Lavine, Jeremy A. Lavine, University of Florida/Jacksonville, Jacksonville, FL
Background: Decompensated heart failure with preserved LV ejection fraction is often 
accompanied by hypertensive episodes. Using a model of LV dysfunction with preserved 
LV ejection fraction (LVDPEF), we previously demonstrated that acute arterial pressure 
elevation resulted in markedly elevated LV diastolic pressures. We hypothesized that the 
marked increase in LV ﬁlling pressures was due to both a prolongation of LV relaxation 
and increased chamber stiffness.
Methods: To test this hypothesis, we utilized a coronary microsphere embolization model 
of LVDPEF (LV ejection fraction>50%) in 10 dogs characterized by increased LV mass 
and interstitial ﬁbrosis. Prior to embolization and with LVDPEF, each dog was paced 10 
beats above baseline and high ﬁdelity LV pressures, echo LV volumes, and transmitral 
Doppler were obtained prior to and following pressure loading with methoxamine.
Results: At baseline, for each LV minimal pressure or end diastolic pressure increase 
of 1 mm Hg, LV systolic pressure increased 17.5+3.7 mm Hg and 8.4+2.8 mm Hg. Tau 
prolonged (26+3 to 32+4 msec (p<0.05), and the chamber stiffness constant increased 
(0.37+0.17 to 0.53+0.27mm Hg/cc, P<0.05). With LVDPEF, for each LV minimal pressure 
or end diastolic pressure increase of 1 mm Hg, LV systolic pressure increased 8.4+1.7 
mm Hg and 5.2+1.8 mm Hg, (p<0.001 vs baseline). Tau prolonged (38+5 to 74+6 msec), 
and the chamber stiffness constant increased (0.50+0.28 to 1.11+0.60 mm Hg/cc) as 
compared to baseline LVDPEF and with peak pressure at baseline, p<0.0001. With 
pressure loading, effective arterial elastance increased from 2.4+0.6 to 3.1+0.9 mm 
Hg/cc at baseline as opposed to 2.3+0.6 to 4.3+0.8 mm Hg/cc with pressure loading in 
LVDNPEF, P<0.001 vs baseline. Pressure volume plots revealed a 7.7 mm Hg pressure 
upper displacement of the peak pressure plot (p<0.001) with no diastolic overlap as 
compared to a 3 mm Hg displacement with normal LV function.
Conclusions: We conclude that pressure loading with LVDPEF results in an exaggerated 
LV ﬁlling pressure response. This response is characterized by an abnormal increase in 
arterial elastance, marked prolonged relaxation, and marked increased chamber stiffness.
942-55 Nesiritide Improves Left Ventricular Compliance in 
Diastolic Heart Failure
Thomas J. Wang, Khurram Shahzad, Sidney Glasofer, Mark D. Handschumacher, 
Kenneth D. Bloch, Dali Fan, Michael H. Picard, Marc J. Semigran, Massachusetts 
General Hospital, Boston, MA
Background: Current diastolic HF (DHF) therapies do not address the LV ﬁlling 
abnormalities believed to underlie this disorder. Preclinical studies suggest that natriuretic 
peptides may improve diastolic function. We studied the hemodynamic and myocardial 
effects of Nesiritide (BNP) in pts with severe DHF. Methods: 12 pts (mean age±SD 
68±12, 6F) with NYHA class 3/4 HF, LVEF>45%, and no signiﬁcant CAD underwent 
micromanometer left and right heart catheterization followed by a 24-hr BNP infusion. 
Hemodynamic and echo parameters were taken at baseline and after 24 hrs of BNP 
titrated to SBP 100 mmHg. The diastolic pressure-volume (P-V) relation was constructed 
with baseline catheterization and echo data (n=8), to test the hypothesis that BNP 
improved LV compliance (reﬂected by a lower end-diastolic P-V point). Results: BNP 
(mean dose 0.02±0.01 mcg/kg/min) decreased ﬁlling pressures and stroke volume 
(Table). There was a decrease in transmitral Doppler deceleration time, but no signiﬁcant 
change in tissue Doppler indices. The 24 hr end-diastolic PCWP was lower than predicted 
by the diastolic P-V relation (median ∆ -5 mmHg, range 0 to -13; signed-rank p= 0.015). A 
representative tracing is shown in the Figure. No symptomatic hypotension occurred, and 
creatinine was unchanged. Conclusion: BNP reduced LV preload in pts with severe DHF, 
attributable in part to improved LV compliance. Possible mechanisms include a direct 
myocardial effect of BNP or a reduction in diastolic interventricular dependence. 
942-56 Increased Left Ventricular Myocardial Stiffness Is the 
Major Cause of Recurrent Decompensation in Patients 
With Diastolic Heart Failure
Satoshi Watanabe, Junya Shite, Hideyuki Takaoka, Toshiro Shinke, Yusuke Imuro, 
Hiromasa Otake, Daisuke Matsumoto, Daisuke Ogasawara, Takahiro Sawada, Oscar Luis 
Paredes, Mitsuhiro Yokoyama, Kobe University Graduate School of Medicine, Kobe, Japan
Background: Patients with diastolic heart failure (DHF) have signiﬁcant abnormalities in 
passive myocardial stiffness which may be a major cause of recurrent decompensation.
Methods: We applied a simpliﬁed echocardiographic and hemodynamic method to 
assess myocardial stiffness in 18 patients with initial decompensated heart failure with 
normal ejection fraction. At steady state after optimal therapy, plasma BNP level was 
measured. Then, we measured the changes of left ventricular (LV) dimensions and wall 
thickness by two-dimensional echocardiography with simultaneous measurement of LV 
pressure during repeated intravenous injection of phenylephrine hydrochloride to alter 
the loading conditions. Diastolic myocardial stiffness constant (Km) was calculated with 
stress-strain analysis and other echocardiographic and hemodynamic variables were 
obtained. After mid-term follow-up (mean 25 months), patients were divided into two 
groups according to the evidence of recurrent congestive heart failure (Re-CHF). Event 
free of Re-CHF was estimated with the Kaplan-Meier method, and the differences were 
evaluated by the log-rank test.
Results: Twelve patients had no evidence of Re-CHF and 6 had Re-CHF. Plasma BNP 
level was higher in Re-CHF group than in No Re-CHF group (mean 308 vs. 113 pg/ml, 
P=0.04). Multivariable analysis revealed that Km was the most signiﬁcant and independent 
hemodynamic factor affecting the plasma BNP level. Km was higher in Re-CHF group 
than in No Re-CHF group (3.91±1.09 vs. 2.94±0.44, P=0.01). Km of ≥3.40 showed 67% of 
sensitivity and 83% of speciﬁcity for Re-CHF. Re-CHF event free was 74.1% in the Low-
Km (<3.40) group and 20.8% in the High-Km (≥3.40) group (P=0.008). By Cox regression 
analysis, Km was identiﬁed as only signiﬁcant and independent factor affecting Re-
CHF (hazard ratio: 7.47, conﬁdence interval: 1.04-53.9, P=0.046), although pulmonary 
capillary wedge pressure, end-diastolic pressure, end-diastolic stress or time constant of 
LV isovolumic-pressure decline were not signiﬁcant factors.
Conclusions: Increased myocardial stiffness is strongly related to the plasma BNP level, 
and is the major cause of recurrent decompensated heart failure.
942-57 Hypertensive Heart Failure with a Normal Ejection 
Fraction: Abnormal Load or Abnormal Ventricular 
Function?
Mathew S. Maurer, Rose Cohen, Raja Wajahat, Inna Titova, Donald L. King, Columbia 
University, New York, NY
Background: Ventricular performance is best characterized using the end diastolic and 
end systolic pressure volume relations together. Stroke work (SW), the area between 
these two curves, quantiﬁes performance and elucidates mechanisms of abnormalities. 
Patients with hypertension and heart failure with normal ejection fraction (HTN+HFNEF) 
have a wide range of LV volumes and slopes of ESPVR suggesting sub-groups may exist. 
Methods: Controls (n=66) and HTN+HFNEF (n=40) underwent freehand 3-D echo to 
measure LV volumes and mass. End-systolic elastance (Ees), an index of contractility 
and arterial elastance (Ea), an index of afterload were measured with non-invasive 
techniques. SW was calculated as SBP*Stroke volume (SV) and indexed to LV mass. 
Results: End diastolic volume (EDV) was increased in HTN+HFNEF subjects compared 
to controls (116±30 vs. 105±28ml, p<0.05) even though HTN+HFNEF were older (73±11 
vs. 55±20 years,p<0.001), female (70% vs. 52%) and shorter (164±11 vs. 169±9 cm, 
p<0.05). Among HTN+HFNEF with an enlarged EDV (n=25), SV, CO and SW were all 
increased (p<0.05) compared to control while indexed SW did not differ from control. 
Among HTN+HFNEF with a small EDV (n=15), SV and CO was lower while Ea and Ees 
were increased compared to control but SW did not differ from control. 
Parameter Normal Controls Hypertensive HFNEF with Decreased EDV
Hypertensive HFNEF with 
IncreasedEDV
EDV (ml) 105±28 85±8* 134±22*
Stroke Volume (ml) 59±15 47±5* 72±13*
Cardiac Output (L/min) 4.0±1.0 3.3±0.5* 4.7±1.1*
Stroke Work (mm Hg*ml) 7245±1957 7065±1080 10434±2852*
Stroke Work/mass (mm 
Hg*ml/gms) 53±9 48±8 56±13
Ea (mm Hg/ml) 2.1±0.8 2.9±0.6* 1.8±0.3*
Ees(sb) (mm Hg/ml) 2.6±1.1 3.5±0.8* 2.2±0.4*
* p < 0.05 compared with Normals
Conclusions: SW and SW indexed to LV mass is normal or increased in HTN+HFNEF 
suggesting that abnormal loading conditions (increased preload volume and arterial 
stiffening) are mechnanism of of hypertensive HFNEF.
942-58 Improvement of Diastolic Function Is related to Left 
Ventricular Reverse Remodeling After Mid-Term 
Cardiac Resynchronization Therapy
Annemieke H. Jansen, Jan Melle van Dantzig, Frank Bracke, Albert Meijer, Kathinka H. 
Peels, Catharina Hospital, Eindhoven, The Netherlands
Background: Reports on diastolic function (DF) after cardiac resynchronisation therapy 
(CRT) are not always unequivocal. We investigated the effect of CRT on diastolic 
function.
Method: Echo-Doppler was performed before and 6 month after implantation in 42 pts 
(30 men, age 70 ± 9 yrs) with ischemic (24 pts) and idiopathic (18 pts) cardiomyopathy.
Baseline QRS duration was 174 ± 29 ms, LV-ejection fraction 20 ± 7 % and LV end 
diastolic volume 229 ± 82 ml. LV reverse remodeling (LV-RR) was deﬁned as a LV end 
systolic volume decrease of > 15%.
According to the standard recommendations, DF was classiﬁed by E/A ratio, deceleration 
time and parameters of left atrial pressure into four categories (see table).
Results: LV-RR was observed in 24 pts (57%). Baseline DF was similar for pts. with or 
without LV-RR (1.7± 0.9 vs 2.1 ± 1.1; p=0.15). However, after 6 month CRT, signiﬁcant 
improvement in DF was only observed in the patients with LV-RR (mean DF from 1.7± 
0.9 to 1.0± 0.9; p=0.0025) in contrast to the patients without LV-RR (mean DF from 2.1 ± 
1.1 to 2.3 ± 0.9; p=0.57) 
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Diastolic Function LV reverse remodelingPre 6mth CRT
No LV reverse remodeling
Pre 6mth CRT
Class 0 4 % 25 % 5 % 0 %
Class I 50 % 63 % 34 % 28 %
Class II 21 % 0 % 5 % 16 %
Class III 25 % 12 % 56 % 56 %
Conclusion: Improvement of diastolic function after CRT is associated with systolic LV 
reverse remodeling.
942-59 Myocardial Fibrosis in Patients with Hypertrophic 
Cardiomyopathy: Correlation with Echocardiographic 
Measurements of Diastolic Dysfunction and Genetic 
Perturbations
Lori A. Blauwet, Michael J. Ackerman, William D. Edwards, Josepha Binder, Steve R. 
Ommen, Mayo Clinic College of Medicine, Rochester, MN
Background: Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically 
heterogenous disorder of the cardiac sarcomere resulting in myocyte hypertrophy, myocyte 
disarray, and myocardial ﬁbrosis. We explored whether the amount of myocardial ﬁbrosis in HCM 
correlated with measures of diastolic dysfunction, presence of HCM-associated myoﬁlament 
mutations, and polymorphisms in the renin-angiotensin-aldosterone system (RAAS).
Methods: Surgical specimens from patients with HCM who underwent septal myectomy 
at the Mayo Clinic between 2001 and 2004 were examined. Digital image analysis was 
used to quantify the amount of ﬁbrosis in each representative microscopic section. Pre-
myectomy echocardiographic data obtained from each patient was reviewed. Patients 
were genotyped for myoﬁlament-HCM using PCR, DHPLC, and direct DNA sequencing 
of the 8 most common HCM-susceptibility, myoﬁlament-encoding genes. RAAS 
polymorphism genotypes were similarly established.
Results: Sixty-three patients (32 men, 31 women) between the ages of 12 and 76 years 
were included in the study. The amount of myocardial ﬁbrosis in each case ranged from 
3 - 45% (mean 17%). Univariate analysis revealed a borderline association between the 
amount of ﬁbrosis and septal wall thickness (p=0.05) as well as mitral annulus e’ velocity 
(p=0.05). Multivariate regression showed that the e’ velocity retained borderline relation 
to ﬁbrosis (p=0.05). There was no correlation between the extent of ﬁbrosis and 13 other 
echo-derived measurements of systolic and diastolic function. There was no association 
between the amount of ﬁbrosis and myoﬁlament-HCM status. Notably, signiﬁcantly 
more ﬁbrosis was observed in patients with > 1 C-encoding allele in CYP11B2-encoded 
aldolase synthase (p = 0.03).
Conclusions: In this study, there was a trend between both the degree of hypertrophy and 
the mitral annulus e’ velocity and the amount of myocardial ﬁbrosis present in the surgical 
myectomy specimen. Our data also suggest that genetic variation in RAAS, rather than 
primary HCM-causing mutations, may contribute to the development of myocardial ﬁbrosis.
942-60 Left Atrial Volume Mirrors Diastolic Dysfunction Caused 
by Hypertension Alone
Norihisa Toh, Hideaki Kanzaki, Satoshi Nakatani, Jun Tanaka, Mahoto Kato, Takahiro 
Ohara, Tetsuhiro Yamano, Tsuyoshi Yoshimuta, Haruhiko Abe, Takuya Hasegawa, 
Jiyoong Kim, Masafumi Kitakaze, National Cardiovascular Center, Osaka, Japan
Background: Left atrial volume index (LAVi) is a marker of the severity of diastolic 
dysfunction of the left ventricle (LV). LV hypertrophy in hypertension causes diastolic 
dysfunction because of the decreased LV compliance. Our objective was to assess the 
hypothesis that hypertension is the independent factor of left atrial (LA) enlargement.
Methods: We studied 261 subjects: 128 with hypertension alone (systolic blood pressure 
>140 mmHg or treated) and 133 age-matched subjects. The echocardiographic Doppler 
study was performed and a serum BNP level was measured. LA dimension from the 
parasternal view, LA short-axis and LA long-axis from the apical four-chamber view were 
measured. LA volume was calculated using the biplane modiﬁed Simpson’s method. LV 
mass index (LVMi) was determined with the Devereux’s method. E/Ea was obtained as a 
marker of diastolic ﬁlling pressure.
Results: Hypertension enlarged LA to both the long and short axial direction (LA 
dimension 36 ± 5 to 39 ± 4 mm, LA short-axis 34 ± 5 to 39 ± 6 mm, LA long-axis 52 ± 
5 to 56 ± 6 mm, all P<0.01). LAVi was increased from 25 ± 8 to 32 ± 8 ml/m2 (P<0.01). 
Hypertension also increased LVMi (89 ± 23 to 102 ± 22 g/m2, P<0.01), E/Ea (8.0 ± 2.3 to 
9.2 ± 2.7, P<0.01), and BNP (23 ± 15 to 28 ± 25 pg/ml, P<0.05). LAVi was correlated with 
LVMi (r = 0.32, P<0.01), E/Ea (r = 0.25, P<0.01), and BNP (r = 0.30, P<0.01).
Conclusions: LA enlargement was caused by hypertension alone. Increased E/Ea and BNP 
suggested that the enlargement was associated with elevated diastolic ﬁlling pressure.
942-89 The Utility of Aminoterminal Pro-B-type Natriuretic 
Peptide for the Detection of Preclinical Systolic and 
Diastolic Dysfunction in the Community
Walter P. Abhayaratna, Niels G. Becker, Thomas H. Marwick, Wayne T. Smith, Katrina 
Abhayaratna, Alice Kam, Pearle Taverner, Ian M. Jeffery, Darryl A. McGill, National 
Centre for Epidemiology and Population Health , Australian National University, 
Canberra, Australia, The Canberra Hospital, Canberra, Australia
Background: There is scant data regarding methods to identify subjects in the community 
with preclinical left ventricular (LV) systolic and diastolic dysfunction.
Methods: A population-based sample of 1229 older adults underwent examination with 
transthoracic echocardiography and measurement of circulating aminoterminal pro-B-
type natriuretic peptide (N-BNP) levels. Heart failure status was ascertained according 
to past history and clinical examination. The ability of N-BNP to detect preclinical LV 
ejection fraction (EF) <=40% and/or moderate-severe LVDD in the entire cohort and a 
high-risk subset (hypertension, diabetes and/or coronary disease) was assessed using 
age/gender-speciﬁc optimal discriminatory levels.
Results: Of the 1150 subjects (48.9% men; mean age 69.2 years) without prior history 
or current clinical evidence of congestive heart failure, 71 subjects (6.2%; 95%CI 4.9-
7.7%) had evidence of preclinical advanced LV dysfunction, of which 6 (0.5%; 95%CI 
0.2-1.1%) had an EF<=40%.The overall N-BNP performance to identify subjects with 
preclinical EF<=40% and/or moderate-severe DD was good (AUC 0.83-0.91). However, 
given the relatively low prevalence of preclinical disease and characteristics of the test, 
41-74% of subjects identiﬁed with N-BNP screening would have “negative” conﬁrmatory 
echocardiograms at the expense of missing 9-22% of cases (Table).
Conclusions: N-BNP performs well as a marker of LV dysfunction, but its screening utility 
is limited in the community.
N-BNP Detection of Preclinical EF<=40% and/or Moderate-Severe LVDD
Preclinical
Disease 
(%)
N-BNP cut-off 
(pg/mL)
AUC
(95%CI)
Sens
(%)
Spec
(%) LR+
Echo 
F/U
(%)
Negative 
Echo
(%)
Missed 
Disease
(%)
All Men: 60-74 years 4.6 173
0.91
(0.84-
0.98)
85 88 7.2 15.2 74.2 15.0
High-risk Men: 60-74 years 6.4 173
0.87
(0.78-
0.97)
80 85 5.4 19.1 73.3 20.0
All Men: 75-86 years 8.6 388
0.83
(0.75-
0.92)
91 78 4.1 28.1 72.2 9.1
High-risk Men: 75-86 years 12.7 467
0.85
(0.76-
0.94)
78 79 4.1 28.1 65.0 22.2
All Women: 60-74 years 4.6 271
0.89
(0.81-
0.98)
81 92 9.5 11.9 68.5 19.0
High-risk Women: 60-74 
years 5.9 271
0.90
(0.81-
0.99)
86 92 10.6 13.1 61.3 14.3
All Women : 75-86 years 14.3 375
0.90
(0.81-
0.99)
84 88 6.9 22.6 46.7 15.8
High-risk Women : 75-86 
years 17.7 403
0.90
(0.78-
0.99)
87 87 6.7 25.9 40.9 13.3
 
942-90 Characteristics, Treatments and Outcomes of Patients 
Hospitalized for Heart Failure with Preserved Systolic 
Function: A Report from OPTIMIZE-HF
Wendy Gattis Stough, Gregg C. Fonarow, William T. Abraham, Nancy M. Albert, Mihai 
Gheorghiade, Barry Greenberg, Christopher M. O’Connor, Jie-Lena Sun, Clyde Yancy, 
James B. Young, OPTIMIZE-HF Investigators and Hospitals, Duke University Medical 
Center, Durham, NC
Introduction: Few clinical trial data exist regarding the management of pts hospitalized 
with symptoms of heart failure (HF) and preserved systolic function (PSF). The differences 
in characteristics, treatments, and outcomes between HF pts with PSF and those with 
reduced SF have not been well studied.
Methods: OPTIMIZE-HF is a national registry/performance improvement program for 
pts hospitalized with HF. 60-90 day post-discharge follow-up data were prospectively 
collected in a pre-speciﬁed 10% sample.
Results: Of 48,612 pts hospitalized at 259 hospitals with a primary diagnosis of HF, 
40,757 had LV function assessed and 21,149 (51.2%) had EF>40% or a qualitatively 
normal EF. Pts with PSF were more likely to be female, white, and have a non-ischemic 
etiology. These pts were less likely to be treated with ACEI, BB, or digoxin. When 
compared to pts with reduced SF, net weight loss (-2.5 vs -2.8 kg) and median length of 
stay (4.0 vs 4.0 days) were similar, but the risk of in-hospital mortality was less (2.9% vs 
3.9%, P<.0001). During 60-90 day f/u, pts with PSF (n=2,397) had similar mortality risk 
(7.9% vs 8.4%, P=.52) and re-hosp rates (29% vs 30%, P=.59).
Conclusions: Data from OPTIMIZE-HF reveal a high prevalence of HF with PSF. These 
pts have similar mortality risk and equally high rates of re-hosp to pts with reduced SF. 
Despite this risk, data are lacking on therapeutic strategies to reduce this risk. Research 
is urgently needed to identify effective agents to reduce the mortality and hosp risk in pts 
with HF and PSF.
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Table 1: Patient Characteristics and Treatments
Characteristics at Admission / 
Discharge Medication Usage
Patients with 
LVSD
(n = 20,118)
Patients with No 
LVSD
(n = 21,149)
P value
Age mean (years) 70.3 75.0 <.0001
Sex (% Men) 61 38 <.0001
African American (%) 21 15 <.0001
Ischemic Etiology (%) 54 38 <.0001
SBP on admission (mm Hg) 135.2 148.9 <.0001
BNP on admission, mean (pg/mL) 1,627 974 <.0001
Mean LVEF (%) 24.3 54.7 <.0001
Discharge use of
ACEI (%)
Beta-Blocker (%)
ARB (%)
Digoxin (%)
Adosterone antag (%)
62
73
11
38
18
48
60
13
19
8
<.0001
<.0001
<.0001
<.0001
<.0001
 
942-91 Improved LV Relaxation Measured by Tissue Doppler 2 
Years After Gastric Bypass Surgery
Divya Kapoor, Kimberly Morely, Zachary Williams, Robert C. Pendleton, Michael Strong, 
Frank Yanowitz, Erick Avelar, Ted Adams, Steven Hunt, Sheldon E. Litwin, University of 
Utah, Salt Lake City, UT
Background: Obesity is associated with an increased risk of heart failure. Tissue Doppler 
(TD) measurements of left ventricular (LV) contraction and relaxation are reduced in 
obesity.
Methods: We studied 400 severely obese patients 2 years after randomization to nonsurgical 
therapy (NonSurg) or roux en Y gastric bypass surgery (GBS). Echocardiograms, exercise 
tests (80% of max heart rate) and lab testing were performed. TD velocities of the medial 
mitral annulus were measured in early (E’) and late diastole (A’).
Results: The 2 groups were similar at baseline (age, gender, BMI, comorbidities). At 
2 year follow up, the GBS patients had lower BMI and systolic blood pressure (SBP), 
and increased exercise duration (ExDur; Table, * p < 0.05 vs. NonSurg). Serum glucose 
and HOMA (insulin resistance index) also decreased. E’ was signiﬁcantly higher in the 
patients who had GBS than those who did not, indicating improved myocardial relaxation 
rate. A’ velocity was lower in the GBS subjects, suggesting less forceful atrial ejection. E‘ 
correlated most strongly with SBP (r = 0.30, p < 0.001). ExDur correlated highly with BMI 
(r = -0.57, p < 0.001) and HOMA (r = 0.53, p < 0.001) and moderately with the ratio of E’ 
to A’ (r = 0.30, p < 0.001)
Conclusion: Marked weight loss following Roux en Y GBS is accompanied by a 
signiﬁcant increase in E’ velocity and a decrease in A’ velocities measured by TD. These 
data provide direct evidence that GBS may be associated with long-term favorable effects 
on myocardial function.
Tissue Doppler velocities after Gastric Bypass Surgery
BMI (kg/m^2) SBP (mmHg) ExDur (s) E’ (cm/s) A’ (cm/s)
NonSurg (2 yrs) 43+8 125+19 969+368 9.2+2.3 11.1+2.6
GBS 2 (yrs) 31+7* 116+18* 1365+293* 10.3+2.6* 10.1+2.1*
942-92 Brain Natriuretic Peptide and Systolic or Isolated 
Diastolic Heart Failure in the Community
Francesca Bursi, Margaret M. Redﬁeld, Susan A. Weston, Steven J. Jacobsen, Serguei 
Pakhomov, Vuyisile T. Nkomo, Ryan A. Meverden, Veronique L. Roger, Mayo Clinic 
College of Medicine, Rochester, MN
Background Brain natriuretic peptide (BNP) helps distinguish heart failure (HF) from 
other causes of dyspnea, but its role in further categorizing HF is unknown. Yet, HF is 
a heterogeneous syndrome where ejection fraction (EF) can be preserved and diastolic 
dysfunction (DD) predominant.
Purpose To examine the distribution of BNP in systolic (EF<50%) and isolated DD 
(EF≥50% and DD) among pts with HF in the community.
Methods All in- and out-pts with HF in Olmsted County (n=401) were identiﬁed via 
electronic medical records and enrolled prospectively. EF and DD were measured by 
echo-Doppler and BNP by the Shionoria® assay.
Results Echo and BNP were assessed at a median (25th-75th percentile) of 2 (1-6) and 
4 (2-9) days of diagnosis. Median BNP was higher among pts with reduced EF (45% of 
cohort), than among pts with preserved EF (median 407 (207.5-720.0) pg/dL and 199.5 
(83.7-357.3) pg/dL, respectively; p<0.001). By ROC curve, the AUC was 0.71 (0.65-0.77), 
indicating marginal power to discriminate between HF with normal or reduced EF. Among 
pts with isolated DD (42% of cohort), median BNP was 168 (12.3-454.0) pg/dL in mild, 
196 (86-334.5) pg/dL in moderate, and 287 (207-580) pg/dL in severe DD (p for trend 
0.003) with noticeable overlap between categories. (Figure)
Conclusion In the community, among prospectively evaluated pts with HF, BNP is higher 
when EF is reduced. Among pts with preserved EF, while BNP increases with greater 
degrees of DD, the overlap between DD categories limits its diagnostic use.
942-93 Cardiac Troponin T and Brain Natriuretic Peptide in 
Patients with Heart Failure and Preserved Versus 
Depressed Left Ventricular Systolic Function
Ryoji Taniguchi, Yukihito Sato, Takeshi Kimura, Toru Kita, Kyoto University, Kyoto, Japan, 
Hyogo Prefectural Amagasaki Hospital, Hyogo, Japan
Background: Elevated serum concentrations of cardiac troponin T (cTnT) are a highly 
sensitive and speciﬁc marker of myocardial injury. Although approximately 50% of patients 
with CHF have a preserved left ventricular (LV) ejection fraction (EF), the signiﬁcance of 
cTnT measurements in patients with relatively preserved LV systolic function (SF) has 
not been described.
Methods: We retrospectively studied 115 consecutive patients admitted to our hospital 
for evaluation or management of CHF. No patient had suffered from acute coronary 
syndrome. A preserved LVSF was deﬁned as a LVEF >45% at initial presentation. cTnT 
concentrations>0.01 ng/ml were considered abnormal. Major adverse cardiac events 
(MACE) were deﬁned as deaths or re-hospitalisation of the patient for management of 
cardiac decompensation.
Results: Among 115 patients presenting with CHF, 50 had a LVEF >45%. At baseline, the 
mean BNP, the percentages of patients with elevated cTnT concentrations, and the mean 
cTnT were not signiﬁcantly different in patients with preserved versus depressed LVSF. 
The mean BNP were signiﬁcantly higher among patients with elevated cTnT than among 
patients with low cTnT in both the preserved [p <0.005] and the depressed LVSF [p <0.05] 
groups. After a mean follow-up of 29.4±2.0 days, blood samples were obtained. Although 
BNP decreased signiﬁcantly in both groups, the concentrations of cTnT remained 
elevated in 29% of patients with preserved and 27% with depressed LVSF, and the mean 
cTnT concentrations were similar in both groups. As was observed at baseline, the mean 
BNPconcentration was signiﬁcantly higher among patients with high than among patients 
with low cTnT, in both the preserved (p <0.01) and the depressed (p <0.05) LVSF groups.
During follow up, MACE occurred in 5 patients with preserved, versus 14 patients with 
depressed LVSF (ns). The incidence of MACE was signiﬁcantly higher among patients 
with high than among patients with low cTnT, in both the preserved (p <0.05) and the 
depressed (p <0.05) LVSF groups ( the median follow-up periods 17.5 months).
Conclusion: cTnT measurement in patients with relatively not only depressed but also 
preserved LVSF is a highly sensitve and porognosis marker.
942-94 Diastolic Dysfunction and Systemic Sclerosis with 
Normal Left Ventricular Mass
Pareena Bilkoo, Sirtaz Adatya, Peyman Soltani, David Silverman, Naomi Rothﬁeld, 
David W. Hager, University of Connecticut, Farmington, CT
Background: Systemic sclerosis is a connective tissue disease characterized by multi-
organ ﬁbrosis including the myocardium and arterial walls. Our goal was to assess 
exercise hemodynamics and left ventricular mass in patients with scleroderma and 
dyspnea but no evidence for primary pulmonary hypertension.
Methods: 19 patients had a cardiac catheterization, an EKG and an echocardiogram. 
Cardiac output, pulmonary wedge pressure (PCWP), mean arterial and pulmonary 
pressures (MAP, MPAP), heart rate and systemic and pulmonary vascular resistances 
(SVR, PVR) were determined at baseline and with supine isotonic arm exercise. Left 
ventricular hypertrophy and mass were determined by EKG and echocardiography.
Results: All patients had normal coronaries and an ejection fraction ≥ 55%; one had 
hypertension. Exercise induced a modest but signiﬁcant increase in cardiac output and a 
dramatically signiﬁcant increase in MPAP, PCWP and MAP. Neither PVR or SVR decreased. 
All patients had a normal left ventricular mass and no evidence of hypertrophy.
Conclusions: The rise in PCWP with exercise seen in these patients signiﬁes an upward 
shift in the diastolic pressure-volume curve, a hallmark of diastolic dysfunction. The 
inability to lower SVR with exercise reﬂects arterial stiffening so that a small increase in 
ﬂow results in an exaggerated increase in blood pressure. These ﬁndings are not a result 
of increased muscle mass, but are secondary to myocardial and arterial ﬁbrosis and/or 
microvascular ischemia. 
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Exercise Hemodynamics (* p <0.05)
Baseline Exercise
MPAP (mm Hg) 18±5 34±7*
PCWP (mm Hg) 10±4 26±5*
MAP (mmHg) 92±19 136±23*
Heart rate (beats/min) 82±14 119±21*
Cardiac Output (L/min) 5.3±1.5 8.3±2.8*
SVR (dynes-s-cm-5) 1514±539 1376±438
PVR (dynes-s-cm-5) 115±53 94±49
Left Ventricular Mass Index (g/m2) 93.7±32
Age (years) 53±13
 
942-95 Metoprolol Prevents Progression of Diastolic 
Dysfunction in Patients With Asymptomatic Left 
Ventricular Systolic Dysfunction: Observations From 
the REVERT Trial
Theodore J. Kolias, Wilson S. Colucci, Jennifer Sugg, William F. Armstrong, on behalf of 
the REVERT Study Group, University of Michigan, Ann Arbor, MI
Background: We previously demonstrated that the active relaxation component of diastolic 
function, assessed by Doppler-derived -dP/dt, is related to prognosis in patients (pts) with 
heart failure secondary to left ventricular systolic dysfunction (LVSD). In this study, we 
evaluated the effect of extended-release metoprolol succinate (MET) on Doppler-derived 
-dP/dt in a subset of pts enrolled in REVERT, a multicenter trial of the effect of MET on left 
ventricular remodeling in pts with asymptomatic LVSD (NYHA Class I).
Methods: Doppler-derived -dP/dt was obtained during echocardiography performed at 
baseline and at 6 and 12 months in stable NYHA Class I pts with LVEF < 40% and LV 
end-diastolic volume index > 75 ml/m2 who were randomized to placebo vs. MET 50 
mg or 200 mg per day. Pts were included in the substudy if they had at least 2 serial 
measurements of -dP/dt, including a baseline measurement (n=36: age 66 ± 11, 25% 
female, 61% ischemic etiology).
Results: Pts randomized to placebo had signiﬁcant worsening of -dP/dt at 12 months (or 
last observation) compared to MET (p=0.012). The changes in -dP/dt are shown in the 
table (*p<0.05 vs. baseline by Wilcoxon signed rank test; #p<0.05 vs. placebo by Wilcoxon 
rank sum test).
Conclusions: MET prevented worsening of the active relaxation component of diastolic 
function (-dP/dt) that was seen in placebo treated pts over 1 year of therapy. This ﬁnding 
suggests that beta blockade may play an important role in preventing deterioration of 
diastolic function in pts with LVSD.
 
-dP/dt
[baseline]
-dP/dt (mm Hg/s)
[12 mo./last observ.] Change in -dP/dt
Placebo (n=19) 660 ± 123 579 ± 145 -80 ± 143 *
MET (n=17) 553 ± 139 621 ± 146 68 ± 128 #
942-96 Comparative Metabolic Effects of Ramipril and 
Candesartan in the Treatment of Hypertensive Patients
Kwang K. Koh, Michael J. Quon, Seung Hwan Han, Wook-Jin Chung, Gachon Medical 
School, Incheon, South Korea, Diabetes Unit, NIH, Bethesda, MD
Background: Whether angiotension converting enzyme inhibitor combined with 
angiotensin II type 1 receptor blocker would be better than either monotherapy is 
controversial. Therefore, we investigated metabolic responses to these therapies either 
alone or in combination in hypertensive patients.
Methods: This was a randomized, double-blind, placebo-controlled cross-over trial with 
three treatment arms (each 2 months) and two washout periods (each 2 months). Thirty-
four patients were given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 
mg, or candesartan 16 mg and placebo daily during each 2 month treatment period.
Results: Ramipril, combined therapy, or candesartan signiﬁcantly reduced systolic and 
diastolic blood pressure after 2 months administration compared with baseline. All three 
treatment arms signiﬁcantly improved ﬂow-mediated dilator response to hyperemia. 
However, combined therapy signiﬁcantly improved ﬂow-mediated dilation to a greater 
extent than ramipril or candesartan alone (P<0.001 by ANOVA). Ramipril, combined 
therapy, or candesartan signiﬁcantly increased plasma adiponectin levels relative to 
baseline measurements. However, combined therapy signiﬁcantly increased plasma 
adiponectin levels to a greater extent than ramipril or candesartan alone (P=0.020 by 
ANOVA). Interestingly, only combined therapy signiﬁcantly reduced plasma insulin 
levels and increased insulin sensitivity (determined by QUICKI) relative to baseline 
measurements (P=0.001 and 0.002, respectively). Ramipril, combined therapy, or 
candesartan signiﬁcantly increased plasma potassium and renin levels and reduced 
plasma aldosterone levels relative to baseline measurements (all P<0.05) with no 
signiﬁcant differences among the three theapies (by ANOVA). There were signiﬁcant 
correlations between percent changes in adiponectin levels and percent changes in 
insulin (r=-0.358, p=0.038) and QUICKI (r=0.482, p=0.004) following combined therapy.
Conclusions: Ramipril combined with candesartan increases plasma adiponectin levels 
to a greater extent than monotherapy with either drug in hypertensive patients.
942-97 Value of Electrocardiographic Findings in Predicting 
Rest Left Ventricular Diastolic and Systolic Function in 
Community Dwelling Adults
Khawaja A. Ammar, Richard J. Rodeheffer, Mayo Clinic, Rochester, MN
Background: In clinical, imaging laboratory based studies, a normal electrocardiogram 
(ECG) reliably predicts the absence of reduced ejection fraction (EF) with negative 
predictive value (NPV) of 95-96% reported in two separate studies.
Objective: To determine the predictive characteristics of the ECG for reduced EF or DD 
in the population based setting, as it has not been done.
Methods: A random cross-sectional sample of 2,042 Olmsted County residents, age ≥45 
years, were studied by comprehensive Doppler echocardiography for EF assessment and 
diastolic function grade (Normal, Grade I (impaired relaxation), Grade II (pseudonormal), 
and Grade III (restrictive). The Minnesota Code, utilized to classify the 12 lead ECG as 
normal or abnormal, uses normal as a diagnosis of exclusion with any deviation (minor or 
major) from the norm classiﬁed as abnormal.
Results: In the entire population, 6% had EF≤ 50%, 2% had EF≤ 40%, 21 % had Grade 
I DD, 7% had Grade II DD and 1% had Grade III DD. Only 401 subjects had a completely 
normal ECG. The NPV for any (EF≤ 50%) and for moderate-severe (EF≤ 40%) were high 
and comparable to that observed in clinical studies. The NPV for any DD was poor but for 
moderate-severe DD was comparable to that observed for reduced EF.
Conclusions: While the NPV of a normal ECG for moderate-severe impairment in 
systolic or diastolic function are high, its value as a screening test in the population is 
limited by very poor speciﬁcity
.
PPV 
(%)
NPV 
(%)
EF <50 EF <40
Any 
DD
Grade II-III 
DD EF <50
EF 
<40
Any 
DD
Grade II-III 
DD
Any ECG 
Abnormality 6.8 2.4 31.4 11.2 97 99.8 84.2 95.4
 
942-98 Preservation of Diastolic Kinetic Energy: A Marker of 
Ventricular Efﬁciency?
Ann Bolger, Einar Heiberg, Andreas Sigfridsson, John-Peder Escobar Kvitting, Jan 
Engvall, Lars Wigstrom, Matts Karlsson, Bengt Wranne, University of California, San 
Francisco, CA, Linkoping University, Linkoping, Sweden
Background: The kinetic energy (KE) of left ventricular (LV) inﬂow, if it is preserved 
during transit through the ventricle, may diminish the incremental energy that is required 
for ejection of the stroke volume. Changes in inﬂow KE will occur all along the bood 
ﬂow’s complex path through and out of the LV. Quantiﬁcation of the cumulative changes in 
inﬂow KE in vivo has been difﬁcult, as it requires a time-resolved and three dimensional 
method for accurately measuring blood ﬂow velocities. We hypothesized that the amount 
of preserved inﬂow KE would be a marker of overall LV efﬁciency which would differ 
between normal and abnormal subjects. 
Methods: We used phase contrast MRI to quantify three-dimensional LV blood ﬂow 
using particle trace technique. We separated total LV inﬂow into subsets depending on 
whether inﬂow exited the LV within one heart beat (Direct) or remained for more than one 
cardiac cycle (Retained). We measured volume and change in KE for these subsets at 
each diastolic time step in 17 normal subjects (44+14 years), and in a patient with mildly 
dilated, compensated heart failure (51 years, LVEF 34%, LV diastolic diameter 6.1 cm). 
Results: Among normal subjects, 44+11% of total inﬂow was Direct, and followed a 
short, curving route in the basal and mid LV. Retained ﬂow was directed into the more 
lateral and distal LV regions, and was not ejected until a subsequent heart beat. Direct 
ﬂow had a lower change in KE than Retained ﬂow (1.6+1 vs 8.2+1.9 mJ), and accounted 
for 16+8% of the total diastolic KE costs. The energy cost per cc of Direct ﬂow was not 
different for normals versus the patient, but only 11% of inﬂow was Direct in the patient 
and this accounted for 5% of total diastolic KE costs. 
Conclusions: Approximately half of normal LV inﬂow follows a highly efﬁcient route 
through the LV which preserves its KE into the ejection phase. Even in a mildly dilated 
LV, the amount and temporal course of this Direct ﬂow is severely distorted. The analysis 
of LV ﬂow subsets may be a tool for estimating relative efﬁciency between ventricles and 
investigating the effects of medical, surgical and electrophysiologic treatments for heart 
failure.
942-99 Changes in Doppler Tissue Indices Are More Related 
With Improvement of Functional Status in Diastolic 
Heart Failure Than BNP Levels
Duk-Hyun Kang, Mi-Jeong Kim, Kyoung-Min Park, Jong-Min Song, Kee-Jun Choi, Jae-
Kwan Song, Jae-Joong Kim, You-Ho Kim, Asan Medical Center, Seoul, South Korea
Backgrounds: Although B-type natriuretic peptide (BNP) levels and tissue doppler 
derived E/Ea (transmitral E velocity / annular early diastolic velocity) correlate well with 
left ventricular (LV) diastolic pressure, the role of BNP and E/Ea is not known in monitoring 
patients with diastolic heart failure.
Methods: We prospectively studied a total of 42 consecutive patients (age; 63±10 yrs, 
14 men) with diastolic heart failure (DHF). The inclusion criteria were 1) presence of 
exertional dyspnea, 2) preserved LV systolic function, 3) exclusion of pulmonary disease, 
4) documentation of diastolic dysfunction deﬁned as fulﬁlling two of the following three 
echocardiographic variables: LV hypertrophy, abnormal LV ﬁlling pattern, E/Ea > 10, 5) 
BNP > 15 pg/ml. The patients had clinical examination, measurement of E/Ea and BNP 
level at baseline and 1 year after pharmacologic treatment.
Results: There were signiﬁcant correlations between age (r=0.46), LV mass index 
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(r=0.44) BNP (r=0.47) and E/Ea at baseline. After treatment, blood pressure (BP) was 
signiﬁcantly decreased from 162±26/91±15 to 141±16/80±12 mmHg (p < 0.001), New 
York Heart Association (NYHA) functional class from 2.3±0.7 to 1.7±0.6 (p < 0.001), and 
E/Ea from 15.9±5.7 to 13.8±5.1 (p < 0.01). BNP levels showed signiﬁcant correlation with 
NYHA functional class at baseline (r=0.39) and follow-up (r=0.43), but BNP levels did not 
change signiﬁcantly from 213±404 to 208±464 pg/ml following treatment. In the patients 
with improvement in functional status, BP was signiﬁcantly decreased and E/Ea was also 
signiﬁcantly decreased from 15.9±5.2 to 13.8±4.7 (p<0.001), but BNP was not decreased 
signiﬁcantly from 167±351 to 155±423 pg/ml. There were similar extent of BP reductions 
also in the patients without improvement (p < 0.01), but no signiﬁcant changes in E/Ea 
and BNP levels in these patients during follow-up.
Conclusions: In patients with DHF, tissue doppler derived E/Ea is the better index for 
monitoring changes in functional status than BNP.
POSTER SESSION
943 
Diastolic Function in Hypertrophic 
Cardiomyopathy
Sunday, March 12, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
943-100 Extent of Delayed Hyperenhancement in Cardiovascular 
Magnetic Resonance was Associated With Chronic 
Left Ventricular Diastolic Burden in Patients With 
Hypertrophic Cardiomyopathy
Dae-sik Choi, Jong-Won Ha, Byoung-Wook Choi, Eui-Young Choi, Seok-Min Kang, Se-
Joong Rim, Namsik Chung, Yonsei University College of Medicine, Seoul, South Korea
Background: In patients with hypertrophic cardiomyopathy (HCM), delayed 
hyperenhancement (DE) in cardiac MRI is considered to be in concordance with 
myocardial ﬁbrosis. The aim of this study was to determine whether the extent of DE is 
associated with left ventricular (LV) function and functional status in patients with HCM. 
Methods: Thirty-three patients with non-apical HCM (23 male, mean age 53 ± 15, 11 with 
LV outﬂow tract obstruction) had undergone MRI and echocardiography. The extent of DE 
was expressed as DE mass and DE percentage to LV mass. Results: DE was present in 
27 (82%) of 33 patients and its mean mass was 45.9 ± 40.7 g and mean percentage to LV 
mass was 19.9 ± 18.6%. DE mass and percentage was positively correlated with left atrial 
volume index (LAVI, r = 0.407, p = 0.019 and r = 0.419, p = 0.015, respectively). However, 
there was no signiﬁcant correlation between functional class, ejection fraction, mitral 
ﬂow and annular velocities and DE mass and percentage. The associations between 
extent of DE and clinical and echocardiographic parameters were analyzed as tertiles.
In the third tertile, LAVI was signiﬁcantly larger than those of the ﬁrst tertile(Figure). 
Conclusions: The DE was commonly observed in patients with HCM and the extent of 
DE was positively correlated with LAVI, a surrogate marker of chronic diastolic burden. 
These ﬁndings suggest the extent of myocardial scarring may be a pathologic substrate 
for chronic diastolic dysfunction in patients with HCM.
943-101 Diastolic Dysfunction in Hypertrophic Cardiomyopathy 
Is Related to Myocardial Fibrosis as Determined by 
Cardiovascular Magnetic Resonance
Ahmed A. Alsaileek, Uma Valeti, Lucia Alvarez, Jerom Breen, Steve Ommen, James B. 
Seward, Rich A. Nishimura, Mayo Clinic, Rochester, MN
Introduction: Diastolic dysfunction (DD) is common in hypertrophic cardiomyopathy 
(HCM) and is a major determinant of associated heart failure. Left atrial volume index 
(LAVI) is a marker of the chronicity and severity of DD. Cardiac magnetic resonance 
(CMR) can be used to assess the magnitude of myocardial ﬁbrosis. We hypothesized 
that the severity of myocardial ﬁbrosis visualized as myocardial delayed enhancement 
(MDE) using CMR is associated with increased myocardial stiffness, and therefore a 
larger LAVI.
Methods: Cine and gadolinium-enhanced CMR was performed in 100 consecutive HCM 
patients (mean age 53.8 years, 51 % male). LAVI was obtained from CMR images using 
the biplane area-length method. The extent of MDE was quantiﬁed from the short-axis 
contrast-enhanced images. The echo variables (table) were determined within one month 
of CMR.
Results: LAVI measured 58.1 + 22.9 mL/m2. Normal LAVI (<32mL/m2) was present in 
5(5%) pts. MDE was present in 57 pts (57 %) with the median 5.8 g (range 1.1 to 40). 
Increasing LAVI was signiﬁcantly associated with extent of MDE (r=0.17, p<0.0001). On 
multivariate regression analysis, LAVI was independently associated with MDE (p=0.004) 
after adjustment for age, gender and other variables found to be signiﬁcant on univariate 
analysis (Table).
Conclusion: In pts with HCM the severity of LAVI enlargement was independently 
associated with the extent of MDE (ﬁbrosis). These ﬁndings support the role of myocardial 
ﬁbrosis (stiffness) on DD as reﬂected in LAVI
.
Table Univariate and multivariate linear regression analysis of the LAVI
Univariate analysis Multivariate analysis
Variables Estimate p-value Estimate p-value
Age, yrs. -0.065 0.6684 0.237 0.0759
Male sex 3.53 0.4442 -5.947 0.1372
Echo 
Max. LVOT gradient, mmHg 0.129 0.0152 -0.024 0.5998
Mitral regurgitation > mild 14.07 0.0021 5.296 0.1825
CMR 
MDE, g 1.079 <0.0001 0.701 0.0038
LVEDV index, mL/m2 0.662 <0.0001 0.459 <0.0001
LV mass index, g/m2 0.375 <0.0001 0.261 0.0012
LV EF, % -0.015 0.9538 - -
 
943-102 Late Gadolinium Enhanced Cardiovascular Magnetic 
Resonance as a Novel Technique to Predict Major 
Adverse Cardiac Events in Patients With Left 
Ventricular Systolic Dysfunction Without Obstructive 
Coronary Artery Disease
Ippei Shimizu, Nobuo Iguchi, Hiroyuki Watanabe, Jun Umemura, Tetsuya Tobaru, Ryuta 
Asano, Kazuhiko Misu, Masatoshi Nagayama, Etsuko Magosaki, Masaru Aikawa, 
Tatsuya Sumiyoshi, Sakakibara Heart Institue, Fuchu, Japan
Background: The late gadolinium-enhanced-cardiovascular magnetic resonance 
(LGE-CMR) can detect changes in tissue composition; it has a potential to visualize the 
progression of myocardial remodeling. We examined whether LGE-CMR can predict 
the prognosis of the patients with left ventricular systolic dysfunction without obstructive 
coronary artery disease (CAD).
Methods: We studied 44 consecutive patients with left ventricular systolic dysfunction 
without obstructive CAD, whose left ventricular ejection fraction (LVEF) were < 45% 
by transthoracic echocardiography. LGE-CMR study was performed in a 1.5-T system 
(Siemens) . The echocardiographic study was also performed in all patients, and LVEF 
was calculated with the biplane Simpson’s method. We divided the study patients 
into two groups; LGE area that becomes 10% or more of the MRI short axis image 
was classiﬁed into group-A, and LGE area less than 10% was classiﬁed into group-B. 
Coronary arteriography , left ventriculography , MIBG scintigraphy , Holter ECG were 
also performed.
Results: There were 15 cases (34%) in group-A and 29 cases in group-B. Comparing 
these two groups, the incidence of Major Adverse Cardiac Event (MACE) in the group-
A was signiﬁcantly higher than that in the group-B (27% vs 0%, respectively, p<0.05). 
Restrictive pattern of LV inﬂow by
transthoracic echocardiography (45% vs 24%), LVEDVI (ml/m2) (148±97 vs 127±86), 
LVESVI(ml/m2) (106±43 vs 89±63), BNP (pg/ml)(472±920 vs 252±599) were higher in 
the group-A. Mean LVEF (%) was almost the same between the two groups (29.5±21 
vs 31.6±20)).
Conclusions: LGE-CMR is a useful tool to predict MACE in patients with left ventricular 
systolic dysfunction without obstructive CAD.
943-103 Relationship Between Left Atrial and Left Ventricular 
Function in Hypertrophic Cardiomyopathy: A Real Time 
3D Echocardiographic Study
Mi-Seung Shin, Shota Fukuda, Jong-Min Song, Masao Daimon, Hung Tran, James D. 
Thomas, Takahiro Shiota, Gachon Medical School, Incheon, South Korea, Cleveland 
Clinic Foundation, Cleveland, OH
Background: The purpose of this study is to investigate left atrial (LA) and left ventricular 
(LV) volume change and function with real time 3D echocardiography (RT3DE) and 
to investigate association between LA and LV function in patients with hypertrophic 
cardiomyopathy (HC).
Methods: We performed RT3DE on 30 patients with HC (age: 55 ± 16 years) and 15 
healthy controls with a Sonos 7500. LA and LV time-volume curves were obtained from 
RT3DE and the maximal slope of the time-volume curve was expressed as dV/dt. LA active 
emptying fraction (ActEF) and LA expansion index were calculated as shown in ﬁgure.
Results: The maximal LA volume divided by body surface area was increased in HC 
compared with controls (50.8 ± 15.2 vs 30.1 ± 6.8 ml/m2, p < 0.05). LA ActEF and LA 
expansion index were lower in HC than controls (32.1 ± 14.7 and 94.1 ± 58.6 % vs 40.4 ± 
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8.6 and 171.3 ± 52.5 %, p < 0.05). LA ActEF showed a good correlation with atrial ﬁlling 
fraction (r=0.55, p < 0.01) of diastolic transmitral ﬂow, but a negative correlation with the 
pre-contraction LA volume (r= -0.61, p < 0.01) in HC. HC showed decreased LV early 
diastolic dV/dt compared with controls (0.08 ± 0.03 vs 0.15 ± 0.05 ml/msec, p < 0.01). LA 
passive and active emptying dV/dt were correlated with LV early and late diastolic dV/dt, 
respectively (r = 0.44, p = 0.05 and r = 0.45, p = 0.05).
Conclusions: Increased LA volume in HC was related to decreased LA contraction. LA 
passive function was related to LV relaxation while LA active contraction to LV stiffness.
943-104 Left Atrial Emptying Rate: A Marker of Hypertrophy and 
Diastolic Dysfunction in Patients With Hypertrophic 
Cardiomyopathy
Hua Yang, Anna Woo, Michal Jamorski, E. Douglas Wigle, Harry Rakowski, Toronto 
General Hospital, Toronto, ON, Canada
Background: Patients (pts) with hypertrophic cardiomyopathy (HCM) often have 
impaired diastolic function with preserved left ventricular (LV) ejection fraction (LVEF). Left 
atrial (LA) volume is a marker for impaired LV ﬁlling. We used LA emptying rate, derived 
from real time 3-dimensional echo (3D echo), to correlate LV hypertrophy and diastolic 
dysfunction in pts with HCM.
Methods: We studied 16 HCM pts and 14 clinically normal subjects. In 40 % of HCM 
pts LV outﬂow tract rest peak pressure gradients were > 30mmHg. LV basal septal (IVS) 
thickness, isovolumic relaxation time (IVRT), mitral inﬂow E velocity and tissue Doppler 
diastolic peak velocity E’ at the septal (E’-Sep) and lateral (E’-Lat) mitral annulus were 
obtained and LA pressure was calculated (LAP=E/E’-Lat ×1.24+1.9). 3D echo (Sonos 
7500) images of the LV were obtained from the apex. We used 4D LV-Analysis software 
(TomTec) to trace LV and LA endocardial border. LV and LA end-diastolic (LVEDV and 
LAEDV) and end systolic (LVESV and LAESV) volumes (ml) were determined. LA 
emptying rate (LAER) was measured: LAER=(LAESV-LAEDV) / LAESV × 100%.
Results: Two groups had similar age and gender rate. As shown in the table, HCM pts 
had smaller LV, larger LA volume and lower LAER. LAER correlated with IVS (r = - 0.76, p 
< 0.001), E’-Sep (r = 0.66, p < 0.001), and LAP (r = - 0.50, p < 0.01).
Conclusions: HCM pts have decreased LA emptying rate with normal LVEF. This is 
associated with increased hypertrophy, decreased LV diastolic function and higher LV 
ﬁlling pressure.
*p<0.05, †p<0.01.
LVESV LVEDV LVEF LAEDV LAESV LAER IVRT E’-Sep LAP
Controls 36±5 102±16 65±4 15±6 37±12 61±10 79±9 11±3 10±5
HCM 30±7* 87±11† 66±5 39±16† 64±15† 41±13† 96±16† 5±2† 17±7†
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Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
944-105 Rapamycin Therapy Improves Coronary Physiology 
After Cardiac Transplantation
Seema S. Sinha, David P. Lee, Michael X. Pham, Randall H. Vagelos, Sharon A. Hunt, 
Hannah A. Valantine, Alan C. Yeung, William F. Fearon, Stanford University Hospital and 
Clinics, Stanford, CA
Background:Immunosuppressive therapy with rapamycin has been shown to decrease 
anatomic evidence of cardiac allograft vasculopathy (CAV), but its impact on coronary 
physiology is unknown. We investigated the effect of rapamycin on the progression of CAV 
by measuring fractional ﬂow reserve (FFR), coronary ﬂow reserve (CFR), and the index of 
microcirculatory resistance (IMR) at baseline and one year following transplantation.
Methods: Twenty seven patients without coronary artery disease underwent FFR, 
CFR, and IMR measurements at baseline and one year following transplantation using 
a pressure sensor/thermistor-tipped guidewire in the left anterior descending coronary 
artery. FFR, an epicardial speciﬁc index, was deﬁned as the mean distal coronary 
pressure divided by the mean proximal pressure at peak hyperemia. Coronary ﬂow was 
determined using a validated thermodilution technique. CFR, both an epicardial and a 
microvascular index, was deﬁned as hyperemic coronary ﬂow divided by resting ﬂow; 
IMR, a microvascular speciﬁc index, was deﬁned as distal coronary pressure divided by 
ﬂow at peak hyperemia. Maximal hyperemia was achieved using intravenous adenosine 
or intracoronary papaverine. Measurements were compared between two subgroups : the 
treatment arm, which included patients that were on rapamycin for at least three months 
during the ﬁrst year after transplantation (n=9), and the control arm (n=18).
Results: At baseline, there was no signiﬁcant difference in FFR, CFR, or IMR between 
the treatment and control groups. There was a signiﬁcant decline in FFR at one year 
in the control group alone (0.87 ± 0.03 to 0.82 ± 0.03, p=0.009). FFR was signiﬁcantly 
higher in the treatment arm than the control arm at one year (0.89 ± 0.03 vs. 0.82 ± 0.03, 
respectively, p=0.006). CFR and IMR improved signiﬁcantly at one year in the treatment 
group alone, from 2.3 ± 0.5 to 3.8 ± 0.9 and 27.0 ± 7.5 to 17.6 ± 4.9, respectively 
(p<0.03).
Conclusions: Rapamycin therapy improves coronary physiology following cardiac 
transplantation by slowing progression of cardiac allograft vasculopathy, both in the 
epicardial artery and the microvasculature.
944-106 Renal Dysfunction and New Onset Proteinuria 
Predict Mortality in Heart Transplant Patients After 
Replacement of Calcineurin Inhibitors With Sirolimus
Ibrahim S. Abu Romeh, Sevag Demirjian, Emilio D. Poggio, W. H. Wilson Tang, David O. 
Taylor, Randall C. Starling, Nicholas Smedira, Mohamad H. Yamani, Cleveland Clinic 
Foundation, Cleveland, OH
Background:Calcineurin inhibitor (CNI) induced nephrotoxicity is a major cause of renal 
failure in heart transplant recipients. The purpose of this study was to assess the effect 
of deteriorating renal function and new onset proteinuria on mortality in heart transplant 
patients after replacement of CNI with sirolimus.
Methods: 144 heart transplant recipients, mean age 52 yrs, were converted to a sirolimus 
based regimen either for renal rescue (n=73) or vasculopathy (n=71) purposes.
Results: Renal function estimated by 4-var MDRD equation was signiﬁcantly decreased 
at 12 mo post conversion (within subjects) (see table). Presence of baseline proteinuria 
(before conversion), did not accelerate renal deterioration. The latter and other baseline 
variables such as age, duration of transplant and comorbitidies were evaluated using 
MANOVA. 
Before 
Conversion
Baseline GFR 
(ml/min)
3 months GFR 
(ml/min)
6 months GFR 
(ml/min)
12 months GFR 
(ml/min)
No proteinuria 
(n=118) 57 56.3 52.6 51.7
Proteinuria 
(n=26) 43 42.6 37.8 36.5
By 12 mo post conversion 33.6 % of patients had a decrease of GFR more than 25% 
from baseline which was associated with an increased overall mortality (26.7 vs. 6.7 %, 
p=0.0014). Moreover, new onset overt proteinuria (noted in 25/118 {21%} patients) by 
12 mo post conversion was associated with increased mortality (16% vs. 12%, p=0.043). 
The estimated annual decline of GFR among heart transplant patients after conversion to 
sirolimus is ~4.6 ml/min/1.73m2.
Conclusions: Worsening renal function and new onset proteinuria predict mortality in 
heart transplant patients converted to sirolimus based immunosuppression.
944-107 Sirolimus as a Primary Immunosuppressant in 
Calcineurin-Inhibitor induced Nephrotoxicity
Sudhir S. Kushwaha, Zain Khalpey, Robert P. Frantz, Richard J. Rodeheffer, Alfredo L. 
Clavell, Brooks S. Edwards, Mayo Clinic, Rochester, MN
Background: Calcineurin inhibitor (CNI) immunosuppressants are a major cause of renal 
dysfunction in cardiac transplant recipients leading to increased morbidity and mortality. 
The feasability of complete CNI withdrawal and replacement with mTOR inhibitors, such 
as Sirolimus, remains ill-deﬁned. This study evaluates the efﬁcacy and safety of CNI 
withdrawal and substitution with Sirolimus as the primary immunosuppressant, as well 
as assesses the effect on renal function in cardiac transplant recipients with CNI induced 
renal impairment.
Methods: We evaluated the safety of a stepwise CNI withdrawal and substitution with 
Sirolimus in 58 cardiac transplant recipients (Group A) of whom 39 had CNI induced renal 
impairment (Glomerular Filtration Rate (GFR) <50ml/min with no other cause of renal 
failure). A further 24 patients (group B), were retrospective controls maintained on CNI, 
who also met criteria for CNI induced renal impairment. GFR baselines were measured 
using iothalamate clearances before starting Sirolimus and within 4 to 12 months 
following complete CNI withdrawal. Secondary immunosuppressants (azathioprine or 
mycophenolate mofetil, + prednisone) were left unchanged.
Results: GFR signiﬁcantly improved (baseline 42.7+16.7 to 54.6+23.7 ml/min, p<0.001, 
following CNI withdrawal) without exacerbating rejection or compromising cardiac function. 
Furthermore we noted a fall in serum creatinine (baseline 1.97+0.49 to 1.74+0.52 mg/dl, 
p<0.05). In contrast, in control group B, the GFR declined from 40.04+1.86 to 34.63+1.6 
ml/min over the course of one year (P<0.01). ISHLT grades of rejection in both groups 
were unchanged during the trial.
Conclusions: Substitution of CNIs with Sirolimus in cardiac transplant recipients is safe, 
effective and leads to an improvement in renal function, without compromise in cardiac 
function and rejection.
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Standard Therapy
Monday, March 13, 2006, 9:00 a.m.-10:30 a.m.
Georgia World Congress Center, Room B313
9:00 a.m.
809-3 Isosorbide Dinitrate-Hydralazine Decreased Blood 
Pressure in Patients with High But Not Low Blood 
Pressure and Improved Survival Independent of 
Baseline Blood Pressure in African American Heart 
Failure Trial
Inder S. Anand, S. William Tam, W. Tad Archambault, Adeoye Olukotun, Kirkwood F. 
Adams, Manuel Worcel, Michael L. Sabolinski, Anne L. Taylor, Jay N. Cohn, VA Medical 
Center, Minneapolis, MN, University of Minnesota, Minneapolis, MN
Background: Fixed-dose combination of Isosorbide Dinitrate and Hydralazine (ISDN/
HYD) improved outcomes in black patients with heart failure (HF) in the African American 
Heart Failure Trial (A-HeFT). Because the ISDN/HYD combination caused a signiﬁcant 
reduction in systolic blood pressure (SBP) during the study, concerns have been raised 
about its effects in HF patients with low BP.
Methods: The average placebo corrected change in SBP in baseline SBP quartiles 
≤112, >112 and ≤126, >126 and ≤140, and >140 mmHg was calculated. Multivariable 
Cox proportional hazard regression models were used to assess the time to death, and 
time to death or ﬁrst hospitalization for HF separately in patients with baseline SBP above 
and below the median of 126 mmHg.
Results: The median baseline SBP was 126.3±10.2 mmHg. Patients with lower baseline 
SBP had features of worse heart failure with lower EF, higher LV volumes, and greater use 
of diuretics and digoxin. ISDN/HYD caused an average placebo corrected change in SBP 
of -0.48, -3.4, -5.6, and -3.3 mmHg in the four baseline SBP quartiles. In the quartile with 
the lowest SBP, ISDN/HYD and placebo increased mean SBP from baseline by 6.4 and 
6.9 mmHg, respectively. Overall, ISDN/HYD was associated with a 43% risk reduction for 
mortality (HR 0.70, 95% CI, 0.12-0.75, p=0.012), and 37% risk reduction for mortality or 
ﬁrst hospitalization for HF (HR 0.63, 95% CI 0.49-0.81, p<0.001). Multivariable analyses 
that included baseline SBP, change in SBP, and other HF predictors as covariates showed 
that in patients with SBP < 126 mmHg (mean SBP 112 mmHg), mortality decreased by 
45% (HR 0.55, 95% CI 0.32-0.96, p=0.03, n=348) and mortality or ﬁrst hospitalization for 
HF decreased by 36% (HR 0.64, 95% CI 0.47-0.88, p=0.006,). In patients with SBP>126 
mmHg (mean SBP 141 mmHg), ISDN/HYD decreased mortality (HR 0.44, 95% CI 0.144-
1.32, p=0.22, n=318) and decreased mortality or ﬁrst hospitalization for HF by 47% (HR, 
0.53, 95% CI 0.32-0.86 p=0.01).
Conclusions:
These data suggest that ISDN/HYD reduces BP in patients with higher BP but not in 
those with lowest BP. The beneﬁcial effects of ISDN/HYD on outcomes are independent of 
BP and are at least as great in the lower BP group as in the higher BP group.
9:15 a.m.
809-4 Incidence and Predictors of Hyperkalemia in Patients 
With Heart Failure - An Analysis of the Candesartan in 
Heart failure - Assessment of Reduction in Mortality 
and morbidity (CHARM) Program
Akshay S. Desai, Karl Swedberg, John J.V. McMurray, Christopher B. Granger, Salim 
Yusuf, James B. Young, Mark E. Dunlap, Scott D. Solomon, James W. Hainer, Bertil 
Olofsson, Eric L. Michelson, Marc A. Pfeffer, CHARM Investigators, Brigham and 
Women’s Hospital, Boston, MA, Sahlgrenska University Hospital/Ostra, Goteborg, 
Sweden
Background: When used in optimal doses to treat patients with heart failure (HF), 
inhibitors of the renin-angiotensin-aldosterone system (RAAS) improve clinical outcomes, 
but can cause hyperkalemia. We used the CHARM Program to assess the incidence and 
predictors of hyperkalemia in a broad HF population. Methods: CHARM participants were 
randomized to conventional therapy plus candesartan (C) or placebo, titrated as tolerated 
from 4 mg to 32 mg once daily with recommended monitoring of serum potassium. We 
determined the incidence of hyperkalemia prompting study drug discontinuation (HK-DC) 
in CHARM-Overall (n=7599), comparing treatments using Fisher’s Exact test for differences 
in proportions and a Breslow-Day statistic for interactions. Results: C increased the rate 
of HK-DC from 0.6% to 2.4% (difference 1.8%, p < 0.0001). Independent of treatment 
assignment, the risk of HK-DC increased with age ≥ 75 years, diabetes, creatinine ≥ 2.0 
mg/dL, potassium ≥ 5.0 mmol/L, and background use of ACE-inhibitors or spironolactone 
(Table). The beneﬁt of C in reducing cardiovascular death or HF hospitalization (16%, 
p<0.0001) was uniform in these subgroups, as was the incremental risk of HK-DC 
(p for interaction = NS). Conclusion: The risk of HK-DC is increased in HF patients 
with advanced age, baseline hyperkalemia, renal failure, or diabetes and ampliﬁed by 
combined RAAS blockade. Though these groups derive clinical beneﬁt from candesartan, 
they require particularly careful monitoring of serum potassium.
9:30 a.m.
809-5 Candesartan Improves Outcome in Patients With 
Low Ejection Fraction Heart Failure, Irrespective of 
Background Dose of ACE Inhibitor: An Analysis of the 
CHARM-Added Trial
John J. McMurray, James B. Young, Mark E. Dunlap, Christopher B. Granger, James W. 
Hainer, Eric L. Michelson, Steven Earle, Bertil Olofsson, Jan Ostergren, Salim Yusuf, 
Karl Swedberg, Marc A. Pfeffer, for the CHARM committees and investigators, Western 
Inﬁrmary, Glasgow, United Kingdom
Background: To further examine the clinical value of adding an angiotensin receptor 
blocker (ARB) to an ACE inhibitor (ACE-I) in patients with NYHA class II-IV heart 
failure (HF) and a LVEF ≤ 0.40, we examined the effects of randomized treatment in 
the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity 
(CHARM)-Added trial according to background dose of ACE-I.
Methods: The effect of the ARB candesartan (target dose 32 mg QD) compared 
to placebo, added to conventional therapy, on pre-speciﬁed primary and secondary 
outcomes in the 2548 patients randomized in CHARM-Added was analyzed according 
to: i) ACE-I and dose taken at baseline ii) ACE-I dose taken during follow-up and iii) 
combination treatment with ACE-I and beta-blocker at baseline.
Results: The beneﬁt of candesartan (mean dose 24 mg QD) was not modiﬁed by 
dose of background ACEI (with or without concomitant beta-blocker treatment). In all 
patients (n=2548), the candesartan:placebo hazard ratio (HR) for the primary outcome 
of cardiovascular death or HF hospitalization was 0.85 (95% CI 0.75, 0.96). In a pre-
speciﬁed subgroup analysis, in patients taking a guideline “recommended” or higher 
dose of ACE-I at baseline (n=1291), this HR was 0.79 (95% CI 0.67, 0.95; interaction P 
value 0.26). In a post hoc analysis, undertaken at the request of the US Food and Drug 
Administration, 529 patients were taking a “maximum” or higher dose of ACE-I (daily 
dose > enalapril 40 mg, lisinopril 20 mg, captopril 300 mg, ramipril 10 mg, trandolapril 4 
mg, perindopril 16 mg, quinapril 80 mg, fosinopril 40 mg and benazepril 80 mg). In those 
patients, the HR was 0.75 (95% CI 0.57, 0.98; interaction P value 0.29). The beneﬁt of 
candesartan was not modiﬁed in patients taking beta-blockers in addition to a higher dose 
of ACE-I and in patients maintaining a high dose of ACE-I throughout follow-up.
Conclusions: These clinical ﬁndings support the pharmacological evidence that ACE-Is 
and ARBs have distinct mechanisms of action and that their combined use with the ARB 
candesartan improves outcomes in patients with HF and reduced systolic function more 
than an evidence-based or “maximum” dose of ACE-I alone.
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809-6 Effect on New York Heart Association Class and Signs/
Symptoms of Heart Failure of Initiation of Treatment 
for Chronic Heart Failure With Bisoprolol Followed 
by Additional Enalapril Compared to the Opposite 
Sequence: Results of the Randomized CIBIS-III Trial
Ronnie Willenheimer, Dirk J. van Veldhuisen, Bernard Silke, Erland Erdmann, Ferenc 
Follath, Henry Krum, Piotr Ponikowski, Allan Skene, Louis van de Ven, Patricia 
Verkenne, Philippe Lechat, on behalf of the CIBIS-III investigators, Lund University, 
Malmö University Hospital, Malmö, Sweden
Background: In CIBIS III, 1010 patients >=65 years old, with stable, mild/moderate 
chronic heart failure (CHF) and left ventricular ejection fraction <=35%, without 
angiotensin-converting-enzyme inhibitor, betablocker or angiotensin-receptor-blocker 
therapy, were randomized to monotherapy with either bisoprolol (B) (target dose 10 mg 
o.d., n=505) or enalapril (E) (target dose 10 mg b.i.d., n=505) for six months, followed by 
their combination for 6-24 months. The two strategies were similar in terms of mortality, 
hospitalization and safety. We aimed to compare the two strategies with regard to effect 
on New York Heart Association (NYHA) class and signs/symptoms of CHF.
Methods: At baseline, at the end of the monotherapy phase and at study end, we 
assessed NYHA class and absence/presence of 13 signs/symptoms of CHF.
Results: At baseline, in the B-ﬁrst group, 48.5% were in NYHA class II and 51.5% in class 
III. In the E-ﬁrst group 49.5% were in NYHA class II and 50.5% in class III. At the end of the 
monotherapy phase there was a shift towards lower classes in both treatment groups. The 
percentage of patients in class I, II, III and IV was 6.4, 62.0, 30.6 and 1.0, respectively, in 
the B-ﬁrst group versus 6.6, 61.7, 31.7 and 0, respectively, in the E-ﬁrst group (between-
group difference P=NS). At the end of the combination phase, there was a further shift 
towards lower classes in both treatment groups. The percentage of patients in class I, II, 
III and IV was 11.4, 65.9, 20.8 and 1.8, respectively, in the B-ﬁrst group versus 9.3, 65.2, 
25.1 and 0.5, respectively, in the E-ﬁrst group (between-group difference P=NS). In both 
treatment groups, there was a general shift towards lesser signs/symptoms of CHF at the 
end of the monotherapy phase, with further improvement at study end. There were no 
signiﬁcant differences between the two treatment strategies.
Conclusions: No signiﬁcant differences were found in terms of effect on NYHA class or 
signs/symptoms of CHF, between an initial treatment strategy beginning with B followed 
by the addition of E, as compared with the opposite sequence. These ﬁndings further 
support a free choice between B and E as initial therapy for patients with stable, mild to 
moderate, systolic CHF.
10:00 a.m.
809-7 Regression of Left Ventricular Mass and Improvement 
in Left Ventricular Ejection Fraction Following Long-
Term Aldosterone Receptor Antagonist Therapy in 
Patients with Chronic Systolic Heart Failure
Stephen Y. Chen, Gary S. Francis, W. H. Wilson Tang, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Aldosterone receptor antagonists (ARAs) improve survival in patients 
with chronic or post-MI heart failure (HF). In hypertension and post-MI, ARAs can 
attenuate myocardial collagen formation and reduce left ventricular (LV) hypertrophy. 
We hypothesize that long-term ARA therapy may reduce LV mass and improve cardiac 
performance in patients with chronic systolic HF.
Methods: We reviewed 795 consecutive patients who were initiated on ARAs for chronic 
systolic HF between 2001-5. We excluded heart transplant recipients, those without echo 
within one year before and 6-12 months after ARA initiation, or those with incomplete 
clinical data. Patient characteristics and echo indices were determined by chart review. 
Mortality was determined by SSDI.
Results: Mean LV mass was signiﬁcantly reduced with ARA (395 ±130g vs 380 ±134g at 
6 months, p=0.003; vs 375 ±131g at 12 months, p<0.001). Modest improvement in LV end-
diastolic diameter (from 6.3 ±1.1cm to 6.2 ±1.1 at 6-12 months, both p=0.001) as well as 
in LV ejection fraction (LVEF, from 21.7 ±10% to 22.9 ±10% at 6 months, p=0.002, to 24.1 
±11% at 12 months, p<0.001) were also observed. Following ARA initiation, improvement 
of LVEF (48% in a subset of 355 patients with follow-up) was directly associated with 
improved long-term survival (see Figure).
Conclusions: The use of ARAs in chronic systolic HF leads to reversal of left ventricular 
mass, and modest improvement in LV dimension and function can be directly associated 
with improvement in survival.
10:15 a.m.
809-8 Carvedilol Use at Discharge in Patients Hospitalized 
for Heart Failure is Associated with Markedly Improved 
Survival
Gregg C. Fonarow, William T. Abraham, Nancy M. Albert, Wendy Gattis Stough, Mihai 
Gheorghiade, Barry Greenberg, Christopher O’Connor, Jie-Lena Sun, Clyde Yancy, 
James B. Young, OPTIMIZE-HF Investigators and Hospitals, UCLA, Los Angeles, CA
Introduction: Pre-discharge initiation of carvedilol in patients hospitalized for heart failure 
(HF) has previously been shown to improve treatment rates and be safe in the IMPACT-
HF trial. However, whether there is an early survival beneﬁt with carvedilol in this patient 
population is unknown.
Methods: OPTIMIZE-HF is a registry/performance improvement program for pts 
hospitalized with HF. 60-90 day post-discharge follow-up (f/u) data were prospectively 
collected. Cox proportional hazard modeling and propensity matching was used to test 
the association with clinical outcomes of carvedilol use at hospital discharge in eligible 
pts with left ventricular systolic dysfunction (LVSD) versus those eligible but who received 
no β-blocker at discharge.
Results: Mean pt age was 69.5 years with 37% women, 75% Caucasian, 34% ischemic 
etiology. Of the 2,720 pts with LVSD, 2,373 (87.2%) were eligible to receive a β-blocker at 
dc. Carvedilol was prescribed at discharge in 1,146, with 94.2% remaining on Rx during 
f/u. In eligible pts not discharged on any β-blocker (n=361), only 30.4% were started on 
β-blocker Rx post-dc. Carvedilol use was associated with signiﬁcantly decreased risk for 
death, OR 0.46 (0.30-0.72) P=0.006 and death or rehospitalization, OR 0.71 (0.53-0.91) 
P=0.02, without early hazard for recurrent decompensation.
Conclusions: Carvedilol use at hospital discharge is exceptionally well tolerated and 
associated with improved treatment rates and early survival in patients hospitalized with HF.
POSTER SESSION
963 
Myocardial Function/Heart Failure:  
Basic Animal Models
Monday, March 13, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
963-47 Xanthine Oxidase Inhibition Causes Reverse 
Remodeling in Rats with Dilated Cardiomyopathy
Khalid M. Minhas, Roberto M. Saraiva, Karl H. Schuleri, Stephanie Lehrke, Meizi 
Zheng, Anastasios P. Saliaris, Christine Berry, Konrad M. Vandegaer, Dechun Li, 
Joshua M. Hare, The Johns Hopkins University, Baltimore, MD, West Virginia University, 
Morgantown, WV
Background: Increased oxidative stress (OS) is implicated in cardiac remodeling in heart 
failure (HF). As xanthine oxidase (XO) is one of the major sources of OS, we tested if XO 
inhibition could improve cardiac performance and induce reverse remodeling in a model 
of established HF, the spontaneously hypertensive/HF (SHHF) rat.
Methods: We randomized Wistar Kyoto, controls, and SHHF rats to oxypurinol, a XO 
inhibitor (n=4 and n=15, respectively), or placebo (n=3 and n=10, respectively) for 4 
weeks. Echocardiography was performed at baseline and at 4 weeks of treatment. The 
hearts were either ﬁxed in paraformaldehyde for histological studies or snap-frozen for 
molecular studies, including: mRNA expression of fetal gene program (FGP) and XO, XO 
activity, O.2
- production, NADPH-dependent O.2
- production, and the abundance of Ca2+ 
cycling proteins and NADPH oxidase subunits.
Results: Oxypurinol treated SHHF rats improved fractional shortening, smaller LV end 
diastolic and end systolic dimensions, and lower LV mass as compared to non-treated 
rats (P<0.01). The increased cardiac myocytes width in SHHF (P<0.05 vs controls) was 
signiﬁcantly regressed by oxypurinol (P< 0.05). Oxypurinol restored the sodium-calcium 
exchanger upregulation in SHHF towards normal and partially restored the sarcoplasmic 
reticulum Ca+2 ATPase downregulation in SHHF. Elevated atrial natriuretic peptide, B-
type natriuretic peptide, β-myosin heavy chain, and α-skeletal actin, and decreased α-
myosin heavy chain mRNA in SHHF (P<0.05 vs. controls) were restored towards normal 
by oxypurinol (P<0.05 vs. placebo-SHHF). SHHF rats exhibited increased XO mRNA 
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expression and activity, and oxypurinol treatment reduced XO activity and O.2
- production 
towards normal, but not expression. NADPH oxidase activity and protein abundance were 
similar in treated and untreated SHHF rats.
Conclusion: Chronic inhibition of XO derived OS in SHHF rats improved the HF phenotype, 
by reversing maladaptive cardiac remodeling through effects on cardiac structure, function, 
Ca2+ cycling proteins and FGP activation. Thus, these data suggest that XO inhibition has 
the potential to play a therapeutic role in patients with established HF.
963-48 Chronic Therapy with the Acorn Cardiac Support 
Device Normalizes mRNA Gene Expression of Fatty 
Acid Oxidation Regulatory Enzymes in Dogs with Heart 
Failure
Sharad Rastogi, Robert Brewer, Ramesh C. Gupta, Rob Walsh, Hani N. Sabbah, Henry 
Ford Health System, Detroit, MI, Acorn Cardiovascular, Inc., St. Paul, MN
Background: The normal (NL) myocardium relies primarily on fatty acid oxidation 
(FAO) for energy and to a lesser extent on glucose oxidation. In heart failure (HF) key 
enzymes involved in both synthesis and metabolism of fatty acids are down-regulated. 
We previously showed that chronic therapy with the Acorn Cardiac Support Device (CSD) 
reversed LV remodeling and improved ejection fraction (EF) in dogs with HF (LV EF 25%). 
This study tested the hypothesis that reverse LV remodeling with long-term CSD therapy 
leads to normalization of cardiac FAO enzymes. 
Methods: RNA was extracted from LV tissue of 6 CSD-treated HF dogs, 5 sham-operated 
HF dogs and 6 NL dogs. mRNA expression for the FAO enzymes carnitine palmitoyl 
transferase-I (CPT-I), medium (MCAD) and long chain acyl-CoA dehydrogenase (LCAD) 
and the house keeping gene GAPDH were measured using reverse transcriptase 
polymerase chain reaction (RT-PCR). Bands were quantiﬁed in densitometric units (du).
Results: Data are shown in the table. There were no differences in GAPDH among the 3 
groups. Compared to NL, expression for CPT-I, LCAD and MCAD decreased signiﬁcantly 
in HF-sham compared to NL dogs. Therapy with the CSD restored expression of CPT-I, 
LCAD and MCAD to near normal. 
Conclusions: In dogs with HF, mRNA expression of key FAO enzymes is decreased. Up-
regulation of these enzymes following CSD therapy suggests a restoration toward normal 
cardiac metabolism physiology possibly as a result of reverse LV remodeling afforded 
by the CSD.
mRNA expression of FAO regulatory enzymes
NL HF-Sham-Opreted HF+CSD
GAPDH mRNA (du) 277 ± 4 269 ± 7 268 ± 9
CPT-I mRNA (du) 399 ± 36 239 ± 8* 357 ± 16^
MCAD mRNA (du) 34 ± 3 21 ± 1* 28 ± 3^
LCAD mRNA (du) 40 ± 2 26 ± 1* 36 ± 2^
*=p<0.05 vs. NL; ^=p<0.05 vs. HF-Sham-Operated
 
963-49 Myocardial Dysfunction and Neurohumoral Activation 
Without Remodeling in the Left Ventricle of 
Monocrotaline-Induced Pulmonary Hypertensive Rats
André P. Lourenço, Roberto Roncon-Albuquerque, Jr., Carmen Brás-Silva, Bernardo 
Faria, Joris Wieland, Tiago Henriques-Coelho, Jorge Correia-Pinto, Adelino F. Leite-
Moreira, Faculty of Medicine, Porto, Portugal
Background: In the rat experimental model of monocrotaline (MCT)-induced pulmonary 
hypertension (PH) only the right ventricle (RV) endures increased load, but both ventricles 
are exposed to enhanced neuroendocrine stimulation. We hypothesized that in advanced 
PH the molecular/contractile phenotype of the left ventricular (LV) myocardium could be 
disturbed.
Methods: We evaluated in vivo hemodynamics (pressure micromanometers), myocardial 
function (isolated muscle strips), histology (immunohistochemistry) and gene expression 
(Real-Time RT-PCR) of autocrine/paracrine systems in the RV and LV of rats with severe 
PH and heart failure 6 weeks after subcutaneous injection of 60mg/Kg MCT.
Results: The pressure overloaded RV underwent myocardial hypertrophy (P<0.001) and 
ﬁbrosis (P=0.014) as well as increased expression of angiotensin-converting enzyme 
(ACE) by nine-fold (P<0.001), endothelin-1 (ET-1) by three-fold (P=0.019) and type-B 
natriuretic peptide (BNP) by eleven-fold (P<0.001). Despite the presence of a similar 
seven-fold upregulation of ET-1 (P=0.012) with concomitant four-fold overexpression of 
ACE (P=0.007) but without BNP elevation, the non-pressure overloaded LV myocardium 
was neither hypertrophic nor ﬁbrotic. LV indexes of contractility dP/dTmax (P<0.001) and 
relaxation τ (P=0.03) however were abnormal, and LV muscle strips from MCT-treated 
rats in opposition to sham presented negative force-frequency relationships (P=0.003). 
Despite higher ET-1 production, BQ-123 (ETA antagonist) did not alter LV muscle strip 
contractility in MCT-treated rats (P=0.003) distinctly from the negative inotropic effect 
exerted on sham.Conclusions: The LV myocardial molecular/contractile phenotype 
is altered in advanced MCT-induced PH. It undergoes neuroendocrine activation and 
presents contractile dysfunction in the absence of hypertrophy or ﬁbrosis.
963-50 Increased Expression of Phospholemman in Left 
Ventricular Myocardium of Explanted Failed Human 
Hearts and in Dogs with Experimentally-Induced Heart 
Failure
Robert C. Gupta, Janet Ugolino, Priya Goyal, David Demos, Sudhish Mishra, Sharad 
Rastogi, Robert Brewer, Hani N. Sabbah, Henry Ford Health System, Detroit, MI
Background: Phospholemman (PLM), a 72 amino acid transmembrane sarcolemmal 
protein, has recently been recognized as a regulator of the activity of the Na+-K+-ATPase 
and Na+-Ca2+ exchanger in cardiac tissue. PLM overexpression in rat cardiomyocytes 
resulted in contractile abnormalities along with abnormalities in Ca2+ transient. In this study 
we tested the hypothesis that the failing LV myocardium manifests increased expression 
of PLM. Methods: RNA was extracted and homogenate was prepared from LV tissue of 
6 explanted failed human hearts due to ischemic cardiomyopaty (ICM), 6 explanted failed 
human hearts due to idiopathic dilated cardiomyopathy (IDC), and 6 donor (DNR) hearts 
from the patients deemed not suitable for transplantation. In addition, RNA was extracted 
and homogenate prepared from LV tissue of 6 dogs with microembolization-induced 
heart failure and 6 normal (NL) dogs. mRNA expression of PLM was measured using RT-
PCR and protein expression was measured by Western blotting. Bands were quantiﬁed 
in densitometric units (du). Results: Data are shown in the table. mRNA and protein 
expression of PLM increased signiﬁcantly in human ICM and IDC hearts compared to 
human DNR hearts. Similarly, PLM mRNA and protein expression increased signiﬁcantly 
in HF dogs compared to NL dogs. Conclusions: mRNA and protein expression of PLM is 
increased in failed LV myocardium. The is consistent with abnormalities of transmembrane 
Ca2+ homeostasis that is characteristic of the failing LV myocardium.
mRNA and Protein Expression of PLM
Dog LV Tissue Human LV Tissue
NL HF DNR ICM IDC
PLM mRNA (du) 30 ± 2 137 ± 7* 14 ± 1 35 ± 2** 31 ± 3**
PLM Protein (du) 38 ± 2 101 ± 3* 25 ± 2 52 ± 3** 55 ± 3**
*=p<0.05 vs. NL; **=p<0.05 vs. DNR
 
963-51 GLP-1 Depresses Myocardial Contractility, but 
Increases Myocardial Glucose Uptake in Isolated Rat 
Hearts Independent of cAMP or Akt-1 Activation
Siva Bhashyam, Pratik Parikh, Indu G. Poornima, Hakki Bolukoglu, George G. Sokos, 
Carol Stolarski, Laurie Machen, Teresa Hentosz, Richard P. Shannon, Allegheny 
General Hospital, Pittsburgh, PA
Background: GLP-1 increases heart rate and blood pressure in intact rodents through 
CNS stimulatory effects. Whether GLP-1 has direct effects on the myocardium is 
uncertain. mRNA for GLP-1 receptors (GLP-1R) has been found in rodent myocardium 
but whether GLP-1R is coupled to adenylyl cyclase in the heart as in pancreatic islet 
cells is uncertain.
Methods: We studied the direct effects of GLP-1 (7-36) amide (400 pmol/L) on myocardial 
contractility and glucose uptake (MGU) in isolated, isovolumic rat hearts from 31 Sprague 
Dawley rats. Preparations were perfused at constant pressure (70 mmHg) for 60 minutes 
(n=11) with KH buffer containing glucose (5 mM) and insulin (40 µU/ml). In 10 rats, GLP-1 
was added at 30 minutes and in 10 rats GLP-1 was added at 30 minutes after 30 minutes 
perfusion with the GLP-1R antagonist (GLP-1 9-39, 3nM). Hearts were then snap frozen and 
prepared for analysis of Akt-1 activation, AMP kinase activity, and adenylyl cyclase activity.
Results: GLP-1 decreased (p<0.05) contractility without altering heart rate or coronary 
ﬂow or cAMP. GLP-1 increased MGU but did not increase Akt-1 or AMP kinase activity or 
GLUT-4 translocation. Instead, GLP-1 stimulated NO production and GLUT-1 translocation. 
The effects of GLP-1 were abolished by pretreatment with the GLP-1R antagonist.
Conclusions: GLP-1 increases MGU but depresses myocardial contractility through 
myocardial GLP-1Rs. These effects do not involve cAMP or Akt-1 activation, but are 
associated with increased nitric oxide production. 
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964-52 Diabetes-Related Increased Mortality in Women With 
Heart Failure Is Modiﬁed by Non-Potassium-Sparing 
Diuretics
Ali Ahmed, Inmaculada B. Aban, Jiannan Zhao, University of Alabama at Birmingham, 
Birmingham, AL, VA Medical Center, Birmingham, AL
Background Heart failure (HF) and diabetes (DM) are associated with activation renin-
angiotensin system (RAS). DM-related mortality in HF is worse in women. Non-potassium-
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sparing diuretic use is also associated with RAS activation. However, little is know about 
the interaction between DM and diuretic on women with HF. We examined if the effect of 
DM in women with HF was affected by diuretic use.
Methods Of the 7,788 Digitalis Investigation Group trial participants, 2,218 had diabetes. 
Propensity score for diabetes, calculated from a multivariable logistic regression 
model, was used to match 2,056 diabetic and 2,056 non-diabetic patients (post-match 
standardized difference <10% for all 32 covariates). Cox regression analyses were used 
to estimate the effect of diabetes on mortality at a median 37-month follow-up, adjusting 
for 2-way interactions of DM with women and diuretic use.
Results DM and no-DM death rates were respectively 40% and 33% (p<0.0001). 
Diabetes was associated with all-cause mortality (adjusted hazard ratio {AHR}, 1.22; 
95% conﬁdence interval {CI}, 1.09 - 1.37). There was a signiﬁcant three-way interaction 
between gender, diuretic use and diabetes (p=0.008). HR (Bonferroni adjusted 98.75% 
CI) for DM-related death in men and women receiving and not receiving diuretics are 
displayed in Table 1.
Conclusions In a large sample of propensity-matched ambulatory chronic HF patients, 
DM-related increased death in women was modiﬁed by the non-potassium-sparing 
diuretics. 
Table 1. All-Cause Death In Heart Failure Patients With And Without Diabetes (DM), 
By Sex And Diuretic Use
% DM 
Patients 
Dead
(Death / 
Total)
% No-DM Patients 
Dead (Death / Total)
Adjusted 
HR
(98.75% 
Bonferroni
adjusted 
CI)
P for comparing hazards 
of DM with no DM
Women /
no 
diuretic
24%
(16 / 67)
13%
(9 / 72)
2.56
(1.57-4.18) <0.0001
Women / 
diuretic
41%
(200 / 492)
26%
(126 / 477)
1.68
(1.27-2.23) < 0.0001
Men /
no 
diuretic
33%
(91 / 273)
19%
(50 / 266)
1.79
(1.18-2.71) 0.0004
Men / 
diuretic
42%
(518 / 1224)
39%
(485 / 1241)
1.18
(1.00-1.38) 0.011
P for two-way interactions of DM with sex and diuretic use are respectively 0.0044 
and 0.0148
 
964-53 The Association of Insulin Resistance with Global 
and Regional Left Ventricular Dysfunction in Four 
Racioethnic Groups: The Multi-Ethnic Study of 
Atherosclerosis (MESA)
Hossein Bahrami, David A. Bluemke, Boaz D. Rosen, Mary Cushman, João A.C. 
Lima, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, 
Colchester Research Facility, University of Vermont, Colchester, VT
Insulin resistance (IR) is frequently observed in patients with left ventricular dysfunction 
(LVD) and heart failure. Mechanisms by which IR inﬂuences LV function in different ethnic 
groups remain unclear. We assessed the association of IR with global and regional LVD 
in a multi-ethnic cohort.
Methods: Study population includes 6,814 men and women, aged 45-85 years. 
Fasting glucose and insulin were measured at baseline to calculate the homeostasis 
model assessment (HOMA). Global LVD was measured by MRI and regional LVD was 
determined by tagged MRI (in a random subset of 1835).
Results: The highest mean HOMA score was seen in Hispanics, followed by Blacks, 
Chinese, and whites. The difference between minority ethnic groups and whites persisted 
after adjustment for age, gender, BMI, income, and education.
IR was strongly associated with parameters of global LVD, except LVEF (Table). In linear 
regression analysis, adjustment for BMI changed the magnitude and/or direction of the 
association of IR with parameters of global LVD, except LVEF. The magnitude of the 
association between IR and regional LVD changed by adjustment for LV hypertrophy 
(LVH), hypertension, and CRP_and not BMI. The association of IR with LVD did not differ 
by ethnicity.
Conclusion: While in this cohort IR differed by ethnicity, the association of IR with global 
LVD was closely related to obesity across all ethnic groups. However, the association of IR 
with regional LVD were mostly mediated by other CAD risk factors like LVH, hypertension, 
and CRP. 
Table. Crude and adjusted magnitude of the association (p-values) of Insulin 
Resistance and LV Function
Global LV Function Parameters Regional LV Function Parameters
Variables LVEF (%)
LV Mass 
(g)
LV End-
Diastolic 
Volume 
(mL)
LV End-
Systolic 
Volume 
(mL)
LV Stroke 
Volume 
(mL)
Systolic Strain (%)†† Time-to-Peak Diastolic Relaxation (ms)
Anterior 
Segment
Posterior 
Segment
Septal 
Segment
Lateral 
Segment
Anterior 
Segment
Posterior 
Segment
Septal 
Segment
Lateral 
Segment
Log HOMA 
score* 
(unadjusted)
-0.13**
(0.36)
10.86
(<0.01)
1.70
(<0.01)
0.74
(0.03)
0.96
(0.01)
0.32
(0.08)
0.82
(<0.01)
0.74
(<0.01)
0.08
(0.63)
-25.81
(<0.01)
-21.54
(<0.01)
-20.65
(<0.01)
-16.47
(<0.01)
Log HOMA 
score † 
(adjusted)
-0.12 
(0.46)
-1.15
(0.09)
-5.01
(<0.01)
-1.43
(<0.01)
-3.63
(<0.01)
0.26
(0.16)
0.60
(<0.01)
0.42
(0.02)
0.04
(0.85)
-21.88
(<0.01)
-21.63
(<0.01)
-25.95
(<0.01)
-16.99
(<0.01)
*HOMA: Homeostasis model assessment score was used as a measure of insulin 
resistance. ** Data presented as coefﬁcient (p-value)
†Adjusted for: age, gender, ethnicity, BMI, hypertension, income, education, LV mass, 
physical activity, smoking, interleukin-6 and C-reactive protein.
†† Systolic strain is a negative number and the smaller numbers indicate higher strain.
 
964-54 Insulin Resistance is a Determinant of Myocardial 
Dysfunction in Apparently Healthy Obese Subjects
Chiew Wong, Rodel Leano, Thomas H. Marwick, University of Queensland, Brisbane, 
Australia
Background. Obese pts have subclinical myocardial dysfunction that may account for 
their risk of heart failure. We sought the contribution of insulin resistance (IR) to myocardial 
dysfunction in obesity.
Methods. Asymptomatic obese subjects without known cardiac disease underwent 
clinical evaluation, homeostasis model assessment (HOMA score) as a measure of 
insulin sensitivity and echocardiographic assessment. After exclusion of DM, overt 
myocardial dysfunction or ischemia, subclinical myocardial function was assessed by 
myocardial systolic (Sm) and diastolic velocity (Em) in 79 pts. Association was sought 
between myocardial function with clinical and biochemical characteristics.
Results HOMA score categorized 36 pts as non-IR (HOMA<2) and 43 as IR. Although 
BMI was similar, metabolically healthier pts had lower waist circumference, systolic blood 
pressure and greater LV and RV diastolic tissue velocities. LV em correlated signiﬁcantly 
with HOMA (r=-0.3, p<0.01), BMI(r=-0.28, p<0.05) and waist circumference(r=-0.24, 
p<0.05) independent of blood pressure.
Conclusion. Non-IR obese pts had better myocardial diastolic function compared to 
those with IR. Preserved insulin sensitivity could be protective against myocardial disease 
in obese pts.
 
Non IR IR
(n=36, 24f,12m) (n=43, 24f, 19m) p
Age (yrs) 44±10 46±8 ns
BMI (kg/m2) 34±5 36±5 ns
Waist (cm) 105±9 113±10 0.001
HOMA 1.4±0.4 4.0±1.6 0.001
SBP (mmHg) 119±10 125±12 <0.05
LVM index (g/m2) 72±19 79±18 ns
LV sm (cm/s) 6.0±1.0 6.0±1.0 ns
LV em (cm/s) 7.3±1.4 6.5±1.3 0.02
RV sm (cm/s) 8.9±2.0 8.8±1.5 ns
RV em (cm/s) 9.1±2.0 8.2±1.3 0.02
964-55 Does Tight Glycemic Control Improve Survival in 
Diabetic Patients With Chronic Heart Failure Started on 
Insulin Therapy?
Scott T. Weslow, Anil Jain, W. H. Wilson Tang, Cleveland Clinic Foundation, Cleveland, OH
Background: It has long been recognized that the failing heart has altered metabolic 
needs. Recent registry data suggested poorer survival in patients with heart failure (HF) 
treated with insulin. Although tight glycemic control has been the mainstay of diabetic 
therapy, the effect of glycemic control in insulin-treated patients with HF is unclear.
Methods: We identiﬁed 125 consecutive outpatients with chronic HF who were initiated 
on insulin therapy for poor glycemic control (HbA1c ≥ 7%). We examined the mean 
HbA1c prior to and following initiation of insulin therapy, and stratiﬁed according to those 
achieving tight (HbA1c ≤7%) versus poor (HbA1c>7%) glycemic control. Mortality was 
determined by Social Security Death Index.
Results: In our cohort (mean age 62 ±11 years, 60% male, mean LVEF 28 ±12%, 61% 
on oral hypoglycemic agents), the mean HbA1c improved from 8.9 ±1.6% to 8.3 ±1.4% 
following insulin initiation. Only 25 of the 125 patients (20%) achieved tight glycemic 
control with insulin, but over a mean follow-up of 3.1 years, there was a trend towards 
poor long-term survival in this group compared with those with poor glycemic control 
(40% versus 24%, see Figure).
Conclusion: Although limited by relatively small sample size, the strong trend towards 
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poorer survival with tight glycemic control following the initiation of insulin therapy in our 
diabetic HF cohort raises further concerns regarding the appropriate diabetic treatment 
strategies in patients with chronic HF.
964-56 Low Dose Pioglitazone Does Not Adversely Affect Left 
Ventricular Remodeling After Primary PCI in Patients 
With Acute Myocardial Infarction and With Type 2 
Diabetes Mellitus or Impaired Glucose Tolerance
Jin Yokoyama, Naoyuki Sutoh, Takumi Higuma, Daisuke Horiuchi, Chisato Katoh, 
Takashi Yokota, Shingo Sasaki, Masaomi Kimura, Takao Kobayashi, Hiroyuki Hanada, 
Tomohiro Osanai, Ken Okumura, Hirosaki University School of Medicine, Hirosaki, 
Japan
Background: Thiazolidinediones (TZDs) have beneﬁcial effects on markers of 
cardiovascular risk in patients with type 2 diabetes mellitus (DM). It is recommended that 
both patients and health care providers should be cognizant of the risk of congestive heart 
failure (CHF) when TZDs are used in patients with type 2 diabetes. 
Methods: We investigated the effect of low dose pioglitazone (15mg per day) on the left 
ventricular (LV) volume and function in 76 AMI patients with type 2 DM or impaired glucose 
tolerance (IGT) who underwent successful emergency PCI using bare metal stent. The 
patients with LV ejection fraction (LVEF) <35% were excluded. In 39 patients, pioglitazone 
was orally administered for 6 months after stenting while previous anti-diabetic therapy 
being maintained (pioglitazone group). LVEF and LV end-diastolic volume index (LVEDVI, 
ml/mm2) at acute phase and six months after PCI in pioglitazone group were compared 
with those in the other 37 patients (control group) treated with conventional anti-diabetic 
therapy not including pioglitazone.
Results: No adverse events including death, emergency bypass surgery and re-
infarction, occurred in any patients in the hospital. There was no CHF during a follow-up 
period. There was no signiﬁcant difference in the clinical proﬁles including the severity of 
DM before the procedure between the two groups. There was no signiﬁcant difference in 
the culprit vessel, reference vessel diameter, max CPK , the use of intra-aortic balloon 
pumping, and the administration of ACE inhibitor, angiotensin receptor blocker, β-blocker, 
spironolactone, and diuretic agent. LVEF at acute phase and follow up were both similar 
between the two groups. At acute phase, LVEDVI was slightly larger in pioglitazone 
group than in control (95 vs 86, P=0.094), while it was similar between two groups (87 in 
pioglitazone group vs 92 in control, p=0.498) at follow up. ∆-LVEDVI (deﬁned as follow up 
LVEDVI - acute LVEDVI) in pioglitazone group was signiﬁcantly smaller than that in control 
group (-9 vs 5, P=0.042).
Conclusions: Low dose pioglitazone seems to be safe and does not adversely affect LV 
remodeling after AMI treated with emergency PCI in patients with type 2 DM or IGT.
964-57 Obesity and the Metabolic Syndrome are Associated 
With Improved Survival in the Heart Failure Population
Saamir Hassan, Anita Deswal, Biykem Bozkurt, Vinay Thohan, Douglas L. Mann, 
Kamran Sheikh, Allison M. Pritchett, Baylor College of Medicine, Houston, TX, Michael 
E. DeBakey VA Medical Center, Houston, TX
Background: The prevalence of heart failure (CHF) and metabolic syndrome in the 
general population are increasing. Both diseases are associated with signiﬁcant morbidity. 
We sought to determine the prevalence of obesity and metabolic syndrome in a CHF 
population and their effects on mortality.
Methods: 1399 patients admitted with a primary diagnosis of CHF were retrospectively 
identiﬁed from three Baylor College of Medicine afﬁliated hospitals. Modiﬁed Framingham 
criteria for CHF were required for inclusion. The metabolic syndrome was present if 3 of 
the 5 conditions were met: body mass index ≥ 30 kg/m2, triglycerides ≥ 150 mg/dl, HDL 
< 40 mg/dl in men or <50 mg/dl in women, blood pressure > 130/85 mmHg or history of 
hypertension, fasting glucose > 110 mg/dl or history of diabetes. Our patient population 
was compared to the National Health and Education Survey (NHANES 1999-2000) 
population, which was used as a measure of the general population.
Results: The prevalence of the metabolic syndrome was 39.5% (552/1399) and obesity, 
38.2% (535/1399). Hispanics had the highest prevalence of the metabolic syndrome 
(46.5%) compared to Whites (39.8%) and Blacks (37.5%), p=0.08. All races in our 
population had a higher prevalence of metabolic syndrome and obesity compared to 
NHANES data (26.7% and 31.1% respectively). Females and males had a similar rate of 
metabolic syndrome (43.0% vs. 37.7%) and obesity (39.9% vs. 37.4%). Hispanic (50% vs. 
43%) and Black females (48% vs. 33%) had a higher prevalence of metabolic syndrome 
than their male counterparts. Mortality data was available for one of the three hospitals 
or 37% of the overall population. At 1 year of follow-up, 28% (142/512) of patients died. 
Those that died were less likely to be obese (26% vs. 41%, p<0.001) or have metabolic 
syndrome (29% vs. 43%, p<0.001), than those who lived. As the number of criteria for 
metabolic syndrome increased, the mortality decreased, p=0.027.
Conclusion: Patients with CHF have a higher prevalence of metabolic syndrome and 
obesity than the general population. The prevalence of these diseases varies by ethnicity, 
race, and sex. Obesity and the metabolic syndrome were associated with a lower mortality 
rate in the CHF population.
964-58 Prevalence of Sleep Disordered Breathing in 700 State 
of the Art Treated Patients With Symptomatic Chronic 
Heart Failure: Implications for Cardiopulmonary 
Function
Olaf Oldenburg, Volker Toepfer, Barbara Lamp, Dieter Horstkotte, Heart Center North 
Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
Background: Sleep disordered breathing (SDB) is associated with increased mortality 
and is known to be common in patients (pts) with chronic heart failure (CHF). However, 
there are only few large scale studies describing the prevalence of SDB in CHF, and these 
studies were performed, when CHF was treated differently. Especially �-blockers, thought 
to inﬂuence SDB, but also spironolactone were not part of CHF-therapy in these studies. 
The aim of this study was to evaluate prevalence and nature of SDB in CHF pts under 
current guideline therapy.
Methods: We prospectively screened 700 patients with symptomatic CHF (NYHA 
class ≥ II; LV-EF < 40%) using cardiorespiratory polygraphy (Embletta®). In addition, 
echocardiography, symptom-limited bicycle CPX testing and a standard 6-min walk test 
were performed. Heart failure medication inlcuded ACE-inhibitors and/or AT1-receptor 
blocker in ≥ 94%, diuretics in ≥ 89%, β-blockers in ≥ 94%, digitalis in ≥ 62%, and 
spironolactone ≥ 62% of pts.
Results: SDB was present in 531 pts (76%): 40% had central (CSA) and 36% obstructive 
sleep apnea (OSA). In general, CSA pts were more symptomatic (NYHA class 2.9 ± 0.5 
compared to noSDB 2.57 ± 0.5 or OSA 2.57 ± 0.5; p < 0.05) and had more nycturia (2.1 
± 1 compared to noSDB 1.3 ± 0.9 or OSA 1.6 ± 1; p < 0.05). LV-EF was more reduced in 
CSA pts (27.4 ± 6.6%) compared to OSA (29.3 ± 2.6%, p < 0.05). Oxygen uptake (VO2) 
at the individual anaerobic threshold (AT), peak VO2, and predicted peak VO2 was lowest 
in CSA pts: predicted peak VO2 57 ± 15 % in CSA, 64 ± 18% in OSA, and 63 ± 17% in 
noSDB, p < 0.05. Complementary results were seen in the 6-min walk test: 331 ± 111 m 
in CSA, 373 ± 108 m in OSA, and 377 ± 118 m in noSDB pts (p < 0.05).
Conclusions: This ﬁrst large scale study of SDB prevalence in symptomatic CHF pts 
treated according to the current CHF guidelines conﬁrmed the high prevalence of SDB in 
these pts. SDB is present in > 75% of all cases. Especially CSA pts were more symptomatic 
and showed a signiﬁcantly more impaired cardiopulmonary function compared to pts with 
OSA or without SDB. Because of its prognostic signiﬁcance and the availability of modern 
treatment options, cardiorespiratory screening should be implemented in the routine 
evaluation of CHF pts.
964-59 The Efﬁcacy of Continuous Positive Airway Pressure in 
Non-Obese Patients With Obstructive Sleep Apnea and 
Heart Failure
Takatoshi Kasai, Koji Narui, Tomotaka Dohi, Sugao Ishiwata, Tetsu Yamaguchi, Shin-ichi 
Momomura, Juntendo University, Tokyo, Japan, Toranomon Hospital, Tokyo, Japan
Background: Obstructive sleep apnea (OSA) may affect the progression of heart failure 
(HF). Continuous positive airway pressure (CPAP) had been proven as an effective 
therapy for OSA and underlying HF. Although most of patients with OSA are obese (O), 
there are a lot of non-obese (NO) patients with OSA in oriental population. However, the 
efﬁcacy of CPAP for HF in such NO population remains unknown.
Methods: HF patients who revealed left ventricular ejection fraction (LVEF) < 50 % were 
undergone polysomnography. Then, Patients with OSA, deﬁned as apnea-hypopnea 
index (AHI) ≥15/h and of which more than 50 % were obstructive events, were initiated 
CPAP. Patients were divided into two groups according to their body mass index (BMI) ≥25 
(O) or <25 (NO). Systolic (SBP) and diastolic (DBP) blood pressure, LVEF, plasma brain 
natriuretic peptide (BNP) and norepinephrine (NE), New York Heart Association class 
(NYHA) were assessed at the baseline and 3 months later.
Results: Overall 30 male were assessed (age59±13, BMI27±6, LVEF41±9%, AHI48±18/
h). The baseline characteristics inclung severity OSA and HF were similar between O 
(n=14) and NO group (n=16) except BMI. At 3 months, BMI was unchanged in both 
groups. LVEF (41±8 to 50±8in O (P=0.0003) vs. 42±10 to 44±9 % in NO(P=0.04)), NYHA 
class (2.4±0.5 to 1.5±0.5 in O (P=0.003) vs. 2.4±0.5 to 2.2±0.5 in NO(P=0.04)) and NE 
(457±176 to 419±139 in O (P=0.04) vs. 440±151 to 388±174 pg/ml in NO (P=0.02)) 
showed signiﬁcant improvements in both groups. The improvement of LVEF and NYHA 
class were greater in O (P=0.02 in LVEF, P=0.009 in NYHA) whereas the reduction of 
NE was less in O (P=0.04). SBP, DBP, BNP showed signiﬁcant reductions only in O; 
SBP: 131±6 to 123±6 (P<0.0001), 128±8 to 125±7 mmHg (NS), DBP: 89±11 to 82±12 
(P<0.0001), 77±5 to 78±6 mmHg (NS), BNP: 178±78 to 134±56 (P=0.04) and 221±89 
to 201±102 pg/ml (NS).
Conclusions: The treatment with CPAP for OSA had an efﬁcacy for underling HF even 
in NO. Furthermore, the reduction of sympathetic overactivity was signiﬁcantly greater in 
NO. However, the left ventricular pressure overload (expressed by BNP) and afterload 
(expressed by SBP and DBP) were not signiﬁcantly reduced in NO patients.
964-60 Myocardial Contractile Reserve Is Depressed in 
Patients With Obstructive Sleep Apnea
Nobuaki Okuda, Takahide Ito, Tetsuya Hayashi, Michihiro Suwa, Naritsugu Emura, Satoko 
Tonari, Hiroshi Yoneda, Yasushi Kitaura, Osaka Medical College, Takatsuki, Japan
Background: It has been suggested that hypoxia itself affects myocardial contractility 
in patients with obstructive sleep apnea (OSA), although no clinical data are available 
with regard to this relationship. This study was conducted to test the hypothesis that 
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myocardial contractile reserve might be depressed in patients with OSA.
Methods: We performed tissue Doppler imaging with dobutamine stress (TDDS) on 21 
patients with suspected OSA. Patients with resting left ventricular (LV) dysfunction and 
possible coronary artery disease were excluded. Peak myocardial systolic (Sm) and 
diastolic (Em) velocity in the 12 basal- and mid-myocardial segments were averaged, 
and mean Sm and Em were compared between patients with apnea-hypopnea index 
(AHI)<15 (Group I, n=11) and those with AHI>15 (Group II, n=10) at each TDDS stage.
Results: There were no signiﬁcant differences between the two groups with regard to age 
(49±12 years vs. 52±12 years), LV mass index (85±13 g/m2 vs. 92±20 g/m2), or LV ejection 
fraction (56±5% vs. 57±5%). In both groups, Sm progressively increased from rest to 
peak stress. However, the absolute and relative increases in Sm were lower in Group 
II, especially at peak TDDS stage (Figure). Em was persistently decreased throughout 
TDDS in Group II compared with Group I.
Conclusions: OSA affects myocardial contractile reserve, implying an etiologic 
contribution from repetitive hypoxic events. 
964-89 Prognostic Role of Chronic Obstructive Pulmonary 
Disease in Congestive Heart Failure. Data From The IN-
CHF Registry
Gianna Fabbri, Francesco Orso, Maria Cecilia Albanese, Marina Floresta, Lucio 
Gonzini, Giuseppina Lepera, Emanuela Zanelli, Aldo P. Maggioni, on behalf of IN-CHF 
Investigators, ANMCO Research Center, Florence, Italy
BACKGROUND. Non cardiac comorbidities such as chronic obstructive pulmonary 
disease (COPD) are highly prevalent in patients (pts) with heart failure (HF) but the 
association with the outcome is still scarcely investigated. We examined whether the 
presence of COPD inﬂuences one year outcome of outpts with HF.
METHODS. Data concern 8267 outpts enrolled in the IN CHF Registry. Diagnosis of HF 
was clinical, based on the ESC criteria. Diagnosis of COPD was obtained from records of 
speciﬁc (inhalation and/or oral) treatments and from patient history. Multivariable analysis 
was performed to identify the independent predictors of one year outcome.
RESULTS. A history of COPD was present in 1238 (14.3%) of the pts. Pts with COPD were 
signiﬁcantly older, more likely to be in advanced NYHA class and obese than those without 
COPD. No differences were found between the two groups regarding the etiology (ischemic 
or not), systolic blood pressure values, left ventricular function, renal dysfunction and the 
presence of diabetes and atrial ﬁbrillation. Pts with COPD had a higher 1-year all cause 
mortality than those without COPD (13.5%, vs 10.8%, p=0.0047). Also cardiovascular 
mortality was higher in pts with COPD (11.5% vs 9.2%, p=0.0084 respectively). All cause-
hospitalization rate was 26.4% for pts with COPD vs 21.8%, p=0.0003 but no signiﬁcant 
differences were found in the rate of hospitalization for cardiovascular reasons (18.9% vs 
17.0%, p=ns). Multivariable analysis did not conﬁrm the association between COPD and 
the risk of death (HR 1.02, 95% CI 0.86-1.21) or hospitalization rate (HR 1.13, 95% CI 
0.99-1.27). After adjustment, the presence of COPD was not associated with the combined 
end-point of total mortality or hospitalizations for any cause (HR 1.09, 95% CI 0.98-1.22).
CONCLUSIONS. Pts with COPD appeared to be more symptomatic despite a similar 
ventricular function. However, in this unselected population of pts with HF, the presence of 
COPD does not seem to increase the risk of one year all cause death and hospitalization, 
when the possible confounding factors are taken into account.
964-90 Improvement of Obstructive Sleep Apnea in Heart 
Failure Patients After Cardiac Resynchronization
Kristin Ellison, Michael Stanchina, Maria Anderson, Malcolm Kirk, Alfred Buxton, Rhode 
Island Hospital, Providence, RI
Background: Cardiac resynchronization (CRT) has been shown to improve ejection 
fraction and cardiac output in heart failure (HF) pts with dysnchrony from LBBB. Up to 
50% of HF pts have obstructive sleep apnea (OSA). OSA has not consistently improved 
with right ventricular pacing. CRT has been shown to improve central sleep apnea (CSA) 
but unclear in its beneﬁt for OSA. We assessed the effect of CRT therapy in HF patients 
with OSA and CSA, and the effect of increased pacing rate on sleep function.
Methods: Full in-home overnight polysommograms were performed on HF pts indicated 
for CRT. Pts were identiﬁed with disordered breathing (Apnea/Hypopnea Index [AHI] > 10/ 
hr). All pts were implanted with CRT deﬁbrillators. Pts had a baseline and 6 mo post CRT 
echo, sleep study and Minnesota QOL questionnaire. An additional study sleep study was 
performed after 6 mo of CRT with an increase of 15 BPM above the mean sleeping rate.
Results: 24 HF pts were screened ( mean age 68.6yrs, BMI 28.7 kg/m2. Thirteen pts 
(54%) were identiﬁed with sleep disordered breathing: 12/13 OSA, 1 with CSA. The mean 
base line ejection fraction was 22.5 % the mean 6 month post CRT ejection fraction was 
33.6% p<0.001. The Minnesota QOL score decreased from 47 to 33.5 (p=0.3). The AHI 
was reduced from 40.9 to 32.1 events/hr (p=0.045). The Obstructive Apnea Index was 
reduced from 24 to 12 events/hr (p=0.008) The 1 pt with CSA had resolution of central AI 
with CRT. There was no further beneﬁt in sleep function with increased base rate pacing.
Conclusions: CRT improved ejection fraction and OSA. There was resolution of CSA in 
the one patient with CSA. Increased rate pacing made no additional improvements in AHI 
above CRT with base rate pacing. Improvement in cardiac output with CRT may stabilize 
the respiratory control system and thus improve sleep disordered breathing.
964-91 Acute Effect of Continuous Positive Airway Pressure on 
Nocturnal Variation of Atrial Natriuretic Peptide Levels 
in Heart Failure Patients with Obstructive Sleep Apnea
Yoshimi Tagawa, Dai Yumino, Katsuya Kajimoto, Koichi Takeuchi, Eriko Ushikubo, Taku 
Imai, Masayuki Mizuno, Atsushi Takagi, Naoki Matsuda, Yukio Tsurumi, Nobuhisa 
Hagiwara, Hiroshi Kasanuki, Tokyo Women’s Medical University, Tokyo, Japan
Objectives This study was undertaken to determine (1) inﬂuence of obstructive sleep 
apnea (OSA) on baseline and nocturnal variation of atrial natriuretic peptide (ANP) levels, 
and (2) acute effect of nasal continuous positive airway pressure (nCPAP) on ANP in 
heart failure (HF) pts with OSA.
Methods We prospectively studied consecutive 25 pts with HF due to systolic dysfunction. 
All pts underwent polysomnography to establish the diagnosis of OSA with an apnea 
hypopnea index (AHI) >10/hr. ANP levels were measured three times (22 pm before 
sleep, 2 am during sleep, 6 am after waking) to conﬁrm nocturnal variation. In pts with 
OSA, ANP measurements were repeated on nCPAP titration in the same manner.
Results Of 25 studied pts, there were 10 OSA, 11 non-OSA, and 4 central sleep apnea 
pts. Pts with OSA, ANP peaked at 2 am and returned to baseline after waking at 6 am. 
By ANOVA, ANP level in OSA pts was signiﬁcantly higher, compared to those in 11 non-
OSA pts (at 2am; 170.1 vs. 54.5 pg/ml, P<0.001), who did not show nocturnal variation 
(P=0.0014, Figure). A nCPAP applied in pts with OSA reduced AHI (31.9 to 4.0, P<0.001). A 
nCPAP was also associated with siginiﬁcant reduction in ANP level at 2am (170.1 to 126 pg/
ml, P<0.001), that resulted in inhibition of nocturnal variation in HF pts with OSA (Figure).
Conclusions This study showed that the presence of OSA in HF pts was associated with 
notably higher ANP levels during sleep. Moreover, nCPAP acutely decreased ANP levels 
during sleep and inhibited nocturnal variation.
964-92 Using Reference Equations, Percent Predicted Value 
(PPV), for the Six-Minute Walk Test: A Better Indicator 
of Severity of Heart Failure Condition.
Konstantin Balashov, Deborah E. Feldman, Louise Pilote, ACCES-CLINIC co-
investigators group, McGill Universtiy Health Centre, Montreal, PQ, Canada
Background: The 6 minute walk test (6MWT) is a well known measure of functional 
capacity in patients with congestive heart failure (CHF). Norm-referenced equations for 
6MWT, Percent Predicted Value (PPV) for 6 minute walk distance (6MWD), have been 
proposed for CHF patients because that accounts for age, height, weight and gender of 
patients. The PPV has been tested in healthy elderly subjects. We sought to determine 
whether norm-referenced equations applied to CHF patients and if they can be used to 
construct an indicator of severity of CHF condition superior to the 6MWD.
Methods: This research was carried out in the context of a larger longitudinal cohort 
study of patients who newly attended specialized CHF clinics in ﬁve participating centers 
in Montréal, Canada. Simple and multiple regressions, correlation coefﬁcients with quality 
of life score, left ventricular ejection fraction, New York Heart Association Functional 
Class and mean-comparison tests were used to evaluate 6MWD and PPV as indicators 
of severity of CHF.
Results: Mean age of the 213 subjects with CHF was 65.5 (SD=11.2) years and 77.5% 
were men. Compared to the 6MWD, PPV has a slightly better correlation with quality 
of life score (-0.26 vs -0.20), similar correlations with other indicators of severity, more 
predictive power in linear regressions (adjusted r2 = 6.5% vs 4.2%) and gives consistent 
results in mean comparison tests (as opposed to 6MWD). 
Conclusions: The 6MWD in meters often gives misleading results when used as an 
indicator of severity of CHF condition to compare groups with different sex, age and BMI 
distributions. The standardized measure, using PPV norm-referenced equations, should 
therefore be preferred as an indicator of severity of CHF condition instead of the 6MWD 
measured in meters.
964-93 Impact of Obstructive Sleep Apnea for the Impairment 
of Left Ventricular Diastolic Function
Yasuhiro Usui, Yoshifumi Takata, Yuichi Inoue, Hirofumi Tomiyama, Kihiro Asano, Kazuki 
Shiina, Yoji Hirayama, Akira Yamashina, Tokyo Medical University, Tokyo, Japan, Japan 
Somnology Center, Neuropsychiatric Reserch Institute, Tokyo, Japan
Background: Several investigators have reported that obstructive sleep apnea (OSA) 
could affect left ventricular diastolic function, while these results were controversial.
Methods:Forty two OSA patients (36 males and 6 women, 46.8 ± 13.6 years, apnea 
hypopnea index:AHI 39.9±26.3/hour, BMI 26.5 ± 5.3kg/m2) diagnosed by overnight 
polysomnography (PSG) were enrolled in this study. No patient had hypertension, 
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diabetes mellitus, dyslipidemia, atrial ﬁbrillation, less than 50% of left ventricular ejection 
fraction (LVEF), and any history of cardiac disease. Left ventricular diastolic function was 
assessed by the transmitral ﬂow velocity (E/A). Peasons correlation was performed to 
determine the correlations between E/A and parameters which might affect on diastolic 
function (age, AHI, neurohumoral factors, LVEF, left ventricular mass index:LVMI, relative 
wall thickness:RWT ). And multiple linear regression analysis was also performed to 
determine the independent parameters for diastolic function.
Results: E/A of severe OSA group (AHI≥30/h) was signiﬁcantly lower than that of mild 
to moderate OSA (5≤AHI<30/h) groups (1.26±0.29 vs 1.47±0.46, P=0.05). AHI had 
signiﬁcantly inverse correlation with E/A (r=-0.34,P=0.03), while no signiﬁcant correlation 
with RWT and LVMI. And RWT had also signiﬁcantly inverse correlation with E/A (r=-
0.61,P=0.0001) whereas LVMI had no correlation with E/A. Multiple linear regression 
analysis revealed that age (β=-0.47, P <0.0001), AHI (β=-0.28, P <0.02), RWT (β=-0.29, 
P <0.05) were independent explanation variables for E/A (R-square = 0.643).
Conclusions:These results showed that OSA itself impaired left ventricular diastolic 
function independently of left ventricular geometry even in patients without cardiovascular 
risk factors.
964-94 Long-Term Monotherapy with Rosuvastatin Prevents 
Progressive Left Ventricular Dysfunction and 
Remodeling in Dogs with Heart Failure
Makoto Imai, Sharad Rastogi, Anastassia Todor, Mengjun Wang, Victor G. Sharov, Omar 
Habib, Alice J. Jiang, Sidney Goldstein, Hani N. Sabbah, Henry Ford Health System, 
Detroit, MI
Background: HMG-CoA reductase inhibitors or “statins” have been reported to possess 
a host of non-cholesterol lowering properties including inhibition of some matrix 
metalloproteinases (MMPs) and pro-inﬂammatory cytokines. We examined the effects 
of long-term monotherapy with rosuvastatin (RSV) on LV function and dilation in 21 
dogs with microembolization-induced heart failure (HF). We also explored the effects of 
RSV on LV tissue levels of MMP-2 and the cytokine tissue necrosis factor-alpha (TNFα). 
Methods: Dogs were randomized to 3 months oral therapy with low dose (LD) RSV (0.5 
mg/kg once daily), high dose (HD) RSV (3.0 mg/kg once daily) or to no therapy at all 
(Control). The change (∆) (treatment effect) in LV end-diastolic (EDV) and end-systolic 
(ESV) volumes and ejection fraction (EF) was measured in all 3 groups. Protein levels of 
MMP-2 and TNFα in LV tissue were measured using Western blots and bands quantiﬁed 
in densitometric units (du). LV tissue from normal (NL) dogs was used for comparison. 
Results: Data are shown in the table. There were no differences in ∆EDV, ∆ESV and 
∆EF between Controls and LD RSV. In contrast, ∆EDV and ∆ESV were signiﬁcantly lower 
and ∆EF signiﬁcantly higher in HD RSV compared to Controls. HD but not LD RSV also 
normalized protein levels of MMP-2 and TNFα. Conclusions: In dogs with HF, chronic 
therapy with HD RSV prevents progressive LV dysfunction and dilation. This beneﬁt may 
be partly derived from normalization of expression of MMPs and cytokines.
NL HF-Control HF+LD RSV HF+HD RSV
∆EDV (ml) 6.7 ± 1.6 4.4 ± 1.4 1.0 ± 0.5*
∆ESV (ml) 8.0 ± 1.2 5.0 ± 1.7 -0.4 ± 0.5*
∆EF (%) -4.6 ± 0.8 -3.1 ± 1.0 1.6 ± 0.4*
MMP-2 Protein (du) 31 ± 3 174 ± 7† 170 ± 8† 80 ± 8†‡
TNFα Protein (du) 116 ± 12 278 ± 24† 245 ± 17† 165 ± 18‡
*=p<0.001 vs. HF-Control; †=p<0.05 vs. NL; ‡=p<0.05 vs. HF-Control
 
964-95 Evidence Refuting the Obesity Paradox: Weight Loss 
Regardless of Obesity and Independent of Volume 
Status Predicts Outcome in Heart Failure Patients
Audrey H. Wu, Antwon R. Robinson, Todd M. Koelling, University of Michigan, Ann Arbor, MI
Background: Recent studies have suggested higher body mass index (BMI) is associated 
with lower mortality in patients with heart failure (HF). Many previous studies have not 
controlled for the effect of preceding weight change or for volume status.
Methods: The study group included patients with a diagnosis of HF, ejection fraction 
≤ 40%, and who had two right heart catheterizations (RHCs) performed between 
10/22/1990 and 10/12/2004. For analysis purposes, patients were grouped by standard 
BMI classiﬁcation: 18.5 to < 25 kg/m2 (normal), 25 to < 30 kg/m2 (overweight), and ≥ 
30 kg/m2 (obese). As they have established poor prognosis, cachectic patients (BMI 
< 18.5) were excluded. Multivariable Cox modeling was performed to determine effect 
of BMI on risk for the combined endpoint of left ventricular assist device implantation, 
cardiac transplantation as United Network for Organ Sharing status 1, or death, while 
controlling for clinical and hemodynamic factors and follow up time. Continuous variables 
are expressed as median (interquartile range).
Results: 164 patients were identiﬁed. The normal BMI group was signiﬁcantly older 
[normal 59 (53, 63) vs. obese 53 (47, 59) years] and the obese group had higher mean 
arterial pressure [normal 80 (74, 89) vs. obese 88 (79, 98) mm Hg]. Forty-one (71.9%) 
normal BMI patients versus 58 (54.2%) overweight/obese patients reached the combined 
endpoint (p=.03), but when analysis is limited to those who did not have signiﬁcant 
weight change (maintained weight < -10% loss and < +10% gain), the difference is not 
statistically signiﬁcant. Multivariable Cox regression showed that preceding weight loss 
of 10% or more was associated with highest risk of combined outcome [HR 17.59 (95% 
CI 3.73, 83.02); p=.0003], followed by obese BMI [HR 5.58 (95% CI 1.37, 22.73); p=.02]. 
Other factors associated with higher risk included presence of implantable deﬁbrillator 
[HR 3.47 (95% CI 1.04, 11.62); p=.04], higher PCW, and lower mean arterial pressure.
Conclusions: The association between higher BMI and lower mortality in HF appears to 
be negated by adjusting for preceding weight loss, and in fact obese patients appear to 
have greater risk, independent of volume status.
964-96 Flow Mediated Dilation Predicts Improved 
Cardiovascular Outcomes with Atorvastatin Therapy  
in Patients with Nonischemic Heart Failure
Bobby V. Khan, Muhammad Q. Mir, Faiz Cheema, Amar D. Patel, Stamatios Lerakis, 
Emory University School of Medicine, Atlanta, GA
Background: Measurement of ﬂow mediated dilation (FMD) is used for the evaluation of 
vascular endothelial function. FMD can predict cardiovascular events in several disorders 
including heart failure. Despite advances in therapy, morbidity and mortality from HF 
remain high.
Methods: 58 normolipidemic patients with non-ischemic HF and a left ventricular ejection 
fraction less than 35% underwent brachial artery reactivity testing (BART) to determine 
FMD. All patients were on appropriate medical therapy and were free of clinical symptoms 
for at least three months. The patients were then placed on atorvastatin (20 mg/day) for a 
12-month period. A similar group (n=54) was placed on placebo. Cardiovascular morbidity 
and mortality, including cardiovascular death and hospitalization for HF or acute coronary 
syndrome (ACS), were determined in both groups.
Results: In the atorvastatin group, there was a reduction of cardiovascular deaths, 
hospitalizations for heart failure, and acute coronary syndrome by 26%, 32%, and 6%, 
respectively, when compared to placebo. In the cohort of patients treated with atorvastatin, 
37 patients had an FMD less than 7.0% and 21 patients had an FMD greater than 7.0%. 
The most signiﬁcant reduction in clinical events was observed in the group of patients with 
FMD greater than 7.0% (see Table).
Conclusions: Treatment with atorvastatin in patients with non-ischemic HF reduces 
cardiovascular outcomes, notably in patients with higher FMD values.
CV Outcomes:Non-ischemic Heart Failure
CV Death HF Hospitalization ACS
Placebo (n=54) 33.7% 38.9% 17.0%
Atorvastatin
FMD>7.0% (n=21) 19.8% p<0.005 23.7% p<0.005 14.1% p=0.019
Atorvastatin
FMD<7.0% (n=37) 28.9% p=0.043 31.2% p=0.012 17.8% NS
 
964-97 Atorvastatin Might Improve Cardiac Function in 
Patients With Chronic Heart Failure by the Antioxidative 
Effect: A Prospective Randomized Placebo-Controlled 
Study
Takahisa Yamada, Takanao Mine, Takashi Morita, Hidetaka Kioka, Yasumasa 
Tsukamoto, Shunsuke Tamaki, Masaharu Masuda, Keiji Okuda, Masatake Fukunami, 
Osaka General Medical Center, Osaka, Japan
Background: Statins have pleiotropic effects such as anti-inﬂammatory, antioxidative, 
and vascular protective effects, which would be beneﬁcial for patients with chronic heart 
failure (CHF). We sought to investigate the effect of atorvastatin on cardiac function in 
patients with CHF from the viewpoint of inﬂammation and oxidative stress.
Methods: We enrolled 38 mild to moderate CHF outpatients (NYHA class:2.0±0.6, 
ischemic origin: 54%) with radionuclide left ventricular ejection fraction (LVEF) less than 
40% (27.7±8.2%) and serum cholesterol level from 150 to 280 (197±30) mg/dl. These 
patients were randomly assigned to receive atorvastatin (10mg/day) or placebo for 6 
months in a double-blinded fashion. We measured left ventricular end-diastolic dimension 
(LVDd) and LVEF by echocardiography, and the circulating levels of Interleukin-6 and 
high-sensitive CRP, and oxidized low-density lipoprotein (oxLDL) as a maker of oxidative 
stress, before and after 6 months of treatment.
Results: There were no signiﬁcant differences in age, gender, NYHA class, LVDd, LVEF, 
or serum cholesterol level at the entry between patients with atorvastatin (n=19) and 
placebo (control: n=19). After 6 months of treatment, LVDd signiﬁcantly decreased and 
LVEF also signiﬁcantly increased in atorvastatin group (from 66.4±7.2mm and 33.2±7.4% 
to 63.8±6.9mm and 35.8±7.9%, respectively, p<0.05 for both) but not in control group 
(from 65.3±7.3mm and 36.3±10.9% to 65.3±7.0mm and 35.1±10.8, respectively, p=NS 
for both). Interleukin-6 and high-sensitive CRP tended to decrease in atorvastatin group 
after 6 months of treatment, although the change were not statistically signiﬁcant (ANOVA, 
p=0.08). After 6 months of treatment, oxLDL signiﬁcantly decreased in atorvastatin group 
(from 128±46 to 87±26 U/l, p<0.01) but not in control group (from 110±38 to 115±44 
U/l). Furthermore, the change in oxLDL signiﬁcantly correlated with the changes in LVDd 
(r=0.38, p<0.05) and LVEF (r=-0.39, p<0.05) before and after 6 months of treatment.
Conclusion: Atorvastatin therapy might improve cardiac function in CHF, partially by the 
reduction of oxidative stress.
964-98 Anemia Is Related to Blunted Erythropoietin Production 
and Impaired Renal Function in Chronic Heart Failure 
Patients
B. Daan Westenbrink, Tom D.J. Smilde, Erik Lipsic, Gerjan Navis, Adriaan A. Voors, 
Hans L. Hillege, Wiek H. van Gilst, Dirk J. van Veldhuisen, University Medical Centre 
Groningen, Groningen, The Netherlands
Background: Anemia is common in chronic heart failure (CHF), and is associated with 
increased morbidity and mortality. The cause of anemia in CHF frequently unknown. The 
aim of the present study was to investigate renal function and erythropoietin production 
in anemic CHF patients.
Methods: Clinically stable CHF patients with LVEF< 45%, were considered for participation 
in the study. Glomerular ﬁltration rate (GFR) was determined by iothalamate clearance. 
Hematinics and serum EPO levels were determined. Moreover, observed/ predicted (O/P) 
logEPO ratio, and renal blood ﬂow (RBF; Hippuran clearance /1-Ht) were calculated.
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Results: We studied 90 CHF patients (age 58 ± 12, LVEF 27 ± 10 %), of whom 19 were 
anemic according to the WHO criteria (HB<13 g/dl in men, HB<12 g/dl in women). Iron 
deﬁciency explained anemia in 4 patients (14%), in the other patients no hematinic 
deﬁciencies were observed. A signiﬁcantly reduced O/P logEPO ratio was observed in 
the anemic group (p=0.001), indicating blunted EPO production. In anemic compared to 
non anemic CHF patients both GFR (79 ± 2.8 vs 56 ± 7.3 mL/min /1.73 m2 p= 0.002) 
and RBF (502 ± 18 vs 348 ± 31 mL/min /1.73 m2 p= <0.001) were signiﬁcantly impaired. 
Conclusions: EPO production was blunted in anemic CHF patients. In these patients 
RBF and GFR were concomitantly impaired, possibly contributing to the high incidence 
of anemia in CHF.
964-99 Low Serum Total Cholesterol Is Associated With 
Increased Mortality in Non-Ischemic Heart Failure
Nasim Afsarmanesh, Tamara B. Horwich, Gregg C. Fonarow, University of California, 
Los Angeles, Los Angeles, CA
Background: Prior studies have demonstrated that low serum total cholesterol (TC) is 
associated with increased mortality in heart failure (HF), however this association has not 
been consistently observed in non-ischemic HF.
Methods: We analyzed a cohort of 715 patients with non-ischemic HF (left ventricular 
ejection fraction [EF] <40%) who presented to a single center. Fasting lipid panels were 
drawn at time of referral. Patients were stratiﬁed into quartiles of TC (Q1 <133, Q2 134-168, 
Q3 169-209, and Q4 >210 mg/dL), as well as quartiles of LDL, HDL, and Triglycerides. 
Results: The cohort was 67% male, mean age of 48 ± 14, and EF of 24 ± 7. Pts with lower 
serum TC had worse hemodynamic proﬁles, lower EF, higher NYHA class, and higher 
BNP levels; trends observed with HDL, LDL and TG quartiles. Low TC was associated with 
increased risk of one-year death and urgent transplant (UT) (49%, 29%, 18%, 14% for Q1-4 
respectively, P<0.0001) as well as all cause mortality (P<0.0001). On multivariate analysis, 
adjusting for multiple other HF prognostic factors, low TC proved to be an independent 
predictor of outcomes, hazard ratios for death + UT 4.5, 2.5, 1.3 for Q1-3, compared with Q4. 
Based on ROC analysis for prediction of death + UT, the best cutoff for TC was 161 mg/dL.
Conclusions: Low TC is strongly associated with increased mortality in patients with 
non-ischemic, systolic HF. Further research is necessary to determine the nature of this 
relationship and the potential role of cholesterol levels in the progression of HF.
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965-100 Aging Modiﬁes Cardiac Phenotype of Mice Expressing 
Familial Hypertrophic Cardiomyopathy Linked Troponin 
T Mutants
Thinn Hlaing, Tariq Aziz, Barbara E.C Knollmann, Kenneth D. Horton, Laura Perrotta, 
James D. Potter, Neil J. Weissman, Bjorn C. Knollmann, Georgetown University, 
Washington, DC, Washington Hospital Center, Washington, DC
Background: Young mice heart expressing troponin T (TnT) mutations such as TnT-
I79N are hypercontractile and develop cardiac arrhythmias, but often lack other features 
(cardiac hypertrophy, myocyte disarray, interstitial ﬁbrosis) that are characteristically found 
in patients carrying TnT mutations associated with familial hypertrophic cardiomyopathy 
(FHC). We hypothesized that the cardiac tissue changes are secondary effects that 
develop over time and may contribute to functional deterioration.
Methods: To test this hypothesis, we compared young (2 months, n=63) and old (22 
months, n=39) mice expressing TnT-I79N and TnT-R278C under control of the alphaMHC 
promoter. Young and old mice expressing human wild-type TnT (WT) and non-transgenic 
littermates (NTG) served as controls.
Results: Young TnT-I79N and R278C mice had signiﬁcantly smaller heart weights 
compared to WT and NTG mice. On echocardiography, left ventricular end-diastolic 
dimension (LVED) was signiﬁcantly smaller, yet LV fractional shortening (LVFS) was 
signiﬁcantly increased in TnT-I79N group (137±8 % of control, p<0.01). Though increased 
in contractile function, not such a degree of hypercontractility was found in R278C 
group. No signiﬁcant myocyte disarray or interstitial ﬁbrosis was present in both TnT-
I79 and R278C mutants. In contrast, old TnT-I79N and R278C hearts had signiﬁcantly 
higher degree of interstitial ﬁbrosis and myocyte disarray on both atrial and ventricular 
sections compared to WT and NTG hearts (LV ﬁbrosis score: I79N 1.3±0.3, n=7, R278C 
1.2±0.2, n=8, WT 0.6±0.2, n=11, NTG 0.5±0.3, n=4). TnT-I79N and R278C hearts were 
no longer hypercontractile on echocardiography (LVFS 100±7 % of control, p= >0.05), 
and there was a trend towards increased heart weights in the TnT-I79N group. In addition 
a signiﬁcantly prolonged PR interval on surface ECG was noted in TnT-I79N group 
compared to controls..
Conclusions: Time-dependent effects contribute importantly to the cardiac phenotype 
of transgenic mice expressing FHC-linked TnT mutations and a more pronounced 
remodeling response was found in TnT-I79N mutants.
965-101 Mutations in the Genes for Sarcomeric Proteins 
in Japanese Patients With Elderly-Onset Sporadic 
Hypertrophic Cardiomyopathy
Ryuichiro Anan, Hirohisa Shono, Hideshi Niimura, Shinichi Minagoe, Yataka Otsuji, 
Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: Molecular genetic approaches have demonstrated that familial hypertrophic 
cardiomyopathy is caused by mutations in genes encoding sarcomeric proteins. Recent 
studies have shown that sarcomeric gene mutations can also be molecular etiology of 
elderly-onset or sporadic hypertrophic cardiomyopathy. However, genotype data are 
available for only a limited number of elderly-onset or sporadic patients with hypertrophic 
cardiomyopathy. We assessed the hypothesis that mutations in the genes for sarcomeric 
proteins can also be molecular etiology of Japanese patients with elderly-onset sporadic 
hypertrophic cardiomyopathy. 
Methods: We have studied elderly-onset sporadic hypertrophic cardiomyopathy 
patients whose diagnosis of hypertrophic cardiomyopathy was made after 40 years of 
age. Electrocardiography and echocardiography were performed in all the patients and 
available ﬁrst degree relatives. After written informed consent was obtained, DNA was 
extracted from peripheral blood. Sequence analyses were performed for the β cardiac 
myosin heavy chain (βMHC), cardiac troponin T, cardiac troponin I, cardiac myosin 
binding protein-C (MyBP-C), myosin ventricular regulatory light chain, and myosin 
ventricular essential light chain genes. 
Results: Forty-one patients with elderly-onset sporadic hypertrophic cardiomyopathy (31 
men and 10 women, mean age 63+10 years) were studied. A missense mutation in the βMHC 
gene (Arg663His) and 4 missense mutations in the MyBP-C gene (Arg160Trp, Glu334Lys, 
Gly507Arg, and Thr1046Met) were detected in 5 of the 41 patients. Four mutations in the 
MyBP-C gene were novel mutations, and a mutation in the βMHC gene was a previously 
reported mutation for familial hypertrophic cardiomyopathy with atrial ﬁbrillation. 
Conclusions : Missense mutations in the genes for sarcomeric proteins have been found 
in 5 of 41 patients with elderly-onset sporadic hypertrophic cardiomyopathy. Mutations 
in the cardiac myosin binding protein-C and β cardiac myosin heavy chain genes can 
also be molecular etiology of Japanese patients with elderly-onset sporadic hypertrophic 
cardiomyopathy.
965-102 Phenotypic Comparison Between Myoﬁlament 
Positive and Myoﬁlament Negative Hypertrophic 
Cardiomyopathy Among Italians
Francesca Girolami, Iacopo Olivotto, Michael J. Ackerman, Jeanne L. Stocker, Rachael 
A. Vaubel, J. Martijn Bos, Steve R. Ommen, Ilaria Passerini, Stefano Nistri, Francesca 
Torricelli, Franco Cecchi, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, 
Mayo Clinic College of Medicine, Rochester, MN
Background: Prevalence and clinical correlates of myoﬁlament-hypertrophic 
cardiomyopathy (HCM) among Italians is unknown. Here, genetic testing for myoﬁlament-
HCM was performed in a consecutive cohort of 88 unrelated Italians with HCM.
Methods: Comprehensive open reading frame/splice site mutational analysis of the 8 
most common HCM-associated myoﬁlament-encoding genes was performed using PCR, 
DHPLC, and direct DNA sequencing. Clinical data were extracted from patient records 
blinded to genotype.
Results: We identiﬁed 43 distinct HCM-associated myoﬁlament mutations in 54/88 
(61%) index patients (pts): MYBPC3-HCM (28 pts), MYH7 (15), TNNT2 (2), MYL2 (2), 
TPM1 (1), and ACTC (1). No pts had either TNNT2- or MYL3-HCM. Five pts (9%) had 
multiple mutations involving MYBPC3 and MYH7. Mutations were absent in 200 ethnic-
matched reference alleles, involved conserved residues, and were mostly novel (39/59) 
and mostly “private” (41/43) patient-speciﬁc mutations. E258K-MYBPC3 was found in 12 
pts and R869H-MYH7 in 5 pts suggesting possible founder mutations. Compared to the 
34 genotype negative pts, those with myoﬁlament-HCM i) were younger at diagnosis (39 
± 18 vs. 48 ± 17 years, p=0.026), ii) more often had a positive family history for HCM (56% 
vs. 25%, p=0.029), iii) had greater maximum LV wall thickness (23 ± 6 vs. 20 ± 3 mm, 
p=0.02), iv) trended towards greater likelihood of non-sustained ventricular tachycardia 
on Holter monitoring (61% vs. 33%, p=0.06), and had more severe congestive symptoms 
(NYHA III-IV 22% vs. 6%, p<0.05). There were no differences with regard to either sex, 
prevalence of LV outﬂow obstruction, or atrial ﬁbrillation.
Conclusion: The study represents the ﬁrst comprehensive mutational analysis of 
myoﬁlament-HCM among Italians. Even after excluding the 2 possible founder mutations, 
over 40% of this cohort was genotype positive for myoﬁlament-HCM with MYBPC3- and 
MYH7-HCM representing the two most common subtypes similar to the largest cohort 
study from the United States. Patients with myoﬁlament-HCM had evidence of earlier 
disease onset and more severe phenotypic expression with greater hypertrophy and 
higher rate of progression towards severe heart failure.
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965-103 Adiponectin in Patients With Hypertrophic 
Cardiomyopathy
Hiroaki Kitaoka, Toru Kubo, Takayosi Hirota, Makoto Okawa, Nobuhiko Hitomi, Masanori 
Nishinaga, Yoshinori Doi, Kochi Medical School, Kochi, Japan
Background: The adipocytokine adiponectin is an adipose-derived plasma protein 
with anti-atherosclerogenic and insulin-sentitizing activities. Adiponectin has recently 
been shown to inhibit hypertrophic signaling in the myocardium through activation of 
AMP-activated protein kinase signalings. However, signiﬁcance of plasma adiponectin 
concentration has not been determined in patients with hypertrophic cardiomyopathy 
(HCM).
Methods: Plasma adiponectin concentration was evaluated in 90 HCM patients (63±13 
years, 59 males). The phenotypic subtypes of HCM included non-obstructive HCM 
(HNCM; n=59), apical HCM (n=19), obstructive HCM (HOCM; n=6), and dilated HCM 
(d-HCM; n=6).
Results: (1) The plasma adiponectin concentration in d-HCM was signiﬁcantly higher 
than those of the other three subtypes (d-HCM: 23.7±11.7 µg/ml, HNCM: 11.9±6.6 
µg/ml, apical HCM: 10.5±6.5 µg/ml, HOCM: 9.7±4.9 µg/ml, p=0.0007). (2) The plasma 
adiponectin concentration was inversely related to the maximum left ventricular wall 
thickness in all patients (r=-0.33, p=0.001) and in 84 patients excluding d-HCM (r=-0.25, 
p=0.02). Conclusions: The lower adiponectin concentration was related to thicker left 
ventricular wall in HCM. The plasma adiponectin may have anti-hypertophic effect and 
may act as the modiﬁer factor of phenotypic manifestation in HCM.
965-104 Growth Factors Inﬂuence Collagen Metabolism and 
Hypertrophy in Hypertrophic Cardiomyopathy
Raffaella Lombardi, Sandro Betocchi, Claudia Esposito, Fabio Pastore, Maria A. Losi, 
Marianna Miranda, Massimo Chiariello, Federico II University of Naples, Naples, Italy
Background: Activation of Insulin like Growth Factor 1 (IGF-1) and Transforming Growth 
Factor β1 (TGF-β1) has been shown in hypertrophic cardiomyopathy (HCM). We test the 
hypothesis that IGF-1 and TGF-β1 inﬂuence collagen turnover and LV anatomy in HCM.
Methods: We studied 43 HCM patients (32 men; age 34±10 years). Patients underwent 
echocardiography to assess LV hypertrophy as Maximal Wall Thickness (MWT), and 
passive diastolic function as difference in duration between transmitral forward and 
pulmonary venous retrograde A waves (A-Ar). Collagen turnover was assessed on 
sera by ELISA assay of matrix metalloproteinases (MMPs) and by radioimmunoassay 
measurement of peptides resulting from collagen I synthesis (PINP) and degradation 
(ICTP); their molar difference reﬂects collagen I buildup. Free IGF-1 and TGF-β1 serum 
levels were assayed by ELISA.
Results: Free IGF-1 was directly related to PINP (Figure), ICTP (r=.353, p=.048), and 
their molar difference (r=.579, p= .001); besides it was inversely related to A-Ar (r=-.353, 
p=.047). TGF-β1 was directly related to MWT (Figure) and inversely related to A-Ar (r=-
.371, p=.026). There were no correlations with MMPs levels.
Conclusions: in HCM, IGF-1 stimulates collagen synthesis causing an imbalance in 
collagen turnover toward accumulation. Higher levels of TGF-β1 are associated with 
higher degrees of LV hypertrophy. Hence, both growth factors negatively inﬂuence 
passive diastolic function 
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966-105 Outcomes in Cardiac Transplant Recipients Using 
Donor Allografts With Left Ventricular Hypertrophy
Sorel Goland, Lawrence S.C Czer, Robert M. Kass, Robert James Siegel, James 
Mirocha, Michele De Robertis, Sharo Raissi, Wen Cheng, Gregory Fontana, Bernice 
Coleman, Alfredo Trento, Cedars-Sinai Medical Center, Los Angeles, CA
Background. Despite high mortality rates on waiting lists, transplanting hearts with left 
ventricular hypertrophy (LVH) remains a contraindication. The selection of donor hearts 
with LVH to expand the donor pool is still a matter of investigation.
Aim. To evaluate the outcomes of orthotropic heart transplantation (OHT) using donors 
with LVH.
Methods. We reviewed 427 patients undergoing OHT from 1989 to 2004. 62 recipients 
received hearts with LVH (intraventricular septum (IVS) or posterior wall (PW) thickness 
≥ 12 mm) by echocardiography. The remaining 365 patients received hearts without LVH.
The Cox proportional hazard model was used for statistical analysis of survival.
Results. Median follow-up was 3.8 years (range 0 to 17 years). Mean recipient age 
was 56.3±11.4 and donor age 30.3±2.1 years. Recipient age, gender, UNOS status, 
indications for OHT, and hemodynamics were similar in both groups. Ischemic time >240 
min occurred only in patients with LVH (22(6%), p=0.03).The mean donor age was greater 
in the LVH group (35±12 vs 29±12, p=0.001) and they had higher incidence of intracranial 
hemorrhage (24(38%) vs 56(15%), p=0.001), but other donor characteristics were not 
signiﬁcantly different. LV wall thickness was increased in the LVH group compared with 
non-LVH donors (IVS: 12.6±1.9 vs 8.5± 1.1, PW: 12.7± 1.0 vs 9.0±1.0 mm, p= 0.0001).
More than mild LVH (IVS or PW ≥13 mm) was found in 60% of donors. Signiﬁcant 
regression of LVH occurred (IVS: -1.6± 2.0 mm, p=0.0004, PW: -1.8± 0.2 mm, p=0.001) 
and 56% of patients had no LVH at mean follow-up of 4±2 years. Recipients of cardiac 
allografts from donors with LVH and without LVH had no signiﬁcant difference in 30-day 
(1.6% vs 3.3%,p=0.7), 1-year mortality (3.5% vs 9.5%,p=0.2) and long-term survival (at 
8 years: 0.60 ± 0.11 vs 0.50 ± 0.03, p=0.11).The incidences of rejection and graft CAD 
were similar in two groups. Multivariate analysis revealed no evidence that donor LVH was 
associated with increased mortality.
Concusions. Although older donor age and longer ischemic time were found in the LVH 
group, no negative inﬂuence on short- and long-term survival was seen. These results 
suggest that donor hearts with LVH can be successfully used in heart transplantation.
966-106 Cause of Death and Serum Cardiac Troponin Levels 
Predict Cardiac Function in Heart Transplant Donors
Alexander Butkevich, Naushad Shaik, Cezar Iliescu, Mihai Croitoru, University of Texas 
Health Science Center, Houston, TX
Background: Echocardiography is a powerful tool in the evaluation of cardiac function 
in prospective heart donors. However echocardiography may not be feasible in some 
instances. Aim of our study was to determine the utility of cardiac troponins in predicting 
cardiac function in heart donors.
Methods: We analyzed evaluations of all prospective heart donors performed at our 
instituition between January 2002 and March 2004 and determined the probability of 
obtaining a normal echocardiogram based on the cause of death and cardiac troponin 
(troponin T and /or tropnin I).
Results: Study consisted of 72 subjects. Cardiac troponin levels were obtained in 70 
donors (97%). Mean age of donors was 32 +/- 14 yrs, 22 (31%) were women. Cause 
of death was trauma in 53 subjects (72%), 19 subjects (28%) died of medical causes 
(cerebrovascular accidents ). Normal levels of cardiac troponins were 100% predictive of 
a normal echocardiogram in subjects who had died of traumatic injuries. Elevated levels 
of cardiac troponins were associated with a 62% chance of a normal echocardiogram. 
This difference was statistically signiﬁcant. There was a signiﬁcant association between 
serum troponin levels in subjects who died of medical causes, however they were less 
predictive of normal cardiac function in this group.
Conclusions: Serum troponin levels may be of value in evaluating cardiac function 
in prospective heart donors. In subjects who died of traumatic causes , normal serum 
troponin levels are predictive of normal echocardiograms.
Probability of a normal echocardiogram by cause of death and serum 
troponin levels
Troponin Levels Troponin Levels
Cause of Death Normal Elevated P
Trauma 100% 62% <0.001
Medical Causes 89% 22% 0.017
 
966-107 The Risk of Primary Allograft Failure Using Hearts From 
Older Donors
Katherine Lietz, Ranjit John, Kenneth Liao, Lyle Joyce, Leslie W. Miller, University of 
Minnesota, Minneapolis, MN
Background: Expansion of donor pool is concerning as it increases the risk of primary 
graft failure (PGF) in recipients of organs from older donors. Using data obtained from 
the Scientiﬁc Registry of Transplant Recipients we sought to identify donor risk factors 
associated with PGF in heart transplant (HT) recipients.
Methods: The studied population included 25,463 HT recipients btw Jan 1990 and Jan 
2003 in the United States. PGF was deﬁned as death within 30 days from HT due to 
primary, non-speciﬁc or other non-rejection related graft failure. Multivariable regression 
models were employed to derive risk factors for PGF.
Results: The average 2.8% incidence of PGF (39% of early deaths)remained unchanged 
throughout the last decade despite increased use of donors > 40 yrs from 16.2% of HT 
recipients in 1990 to 31.2% in 2000 with a slight decline in 2002 to 27.8%. By multivariable 
analysis risk factors for PGF included: donor age > 40 yrs (RR=1.3)*, donor female gender 
(RR=1.3) **, donor death due to stroke (RR=1.6) **, ischemia time > 4 hrs (RR=1.6) 
** and graft implantation into the sickest heart failure pts, such as those on ventilatory 
(RR=2.6) ** or circulatory support with IABP (RR=1.3) * or LVAD (RR=1.4) ** and pts 
with additional risk factors such as PRA > 10% (RR=1.4) **, retransplant (RR=1.6) * and 
ischemic RR=1.4) ** or congenital cardiomyopathy (RR=2.5) **.
Conclusions: Cardiac allografts obtained from donors who died of stroke, particularly 
females, are associated with increased risk of PGF. Since stroke victims are currently the 
main source of organs from donors > 40 yrs (65%), avoiding prolonged ischemia time 
and transplantation into the sickest heart failure pts may be an important strategy when 
considering the use older donor hearts.
*P<0.05 **P<0.001
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816-3 Renal and Neurohormonal Effects of Intravenous 
and Intra-Renal Nesiritide in Patients with Renal 
Insufﬁciency: A Multicenter, Randomized, Placebo-
Controlled Trial
Paul Teirstein, Matthew Price, Luis Guzman, Vandana Mathur, Scripps Clinic, La Jolla, 
CA, University of Florida - Jacksonville, Jacksonville, FL
Background: The renal effects of nesiritide (NES) are debated. We hypothesized that 
local intra-renal (IR) infusion of NES would have greater renal and adrenal effects than 
intravenous (IV) NES due to (1) greater renal and adrenal drug delivery and (2) lesser 
blood pressure (BP) effect due to renal ﬁrst pass elimination. 
Methods: We report interim data from an ongoing trial in which patients with creatinine 
clearance < 80 cc/min undergoing angiography are randomized 1:1:1 to IV NES, IR NES, 
or placebo for ≥30 minutes. NES dose is 0.02 mcg/kg/min. Glomerular ﬁltration rate (GFR, 
inulin clearance), renal plasma ﬂow (para-aminohippurate clearance) and aldosterone 
are measured at 30 minutes (pre-contrast). IR NES is delivered using a bifurcated renal 
infusion catheter (Benephit Infusion System, FlowMedica). 
Results: The 3 groups were similar at baseline. The mean age was 71.9±2.6 years, 88% 
were male, mean creatinine was 1.5±0.05 mg/dl, and 50% were diabetic. Compared to 
IV NES, IR NES yielded B-type natriuretic peptide levels that were 27% lower (p = 0.14). 
Systolic BP declined by 10.6 mmHg from 147.3±8.3 during IR NES (p = NS) and by 23.7 
mmHg from 147.2±10.9 during IV NES (p = 0.01). NES, but not placebo, signiﬁcantly 
increased GFR, while only IR NES signiﬁcantly suppressed aldosterone and tended to 
increase renal plasma ﬂow (Figure). 
Conclusions: IR NES increased GFR by 22% within 30 minutes and signiﬁcantly suppressed 
aldosterone while affecting BP less than IV NES. Complete results will be presented. . 
11:15 a.m.
816-4 Prevalence of Atrial Fibrillation and Flutter by Different 
HMG-CoA Reductase Inhibitors and Doses in Heart 
Failure
Somjot S. Brar, In-Lu A. Liu, Steven S. Khan, Adam Kotlewski, Albert Y-J Shen, Kaiser 
Permanente, Los Angeles, CA, UCLA School of Medicine, Los Angeles, CA
Objective: We sought to determine the differences in prevalence of atrial ﬁbrillation 
and ﬂutter (AF) in patients with heart failure (HF) receiving lovastatin, simvastatin, or 
atorvastatin at differing doses.
Background: It has been suggested that HMG-CoA reductase inhibitors (statins) may 
be associated with less AF with the possible beneﬁt attributed, in part, to their pleiotropic 
properties in addition to cholesterol lowering effects.
Methods: We used existing care management databases to identify 28,008 patients with 
HF by ICD-9 codes and/or medication records from January 1999 to March 2005. Of 
these, 9,997 were prescribed statins in the most recent 12 month period with at least >1 
reﬁll. Multiple logistic regression was used to compare different statins and doses.
Results: The mean age for the cohort was 71.4 ±13yrs, and 45.7% were female. The 
mean ejection fraction was 43 ±17% for the entire population and did not differ between 
statins (p=0.14). Multiple logistic regression models follow. 
Odds Ratio of AF by Statin and Dose
Unadjusted Adjusted
High dose OR (95% CI) p-value OR (95% CI) p-value
Lovastatin >=40mg vs. 10mg 0.72 (0.63-0.81) <0.0001
0.72 (0.64-
0.92) <0.0001
Simvastatin 80mg vs. 40mg 0.72 (0.57-0.91) 0.006
0.72 (0.56-
0.92) 0.009
Atorvastatin 80mg vs. 20mg 0.70 (0.37-1.36) 0.28
0.64 (0.32-
1.30) 0.21
Intermediate dose
Lovastatin 20mg vs. 10mg 1.0 (0.87-1.14) 0.96 0.97 (0.84-1.12) 0.70
Atorvastatin 40mg vs. 20mg 1.32 (0.61-2.83) 0.47
1.54 (0.66-
3.57) 0.31
Between Statins
Simvastatin 80mg vs. Lovastatin 
10mg
0.55 (0.46-
0.65) <0.0001
0.64 (0.53-
0.79) <0.0001
Atorvastatin 80mg vs. Lovastatin 
10mg
0.43 (0.30-
0.60) <0.0001
0.40 (0.28-
0.57) <0.0001
Atorvastatin 80mg vs. Simvastatin 
80mg
0.78 (0.54-
1.11) 0.17
0.67 (0.46-
0.98) 0.041
Adjusted models included: age, gender, valvular surgery or valvuloplasty, rheumatic and 
non-rheumatic valvular disease, thyroid disease, hypertension, diabetes, CAD, COPD, 
income, and education.
Conclusion: These data show that the prevalence of AF in HF was signiﬁcantly lower at 
higher doses of each statin. The reduction was greatest for the higher potency statins, 
simvastatin and atorvastatin. This dose dependent relationship across statins supports a 
protective effect of statins against AF in HF.
11:30 a.m.
816-5 Randomized, Double-Blind, Placebo-controlled Study 
to Evaluate the Effect of two Dosing Regimens of 
Darbepoetin Alfa on Hemoglobin Response and 
Symptoms in Patients With Heart Failure and Anemia
Dirk J. van Veldhuisen, Kenneth Dickstein, Alain Cohen-Solal, Dirk JA Lok, Scott M. 
Wasserman, Nigel Baker, Dylan Rosser, Piotr Ponikowski, University Medical Center, 
Groningen, The Netherlands, Amgen Inc., Thousand Oaks, CA
Background: Anemia is common in patients with heart failure (HF) and is associated with 
severe symptoms and poor outcomes. This multicenter Phase 2 study evaluated the effect 
of two darbepoetin alfa (DA) dosing regimens on hemoglobin (Hb) rate of rise, exercise 
performance, symptoms and clinical status in patients with HF and anemia.
Methods: Patients with symptomatic HF (≥ 3 months), LVEF ≤ 40% and Hb 9.0 to 12.5 
g/dL were randomized to DA subcutaneously every 2 wks for 26 wks at starting doses of 
0.75 mcg/kg (n = 56) or 50 mcg (ﬁxed dose; n = 54) or placebo (n = 55), to achieve and 
maintain a target Hb of 14.0 ± 1.0 g/dL. Endpoints were rate of Hb rise per week during 
titration (equivalence of ﬁxed to weight-based dosing was concluded when 95% CI for 
difference of the means is within -0.5 and 0.5 g/dL/wk); change from baseline to month 
6 in 6-minute walk distance, Patient’s Global Assessment (PGA), Minnesota Living With 
Heart Failure Questionnaire (MLHFQ) and Kansas City Cardiomyopathy Questionnaire 
(KCCQ) scores, safety (DA vs placebo).
Results: At baseline, most subjects were NYHA class II (39%) or III (56%) and received 
beta blockers (83%); the mean (± SD) age was 71 ± 10 years, LVEF 28.4 ± 9.6%, Hb 11.5 
± 0.7 g/dL. Baseline demographics and clinical characteristics of DA and placebo groups 
were similar. The rate of Hb rise during titration in the ﬁxed dosing group was equivalent 
to that in the weight-based group (difference: 0.05 g/dL/wk; 95% CI 0.01, 0.09). There 
were statistically nonsigniﬁcant improvements (means) in the DA group vs placebo for 
6-minute walk distance (34.2 m vs 11.4 m; P = 0.074), PGA score (percentage improved: 
65% vs 49%; P = 0.057), and MLHFQ total score (-10.1 vs -7.4; P = 0.413); there was 
a signiﬁcant improvement in KCCQ total score (8.2 vs 1.5; P = 0.027) and no change in 
NYHA class (-0.30 vs -0.23; P = 0.473). The number of adverse events was similar across 
treatment groups.
Conclusion: In patients with symptomatic HF and anemia, treatment with DA was safe, 
effectively raised Hb and signiﬁcantly improved KCCQ total score. Statistically nonsigniﬁcant 
improvements in PGA, MLHFQ total score and 6-minute walk distance were observed. 
Fixed dosing was as effective as weight-based dosing in raising Hb levels.
11:45 a.m.
816-6 The Rosuvastatin Impact on Ventricular Remodeling 
Cytokines and Neurohormones (UNIVERSE) Study
Henry Krum, Andrew Tonkin, Monash University, Melbourne, Australia
Background: HMGCoA reductase inhibitors (“statins”) � mortality in patients (pts) with 
coronary artery disease. However, pts with established chronic heart failure (CHF) were 
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often excluded in such trials. Statins possess pharmacological properties (independent of 
cholesterol-lowering) that may be beneﬁcial on ventricular remodeling in pts with CHF.
Methods: We conducted a 6 month randomised placebo (PBO)-controlled study of 
rosuvastatin (ROS, target dose 40mg/day) in pts with systolic (left ventricular ejection 
fraction [LVEF] <40%) CHF of ischemic or non-ischemic etiology. The primary end-point 
of the study was change in LVEF by radionuclide ventriculogram (RNVG). Secondary 
end-points included change in echocardiographic (echo) parameters, neurohormonal 
and inﬂammatory markers. Clinical end-points assessed included Packer composite 
score, death and heart failure hospitalization. Cholesterol-lowering efﬁcacy and safety 
parameters (LFTs, CK, renal function) were also assessed.
Results: Pts were well matched for baseline values. Compared to PBO (n=46), ROS 
pts (n=40) had a signiﬁcant (sig.) ↓ in LDL plasma cholesterol (PBO +3, ROS -54%, 
P<0.001). There was no sig. change in LVEF by RNVG (PBO +5.3, ROS +3.2%), fractional 
shortening by echo (PBO +2.7, ROS +1.8%), LVEDD (PBO -1.7, ROS +0.8 mm), LVESD 
(PBO -1.9, ROS +0.1 mm). Furthermore, there were no sig. differences between PBO and 
ROS in plasma norepinephrine, endothelin-1, BNP, hsCRP, TNFa and IL-6, patient global 
assessment, Packer composite and death/heart failure hospitalization. Adverse events 
including muscle, liver and kidney disorders were similar between PBO and ROS.
Conclusions: Despite being safe and effective at ↓ plasma cholesterol in systolic CHF 
pts, high dose ROS did not beneﬁcially alter parameters of LV remodeling. Reason(s) for 
absence of beneﬁt are uncertain but could include patient population studied, high dose 
of ROS used and/or high use of effective background CHF medications. UNIVERSE thus 
contributes important mechanistic information to the ongoing CORONA and GISSI-HF studies 
determining clinical outcomes after administration of statins to pts with established CHF.
Noon
816-7 Conivaptan, a Novel Arginine Vasopressin Antagonist, 
Increased Serum Sodium Concentration in Patients 
With Heart Failure and Euvolemic or Hypervolemic 
Hyponatremia
Jalal K. Ghali, Joseph G. Verbalis, Peter Gross, Walker A. Long, Neila Smith, Louisiana 
State University Health Sciences Center, Shreveport, LA
Background: Hyponatremia, often due to elevated levels of arginine vasopressin (AVP), 
can occur secondary to heart failure (HF). Conivaptan (CNV), an AVP V1A/V2-receptor 
antagonist, produces aquaresis, the electrolyte-sparing excretion of water. Efﬁcacy 
and safety of CNV were evaluated in 241 patients with euvolemic or hypervolemic 
hyponatremia of various causes in 3 randomized, double-blind, placebo (PBO)-controlled 
trials (1 intravenous [IV], 2 oral). A subset of 94 (39.1%) patients with HF was analyzed 
retrospectively.
Methods: In the IV trial, patients received a PBO or CNV 20-mg loading dose, followed by 
continuous 4-d infusion of CNV 40 or 80 mg/d. Patients in the oral trials received CNV 40 
or 80 mg/d or PBO in 2 divided doses for 5 d. Efﬁcacy measures included time to achieve 
a 4 mEq/L increase in [Na+], total time serum [Na+] was ≥4 mEq/L above baseline, and 
number of patients achieving a ≥6 mEq/L increase in serum [Na+] or normal serum [Na+] 
(≥135 mEq/L).
Results: IV administration of 40 or 80 mg/d CNV signiﬁcantly improved serum [Na+] and 
all other efﬁcacy parameters (Table). Similar efﬁcacy was observed in the 2 oral trials. 
The incidence of death and that of discontinuation in HF patients were similar between 
placebo and CNV groups. Most adverse events were mild to moderate. 
Efﬁcacy of IV CNV in Patients With Hyponatremia and HF
IV Trial Oral Trial 1 Oral Trial 2
Placebo
(n=9)
IV 40 mg/d 
CNV
(n=10)
IV 80 mg/d 
CNV
(n=8)
Placebo
(n=10)
Oral 40 mg/d 
CNV
(n=13)
Oral 80 mg/d 
CNV
(n=9)
Placebo
(n=12)
Oral 40 mg/d 
CNV
(n=12)
Oral 80 mg/d 
CNV
(n=11)
Baseline serum [Na+], mean ± 
SD mEq/L
124.9 ± 
3.19
123.3 ± 
5.62
124.2 ± 
3.84
126.9 ± 
2.37
125.8 ± 
5.72
126.2 ± 
3.16
122.7 ± 
4.87
125.3 ± 
2.01
124.0 ± 
5.28
Change from baseline to end of 
treatment in serum [Na+] mean 
± SD mEq/L
2.1 ± 
3.19
5.6 ± 
2.39*
8.1 ± 
4.32†
0.4 ± 
3.74
4.7 ± 
4.08*
7.7 ± 
4.86†
3.6 ± 
4.47
6.8 ± 
4.77
7.1 ± 
6.10
Time from ﬁrst CNV dose to ≥4 
mEq/L increase from baseline in 
serum [Na+], median h
NE 27.2 23.9† NE 72.0* 24.0† 64.8 25.3* 27.8†
Total time patients had
a ≥4 mEq/L increase from 
baseline in serum [Na+], mean 
± SD h
15.6 ± 
25.46
48.0 ± 
33.77*
68.6 ± 
27.96†
12.6 ± 
27.18
51.7 ± 
45.75*
80.1 ± 
42.28†
44.6 ± 
39.15
76.6 ± 
43.12
74.2 ± 
39.50
% of patients with
≥6 mEq/L increase in
serum [Na+] or serum [Na+] 
≥135 mEq/L
11.1 60.0* 87.5† 10.0 53.8 77.8† 41.7 75.0 72.7
NE = not estimable; *P<.05, †P<.01 vs placebo
Conclusions: IV CNV 40 and 80 mg/d signiﬁcantly increased serum [Na+] in patients with 
hyponatremia and HF and was well tolerated.
12:15 p.m.
816-8 Progressive Reversal of LV Remodeling in Postinfarct 
Patients Underwent Left Ventricular Aneurysmectomy: 
The Dor Procedure
Fumie Kureha, Tomoko Tani, Minako Tani, Minako Katayama, Natsuhiko Ehara, 
Tomoyuki Oda, Koichi Tamita, Makoto Kinoshita, Shuichro Kaji, Atsushi Yamamuro, 
Kunihiko Nagai, Kazuaki Tanabe, Shigefumi Morioka, Michihiro Nasu, Yukikatsu Okada, 
Yasuki Kihara, Kobe General Hospital, Kobe, Japan
Background: Ventricular reconstruction with the Dor procedure is a surgical option in 
postinfarct patients with left ventricular aneurysm. There were few studies regarding serial 
assessments of left ventricular (LV) function for over years after operation.
Methods: Among 24 patients with anterior myocardial infarction and LV aneurysm who 
underwent the Dor procedure between 1998 and 2003, 11 patients were serially studied 
18±44 days before, and 2±3 months, and one year after surgery. We evaluated LV end-
diastolic (LVDd) and end-systolic (LVDs) dimensions, ejection fraction (EF), LV end-
diastolic (EDVI) and end-systolic (ESVI) volumes per body mass index, LV end-systolic 
sphericity (length-width ratio in the apical four chamber view; LV D/L), heart rate (HR), and 
mitral regurgitation (MR). We also evaluated the peak velocity of transmitral ﬂow of early 
rapid ﬁlling wave (E), atrial wave (A), peak E/A wave velocity ratio, and the deceleration 
time of E wave (Edct).
Results: EDVI and ESVI were decreased at early post-operative stage, which further 
decreased at 1 year. LVDd, LVDs, EF, LV D/L, HR and MR were not changed signiﬁcantly. 
The E/A ratio increased at the early post-operative stage that was associated with a 
decrease in Edct. However, such impairments of the LV diastolic ﬁlling properties were 
recovered at 1 year.
Conclusions: With the Dor procedure, the progressive reversal of LV remodeling might be 
expected despite the temporal impairment of LV diastolic properties in the early course.
ORAL CONTRIBUTIONS
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817-3 Differences in Protein-Protein Interactions as a Basis 
for the Contrasting Phenotypes of Hypertrophic and 
Dilated Cardiomyopathies Resulting From Different 
Mutations in the Same Sarcomeric Protein
Vinitha Senthil, Suet Nee Chen, Jasvinder S. Sidhu, Robert Roberts, Ali J. Marian, 
Baylor College of Medicine, Houston, TX, University of Ottawa Heart Institute, Ottawa, 
ON, Canada
Background: Hypertrophic (HCM) and dilated cardiomyopathies (DCM) represent the 
opposite spectrum of the phenotypic responses of the heart to stress/injury. Mutations 
in sarcomeric proteins are major causes of HCM and DCM. Genetic data show different 
mutations in a given sarcomeric protein, such as cardiac troponin T (cTnT) can cause 
either of the phenotype. The basis for the contrasting phenotypes arising from different 
mutations in the same sarcomeric protein is unclear.
Methods: We generated transgenic mice expressing either cTnT-Q92, known to cause 
HCM, or cTnT-W141, known to cause DCM, in the heart. We isolated myoﬁbrillar proteins 
and analyzed interactions between the sarcomeric proteins by co-immunoprecipitation 
(Co-IP) and immunoblotting (IB) using transgene-speciﬁc antibody. We then measured 
calcium (Ca+2) sensitivity of the myoﬁbrillar protein ATPase activity.
Results: The cTnT-Q92 mice exhibit a small left ventricle and increased left ventricular 
ejection fraction (LVEF). In contrast, cTnT-W141 mice show a dilated heart with 
decreased LVEF. Transgenic lines with equal expression levels of cTnT-Q92 and cTnT-
W141 were analyzed. Binding of the mutant cTnT-Q92 to cardiac troponin I (cTnI), the 
inhibitory protein of the myoﬁbrillar force generation, was increased as compared to the 
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non-transgenic. In contrast, cTnT-W141 showed weaker binding to cTnI. There were no 
signiﬁcant differences in binding of either of the mutant cTnT protein to α-tropomyosin or 
cardiac α-actin. Ca+2 sensitivity of myoﬁbrillar ATPase activity was reduced in the cTnT-
W141 mice as compared to non-transgenic (n=8, p<0.001). In contrast, it was increased 
in the cTnT-Q92 mice. Hence, pCa50 was lower in the cTnT-Q92 mice as opposed to the 
cTnT-W141 mice.
Conclusions: The results implicate altered interactions between the mutant cTnT proteins 
and cTnI as a mechanism for the contrasting phenotypes of HCM and DCM resulting from 
different mutations in cTnT. We suggest increased LVEF in HCM results from enhanced 
binding of the mutant cTnT-Q92 to cTnI, preventing the inhibitory effects of cTnI on the 
generation of myoﬁbrillar force. The opposite occurs for the DCM mutation.
11:15 a.m.
817-4 Echocardiographic-Determined Septal Morphology in 
Z-Disc Hypertrophic Cardiomyopathy
J. Martijn Bos, Josepha Binder, Jeanne L. Stocker, Melissa L. Will, Bernard J. Gersh, Steve 
R. Ommen, Michael J. Ackerman, Mayo Clinic College of Medicine, Rochester, MN
Background: Hypertrophic cardiomyopathy (HCM) is characterized by signiﬁcant 
genotypic and phenotypic heterogeneity. HCM can be classiﬁed into at least 4 anatomic 
variants based upon the septal contour including reverse curvature-, sigmoidal-, apical-
, and neutral contour-HCM. Recently, we discovered a striking association between 
myoﬁlament-HCM (i.e. mutations involving one of 8 myoﬁlament-encoding genes) and 
reversed septal curvature. Here, we sought to determine whether there was particular 
septal contour associated with Z-disc HCM.
Methods: Using PCR, DHPLC, and direct DNA sequencing, a comprehensive open 
reading frame/splice site mutational analysis of the genes encoding key Z-disc proteins: 
ZASP-encoded Z-band alternatively spliced PDZ-protein, ACTN2-encoded alpha actinin-
2, TCAP-encoded telethonin, and CSRP3-encoded muscle LIM protein, was performed 
on DNA derived from 239 unrelated, myoﬁlament genotype negative patients with HCM. 
Blinded to the genotype, the septal contour was graded qualitatively using standard 
transthoracic echocardiography.
Results: At diagnosis, this myoﬁlament genotype-negative HCM cohort was characterized 
by i) age 45.1 ± 19 years ii) maximum left ventricular wall thickness 20.7 ± 6 mm , iii) 
resting left ventricular outﬂow tract gradient 48.3 ± 42 mm Hg, and iv) sigmoidal septal 
contour in 166 (69%). Seventeen of the 239 patients (7.1%) hosted one of 14 distinct 
HCM-associated Z-disc mutations involving residues highly conserved across species, 
absent in 400 reference alleles: ZASP (9), ACTN2 (3), TCAP (3), and CSRP3 (2). For 
this subset with Z-disc-associated HCM, the septal contour was sigmoidal in 14 (82%), 
reversed curvature in 2 (12%), and apical in 1(6%).
Conclusion: Less than 10% of myoﬁlament-HCM is associated with a sigmoidal septal 
contour whereas over 80% of Z-disc HCM is sigmoidal. Further studies are under way to 
elucidate the mechanisms whereby Z-disc perturbations predispose to the developmental 
of a hypertrophied septum with a sigmoidal contour. In contrast to reversed curvature-
HCM where the yield of myoﬁlament- and Z-disc genetic testing is > 80%, the current 
yield for sigmoidal-HCM is still < 20%.
11:30 a.m.
817-5 ACTN2-Encoded Alpha-Actinin 2: A Novel Hypertrophic 
Cardiomyopathy Susceptibility Gene
J. Martijn Bos, Melissa L. Will, Steve R. Ommen, Matteo Vatta, Jeffrey A. Towbin, 
Michael J. Ackerman, Mayo Clinic College of Medicine, Rochester, MN, Baylor College 
of Medicine, Houston, TX
Background: Alpha-actinin-2 is the major component of the Z-disc in striated muscle and 
it interacts with several proteins: actin, titin, telethonin, metavinculin, muscle LIM protein 
(MLP), and Z-band Alternatively Spliced PDZ-motif protein (ZASP), all of which have 
been implicated previously in the pathogenesis of both hypertrophic (HCM) and dilated 
cardiomyopathy (DCM). Recently, a mutation in ACTN2-encoded α-actinin-2 has been 
identiﬁed as a novel DCM-susceptibility gene. Furthermore, a HCM-associated mutation 
in MLP that disrupts binding with α-actinin-2 has been reported as well. Therefore, we 
explored ACTN2 as a novel candidate gene in the pathogenesis of HCM in a large cohort 
of unrelated patients with HCM.
Methods: DNA was obtained from 389 patients with HCM (215 male, maximum left 
ventricular wall thickness, MLVWT, 21.6 ± 6 mm) and analyzed for mutations in all 21 
protein-coding exons of ACTN2 using PCR, DHPLC, and direct DNA sequencing. Clinical 
data was extracted from patient records and maintained independent of the genotype.
Results: Overall, 4 ACTN2 mutations (3 novel) were found in 4 patients with HCM. All 
α-actinin-2 mutations (Q9R, G111V, T495M, R759T) were missense mutations, absent in 
600 reference alleles, that involved highly conserved residues. Interestingly, the previously 
described, DCM-associated Q9R-ACTN2 mutation was found in 1 patient who was also 
genotype positive for a myosin binding protein C mutation. The clinical phenotype of 
ACTN2-HCM included i) sex (4 males), ii) age at diagnosis, 33.8 ± 7 years, iii) MLVWT, 19 
± 2 mm, iv) sigmoid shaped septum (3), and v) surgical myectomy (3). Familial studies are 
underway to determine the expressivity and penetrance associated with ACTN2-HCM.
Conclusion: This study provides the ﬁrst molecular evidence to implicate ACTN2 as a 
novel HCM-susceptibility gene and adds to the genetic heterogeneity of Z-disc-HCM. In this 
large cohort of predominantly Caucasian patients with HCM, approximately 1% hosted a 
putative HCM-susceptibility mutation in ACTN2. Overall, ACTN2-HCM is more common than 
tropomyosin-, actin-, regulatory myosin light chain-, or essential myosin light chain-HCM.
11:45 a.m.
817-6 Endocardial Radiofrequency Ablation of Septal 
Hypertrophy for Hypertrophic Obstructive 
Cardiomyopathy: A New Modality of Gradient 
Reduction?
Thorsten Lawrenz, Frank Lieder, Christian Leuner, Markus Bartelsmeier, Bianca 
Borchert, Horst Kuhn, Christoph Stellbrink, Bielefeld Klinikum, Bielefeld, Germany
Background and Methods: The anatomic variability of the vessels supplying the obstructing 
septal bulge sometimes limits the therapeutic efﬁcacy of Transcoronary ablation of septal 
hypertrophy (TASH) in HOCM. Thus, we examined an endocardial approach as an 
alternative. This is the ﬁrst report of 7 pts with severe HOCM treated by endocardial 
radiofrequency (RF) ablation of septal hypertrophy (ERASH). In 5 pts we ablated the right 
ventricular and in 2 pts the left ventricular septum by using an echocardiography and 
ﬂuoroscopy guided technique.
Results: After 14 - 40 RF-pulses (60 sec each, irrigated tip catheter, cool-ﬂow 30 ml/min) 
gradients in the left ventricular outﬂow tract diminished (p = 0.042) and a discrete subaortic 
septal contraction disorder was noticeable in all pts. ERASH resulted in a 50% reduction 
of the resting gradients and in a 30% reduction of the provoked gradients (table). Cardio 
MRI examination on day 3 showed a clear demarcation of the RF lesion in the subaortic 
septum (lesion depth up to 2.8 cm). In 2 pts permanent pacemaker implantation was 
performed after induction of total heart block. In one pt a pericardial tamponade occurred 
during right ventricular ablation.
Conclusions: ERASH leads to signiﬁcant reduction of the gradient in HOCM. This new 
modality of gradient reduction can be used to treat pts with severe HOCM, however, 
the extent of gradient reduction after RF ablation seems to be lower compared to TASH. 
Obviously, careful follow-up evaluation is necessary.
Pt. No. age (y)
septal diameter 
(mm)
ablation site 
(LV/RV)
No. of 
RF-pulses
power 
(w)
resting gradient pre 
abl. (mmHg)
resting gradient after 
abl. (mmHg)
post-VE gradient pre 
abl. (mmHg)
post-VE gradient after 
abl. (mmHg)
1 53 26 LV 20 40 100 50 200 160
2 72 20 LV 14 40 140 90 260 130
3 45 28 RV 40 40 100 20 200 140
4 50 30 RV 40 50 120 80 200 170
5 78 20 RV 26 50 80 20 200 140
6 81 20 RV 26 50 120 30 240 80
7 62 22 RV 37 50 80 40 200 160
Noon
817-7 Evidence for Differential Tissue Effects of Alcohol 
Septal Ablation and Surgical Septal Myectomy on Left 
Ventricular Myocardium
Uma S. Valeti, Rick A. Nishimura, Hartzell A. Schaff, David R. Holmes, Philip A. Araoz, 
Jerome F. Breen, Steve R. Ommen, Charanjit S. Rihal, Bernard J. Gersh, A. Jamil Tajik, 
Barry J. Maron, Mayo Clinic, Rochester, MN, Minneapolis Heart Institute Foundation, 
Minneapolis, MN
Background: There is signiﬁcant controversy regarding the different tissue effects of 
surgical septal myectomy (SM) and alcohol septal ablation (ASA) in severely symptomatic 
patients with obstructive hypertrophic cardiomyopathy (HCM). The objective of this study 
was to describe the acute morphologic differences that result from SM and ASA using 
cardiac magnetic resonance imaging (CMR).
Methods: Cine and contrast-enhanced CMR images were obtained in HCM patients 
before and after SM (n=24) and ASA (n=24). The location of the septal reduction and 
extent of myocardial necrosis with each technique were compared.
Results: With SM there was a discrete non-transmural area of resected tissue localized 
to anterior septum, without evidence of post-operative intramyocardial necrosis at or near 
the site of muscular resection (A). In contrast, ASA caused a large infarction, located 
more inferiorly in the basal septum (B) and usually extending into the right ventricular 
side of the septum at mid-ventricular level. Area of infarction due to ASA occupied 8±3% 
of LV mass, 3 fold greater than the average amount of tissue resected by myectomy 
(p<0.0001).
Conclusions: SM and ASA for severely symptomatic patients with obstructive HCM 
have substantially different tissue effects on septal myocardium, in which only ASA 
produced an intramyocardial infarction. This study provides evidence for the absence of 
intramyocardial necrosis after SM and has important implications for patient selection, as 
well as long-term outcome.
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817-8 Anomalous Papillary Muscles as the Predominant 
Cause of Left Ventricular Outﬂow Tract Obstruction 
in Hypertrophic Cardiomyopathy: A Novel Form of 
Disease?
Ross T. Murphy, Ben T. Fitzgerald, Diana Dolney, Nicholas Smedira, E. R. Rodriguez, 
Adel Younoszai, Harry M. Lever, The Cleveland Clinic Foundation, Cleveland, OH
Background: Left ventricular outﬂow tract obstruction (LVOTO) in Hypertrophic 
Cardiomyopathy (HCM) is associated in most cases with systolic anterior motion of the 
mitral valve, for which the mechanisms are now well elucidated. We report a series of 
patients where intrinsic abnormalities of the papillary muscles led to symptomatic LVOTO 
in the context of mild LV hypertrophy.
Methods: Patients with papillary muscle abnormalities were identiﬁed from a large cohort 
(n=2080) referred to a HCM clinic. Transthoracic/transesophageal echocardiographic 
studies were examined and papillary muscle attachment, position and hypertrophy 
were delineated and correlated with cardiac magnetic resonance imaging (MRI) and 
intraoperative ﬁndings, where applicable.
Results:Twenty-ﬁve patients (median age 43, range 12-79, males 16) were identiﬁed 
where the predominant mechanism for LVOTO was papillary muscle anomalies. ECG 
showed LVH in only 11 patients. Mild LV hypertrophy was noted (median interventricular 
wall thickness of 17 mm (range 9-24), posterior wall 13 mm). Signiﬁcant LVOTO obstruction 
was present in all 25 patients with a mean gradient of 51mmHg at rest and 109mmHg on 
provocation with amyl/exercise. Anomalies included papillary muscle attachment directly 
to the mitral valve (n= 8), attachment to the LV free wall or septum (n= 4), tethering by 
accessory chordae to the LV free wall (n= 6) or asymmetrical hypertrophy and malrotation 
of the papillary muscles (n=11). Biﬁd papillary muscle heads were noted in 4 patients. 
Five patients underwent MRI with no evidence of ﬁbrosis/disarray in 4. Thirteen patients 
underwent modiﬁed myectomy with partial excision of the papillary muscle (n = 7), and 
mitral valve repair/replacement (n=6). Histology showed extensive myocardial ﬁbrosis and 
in two cases no disarray or myocyte hypertrophy, suggesting an atypical form of HCM.
Conclusions: Isolated papillary muscle abnormalities in the context of mild LVH may be 
associated with severely symptomatic LVOTO on exercise provocation. These anomalies 
may require surgical therapy targeted at the underlying mechanisms and represent an 
atypical form of disease distinct from sarcomeric HCM.
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985-47 Asymmetrical Dimethylarginine (ADMA) Is Elevated In 
Heart Failure, Independently From Oxidative Stress 
And Inﬂammatory Status
George Andreou, Dimitris M. Tousoulis, Charalambos Antoniades, Carmen Vasiliadou, 
Athanasios Trikas, Maria Karali, Christos Pitsavos, Elli Stefanadi, Gerasimos Siasos, 
Christodoulos Stefanadis, Athens University, A Cardiology Department, Athens, Greece
Background: Heart failure is associated with endothelial dysfunction, which is probably 
due to both decreased nitric oxide (NO) production and increased oxidative inactivation. 
Proinﬂammatory cytokines are also elevated in heart failure, and they also contribute to 
endothelial dysfunction. However, the role of asymmetrical dimethylarginine (ADMA) and 
the regulatory role of oxidative stress and proinﬂammatory cytokines in its synthesis in 
heart failure have not been investigated until now.
Methods: Thirty subjects (aged 67.2±4.4 years old)of both sexes were included in this study: 
13 patients with congestive heart failure and 17 healthy individuals, matched for age and sex 
with patients. Serum levels of oxidized LDL (ox-LDL), ADMA, Interleukin 6 (IL-6) and tumor 
necrosis factor alpha (TNF-α) were evaluated by enzyme-linked immunosorbent assay.
Results: Patients with heart failure had higher levels of ADMA (1.03±0.06IU/L), ox-LDL 
(90.0±8.4IU/L), TNF-α (4.32±1.11pg/ml) and IL-6 (6.43±1.55pg/ml) compared to healthy 
controls (0.62±0.03 IU/L, 59.3±8.8IU/L, 1.90±0.21 pg/ml and 1.21±0.13pg/ml respectively, 
p<0.01 for all). However, among heart failure patients, there was no correlation between 
ADMA and ox-LDL (r=0.319, p=0.228), IL-6 (r=-0.40, p=0.175) and TNF-α (r=-0.368, 
p=0.216). Similarly, there was no correlation between ADMA and ox-LDL (r=0.440, 
p=0.132), IL-6 (r=0.210, p=0.452) and TNF-α (r=-0.372, p=0.172). In stepwise multivariate 
regression, heart failure was the only independent predictor for all the examined variables 
such as ADMA, ox-LDL, IL-6 and TNF-α (p<0.01 for all).
Conclusions: Serum levels of ADMA are elevated in heart failure, contributing to the 
development of endothelial dysfunction in these patients. However, despite the previous 
reports from animal models that free radicals and proinﬂammatory cytokines induced 
ADMA release, we found no association between ADMA and oxidative stress or 
proinﬂammatory cytokines in either patients with heart failure or controls, implying that 
different mechanisms may regulate ADMA levels in different disease states.
985-48 Nitroxyl Increases Contractility in Failing (Gαq 
Overexpressing) Cardiomyocytes That Display Altered 
Cellular Redox Conditions
Carlo G. Tocchetti, Miguel A. Aon, Eiki Takimoto, Manuela Zaccolo, Brian O’Rourke, 
Jeffrey P. Froehlich, Gerald W. Dorn, II, David A. Kass, Nazareno Paolocci, Johns 
Hopkins University, Baltimore, MD
Background: Nitroxyl (HNO), donated by Angeli’s salt (AS), exerts similar in vivo positive 
inotropic action in control and congestive heart failure. Yet, whether and to what extent 
HNO is capable to directly inﬂuence in vitro failing myocyte function is unknown. Altered 
redox conditions are present in CHF and HNO action is blunted by changes in milieu 
redox state. Hence, HNO action can be altered in failing myocytes. 
Methods: We used myocytes isolated by Gαq overexpressing mice, displaying hypertrophy 
and cardiac failure. Using a two-photon microscopy approach, we measured intracellular 
reduced glutathione (GSH) content via production of the ﬂuorescent glutathione adduct 
GSB from the reaction of cell permeant monochlorobimane (MCB) with reduced glutathione. 
For functional studies, myocytes from WT type (FVBN) and Gαq mice were suspended in 
Tyrode’s solution (1mM Ca2+) and ﬁeld stimulated (0.5 Hz, 23°C). Sarcomere shortening 
(SS) was assessed by real-time image analysis. Data are presented at steady-state 
Results: Myocytes isolated from Gαq hearts displayed a marked reduction in intracellular 
thiol content (-14% in ﬂuorescence a.u. vs controls, n=35 each, p<0.005) and were 
insensitive to isoproterenol (ISO) stimulation. Sarcomere shortening was -4±10% and 
19±14 with 2.5 and 10nM ISO, respectively, as opposed to 74±24% and 250±75% in WT 
cells (p=0.02 vs Gαq for both), conﬁrming desensitization to β-agonists in these mice. 
HNO, in contrast, showed a positive inotropic effect: AS increased SS by 22±11% and 
40±11% at 250 and 500µM, respectively (both p<.05 vs baseline, n=10). However, HNO 
action was lower than that obtained in normal myocytes: 61±15% and 103±19% (p<0.05 
and <0.01 vs same doses in Gαq). 
Conclusions: HNO elicits a substantial positive inotropy in myocytes isolated from mice 
displaying compromised β-driven cardiac contractile reserve and reduced antioxidant 
defense. Our data conﬁrm, at cellular level, that HNO cardiotropic action is unrelated to 
β-adrenergic signaling while highlight that changes in reducing equivalents may soften 
HNO response. The cellular mechanisms of the latter effect remain to be elucidated.
985-49 Activation of Focal Adhesion Kinase and Neuronal 
Nitric Oxide Synthase in Right Ventricular Myocardium 
of Rats With Right-sided Congestive Heart Failure
Soban Umar, Marleen H. Hessel, Wilhelmina H. Bax, Cindy Schutte, Paul Steendijk, 
Arnoud van der Laarse, Leiden University Medical Center, Leiden, The Netherlands
Background: Focal adhesion kinase (FAK) is an important component of an integrin-
dependent signaling pathway leading to a hypertrophic response in cardiomyocytes. 
Neuronal nitric oxide synthase (nNOS) induced NO production modulates myocardial 
inotropic state. Matrix metalloproteinases (MMPs) are matrix-degrading enzymes implied 
in ventricular remodeling. We assessed the activation of FAK, nNOS, MMP-2 and MMP-9 
in RV myocardium of rats with right-sided heart failure.
Methods: Rats were treated without (CONT, n=4) or with monocrotaline in low dose (30 
mg/kg, n=5) to induce compensated right ventricular hypertrophy (RVH) and in high dose 
(80 mg/kg, n=5) to induce right ventricular failure (RVF). After 28-33 days RV function was 
determined using the pressure conductance catheter. After sacriﬁce, hearts were dissected; 
RV, LV and interventricular septum were cut free, weighed, ﬁxed and embedded. FAK, 
nNOS and their phosphorylated forms, FAK-P and nNOS-P and immunoreactive MMP-2 
and MMP-9 were quantiﬁed in RV myocardium by immunohistochemical methods.
Results: Ratio of RV over ventricular weight (mean ± SD) was 0.22±0.02 in CONT, 
0.28±0.01 in RVH (p<0.05 vs CONT) and 0.34±0.04 in RVF (p<0.05 vs CONT and vs 
RVH), conﬁrming RV hypertrophy in both groups. RV ejection fraction was 53.2±5.7% in 
CONT, 40.9±9.6% in RVH and 22.7±6.9% RVF (p<0.01 vs CONT), while RV end-diastolic 
pressure (mm Hg) was 1.4±0.4 in CONT, 3.6±0.4 in RVH, and 8.0±1.5 in RVF, conﬁrming 
RV failure in RVF. Myocardial FAK-P concentration as well as the ratio FAK-P / FAK were 
highest in RVH (2.87 and 1.34 times the CONT, respectively) and lowest in RVF (1.76 and 
0.49 times). nNOS-P and the ratio nNOS-P / nNOS were highest in RVF (2.16 and 1.7 
times). MMP-2 was highest in RVH (3.5 times the CONT) and lower in RVF (1.84 times) 
but MMP-9 in RVF was raised (2.65 times).
Conclusions: Phosphorylation of FAK was most pronounced in hypertrophic RV 
myocardium, and lower in failing RV, whereas phosphorylation of nNOS was most 
pronounced in failing RV myocardium. The role of excessive NO formation in failing 
myocardium is not yet fully elucidated, but it may be responsible for peroxynitrite formation 
and MMP activation, leading to ventricular remodeling.
985-50 Sex Determines Differences in Left Ventricular Diastolic 
Properties in the Model of Chronic Estrogen Deﬁciency
Deborah L. Crabbe, Son M. Pham, Alfred Bove, Jie Yang, Steven R. Houser, Temple 
University School of Medicine, Philadelphia, PA
Background: Diastolic heart failure is a disease which primarily affects women, yet 
limited information exists regarding the mechanism behind this observation. Sex-speciﬁc 
differences in LV diastolic properties may contribute to disease development. We sought 
to understand the inﬂuence of sex on LV diastolic properties and the role of ovarian 
hormones in altering diastolic function.
Methods: Lewis-Brown Norway female rats underwent sham and ovariectomy (OVX) 
and were followed for 29 weeks along with age matched males. Volume-pressure (V-P) 
relationships were measured in Langendorff perfused hearts. A regression analysis was 
performed to evaluate the differences between the slopes of the V-P relationship. Data 
are expressed as mean slope ± SEM. The differences between the slopes were analyzed 
using a student’s t test. A p value of <0.05 was considered signiﬁcant.
Results: No statistically signiﬁcant differences in initial ventricular volumes were noted 
between gender. An upward shift in the V-P relation was seen among males compared to 
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females (7.084 ± 0.47 vs. 3.276 ± 0.579, p< 0.001). In contrast, among the OVX females 
there was a trend toward an upward shift in the compliance curves compared to the sham 
group (4.54 ± 0.305 vs. 3.276 ± 0.579, p< 0.06).
Conclusions: In the absence of pathology, a difference exists in the diastolic properties 
of the LV according to sex. These differences may explain the propensity for diastolic 
dysfunction among females.
985-51 Electrical Stimulation of Sympathetic Nervous System 
Delivered Through the Pulmonary Artery Increases 
Contractility
Sandra B. Machado, Zoran Popovic, Xiarong Zhou, Andre G. Machado, Kenneth Baker, 
Ali Rezai, Marc S. Penn, The Cleveland Clinic Foundation, Cleveland, OH
Background: The challenge of improving contractility through sympathetic stimulation 
is to achieve it without affecting heart rate. Animal studies have provided evidence that 
separation of these functions exists at the level of the sympathetic nerve projections 
around the superior, dorsal and rostral area of the common pulmonary artery. The 
purpose of this study was to evaluate a strategy for neuromodulation of those ﬁbers using 
an intravascular approach at the level of the pulmonary artery (PA).
Methods: Five open-chest dogs were instrumented with left ventricle conductance 
catheter and aortic ﬂow probe. A basket-electrode catheter was placed inside the PA and 
used for a graded electrical stimulation. Pulse amplitude was varied between 5-25 mA in 
a 20 Hz frequency and delivered for a period of 1 minute, with an inter-stimulus interval 
of 30 seconds.
Results: The average of increase in dP/dt max and aortic ﬂow during stimulation was 
27.8± 9.9% and 27.2±11.2%, respectively. An average of 3.6± 2.1% decrease in heart 
rate during stimulation. Repeated-measures linear regression showed a moderately 
strong dose-response relationship (r=0.64, p=0.0025; Figure).
Conclusions: Electrical stimulation via a pulmonary artery catheter can produce positive 
inotropic effect with a concomitant decrease in heart rate. The current study demonstrates 
the feasibility of this novel, intravascular approach to neuromodulation of the heart
. 
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986-52 Haemodilution Is the Primary Cause of Mild Anaemia in 
Heart Failure
Lwin L. Tin, Kevin Goode, Ann Tweddel, Trevor Davies, Jonathan Windram, Poay H. Loh, 
Periaswamy Velavan, Rhidian Shelton, John GF Cleland, University of Hull, Kingston-
upon -Hull, United Kingdom, Castle Hill Hospital, Cottingham, United Kingdom
Background Several studies have shown that mild anaemia in heart failure patients 
treated with erythropoeitin and iron led to improvement in quality of life. However anaemia 
may be due to haemodilution rather than an absolute reduction in red cell mass, and 
those patients may need alternate treatment.
Methods Of 366 patients attending a community-based clinic for the management of 
their heart failure over a 6-month period 127 ( 34%) were identiﬁed as having anaemia 
according to the WHO criteria (males haemoglobin (Hb)<13 g/dL; females Hb<12 g/
dL). Those with normal haematinic proﬁles, no clinical evidence of ﬂuid overload and 
no concomitant chronic illness were invited to participate in the study. Patients were 
assessed for haemodilution using Chromium-51 labelled red cell mass (RCM) scan. 
All patients had moderate-severe left ventricular systolic dysfunction (MSLVSD) on 
echocardiography, were optimal and stable medication at least one month. Patients with 
MSLVSD and normal Hb levels were invited to participate as “controls”.
Results 21 patients participated in the study of which 13 were anaemic and 8 controls. 
The anaemic subjects and controls had statistically non-signiﬁcant differences in age 
(72.6 +/- 6.3 v 66.3 +/- 12 years), serum creatinine (134 =/- 42 v 191=/- 211umol/l), 
left ventricular ejection fraction (33.9+/-6.1% v 33.4+/-4%), furosemide equivalent dose 
(51mg v 57 mg). There were also non-signiﬁcant differences in haematinic levels, blood 
pressure, heart rate, left ventricular dimensions, and right ventricular systolic pressures. 
Mean Hb in the anaemic group was 11.5g/dl v 13.2 g/dl in the control group (p< 0.01).
The RCM in both anaemic subjects and controls were within the sex speciﬁc normal 
ranges (1280-2147 ml in males and 1116-1855 ml in females). The mean percentage 
difference between the measured RCM and the mean normal predicted value for the 
individual was 0.97% in the anaemia group and 1.0% in the control group (p=0.57).
Conclusion The results show that patients with MSLVSD and mild anaemia have red 
cell mass within the normal ranges. Anaemia in these patients is due to haemodilution. 
Erythropoeitin therapy in these patients will need to be carefully considered.
986-53 Blunted Hemodynamic Response and Reduced Oxygen 
Delivery With Exercise in Anemic Heart Failure Patients
Javed Butler, Jennifer Listerman, Carrie Giesberg, Mary Alice Nading, Joann Goring, 
Robert Huang, Vanderbilt University, Nashville, TN
Background: Anemic heart failure patients are known to have reduced exercise capacity. 
Whether this is related to poor hemodynamic adaptation to anemia is not known.
Methods: Peak exercise oxygen consumption, systemic and pulmonary hemodynamics, 
and oxygen extraction at rest and at peak exercise were assessed among 209 heart 
failure patients and compared among those who were (n=90) and were not (n=119) 
anemic (deﬁned as <13 mg/dl in men and <12 mg/dl in women).
Results: Mean hemoglobin level was 11.5±1.3 mg/dl in anemic and 14.1±1.4 mg/dl in 
nonanemic patients. Peak exercise oxygen consumption was signiﬁcantly lower among 
anemic patients (11.7±3.3 ml/min/kg vs. 13.4±3.1 ml/min/kg, p=0.01). At rest, right atrial 
pressure was signiﬁcantly higher (10±5 vs. 8±4, p=0.02) and mixed venous oxygen 
saturation lower (62±8% vs.58±10%, p<0.01) among anemic patients. At peak exercise, 
anemic patients had a signiﬁcantly higher pulmonary capillary wedge pressure (27±9 
vs. 24±10, p=0.04). No signiﬁcant absolute differences at peak exercise or proportional 
difference between resting and exercise in heart rate, stroke volume, cardiac output, 
cardiac index, systemic vascular resistance, or oxygen saturation were noted between 
anemic and non-anemic patients. Mean oxygen extraction was 117±9 ml/L vs. 140±10 
ml/L (p<0.01) in anemic vs. non-anemic patients at peak exercise. Proportional oxygen 
extraction was 2.05 in anemic and 2.22 in non-anemic patients which was substantially 
lower than the normal oxygen extraction reserve of 3. These results remained unchanged 
when only patients on beta-blocker therapy were assessed speciﬁcally.
Conclusions: The relative hemodynamic response to exercise among anemic heart failure 
patients is blunted and may contribute to worse exercise tolerance in these patients.
986-54 Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) 
as a Novel and More Stable Prognostic Marker in 
Chronic Heart Failure (CHF)
Stephan von Haehling, Ewa A. Jankowska, Nils G. Morgenthaler, Wolfram Doehner, 
Piotr Rozentryt, Gerasimos S. Filippatos, Friedrich Kohler, Joachim Struck, Piotr 
Ponikowski, Andreas Bergmann, Stefan D. Anker, National Heart and Lung Institute, 
London, United Kingdom, BRAHMS AG, Hennigsdorf/Berlin, Germany
BACKGROUND:Natriuretic peptides are powerful predictors of survival in CHF. ANP 
comprises 98% of all natriuretic peptides in the circulation. Its relative instability compared 
to other natriuretic peptides limits its prognostic value. Mid-regional proANP (MR-proANP) 
is highly stable in vivo and ex vivo.
METHODS: We investigated 567 CHF patients (age 61±12 yrs, NYHA class 2.6±0.8, 
LVEF 31±10%, serum creatinine 110±43 µmol/L, 87% male, 69% ischemic etiology) 
from 5 European centers. MR-proANP was detected using a novel commercial assay 
(B.R.A.H.M.S. Seristra Luminescence Immuno Assay). The functional assay sensitivity 
(inter assay CV <20%) is 20 pmol/L, and the stability of MR-proANP at room temperature 
is >24 hours. Median MR-proANP in 325 healthy individuals in previous investigations 
was 45 pmol/L (95% CI 43-49 pmol/L).
RESULTS: Mean MR-proANP in our CHF population was 336±299 pmol/L (range: 24.5-
2150). MR-proANP increased with NYHA class (I: 173±146; II: 264±223; III: 359±269; 
IV: 577±448 pmol/L, p<0.001 for all comparisons except NYHA I vs II [p<0.05]). In a 
multivariate model, MR-proANP correlated with serum creatinine (r=0.33, p<0.0001) and 
LVEF (r=-0.22, p=0.001), but not with etiology, age, and sex (all p>0.2). During follow-
up (23 to 4879 days in survivors, median 459 days), 122 patients (21%) died after 1 to 
3678 days (median 298 days). The 1- and 5-year mortality were 14% (95% CI 10-18%) 
and 38% (95% CI 30-46%), respectively. In univariate Cox proportional hazard analysis, 
MR-proANP, NYHA class, serum creatinine, LVEF (all p<0.0001), and age (p=0.003) all 
predicted survival. Increasing MR-proANP was a predictor of poor survival (hazard ratio 
1.080 per 100 pmol/L, 95% CI 1.023 to 1.140, p=0.0056), independently of age, sex, 
etiology, LVEF, NYHA class, and creatinine. 18-month mortality was 8% (95% CI 4-12%), 
22% (95% CI 13-31%), 34% (95% CI 26-42%), and 56% (95% CI 50-62%) in ascending 
quartiles of MR-proANP (p<0.0001).
CONCLUSIONS: MR-proANP is a powerful new predictor of mortality in patients with CHF, 
independently of established prognosticators. Its abundance in the circulation and high 
sample stability make it an ideal candidate for screening tests and epidemiological studies.
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986-55 Collagen Turnover is Initiated in the Early Phase of 
Congestive Heart Failure
Satoru Mochizuki, Masaru Ichida, Keiji Yamamoto, Yukihiro Hojo, Sarukawa Mutsuko, 
Kazuyuki Shimada, Jichi Medical School, Tochigi, Japan
Background: Extracellular matrix (ECM) turnover is an essential process found in 
cardiac remodeling in heart failure. Cardiac ﬁbrosis is a major determinant of diastolic 
function and pumping capacity. Measurement of myocardial collagen turnover by use of 
serological markers is a useful tool for monitoring cardiac tissue repair and ﬁbrosis. The 
purpose of the present study was to investigate, in patients with congestive heart failure 
(CHF), the value of these serological markers for cardiac ECM turnover. 
Methods: We determined levels of procollagen type III aminoterminal peptide (PIIINP), a 
marker of collagen type III synthesis, pyridinoline cross-linked carboxyterminal telopeptide 
of type I collagen (ICTP), a marker of collagen type I degradation, IL-6, BNP, aldosterone, 
and angiotensin II in 40 normal subjects, 30 mild CHF patients with NYHA I or II and 29 
severe CHF patients with acute exacerbation (NYHA III or IV). In severe CHF patients, 
blood sampling was performed at admission and on 14 days after admission. 
Results: At admission, PIIINP, ICTP, BNP and IL-6 levels in severe CHF patients were 
higher than those in normal and stable CHF patients (PIIINP; 0.65±0.03 vs. 0.50±0.01 
and 0.54±0.02, p<0.001; ICTP, 7.56±0.74 vs. 3.61±0.20 and 2.94±0.10, p<0.001; 
BNP, p<0.001; IL-6, p<0.001). Although BNP and IL-6 levels were decreased during 
hospitalization (BNP, p<0.001; IL-6, p<0.001), ICTP level was increased (p<0.001). PIIINP 
level, however, didn’t change and continued high level during hospitalization. In acute 
phase of CHF, ICTP level was correlated with BNP and IL-6 levels (r=0.52, p<0.01 and 
r=0.45, p<0.05), respectively. ICTP level showed positive correlation with PIIINP level 
(r=0.56, p<0.01). 
Conclusions: This study demonstrated that the production and degradation of collagen 
were initiated in acute phase of CHF and that collagen degradation remained accelerated 
during hospitalization, leading to cardiac remodeling. These ﬁndings suggested that 
stabilization of collagen turnover is most important in acute phase treatment of CHF.
986-56 Alternate BNP Forms in Preclinical Ventricular 
Dysfunction or Overt Heart Failure
Carolyn S.P. Lam, John C. Burnett, Jr., Richard J. Rodeheffer, Steven J. Jacobsen, 
Margaret M. Redﬁeld, Mayo Clinic and Foundation, Rochester, MN
Background: Biologically active BNP (BNP 77-108) is derived from proBNP (1-108) via 
proteolytic cleavage and is detected by the Biosite Triage assay. Alternative processing 
of proBNP may occur. Two dual antibody assays for potential alternate BNP forms were 
prepared. One targets a unique N terminus (aa 3 of proBNP) and part of BNP 77-108 
(called BNP 3-108 assay) and one targets a unique N terminus (aa 79 of proBNP) and 
part of BNP 77-108 (called BNP 79-108). Both assays require both the speciﬁc N terminus 
and the BNP 77-108 segments for detection.
Objective: To determine if alternate BNP forms detectable by these assays were present 
in the plasma and have diagnostic utility.
Methods: Residents (age>45) of Olmsted County, MN, (n=2042) underwent medical 
review, Doppler echo and measurement of BNP by the Triage, BNP 3-108 and BNP 79-
108 assays (Biosite). Subjects were designated as 1) overt HF, 2) preclinical systolic 
dysfunction (PSD, EF ≤ 40%), 3) preclinical diastolic dysfunction (PDD), and 4) controls
Results: Detectable BNP 3-108 was found in 68.8% controls, 95.5% overt HF, 86.7% 
PSD and 85.7% PDD. Detectable BNP 79-108 was found in 22.3% controls, 41.2% overt 
HF, 13.3% PSD and 19.6% PDD. Table shows area under receiver operating curve (AUC) 
for detection of overt HF, PSD and PDD: 
BNP 77-108 BNP 3-108 BNP 79-108
N Mean level (pg/ml) AUC P value
Mean level 
(pg/ml) AUC P value
Mean level 
(pg/ml) AUC P value
Overt HF 52 140±152 0.85 <0.001 553±406 0.80 <0.001 465±2569 0.60 0.042
PSD 19 107±120 0.84 <0.001 319±362 0.61 0.133 5±14 0.45 0.518
PDD 121 69±78 0.74 <0.001 340±435 0.64 <0.001 45±352 0.49 0.660
Controls 1850 25±28 - - 203±328 - - 99±1096 - -
Conclusion: Neither of these assays was superior to the Triage assay. However, the data 
suggest that alternate forms of BNP circulate and could cross react with existing BNP 
assays but have altered activity.
986-57 Paradoxical Decrease in Plasma N-Terminal-proBNP 
(NT-proBNP) Levels in Patients Receiving Doxorubicin 
Chemotherapy and Declining Left Ventricular Ejection 
Fraction
Rohit Bhatheja, Deepa Taneja, Mihir Bakhru, Wilson Tang, Gary S Francis, Frederick 
Van Lente, Tao Jin, Denise Howard, G Thomas Budd, Brad Pohlman, Steve Andresen, 
David E Weng, Cleveland Clinic Foundation, Cleveland, OH
Background: Doxorubicin is a widely used chemotherapeutic drug. However, dose-
related cardiotoxicity in the form of CHF is the most worrisome complication. BNP is a 
cardioprotective peptide produced in the setting of cardiac dysfunction and increased 
myocardial stretch. Increased level of BNP is known to be associated with left ventricular 
dysfunction (LVD) after chemotherapy. Role of NT-proBNP in monitoring doxorubicin-
induced cardiomyopathy has not been tested prospectively. Recently, animal data 
has shown that doxorubicin inhibits BNP gene expression and its secretion in cardiac 
myocytes.
Methods: We prospectively followed 24 consecutive patients from March 2004 through 
April 2005 who were to receive doxorubicin as initial chemotherapy at a total dose of > 240 
mg/m2. Patients were excluded if they received mediastinal radiation, had history of CHF 
or LVD, or were receiving continuous infusional doxorubicin. Plasma NT-proBNP (Roche) 
was done at baseline and serially with each chemotherapy. Results were blinded to the 
treating physician. An echocardiogram was obtained at baseline and after completion of 
chemotherapy.
Results: In our cohort (mean age 55+10 years), the mean dose of doxorubicin was 280.9 
mg/m2 and the mean NT-proBNP did not change signiﬁcantly over the course of treatment 
(p=0.32). In patients with a decline in LVEF >5% following chemotherapy (n=9), there was 
an inverse correlation (Pearson’s correlation r= -0.69, p=0.039) between the cumulative 
dose of doxorubicin and an overall change in levels of NT-proBNP. Patients with a decline 
in LVEF of >5% received a higher dose of doxorubicin (304.3 mg/m2 vs. 264.5 mg/m2, 
p=0.60) and had a greater reduction in NT-proBNP (-189.1 pg/ml vs. - 32.6 pg/ml, p=0.29) 
when compared to those with preserved LVEF. None of the patients developed clinical 
heart failure.
Conclusions: In patients who have evidence of decreased LVEF after doxorubicin 
chemotherapy, an increased dose of doxorubicin was paradoxically associated 
with a decrease in the levels of NT-proBNP. This new observation suggests an acute 
suppressive effect of doxorubicin on the expression of NT-proBNP and may contribute to 
the pathophysiology of cardiotoxicity of this drug.
986-58 Cardiac Troponin T in Heart Failure: Results from Val-HeFT
Inder S. Anand, Roberto Latini, Michael Kuskowski, Emil Missov, Marjorie Carlson, 
Serge Masson, Tarcisio Vago, Aldo Maggioni, Jay N. Cohn, VA Medical Center, 
Minneapolis, MN, University of Minnesota, Minneapolis, MN
Background:  Small studies have shown that cardiac troponin T (cTnT) is associated with 
adverse outcomes in patients with heart failure (HF). However, little is known about the 
proﬁle of HF patients with elevated cTnT, and whether de novo release of cTnT during 
long-term follow-up of patients with stable chronic HF inﬂuences prognosis.
Methods: cTnT (Roche Diagnostics) was measured at baseline (n=4071) and at 4 months 
(n=3862) in patients randomized to Valsartan Heart Failure Trial. Baseline characteristics 
of patients with or without detectable cTnT were compared using Chi-square or T-tests. 
Cox proportional-hazards regression models were used to assess the association 
between multiple baseline explanatory variables and time to death, ﬁrst morbid event, 
or hospitalization for HF.
Results: At baseline, there were 423 (10.4%) patients with detectable cTnT (median 
0.027 ng/mL, range 0.01 to 0.58 ng/mL). These patients had worse HF with higher NYHA 
class, greater volume overload, lower blood pressure, lower EF, reduced glomerular 
ﬁltration rate, higher CRP, norepinephrine, BNP, aldosterone and plasma renin activity, 
and lower use of beta-blockers (all p<0.01). However, elevated cTnT was not associated 
with ischemic etiology. Presence of cTnT increased the risk of time to death (HR, 3.33, 
95% CI, 2.83-3.93), ﬁrst morbid event (HR 3.0, 95% CI, 2.61-3.44), and ﬁrst hospitalization 
for HF (HR 3.14, 95% CI, 2.61-3.79). In a multivariable model that included age, sex, 
LV size, LVEF, ischemic etiology, use of statin, aspirin and other HF medications, cTnT 
remained a signiﬁcant independent predictor of the risk of mortality (HR, 1.6, 95% CI, 
1.3-2.0), ﬁrst morbid event (HR 1.5, 95% CI, 1.24-1.74), and hospitalizations for HF (HR, 
1.37, 95% CI, 1.09-1.73). During follow-up, de novo release of cTnT was found in 114 
(3.6%) patients at 4 months. This was associated with an even higher adjusted risk of 
subsequent mortality (HR, 3.23, 95% CI, 2.31-4.51), ﬁrst morbid event (HR, 3.0, 95% CI, 
2.26-4.0), and hospitalizations for HF (HR, 3.14, 95% CI, 2.16-4.58).
Conclusions: cTnT is an important prognostic marker for adverse events in HF patients, 
independent of other markers and unrelated to ischemic etiology.
986-59 Do Biomarkers Add Prognostic Information to Routine 
Measures of the Severity of Heart Failure?
Inder S. Anand, Thomas Rector, Roberto Latini, Serge Masson, Aldo P. Maggioni, Jay N. 
Cohn, VA Medical Center, Minneapolis, MN, University of Minnesota, Minnespolis, MN
Background: Several routinely measured variables are associated with mortality in 
patients with heart failure. Additional prognostic information gained by measurement 
of NT-proBNP, norepinephrine (NE), C-reactive protein (hs-CRP), and high sensitivity 
troponin (hs-TnT, Roche Diagnostics, under development) remains unclear.
Method: Baseline variables from Val-HeFT were used to predict death at 1-year. Data 
from patients with all 4 biomarkers were then included in the analysis (n=3720, 320 
deaths). Discrimination of deaths was quantiﬁed by the area under the receiver-operator 
characteristic curve (ROC).
Results: ROC derived by logistic regression of death within 1-year on age, sex, NYHA 
class, systolic BP, cholesterol, blood urea nitrogen, hemoglobin, uric acid (UA), and 
ejection fraction (EF) was 0.69 (95% CI 0.66-0.72). Individual ROCs were 0.71 (0.67-
0.73) for NT-proBNP, 0.70 (0.67-0.73) for hs-TnT, 0.63 (0.60-0.66) for NE and 0.59 (0.55-
0.62) for hs-CRP. Addition of all 4 biomarkers to the model signiﬁcantly increased the 
ROC to 0.73 (0.70-0.76, p<0.001). Sequential deletion of hs-CRP, NE and hs-TnT did not 
reduce the ROC signiﬁcantly. NT-proBNP signiﬁcantly increased the ROC from 0.69 to 
0.72 (0.69-0.75, p<0.001).
Conclusion: NT-proBNP alone discriminated as well as the combined use of several 
routinely measured variables, and added signiﬁcant prognostic information. Measurement 
of hs-CRP, hs-TnT and NE did not improve the identiﬁcation of patients who would die 
within 1-year. 
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986-60 Beta 1 Adrenergic Receptor Gly389Arg Polymorphism 
and the Impact of Fixed-Dose Combination of 
Isosorbide Dinitrate/Hydralazine in Heart Failure: 
Results From the A-HeFT trial
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelman, Amy 
Palmer, Karen Janosko, Arthur M. Feldman, Manuel Worcel, University of Pittsburgh, 
Pittsburgh, PA, NitroMed, Inc, Lexington, MA
Background: The Gly389Arg polymorphism of the beta 1 adrenergic receptor (B1AR) 
modulates adrenergic tone. The Arg389 variant has a greater response to agonists and 
has been linked to greater impact of beta receptor blockade. The interaction of beta 
receptor heterogeneity with the ﬁxed-dose combination of isosorbide dinitrate/hydralazine 
(ISDN/HYD) has not been previously investigated. We examined the interaction of the 
B1AR Gly389Arg polymorphism, ISDN/HYD therapy and clinical outcomes in the A-HeFT 
trial.
Methods: Three hundred and ﬁfty-three subjects from A-HeFT enrolled in the Genetic 
Risk Assessment in Heart Failure (GRAHF) sub-study were genotyped for the Beta 
1 Gly389Arg polymorphism. The impact of ISDN/HYD in A-HeFT was compared by a 
composite score which incorporated heart failure hospitalizations, mortality, and quality of 
life (QOL). In GRAHF, event free survival (all cause death and heart failure hospitalization) 
and composite score were compared by B1AR genotype in subjects receiving placebo 
and in those receiving ISDN/HYD.
Results: In GRAHF 58 subjects were Gly389Gly (16%), 183 Gly389Arg (52%), and 112 
Arg389Arg (32%); 187 were treated with placebo (53%) and 166 (47%) with ISDN/HYD. 
For subjects receiving placebo, the Arg allele was associated with a non-signiﬁcant 
trend toward lower mean composite score (placebo: GlyGly/GlyArg/ArgArg=0.23 /-
0.10/-0.25, p=0.27) which was reversed on ISDN/HYD (ISDN/HYD= -0.11/0.15/0.40, 
p=0.17). In Arg389Arg subjects, ISDN/HYD treatment was associated with signiﬁcantly 
higher composite score (p=0.047). Overall, Arg389 homozygotes had a poorer event 
free survival ( p=0.018). The adverse impact of the this genotype appeared similar when 
analyzed separately in placebo (p=0.038) and ISDN/HYD treated subjects (p=0.18).
Conclusion: The B1AR Arg389Arg genotype was associated with poorer event-free 
survival and greater impact of ISDN/HYD in an African-American cohort with heart failure. 
The impact of ISDN/HYD on sympathetic activation, and the role of B1AR genotype in 
targeting therapy require further investigation.
986-89 C-reactive Protein Concentrations at Emergency 
Department Presentation Strongly Predict One Year 
Mortality in Dyspneic Patients
James L. Januzzi, Jr., Claudia U. Chae, Aaron L. Baggish, Elizabeth Lee-Lewandrowski, 
Patrick Sluss, Kent B. Lewandrowski, Donald M. Lloyd-Jones, Massachusetts General 
Hospital, Boston, MA, Northwestern University, Chicago, IL
Background: In patients with dyspnea, we previously showed elevated amino-terminal 
pro-brain natriuretic peptide (NT-proBNP) levels predict a high risk for death by one year. 
We now investigated if high-sensitivity C-reactive protein (hsCRP) levels are associated 
with one-year mortality in dyspneic patients, and if hsCRP provides additional prognostic 
information to NT-proBNP. 
Methods: 599 dyspneic subjects in an emergency department had NT-proBNP and 
hsCRP (both Roche Diagnostics, Indianapolis, IN) levels measured. Vital status was 
assessed at 1 year. Signiﬁcant predictors of death were identiﬁed using Cox proportional 
hazards analysis.
Results: Of the 593 subjects with available hsCRP data, 93 had died by one year. In 
receiver operating characteristic (ROC) analysis, hsCRP had an area under the curve 
of 0.76 (p<0.0001) for the prediction of death at one year. The optimal hsCRP cut-point 
for predicting mortality was 14.0 mg/L, which was 74% sensitive, 61% speciﬁc, and 
had a negative predictive value of 93%. Compared to those with hsCRP values <14.0 
mg/L (n=329), those with hsCRP ≥14 mg/L (n=264) were older (66±16 vs 60±18 years, 
p<0.001), had higher heart rates (92±23 vs 84±22 bpm, p<0.001), and were more likely 
to have a fever (17% vs 3%, p<0.001); as well, those with hsCRP ≥14 mg/L had higher 
leukocyte counts (11±5.5 vs 8.7±5.3, p<0.001), lower hemoglobin (12.4±2.3 vs 14.3±2.9, 
p<0.001), and higher NT-proBNP levels (1191 vs 178 pg/ml, p<0.001). The median hsCRP 
value at presentation was higher among decedents than in survivors (47.2 vs 7.3 mg/L, 
p<0.001). In multivariate proportional hazards analyses, signiﬁcant predictors of death by 
one year included: NT-proBNP ≥986 pg/ml (HR=2.62, 95% CI=1.51-4.53, p<0.001) and 
hsCRP ≥14 mg/L (HR=2.47, 95% CI=1.52-4.02, p=0.001). Those with both NT-proBNP 
≥986 pg/ml andCRP ≥14 mg/L had an even greater risk of death by one year (HR=6.69; 
p<0.001), compared to those having both marker levels below those cutpoints.
Conclusion: Among patients with acute dyspnea, elevated hsCRP levels strongly predict 
one-year mortality, and provide prognostic information independent of NT-proBNP and 
other covariates.
986-90 Audioelectric Parameters are Superior to BNP for 
Detecting Hemodynamic Evidence of Heart Failure
Andrew D. Michaels, Gregory Marcus, Mark V. Jordan, Ivor L. Gerber, Barry McKeown, 
Michele Huddleston, Elyse Foster, Kanu Chatterjee, University of California San 
Francisco, San Francisco, CA
Background: B-type natriuretic peptide (BNP) is frequently used to detect heart 
failure (HF). However, depending upon the threshold value chosen, using BNP can 
yield suboptimal sensitivity or speciﬁcity for diagnosing HF. We sought to compare the 
diagnostic performances of BNP at several different threshold values vs. electronically 
recorded heart sound data.
Methods: Within a 4-hour period, we performed cardiac catheterization, echocardiography, 
BNP measurement, and audioelectric cardiography (Audicor, Inovise Medical, Inc., 
Portland, OR) on 90 adults. Those with HF were diagnosed by having both LVEDP 
>15 mmHg and LVEF <50%. The Audicor device records and algorithmically interprets 
simultaneous ECG and heart sound data. The audioelectric parameters used were S3, 
S4 and the electromechanical activation time (EMAT; the interval from the onset of the Q 
wave of the ECG to the S1).
Results: Of the 90 patients, 68% were male, the mean age was 62±13 years, 29% were 
diabetic, 80% had hypertension, and 71% had CAD. LVEDP was elevated in 46%, LVEF 
reduced in 28%, BNP >100 pg/mL in 58%, while 21% had both elevated LVEDP and 
reduced LVEF. The table shows the sensitivity, speciﬁcity, positive likelihood ratio (PosLR) 
and the negative likelihood ratio (NegLR) of BNP at 3 cut-points and of the audioelectric 
parameters for the diagnosing patients with elevated LVEDP and reduced LVEF. 
Diagnostic Test Parameters: Diagnosing Heart Failure Patients with 
Elevated LVEDP and Reduced LVEF
Parameter Sensitivity Speciﬁcity Positive LR Negative LR
S3 61% 88% 5.1 0.44
S4 56% 75% 2.2 0.60
EMAT 44% 94% 7.4 0.59
BNP >100 pg/mL 100% 55% 2.2 0
BNP >250 pg/mL 94% 76% 3.9 0.08
BNP >500 59% 91% 6.5 0.45
Conclusions: Audioelectric parameters (S3 and EMAT) have better overall performance 
for detecting decompensated HF than does BNP.
986-91 There is Nothing Grey About It: Dyspnea with 
Intermediate Aminoterminal Pro-B Type Natriuretic 
Peptide Concentrations
Roland R. van Kimmenade, Yigal M. Pinto, John G. Lainchbury, Antonio Bayes-Genis, 
Mark A. Richards, James L. Januzzi, Jr., University Hospital Maastricht, Maastricht, The 
Netherlands, Massachusetts General Hospital, Boston, MA
Background: In acute dyspnea, aminoterminal pro-brain natriuretic peptide (NT-proBNP) 
levels <300 pg/ml exclude acute heart failure (HF), while concentrations above age-
stratiﬁed cut-points of 450, 900, and 1800 pg/ml (for ages <50, 50-75, and >75 years) 
identify higher likelihoods for acute HF. Those with an NT-proBNP levels between the ‘rule 
out’ and ‘rule in’ cut-points are referred to as being in the ‘grey zone’.
Methods: 1256 acutely dyspneic patients with (n=720) or without HF (n=536) were 
examined. An intermediate NT-proBNP level was deﬁned as ≥300 pg/ml but <age stratiﬁed 
cut-offs for identifying acute HF.
Results: Of the 215 subjects (17%) with intermediate NT-proBNP levels, 116 (53%) 
had acute HF. In those with intermediate NT-proBNP, clinical factors independently 
associated with acute HF were: prior HF (odds ratio [OR]=2.63; 95% conﬁdence intervals 
[CI]=1.02-6.80, p=0.05), diuretic use (OR=3.99; 95% CI=1.58-10.1; p=0.003), Paroxysmal 
Nocturnal Dyspnea (OR=4.50; 95% CI=1.31-15.4, p=0.02), Jugular Vein Distention (OR 
=3.05; 95% CI=1.06-8.79, p=0.04) and absence of cough (OR=5.56; 95% CI=1.92-16.7, 
p=0.001). Kaplan-Meier curves depict 60 day mortality rates as function of diagnosis and 
NT-proBNP (Figure).
Conclusions: In acutely dyspneic subjects with an ‘intermediate’ NT-proBNP, clinical 
factors assist in diagnosing acute HF. In those without acute HF, higher rates of death 
are seen in those with ‘intermediate’ NT-proBNP levels, compared to those with NT-
proBNP<300 pg/ml.
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986-92 Prognosis Value of Brain Natriuretic Peptide Kinetics 
During Cardiopulmonary Exercise Test in Chronic Heart 
Failure Patients
Carole Dossetto, Remi Sabatier, Annette Belin, Sophie Perbet, Denis Agostini, Gilles 
Grollier, University Hospital Cote de Nacre, Caen, France, Cardiac Rehabilitation 
Center, Trouville sur Mer, France
Background: The aim of this prospective study was to evaluate Brain Natriuretic Peptide 
(BNP) kinetics during cardiopulmonary exercise test and to determine the prognosis 
value of different BNP kinetics in chronic heart failure (CHF).
Methods: Seventy-two consecutive stable CHF patients were included. All patients 
underwent an echocardiography, a standard cardiopulmonary exercise test and BNP 
measurements before exercise, at peak exercise and 15 minutes after recovery. BNP 
kinetics (K) were deﬁned according to peak and recovery BNP variations (K1: increase- 
decrease; K2: increase-increase; K3: decrease-decrease or decrease-increase).
Results: Most of the patients were in NYHA class 2 (82%) with optimal therapy. Mean 
age was 58 ± 12 years. Exercise signiﬁcantly increased BNP values, and K2 pattern 
was observed in 31% of the patients. With a median follow-up of 328 days, there were 
20 cardiac events including 11 major cardiac events (MCE: cardiac death or threatening 
ventricular arrhythmia). MCE were signiﬁcantly more frequent in patients with type 2 BNP 
kinetic versus others patients (32 % vs. 8 %, p=0.027; RR = 3.98; CI = 1.3-12.2). There 
was no signiﬁcant difference in other characteristics between these 2 groups.
Conclusions: In stable CHF patients, a continuous elevation of BNP both at peak 
exercise and after recovery may indicated an increase risk of cardiac death or threatening 
ventricular arrhythmia. These results may allow identifying high risk NYHA class 2 CHF 
patients.
986-93 N-terminal ProBNP is not Only Related to the Severity 
of Heart Failure
Jochem Hogenhuis, Adriaan A. Voors, Tiny Jaarsma, Hans L. Hillege, Dirk J. van 
Veldhuisen, University Medical Center Groningen, Groningen, The Netherlands
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is increasingly 
used to monitor heart failure (HF) patients during hospitalization. However, besides its 
correlation with severity of HF, NT-proBNP plasma levels are inﬂuenced by several other 
factors. The aim of present study was to investigate the determinants of NT-proBNP levels 
in HF patients after recent HF hospitalisation.
Methods: We studied 543 HF patients who were part of a large-scale study in the 
Netherlands (age 71±11 years, 62% male). All patients had been admitted for progressive 
HF, and NT-proBNP levels were measured at discharge. During treatment cardiologists 
were blinded to NT-proBNP plasma levels. Patient characteristics were divided by quintiles 
of NT-proBNP, and ANOVA trend analyses were performed across the quintiles in order to 
investigate determinants of NT-proBNP plasma levels.
Results: In these hospitalized HF patients, NT-proBNP was related to several well known 
prognostic markers, such as age, left ventricular function, NYHA-class, and hemoglobin 
(all p<0.01). However, NT-proBNP was also stongly and inversely related to body mass 
index (BMI) and glomerular ﬁltration rate (GFR)(both p<0.01, see table)
Conclusions: In this large group of hospitalized heart failure patients, NT-proBNP was 
not only related to markers of the sevirity of heart failure, but was inversely related to 
GFR and BMI as well.
Variable 1st quintile 2nd quintile 3rd quintile 4th quintile 5th quintile p-value
NT-proBNP (median 
[IQR], pg/ml)
628 
(342- 
827)
1582 
(1314- 
1792)
2599 
(2288- 
3083)
4681 
(4183- 
5885)
12073 
(9413- 
19294)
<0.01
LVEF 39±15 34±14 31±14 32±13 27±10 <0.01
Boston Score 7.4±2.8 8.2±2.8 8.5±2.5 8.3±2.5 8.3±2.5 <0.01
NYHA class II/III-IV 58/42% 56/44% 42-58% 42-58% 39-61% <0.01
Mean age 69 70 72 71 74 <0.01
BMI (kg/m2) 29±5 26±5 27±6 24±4 24±4 <0.01
Hb (admission, 
mmol/l) 8.8±1.3 8.5±1.3 8.5±1.2 8.3±1.3 7.8±1.1 <0.01
eGFR 57±20 61±20 54±17 55±20 43±19 <0.01
986-94 Pulmonary Surfactant Protein B for Detection of 
Preclinical Ventricular Dysfunction
Carolyn S.P. Lam, John C. Burnett, Jr., Richard J. Rodeheffer, Steven J. Jacobsen, 
Margaret M. Redﬁeld, Mayo Clinic, Rochester, MN
Background: Pulmonary surfactant protein B (PSAP-B) is produced in the alveolar 
epithelial cells. Elevated pulmonary microvascular pressure related to left heart disease 
may result in release of PSAP-B due to damage to or increased permeability of the 
alveolocapillary membrane. PSAP-B levels correlate with N terminal proBNP levels, 
clinical status, volume changes and risk of heart failure (HF) hospitalization in patients with 
chronic HF. We hypothesized that PSAP-B may serve as a marker of pre-clinical elevation 
of ﬁlling pressures due to systolic and/or diastolic dysfunction in the population.
Methods: Residents (age > 45 yrs) of Olmsted County, MN, with no prior HF diagnosis 
(n=1990) underwent Doppler echocardiography and phlebotomy for PSAP-B (ELISA, 
Biosite) and BNP assay (Biosite Triage Assay) on the same day.
Results: In persons without cardiovascular disease, elevated blood pressure at echo, 
obesity or abnormal LV function (n=530), PASP-B levels increased with age in men (r = 
0.22, p=0.002) and in women (r = 0.33, p<0.0001) and were higher in men than in women 
when adjusting for age (p=0.0002) where as BNP levels increased with age in men (r = 
0.39, p<0.0001) and in women (r = 0.31, p<0.0001) but were higher in women than in men 
when adjusting for age (p<0.0001).
In the entire population, PSAP-B levels varied widely (25, 50, and 75 percentiles were 
6,345; 10,710 and 20,415 pg/ml). Log PASP-B correlated weakly with log BNP (r = 0.14, 
p<0.0001) and Doppler measures of left atrial pressure (E/E’, r = 0.14, p<0.0001).
The area under the receiver operating curve (AUC) for the detection of pre-clinical systolic 
dysfunction (EF<40%) was 0.60 (p=0.25) for PSAP-B and 0.86 (p<0.0001) for BNP. The 
AUC for the detection of preclinical moderate-severe diastolic dysfunction was 0.60 
(p=0.001) for PSAP-B and 0.78 (p<0.0001) for BNP.
Conclusion: While PSAP-B may reﬂect ﬁlling pressures in patients with overt HF, it does 
not appear to be a sensitive marker of left heart disease in the general population.
986-95 Thyroid Dysfunction is More Prevalent in 
Cardiomyopathy Patients Than in the General 
Population
Danya L. Dinwoodey, Elizabeth N. Pearce, Lewis E. Braverman, Wilson Colucci, Boston 
University Medical Center, Boston, MA
Background: Thyroid hormone has many cardiovascular effects. Thyroid dysfunction 
may cause abnormalities in cardiac output, blood volume, ejection fraction, heart rate, 
peripheral oxygen consumption, and systemic vascular resistance. These abnormalities 
occur in patients with both overt (elevated thyroid stimulating hormone (TSH) and low free 
thyroxine (T4)) and sub clinical (elevated TSH and normal free T4) hypothyroidism.
Methods: We evaluated the hypothesis that thyroid dysfunction is more prevalent in 
cardiomyopathy patients than in the general population. A retrospective chart review of 
1225 consecutive patients followed in the Cardiomyopathy Clinic at Boston Medical Center 
over the past 6 years was carried out. Results were then compared to those reported in 
the 1988-1994 National Health and Nutrition Examination Survey (NHANES III). 
Results: 868 of 1225 patients (70.9%) had serum TSH concentrations in the database. 
Of these, 41% were women. The mean age was 62.2 years (SD 15.3). The prevalence of 
hypothyroidism, deﬁned as a serum TSH>4.5 or those on thyroid hormone replacement, 
was 13.9% compared with 4.6% in the NHANES III study (p<0.001). The prevalence 
of hyperthyroidism, deﬁned as a serum TSH<.01 or those on antithyroid medications, 
was 0.4% compared with 1.3% in the NHANES III study (p<0.05). Among hypothyroid 
individuals, 24.0% were currently or had previously been on amiodarone. The prevalence 
of hypothyroidism among all patients treated with amiodarone was 22.3%. In comparison, 
the prevalence of hypothyroidism among patients not exposed to amiodarone was 12.3%, 
still greater than the prevalence of hypothyroidism as reported in the NHANES III study 
(p<0.001). The mean TSH for men and women was 2.54 (SD 5.71) and 2.65 (SD 6.34), 
respectively. This is compared with a mean TSH in the NHANES III study for men and 
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women of 1.46 (p<0.001) and 1.49 (p<0.001), respectively. Stratiﬁed analysis suggested 
that the observed differences in hypothyroidism prevalence and serum TSH were not due 
to advancing age.
Conclusions: The prevalence of hypothyroidism is higher in cardiomyopathy patients 
than in the general population. This effect does not appear to be explained by amiodarone 
use alone.
986-96 Tumoral Marker Carbohydrate Antigen 125: An 
Emerging Prognostic Risk Factor in Heart Failure?
Julio Nunez, Eduardo Nunez, Juan Sanchis, Luciano Consuegra, Vicente Bertomeu, 
Vicent Bodí, Maria J. Bosch, Rocio Robles, Gemma Miñana, Lorenzo Fácila, Angel 
Llàcer, Hospital Clínico Universitario, Valencia, Spain
Background: Carbohydrate antigen 125 (CA125) is a glycoprotein often elevated in 
some cancers. More recently, this tumoral marker has been found elevated in heart failure 
(HF), and positively associated with clinical parameters indicative of a disease’s severity. 
This study was designed to assess whether CA125 circulating levels predict subsequent 
all-cause mortality in patients after the index hospitalization for acute HF.
Methods: We analyzed 412 consecutive patients admitted in a single university center. In 
addition to traditional clinical information, CA125 (U/mL) was measured during the early 
course of hospitalization (median 24±12 hours). The independent association between 
baseline CA125 and mortality was assessed with Cox regression analysis.
Results: During a median follow-up of 5.4 months (IQR=1.4-5.9), 68 deaths (16.5%) 
were identiﬁed; 50 (24.6%) and 18 (8.7%) occurred in patients with CA125 above and 
below the median (56 U/ml) (p<0.001) respectively (ﬁgure 1). After adjustment for known 
prognostic factors, the association between CA125 and mortality remained positive (5% 
increase per each 25 U/ml; p<0.001, or almost three-fold increases in mortality (HR=2.81, 
95% CI=1.59-4.94; p<0.001) when having values above the median).
Conclusions: Serum levels of CA125 obtained in patients admitted with a diagnosis of 
decompensated HF shows to be an independent predictor of all-cause mortality.
986-97 Diagnostic Utility of NT-proBNP in the Evaluation of 
Congestive Heart Failure in the Emergency Department 
in Elderly Patients with Multiple Cardiac Morbidities
Mazhar Afaq, Azadeh Shoraki, Oleg Ivanov, Janardhan Srinivasan, Inder Mayall, 
Lawrence Bernstein, Young Choi, Stuart Zarich, Bridgeport Hospital, Bridgeport, CT
Background: Although brain-type natriuretic peptide (BNP) is commonly used in the 
evaluation of congestive heart failure (CHF), only limited data exists on the value of NT-
proBNP. Prospective data on cut-off values for NT-proBNP in CHF are only available from 
a single trial (PRIDE) and the manufacturer.We postulated that the utility of NT-proBNP in 
CHF would be limited in elderly patients (pts) with multiple co-morbidities.
Methods: We retrospectively examined 503 consecutive pts in whom NT-proBNP values 
were obtained to evaluate CHF.
Results: The mean age of our cohort was 71.4 yrs (55% female). Prior CHF was present 
in 41.6%, prior myocardial infarction in 18.5% and known coronary disease in 36.6% of 
pts. CHF was diagnosed in 60%. The area under the receiver operating curve (AUC) for 
NT-proBNP was .74. Diagnostic analyses for the manufacturer’s and PRIDE cut-offs are 
shown. Although the PRIDE algorithm was clearly superior, the positive predictive value of 
NT-proBNP remained poor. Age and serum creatinine correlated directly with NT-proBNP 
levels, while hematocrit correlated indirectly. Only age < 50 (AUC=.83; p=0.003) and 
hematocrit < 30% (AUC=.64; p=0.08) affected the diagnostic accuracy of NT-proBNP.
Conclusions: The diagnostic accuracy of NT-proBNP for the evaluation of CHF appears 
limited in an elderly population with a high prevalence of prior CHF. Age and hematocrit 
levels are important determinants of NT-proBNP diagnostic accuracy. Further studies are 
warranted in this high-risk population.
Cut-off Point Sensitivity Speciﬁcity Positive Predictive Value Negative Predictive Value Diagnostic Accuracy
PRIDE 81.4% 53.2% 72.3% 65.6% 70.1%
MANUFACTURER 96.0% 21.3% 64.7% 78.2% 66.1%
 
986-98 Elevated Blood Urea Nitrogen Level Predicts 
Cardiovascular Death in Patients Admitted for 
Decompensated Heart Failure Irrespective of the 
Presence of Left Ventricular Systolic Dysfunction
Takahisa Yamada, Takanao Mine, Takashi Morita, Hidetaka Kioka, Yasumasa 
Tsukamoto, Shunsuke Tamaki, Masaharu Masuda, Keiji Okuda, Masatake Fukunami, 
Osaka General Medical Center, Osaka, Japan
Background: Hospitalization for acutely decompensated heart failure is associated 
with a high mortality after discharge. Renal function is affected by heart failure and it 
relates to both cardiovascular and hemodynamic properties. It remains unclear whether 
the prognostic importance of renal function in patients with decompensated systolic 
heart failure would be similar to that in those without left ventricular systolic dysfunction 
(SHF). We studied the relation between renal dysfunction and cardiovascular mortality in 
patients admitted for decompensated heart failure, from the viewpoint of the presence or 
absence of SHF.
Methods and Results: The prognostic importance of three measures of renal function 
- serum creatinine, creatinine clearance estimated by the Cockcroft-Gault equation, blood 
urea nitrogen (BUN) - was evaluated in 279 consecutive patients who were admitted for 
clinical decompensation (NYHA class: 3.5±0.5, left ventricular ejection fraction(LVEF): 
38±15%). SHF (LVEF<40%) was observed in 166 of 279 patients, while the remaining 
113 patients had not SHF. During a mean follow-up of 792±621 days, 50 patients had 
cardiovascular death (41 patients with SHF and 9 patients without SHF). At univariate 
Cox analysis, all of the three variables of renal function were signiﬁcantly associated with 
cardiovascular death, irrespective of the presence or absence of SHF. At multivariate 
Cox analysis, BUN was the only signiﬁcant predictor of cardiovascular death (p=0.0066). 
Cardiovascular death was signiﬁcantly frequently observed in patients with the highest 
quartile of BUN (≥30 mg/dl) than those with the other three quartiles (BUN<30 mg/dl) (31 
% vs 14%, p=0.0001). The risk of cardiovascular death increased in the highest quartile 
with odds ratio of 2.80 (95% CI: 1.47 to 5.35) as compared with the other three quartiles. 
The odds ratio in patients with SHF (2.69, 95%CI 1.26 to 5.75) was similar to that in 
patients without SHF (2.78, 95%CI 0.68 to 11.3).
Conclusion: BUN could be a simple predictor of cardiovascular death in patients 
admitted for decompensated heart failure, irrespective of the presence of left ventricular 
systolic dysfunction.
986-99 Cyclooxygenase Products Sensitize Muscle 
Mechanoreceptors in Heart Failure Patients
Alice A. Perlowski, Michele A. Hamilton, Gregg C. Fonarow, Antoine Hage, Jignesh 
Patel, W. Robb MacLellan, Jaime Moriguchi, Holly R. Middlekauff, UCLA-David Geffen 
School of Medicine, UCLA Medical Center, Los Angeles, CA
Background: Muscle mechanoreceptor(MR) activation of muscle sympathetic nerve 
activity (MSNA) during exercise is exaggerated in heart failure (HF) patients, and may 
contribute to exercise intolerance. Endogenous prostaglandins(PG) sensitize MR control of 
MSNA in healthy subjects during rhythmic exercise. We hypothesized that cyclooxygenase 
(COX) products would sensitize muscle MR control of MSNA in HF patients.
Methods: In a randomized, double blinded study, patients with stable NYHA Class II-III 
HF due either ischemic or idiopathic cardiomyopathy, were recruited from the UCLA-
Ahmanson Cardiomyopathy Center. All patients underwent baseline microneurography 
(peroneal nerve) during 3 minutes of low level rhythmic handgrip exercise (RHG). 
Patients were randomized to intra-arterial (brachial artery) administration of indomethacin 
(inhibiting COX enzyme), versus placebo (saline), and RHG exercise was repeated. 
MSNA was recorded during all stages.
Results: Twelve patients underwent the study protocol, 83% with nonischemic 
cardiomyopathy, and 17% with ischemic cardiomyopathy. Fifty percent of the patients 
were female, with mean age of 46.5 (+ 9.9 years). All had systolic HF, with average 
ejection fraction 24.5% (+5.4%). During saline control, total MSNA amplitude increased 
almost immediately upon initiation of exercise, and was signiﬁcantly greater than baseline 
during the ﬁrst minute of exercise (p=0.007). Also during saline control, MSNA was 
increased compared to baseline during each minute of exercise. In contrast, indomethacin 
eliminated the increase in MSNA during exercise compared to saline during all 3 minutes 
of exercise. [p=0.02 (minute 1); p=0.01 (minute 2); p=0.001 (minute 3)].
Conclusions: In contrast with healthy humans, MSNA increases during the ﬁrst minute 
of exercise in HF patients consistent with chronic sensitization of muscle MR. The 
signiﬁcant blunting of MSNA by the COX inhibitor indomethacin during exercise indicates 
that muscle MR are further sensitized by endogenous prostaglandins in HF. Our ﬁndings 
provide evidence that COX byproducts may play a signiﬁcant role in the exaggerated 
muscle MR-mediated sympathetic activation in heart failure.
ACC_2006_2_CardiacFunct A.indd   69 1/4/06   5:08:10 PM
70A ABSTRACTS - Cardiac Function and Heart Failure JACC February 21, 2006
C
ar
di
ac
 F
un
ct
io
n 
an
d 
H
ea
rt
 F
ai
lu
re
POSTER SESSION
987 
Pathogenesis of Uncommon 
Cardiomyopathies
Monday, March 13, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
987-100 Alteration in Iron Kinetics May Contribute to 
Doxorubicin Cardiotoxicity
Gurusher S. Panjrath, Diwakar Jain, Drexel University College of Medicine, New York, NY
Back ground: Doxorubicin (DOX) chemotherapy is limited by severe and life threatening 
cardiotoxicity. Iron may play a role in DOX cardiotoxicity. Effect of DOX on iron kinetics 
is not well understood. We used an in-vivo rodent model to study the effect of DOX on 
iron kinetics.
Methods: Male Sprague Dawley rats (200-250 grams) were treated with single DOX dose 
(6 mg/kg, i/v, n=4) or saline (n=4), or multi DOX doses (2.5 mg/kg ip biweekly x 4 weeks, 
cumulative dose 20 mg/kg, n=4) or saline (n=4). Single DOX dose and controls were 
sacriﬁced 3 weeks post DOX treatment and multi DOX dose animals 1 week after the 
last dose. Serum iron, Transferrin (TIBC), % TIBC saturation and non-heme iron in heart 
and liver were measured. Pearl’s and caspase-3 stain of myocardial and hepatic tissue 
specimens were performed.
Results: DOX treatment resulted in a profound drop in serum iron and TIBC levels in 
both groups of DOX treated groups. There was a mild increase in myocardial but profound 
increase in hepatic iron content. Pearl’s stain showed no stainable myocardial iron but 
intense staining for iron in kupffer cells as well as hepatocytes in DOX treated groups. 
Marked increase in Caspase-3 stain was observed in DOX treated groups compared to 
none in saline treated groups.
Conclusions: DOX treatment resulted in profound drop in serum TIBC and iron levels 
with abnormal deposition in liver and myocardium associated with marked increase in 
apoptosis. This may play a signiﬁcant role in DOX induced cardiotoxicity. 
Serum Iron 
(µg/dl)
TIBC
(µg/dl)
% TIBC 
saturation
Myocardial iron (µg 
/ dry wt)
Hepatic iron (µg / 
dry wt)
Saline (n=7) 117 ± 9 473 ± 21 25 ± 1.8 45 ± 3 87 ± 5
Single DOX 
(n=4) 12.0 ± 7*
40 ± 
7 * 27 ± 17 52 ± 3 † 337 ± 72 *
Multiple 
DOX
(n=3)
27 ± 5 ** 86 ± 18** 36 ± 16 51 ± 5 239 ± 28 *
* P< 0.001, ** P< 0.005, † P< 0.01
987-101 Gene Expression Proﬁling in Fabry Cardiomyopathy
Luisa Nanni, Milena Bellin, Maurizio Pieroni, Cristina Chimenti, Attilio Maseri, Andrea 
Frustaci, Gerolamo Lanfranchi, Università Vita Salute San Raffaele, Milan, Italy, CRIBI 
Biotechnology Center, Università di Padova, Padova, Italy
Background: Fabry cardiomyopathy (FC) is characterized by cardiac walls thickening 
with increased ECG voltages. Whether this is sustained by a real hypertrophy 
with enhanced cardiac myoﬁbrillar content or by an electrical effect of glycolipids 
accumulation, is still unclear.
Methods: We studied frozen endomyocardial biopsies from 5 patients (pts) with FC 
and 5 pts with hypertrophic cardiomyopathy (HCM) presenting the same degree of LV 
hypertrophy at echocardiographic evaluation. Total RNA was extracted, subjected to 2 
rounds of linear ampliﬁcation and used as target for hybridizations. The platform used 
was a tissue-speciﬁc microarray containing 5000 different 3’-end cDNA tags from skeletal 
and cardiac muscles.
Results: A total of 100 commonly deregulated transcripts were identiﬁed. A down-
regulation of genes of the ANP/BNP system (NPPA and NPR1), ion pumps (Na+/K+, H+, 
and Ca++-transporting ATPases) and some LIM-associated cytoskeletal proteins (PDLIM3 
and PDLIM1) occurred in both FC and HCM. All these genes were previously recognized 
to be important in cardiac hypertrophy. In addition a down-regulation of some genes with 
hydrolase activity was observed in FC but not in HCM, suggesting a co-regulation with 
alpha-galactosidase A, whose deﬁciency causes FC.
Conclusion: Deregulation of genes involved in the development of myocardial hypertrophy 
are observed in FC along with HCM. This suggests that increased ECG voltages really 
express an enhancement of cardiac myoﬁbrillar material. 
987-102 Molecular Basis in the Development of Alcoholic 
Cardiomyopathy in Monkeys: Contrasting Changes 
Between Cardiac Beta1-Adrenergic Receptor 
Expression
Heng-Jie Cheng, Chun-Xian Zhang, Satoshi Masutani, Michael Cross, Kathleen A. 
Grant, James B. Daunais, David P. Friedman, William C. Little, Che-Ping Cheng, Wake 
Forest University School of Medicine, Winston-Salem, NC
Background. Chronic alcohol intake is associated with a diminished positive inotropic 
response to β-adrenergic receptor (AR) stimulation. Contrasting changes in cardiac β1- 
and β3-AR expression may contribute to this effect.
Methods. We compared β1- and β3-AR expression and contractile and [Ca2+]i transient 
([Ca2+]iT) responses to β1-AR and β3-AR stimulation in freshly isolated left ventricular (LV) 
myocytes obtained from 10 control cynomolgus monkeys and 12 monkeys with self-
administered oral alcohol for 9 months (7 moderate and 5 heavy drinkers with mean daily 
intake of alcohol of 1.9 and 3.4 g/kg, respectively).
Results. Compared with normal control myocytes, in alcoholic cardiomyocytes, cell 
contraction (dL/dtmax, -37%, 58.7 vs 92.6 µm/s) and relaxation (dR/dtmax, -32%, 54.2 vs 79.8 
µm/s) and [Ca2+]iT (-36%, 0.14 vs 0.22) were signiﬁcantly reduced. Compared with control 
myocytes (0.41±0.05), the protein levels of β3-AR protein were increased 41% and 68% in the 
myocytes obtained from moderate (0.58±0.06) and heavy drinkers (0.69±0.09), respectively. 
In contrast, compared with controls (0.56±0.11), β1-AR protein levels in moderate and heavy 
drinkers were decreased 30% (0.39±0.04) and 50% (0.28± 0.06) (p<0.01), respectively. 
These changes were associated with reduced myocyte functional responses to β-AR agonist, 
isoproterenol (ISO, 10-8 M), and β3-AR agonist, BRL-37344 (BRL, 10-8 M). Superfusion of ISO 
caused much less increases in dL/dtmax (49% vs 78%) and dR/dtmax (15% vs 26%) (p<0.01). In 
contrast, in alcoholic cardiomyocytes, BRL produced a much greater decrease in the percent 
shortening (18.4% vs 7.3%), dL/dtmax (17.9 vs 6.9%), and [Ca
2+]iT (28.2 vs 18.7%). These 
responses were prevented with L-748,337, a β3-AR antagonist.
Conclusion. Chronic alcohol intake down-regulates cardiac β1- and up-regulates β3-
ARs, contributing to the abnormal responsiveness of catecholamines in alcoholic dilated 
cardiomyopathy. The progressive up-regulation of cardiac β3-AR signaling in chronic 
alcohol consumption may precede the development of alcoholic dilated cardiomyopathy.
987-103 Signiﬁcance of 8-hydroxy-2’-deoxyguanosine Levels in 
Patients With Idiopathic Dilated Cardiomyopathy
Eri Watanabe, Masatoshi Kawana, Naoki Matsuda, Katsuya Kajimoto, Hirotaka Kawarai, 
Yoichi Ajiro, Hiroshi Kasanuki, Tokyo Women’s Medical University, Tokyo, Japan, Tokyo 
Women’s Medical University Aoyama Hospital, Tokyo, Japan
Background: Although oxidative stress mediated by reactive oxygen species (ROS) 
plays an important role in the pathogenesis of heart failure (HF), good clinical markers 
for ROS in patients with HF have not been established. 8-hydroxy-2’-deoxyguanosine 
(8-OHdG) is formed from deoxyguanosine in DNA by hydroxyl free radicals and might 
serve as a sensitive biomarker of intracellular oxidative stress in vivo. Thioredoxin (TRX) 
is known to be induced in cells as a radical scavenger against oxidative stress. The aim of 
this study is to evaluate the clinical signiﬁcance of the serum 8-OHdG and TRX of patients 
with chronic HF with idiopathic dilated cardiomyopathy (DCM).
Methods: We measured serum 8-OHdG and TRX levels using ELISA in 32 patients with 
DCM (male, 24; mean age, 46.6years). We examined the relationship between 8-OHdG, 
TRX and NYHA functional class, cardiac function, plasma brain natriuretic peptide (BNP) 
and various clinical parameters.
Results: Serum 8-OHdG levels signiﬁcantly increased in proportion to the severity of 
NYHA functional class; 0.24+-0.08ng/ml in patients class I, 0.32+-0.11ng/ml in class II, 
and 0.75+-0.57ng/ml in class III (class I vs. class II: p=0.04, class I vs. class III: p=0.003). 
In contrast, there was no relationship between serum level of TRX and the severity of HF. 
Serum levels of 8-OHdG were signiﬁcantly correlated with left atrial diameters (r=0.54, 
p=0.002), left ventricular end-diastolic diameters (r=0.65, p<0.0001), left ventricular end-
systolic diameters (r=0.66, p<0.0001) and plasma levels of BNP (r=0.44, p=0.01). No 
association was found between serum TRX levels and left ventricular diameters, left atrial 
diameters, BNP levels, and serum 8-OHdG levels.
Conclusions: These data suggest oxidative DNA damage is increased in patients with 
DCM according to the severity of HF. Serum levels of 8-OHdG may represent clinically 
useful markers of LV remodeling.
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987-104 High Frequency of Anti-heart Autoantibodies in Acute 
Myocardial Infarction With Angiographically Normal 
Coronary Arteries: Evidence for Undiagnosed Immune-
mediated Myocarditis
Alida L. Caforio, Luciano Daliento, Annalisa Angelini, Francesco Tona, Annalisa Vinci, 
Natalia Golia, Cristina Basso, Angelo Ramondo, Sabino Iliceto, Gaetano Thiene, Padua 
University, Padua, Italy
Background. Acute myocardial infarction with angiographically normal coronary arteries 
(MINC) is a poorly understood and highly heterogeneous entity. Acute biopsy-proven 
myocarditis (My) may present as MINC. Anti-heart autoantibodies (AHA) are speciﬁc 
serum markers of immune-mediated My. Methods. To assess whether MINC may 
represent immune-mediated My, we compared features at diagnosis, including AHA, in 
consecutive patients with MINC vs those with biopsy-proven My and pseudo-ischemic 
presentation (chest pain and abnormal troponin I ). We studied 58 MINC patients, 31 
male, aged 41± 21 years, 56 in NYHA I-II, 2 III, follow-up 17 ± 22 months and 48 My pts, 
36 male, aged 35 ± 15 years, 47 in NYHA I-II, 1 III, f-u 35 ± 30 months. Left ventricular 
ejection fraction (LVEF) by echocardiography and angiography was: 55 ± 10% and 64 
± 12% in MINC; 55 ± 10% and 60 ± 13% in My. Coronaries were always normal. My 
(Dallas criteria) was lymphocytic in 47 pts, giant cell in 1. AHA were detected by indirect 
immunoﬂuorescence on human myocardium and skeletal muscle. Controls included 141 
patients with angiographically proven coronary heart disease (CAD) (131 male, aged 
51 ± 12 years) and 270 normals (123 male, 35 ± 11 years). Features at diagnosis were 
compared in MINC vs My by univariate analysis. Results. The proportion of females was 
higher in MINC (47%) than in My (25%, p=0.02). MINC was associated with lower left and 
right ventricular enddiastolic pressure (p=0.009; p=0.02), higher left ventricular systolic 
(p=0.001) and lower right ventricular systolic pressure (p=0.02); lower mean right atrial 
pressure (p=0.01) and lower pulmonary artery systolic pressure (p=0.02). Peak troponin 
I tended to be lower in MINC than in My (p=0.05). AHA were found in 51% of MINC and 
in 54% of My patients (p=NS). AHA frequency was higher in MINC or My than in CAD 
(2%, p=0.0001) or in normals (5.5%, p=0.0001). At follow-up 50 MINC and 44 My patients 
were alive, of whom 1 transplanted, 12 lost to follow-up; all patients were in NYHA I/II, with 
LVEF of 63 ± 8% in MINC and 64± 9% in My. Conclusion. The ﬁnding of AHA supports 
an immune-mediated pathogenesis in about 50% of MINC pts. MINC may represent 
undiagnosed mild My with pseudo-ischemic presentation in females.
POSTER SESSION
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Cardiac Transplantation Assist Devices 
and Ventricular Assist Devices
Monday, March 13, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
988-105 Effects of Left Ventricular Assist Devices With Different 
Flow Characteristics on Vasopressin Levels
Reynolds M. Delgado, III, Branislav Radovancevic, Rajko Radovancevic, Gabriel 
Rodriguez, O. H. Frazier, Texas Heart Institute, Houston, TX
Background: Neurohormonal systems are activated by low cardiac output and arterial 
pressure. This can accelerate the progression of heart failure with increased morbidity 
and mortality. Vasopressin regulates vascular tone and free-water reabsorption. Limited 
data exists on effects of left ventricular assist devices (LVADs) on vasoactive peptides, 
speciﬁcally in regard to continuous vs. pulsatile types of LVADs. We tested the hypothesis 
that the continuous LVADs will improve the levels of these substances and in a shorter 
time frame than previous LVADs.
Methods: We performed a single center, prospective, non-randomized study in heart 
transplant candidates who had mechanical circulatory support with an LVAD. Serum 
samples of 68 patients were collected from November 2000 to December 2004. Thirty-ﬁve 
patients (C group) received continuous ﬂow type LVADs (Jarvik 2000 or Thoratec HeartMate 
II), while 33 received Thoratec HeartMate I pulsatile type LVAD (P group). Blood was taken 
from the patients at baseline, postimplant, and at ﬁxed intervals during support.
Results: The groups were comparable in regard to age, cardiac index, cardiac output, 
blood pressure, pulmonary capillary wedge pressure, creatinine, and total bilirubin levels 
before implantation. Signiﬁcantly more women were in C group 20% vs. 3% in P group, 
P=0.03. In contrast to vasopressin levels in P group, which decreased from average 90.4 
pg/mL to 41.9 pg/mL after 30 days, levels in C group increased from 56.9 pg/mL to 80.4 
pg/mL. Patients who survived on LVAD support had baseline mean arterial pressure 79 
mmHg vs. 68 mmHg in those who died (P=0.004). Average vasopressin level in those 
who died decreased after 30 days by 47% (98.9 pg/mL to 46.7 pg/mL), while in survivors 
increased by 68% (49.5 pg/mL to 72.1 pg/mL), P=0.029.
Conclusions: These data are provocative and indicate a different response in systemic 
autoregulation of vasopressin based on LVAD support type. Diminished pulse pressure 
may play a role in this phenomenon.
988-106 Is Incidence in Arrhythmias Different in LVADs With 
Continuous Versus Pulsatile Flow?
Branislav Radovancevic, Rajko Radovancevic, Laura Damme, Jerry Heatley, Texas 
Heart Institute, Houston, TX, Thoratec Corporation, Pleasanton, CA
Background: Minimal information is available in regard to incidence and consequence 
of arrhythmias in patients (pts) after left ventricular assist device (LVAD) implantation. 
Continuous ﬂow devices due to ability to over-unload the left ventricle have theoretical 
potential of inducing arrhythmias. We sought to determine whether there is a difference in 
incidence in arrhythmias between two types of devices.
Methods: Data on 43 pts who received support with Thoratec Heartmate II continuous 
ﬂow LVAD (HM II group) since October 2003 were available from the Thoratec database. 
Their data were compared to those of 68 pts supported with pulsatile LVAD Thoratec 
Heartmate I (HM I group). We used a Kaplan-Meier method to determine percent of pts 
free of event at 3, 6, 9 and 12 months.
Results: Median age of pts in HM II group was 49 years vs. 67.5 years in HM I group 
pts, P<0.0001. In HM II group 67% of pts had history of arrhythmias prior to implantation. 
No differences in percentage of pts free of any arrhythmia, cardiac arrest, ventricular 
arrhythmia (VA), or supra-ventricular arrhythmia (SVA) were found at any time points, 
P>0.1367. Percent of pts free from event are listed in the table: 
1 m 3 m 6 m 9 m 12 m P=
Group HM 1 / II HM 1 / II HM 1 / II HM 1 / II HM 1 / II
Any arrhythmia 61 / 55 51 / 52 49 / 52 47 / 52 47 / 52 0.549
Cardiac arrest 97 / 90 95 / 90 95 / 90 95 / 90 95 / 90 0.194
VA 86 / 74 77 / 71 73 / 67 69 / 67 69 / 67 0.137
SVA 74 / 69 66 / 69 66 / 69 66 / 69 66 / 69 0.588
There was no signiﬁcant difference in survival in regard to arrhythmia, P=0.143.
Conclusions: These data show that continuous ﬂow device did not exhibit any increase 
in incidence of arrhythmias. Incidence of arrhythmias in LVAD pts is high and warrants 
further investigation of potential therapeutic options.
988-107 Development and In Vivo Testing of a Simple 
Subcutaneous Circulatory Support Device
Steven C. Koenig, Robert D. Dowling, Kenneth N. Litwak, George M. Pantalos, Paul A. 
Spence, University of Louisville, Louisville, KY
Background: Current circulatory support devices are not appropriate for the vast majority 
of heart failure (HF) patients and therefore have minimal epidemiological impact (800 
LVADs/year vs 60,000 BiV ICD/year). We hypothesize that a permanently implanted device 
that can be placed subcutaneously via a limited “pacemaker pocket” approach would 
expand the role of device therapy for heart failure. We report our results with placement 
of an implantable counterpulsation device in a bovine model of heart failure. Methods: 
A valveless single port, 40cc stroke volume device was designed to be anastomosed 
to the subclavian artery. Blood is withdrawn into the pump during systole and ejected 
during diastole. The devices were implanted in calves (60-90kg) with Monensin induced 
HF. Acute (n=8) and chronic (n=2) implants were performed. High ﬁdelity catheters 
measured LA, LV and aortic pressure and LV volume. Flow probes were placed on the 
brachiocephalic, PA, descending AO, coronary and carotid arteries, and device outﬂow 
graft. Results: The counterpulsation device provided durable hemodynamic beneﬁts as 
evidenced by 14% reduction in left ventricular workload (P < 0.05), 19% increase in 
mean diastolic coronary ﬂow (P < 0.05) and 12% increase in cardiac output (P < 0.20). 
Conclusion: The counterpulsation device resulted in signiﬁcant hemodynamic beneﬁts in 
acute and chronic implants in an animal model of heart failure. Development of a device 
that can be implanted subcutaneously via a pacemaker pocket approach may provide an 
additional therapy for patients with advanced heart failure.
ORAL CONTRIBUTIONS
819 
Biomarkers
Monday, March 13, 2006, 2:00 p.m.-3:30 p.m.
Georgia World Congress Center, Room B406
2:00 p.m.
819-3 Direct Comparison of the Prognostic Value of Brain 
Natriuretic Peptide (BNP) and N-terminal ProBNP 
in a Large Population of Patients With Chronic and 
Symptomatic Heart Failure. The Valsartan In Heart 
Failure (Val-HeFT) Data
Serge Masson, Roberto Latini, Inder S. Anand, Tarcisio Vago, Simona Barlera, Emil 
Missov, Aldo P. Maggioni, Gianni Tognoni, Jay N. Cohn, on behalf of the Val-HeFT 
Investigators, Istituto Mario Negri, Milan, Italy, University of Minnesota and VA Medical 
Center, Minneapolis, MN
Background: Differences in the biological role, in vivo metabolism, stability and analytical 
performance of BNP and NT-proBNP could result in differences in their prognostic value 
in HF. We aimed at a direct comparison in a large population of patients with HF enrolled 
in the Val-HeFT trial.
Methods: Plasma concentrations of BNP (IRMA Shionogi) and NT-proBNP (ECLIA 
Roche) were measured at randomization in 3916 patients with chronic and symptomatic 
HF and related to study outcomes, mortality and the combined endpoint of mortality and 
morbidity (mainly hospitalization for HF, M&M). ROC curves for the prediction of outcome 
were used to identify optimal prognostic value and compare area under the curve (AUC) 
with univariate Z-test.
Results: The median [IQR] concentration was 895 pg/mL [374-1984] for NT-proBNP and 
ACC_2006_2_CardiacFunct A.indd   71 1/4/06   5:08:11 PM
72A ABSTRACTS - Cardiac Function and Heart Failure JACC February 21, 2006
C
ar
di
ac
 F
un
ct
io
n 
an
d 
H
ea
rt
 F
ai
lu
re
99 [41-242] pg/mL for BNP (Spearman’s r= 0.77, p<0.0001). The rate of outcome events 
increased in a similar fashion by quartiles of BNP or NT-proBNP. There was no signiﬁcant 
differences in the AUC for predicting mortality (758 events) with NT-proBNP [AUC ± SE(AUC) 
=0.679±0.011)] or BNP [0.665±0.011, p= 0.16]. NT-proBNP showed a better predictive 
value for M&M (1194 events) than BNP [0.688±0.009 vs. 0.674±0.009, p=0.005].
Conclusions: Our ﬁndings, obtained in a large population of well-characterized patients 
enrolled in a multicenter international clinical trial, show that NT-proBNP and BNP provide 
comparable prognostic information in patients with chronic and symptomatic HF.
Mortality (758 events) M&M (1194 events)
NT-proBNP BNP NT-proBNP BNP
Optimal value (pg/mL) 1016 125 1007 125
AUC ± SE (AUC) 0.679±0.011 0.665±0.011 0.688±0.009 0.674±0.009
Sensitivity 0.666 0.636 0.658 0.621
Speciﬁcity 0.600 0.620 0.630 0.650
2:15 p.m.
819-4 Selective Secretion of MMP-8 and -9 in the Coronary 
Circulation in Parallel with BNP in Human Heart Failure 
Paveljit S. Bindra, Esther E. Vorovich, Hemal Nayak, Shashank Desai, Ralph Verdino, 
Martin St. John Sutton, David Callans, Vickas Patel, Henry Hsia, Sanjay Dixit, David 
Lin, Andrea Russo, Francis E. Marchlinski, Edward Gerstenfeld, Thomas P. Cappola, 
University of Pennsylvania Health System, Philadelphia, PA
Background. Matrix metalloproteinase (MMP) levels in the peripheral circulation 
have been proposed as a biomarker for heart failure (HF) progression, but no study 
has determined if they originate from the heart itself. We hypothesized that MMPs are 
elevated in the coronary circulation compared to the periphery in human subjects with 
HF, but not in controls.
Methods. Cases of HF (n=21) undergoing biventricular pacemaker implantation and 12 
controls with structurally normal hearts undergoing SVT ablation were enrolled in this 
case-control study. Blood was drawn from the coronary sinus (CS), venous (V) and 
arterial (A) circulation. Plasma BNP and MMPs 1,2,3,7,8,9,12,13 were quantiﬁed using 
multiplexed ELISAs. Data were analyzed using a 2-way ANOVA.
Results. Cases (age 58.6±11.2 years) had an EF of 19±8% and controls (age 41.8±16 
years) had an EF of 62±7%. As expected, BNP levels were substantially higher in cases 
vs. controls and in the CS vs. periphery (ﬁgure). MMPs-8 and -9 exhibited a similar 
pattern, with a 121% step-up in MMP-9 and a 100% step in MMP-8 from the A to CS in 
cases (p=0.02) but not in controls (p=NS).
Conclusion. This study demonstrates that the human heart secretes MMP-8 and MMP-9 
in parallel with BNP in HF but not in controls. These ﬁndings suggest a pathogenic role 
for MMP-8 and MMP-9 in ventricular remodeling and indicate that they may be speciﬁc 
markers for HF progression in humans.
2:30 p.m.
819-5 Aldosterone Synthase Promoter Polymorphism 
Modulates Outcome In Black Patients With Heart 
Failure: Results From the A-HeFT Trial
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelman, Amy 
Palmer, Karen Janosko, Arthur M. Feldman, Manuel Worcel, University of Pittsburgh, 
Pittsburgh, PA, Nitromed, Inc., Lexington, MA
Background: Little data exist for the genetic modulation of clinical outcomes in black 
subjects with heart failure (HF). A polymorphism exists in the promoter region of the 
aldosterone synthase gene (CYP11B2) at position -344 (C/T). The C-allele is associated 
with higher aldosterone synthase activity but its impact on HF outcomes is unknown. We 
evaluated the effect of the -344Callele on HF outcomes for subjects in the A-HeFT trial.
Methods: 354 Subjects from the Genetic Risk Assessment in Heart Failure (GRAHF) 
substudy of the A-HeFT trial and were genotyped for the aldosterone synthase 
polymorphism. Patients were followed prospectively, and event-free survival (death or 
heart failure hospitalization) was compared by aldosterone synthase (AS) genotype.
Results: Of the cohort, 218 subjects were TT, 114 CT, and 22 subjects were CC. 
Comparisons of ejection fraction, etiology, blood pressure, and functional class were 
not signiﬁcantly different among the three cohorts. Of note, the C-allele was associated 
with signiﬁcantly poorer event-free survival with the best survival among TT subjects, 
intermediate for heterozygotes, and the poorest for CC homozygotes (Figure, p=0.018).
Conclusion: The AS promoter -344C allele linked to higher aldosterone levels is also 
associated with poorer event-free survival in a black population with HF. The role of 
aldosterone receptor antagonists in diminishing this apparent genetic risk remains to be 
explored. 
2:45 p.m.
819-6 Sodium: An Old Enemy or a New Friend for Advanced 
Failured Patients?
Salvatore Paterna, Pietro Di Pasquale, University of Palermo, Palermo, Italy, G.F. 
Ingrassia Hospital, Palermo, Italy
Background: A randomized study was performed to evaluate the effects of the 
normosodic diet
during six months of follow-up versus iposodic diet in the compensated refractory 
congestive heart failure (from IV NYHA class to II class NYHA) patients.
Materials and methods: 188 (68 F/120 M) compensated refractory CHF patients (from 
Class IV to NYHA Class II) of different etiologies, aged 55 to 83 years, were enrolled. 
They had to have an ejection fraction (EF) <35%, serum creatinine <2 mg/dl. The patients 
were randomised in 2 groups: group 1 (36 F/60 M): received a normosodic diet (120 
mEq) plus high dose of furosemide (250-500 mg bid) and the optimal treatment received 
during hospitalization period and subsequent 30 days period. Group 2 (32 F/60 M): 
received an iposodic diet (80 mEq) plus high dose of furosemide (250-500 mg bid) and 
the optimal treatment received during hospitalization and subsequent 30-day period, and 
with a drink ﬂuid intake of 1000 ml daily in both groups. All patients underwent a physical 
examination, measurement of body weight (BW),blood pressure (BP),heart rate (HR), 
evaluation of signs of CHF, and controls of serum Na, K, Cl, bicarbonate, albumin, uric 
acid, creatinine, urea and glycaemia, chest-x ray, ECG, echocardiogram, BNP plasma 
levels were measured at baseline, and 90 and 180 days after. 
Results: The groups were similar for clinical characteristics The BNP values showed 
signiﬁcant intragroup difference, but that plasma levels of BNP were signiﬁcantly lower 
in normosodic group in comparison with iposodic group, 90 days and 180 days after. In 
addition, the normosodic group showed a signiﬁcant reduction in readmission rate. 
Conclusion: our data show that patients receiving normosodic diet with high doses 
of furosemide showed a signiﬁcant reduction in BNP levels, and lower incidence in 
readmissions in the 180 days of follow up. This study indicates the need to challenge our 
current practice of chronic sodium restriction and also how we chronically.dose diuretics.
3:00 p.m.
819-7 How Much Reduction is Needed in BNP Levels to 
Reduce Future Clinical Events with Treatment During 
Hospitalization for Heart Failure?
Amandeep S. Dhaliwal, Anita Deswal, Allison M. Pritchett, Biykem Bozkurt, Michael E. 
DeBakey Veterans Affairs Medical Center, Houston, TX, Baylor College of Medicine, 
Houston, TX
Background:B-type natriuretic peptide (BNP) is a known predictor of outcomes in 
patients with heart failure (HF). Limited data exist on % reduction necessary to achieve a 
signiﬁcant reduction in clinical events.
Methods:Retrospective chart reviews were performed in 383 patients with HF admissions 
fulﬁlling Framingham criteria at the VA Hospital from 4/2002 to 6/2004. Datasets with 
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paired admission and discharge BNP were analysed for % reduction in BNP,occurrence 
of the ﬁrst readmission for HF or death at 90, 180 or 360 days.
Results: At least a 50% reduction in BNP with treatment during HF hospitalizations 
was associated with signiﬁcantly lower rates of death or HF rehospitalization at 90days 
(0.16,0.35;p=0.025); 180 days (0.23,0.5;p=0.003)or 360 days (0.36,0.56;p=0.036) 
compared to < 50% reduction in BNP levels (Figure). Greater % reduction in BNP was 
associated with lower mortality or re-hospitalizations (p=0.04). A similar % reduction 
(mean: 52.9 % + 0.06) could be achieved regardless of baseline BNP levels on admission, 
and the number of datasets with at least a 50% reduction did not differ between various 
levels of initial BNP (p=ns).
Conclusions: Regardless of the baseline levels of BNP, approximately 50 % reduction 
is achieved in BNP levels during hospitalizations for HF. BNP reductions over 50 % are 
associated with lower mortality or rehospitalization at 3, 6 or 12 months. Further studies 
are needed to determine whether therapy targeted at reducing BNP levels >50% would 
lead to better outcomes.
3:15 p.m.
819-8 mRNA Expression and Protein Levels for Granulocyte 
Colony Stimulating Factor are Increased in Left 
Ventricular Myocardium of Patients With Heart Failure
Sharad Rastogi, Victor G. Sharov, Makoto Imai, Hani N. Sabbah, Henry Ford Health 
System, Detroit, MI
Background: Granulocyte colony stimulating factor (G-CSF) is a cytokine that stimulates 
the survival, proliferation, and differentiation of primitive bone marrow stem cells. In mice 
with acute myocardial infarction, G-CSF-mediated translocation of bone marrow stem 
cells was shown to result in signiﬁcant myocardial tissue regeneration. In this study, 
we tested the hypothesis that mRNA and protein expression of G-CSF is increased in 
the failing left ventricular (LV) myocardium as a possible response to ongoing injury, 
degeneration and loss of cardiomyocytes. 
Methods: mRNA and protein expression of G-CSF were measured in LV myocardium 
of explanted failed human hearts due to ischemic cardiomyopathy (ICM, n=6), idiopathic 
dilated cardiomyopathy (IDC, n=6), normal donor human hearts which were deemed 
not suitable for transplantation (NL-Human, n=6). Tissue samples from all groups were 
used to extract RNA. mRNA gene expression for G-CSF was measured using reverse 
transcriptase polymerase chain reaction (RT-PCR). Protein expression was determined 
in SDS-extract of LV tissue homogenate using speciﬁc antibodies. Bands obtained after 
RT-PCR and Western blots were quantiﬁed in densitometeric units (du). 
Results: mRNA gene expression for G-CSF was signiﬁcantly increased in LV myocardium 
of patients with ICM compared to LV myocardium from NL-Human donor hearts (2392 ± 
9 vs. 1576 ± 19 du, p<0.05) and IDC compared to NL-Human donor hearts (5762 ± 
397 vs. 3417 ± 216 du, p<0.05). Similarly, protein expression of G-CSF was signiﬁcantly 
increased in LV myocardium of patients with ICM compared to LV myocardium from NL-
Human donor hearts (48 ± 3 vs. 36 ± 2 du, p<0.05) and IDC compared to LV myocardium 
from NL-Human donor hearts (63 ± 2 vs. 36 ± 2 du, p<0.05). 
Conclusions: The results of this study indicate that in LV myocardium of explanted 
failed human hearts, regardless of etiology, mRNA and protein expression of G-CSF is 
upregulated. This ﬁnding may represent an intrinsic adaptation aimed at stimulating the 
translocation of primitive bone marrow stem cells to the failing myocardium to potentially 
counteract ongoing loss of functional cardiomyocytes.
ORAL CONTRIBUTIONS
820 
Novel Therapeutic Targets for 
Experimental Heart Failure
Monday, March 13, 2006, 2:00 p.m.-3:30 p.m.
Georgia World Congress Center, Room B314
2:00 p.m.
820-3 Intra-Renal Infusion of BNP: A Novel Strategy to 
Overcome the Renal Resistance to BNP in Severe 
Experimental Heart Failure
Horng H. Chen, John A. Schirger, Alessandro Cataliotti, Martin L. Fernando, John C. 
Burnett, Jr., Mayo Clinic College Of Medicine, Rochester, MN
BACKGROUND: BNP has vasodilating, natriuretic and renin inhibiting properties. In 
overt heart failure (HF), there is development of renal resistance to BNP. One strategy 
to overcome this renal resistance is to increase the dose of BNP administered, however 
systemic adverse effects such as hypotension is a limiting factor. The objective of the 
current study is to test the hypothesis that intra-renal (IR) delivery of BNP will overcome 
renal resistance without systemic hypotension.
METHODS: We deﬁned the cardiorenal and humoral effects of intravenous (IV) (n=6) 
or IR (n=6) administration of low (0.01ug/kg/min) and high (0.05ug/kg/min) doses of 
canine BNP in two separate groups of dogs with pacing induced overt HF (240 bpm for 
10 days) complicated by renal dysfunction. We used a commercially available small (3.1 
Fr) bifurcated renal catheter (Flowmedica) for direct bilateral infusion of BNP into both 
renal arteries. * P<0.05
RESULTS: IR BNP resulted in a greater natriuresis (103±6 vs 63±32 uEq/min*), diuresis 
(1.7±0.6 vs 0.6± 0.2 ml/min*) and increase in glomerular ﬁltration rate (GFR) (128±72 
vs 47±26 % change*) as compared to IV BNP. IR BNP suppressed plasma renin activity 
and angiotensin II to a greater extend than IV BNP (*). IR BNP also resulted in increased 
delivery of BNP to the kidney as evident by increased urinary BNP excretion (from 24±10 
to 70±10 pg/min*) associated with a decrease in distal reabsorption of sodium,which was 
not observed with IV BNP (16±7 to 23±4 pg/min*). Most importantly, at both doses, IR 
BNP did not result in a signiﬁcant decrease in mean arterial pressure (MAP)(from 98±2 
to 99±1 and to 98±1 mmHg) that was observed with IV BNP (from 100±3 to 91±5 and 
to 87±4 mmHg*) in a dose dependent manner. Both IR BNP and IV BNP decreased 
pulmonary capillary wedge pressure.
CONCLUSION: In overt experimental HF with renal dysfunction, IR BNP has greater renal 
enhancing effects as compared to IV BNP. These favorable renal effects were associated 
without a signiﬁcant change in MAP. We conclude that IR BNP is a novel strategy which 
may overcome renal resistance to BNP in overt CHF by increasing local delivery of BNP 
to the kidneys without hypotension and compromising renal perfusion pressure.
2:15 p.m.
820-4 Beneﬁcial Impact of Cardiac-Isolated Recirculating 
Delivery of AAV-SERCA2a Gene Therapy in a Large 
Animal Model of Heart Failure
Justin A. Mariani, Anka T. Smolic, Tanneale Marshall, Arthur C. Preovolos, Roger 
J. Hajjar, Adam Bilney, Ken R. Chien, John M. Power, David M. Kaye, Baker Heart 
Research Institute, Melbourne, Australia, Massachusetts General Hospital, Harvard 
Medical School, Boston, MA
Background: Myocardial contractile failure due to defective Ca2+ handling is a key 
feature of heart failure (HF). While the beneﬁt of manipulating Ca2+ handling proteins 
by gene delivery has been shown in small animals, the successful translation to clinical 
practice has been limited by the lack of a safe, efﬁcient delivery system. We assessed 
left ventricular function after adeno-associated virus (AAV) mediated gene transfer of 
sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) in an ovine model of HF using a novel 
recirculation technique. 
Methods: HF was induced by one month of rapid pacing in 14 sheep, determined by 
transthoracic echocardiography (TTE) and conductance catheter. At day 34, the treatment 
group (n = 7) received AAV-SERCA2a gene therapy (5x1012drp), delivered using a novel, 
percutaneous, cardiac-isolated, antegrade recirculation method. Pacing continued for a 
further 28 days in all sheep. At day 62, cardiac function was reassessed. 
Results: AAV-SERCA2a gene therapy resulted in a signiﬁcant improvement in ventricular function 
(Table: Fractional shortening (FS); Slope (Ees) of End-systolic pressure volume relationship). 
Further, minimal systemic expression (kidney, liver, lung) of the transgene was evident. 
Conclusion: We have demonstrated that delivery of SERCA2a gene therapy using a 
novel recirculation technique improves cardiac function in a large animal model of HF, 
laying a strong foundation for translation into clinical studies.
Data is mean ± SEM; p < 0.05 between groups is indicated by *, and 
between treatments by #.
Control Day 
34
Control Day 
62
AAV-SERCA 
Day 34
AAV-SERCA 
Day 62
FS(%) 14.8 ± 0.9 13.2 ± 2.2* 11.0 ± 1.7 20 ± 2.6*#
Ees (mmHg/ml) 3.5 ± 0.2 2.6 ± 0.4 2.9 ± 0.4 4.3 ± 0.6*#
LVEDP (mmHg) 18 ± 4 21 ± 4 19 ± 4 19 ± 4
+ve dP/dt (mmHg/
sec) 1117 ± 79 894 ± 294 1116 ± 198 1042 ± 178
2:30 p.m.
820-5 Novel Injectable Alginate Biomaterial Attenuates 
Progressive Infarct Expansion and Preserves Left 
Ventricular Systolic and Diastolic Function Late after 
Myocardial Infarction
Natalie Landa, Micha S. Feinberg, Radka Holbova, Liron Miller, Smadar Cohen, 
Jonathan Leor, Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-
Aviv University, Tel-ha-Shomer, Israel, Institute of Applied Biosciences, Ben Gurion 
University, Beer Sheva, Israel
Background: Cessation or reversal of progressive left ventricular (LV) dysfunction is a 
major aim of heart failure therapy. We developed a cross-linked concentrated alginate 
solution, which upon solidiﬁcation in tissue becomes a hydrogel. The aim of the present 
study was to test the hypothesis that an injection of this novel alginate solution mimicking 
the extracellular matrix (ECM) into an old scar tissue, late after myocardial infarction 
(MI), will provide physical and biological scaffolding, promote tissue rejuvenation and will 
prevent progressive LV dysfunction.
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Methods and Results: Rats (n=40) were subjected to extensive anterior myocardial 
infarction (MI). Two months later, the survivors were randomized to injection of cross-
linked alginate solution (n=15) or PBS (control, n=12) into myocardial scar. Four 
months after MI and two months after injection, postmortem morphometric analysis and 
histological examination of the hearts revealed that alginate solution injection promoted 
intensive neovascularization and increased vessel density (106±15 vs. 43±18mm2; 
p<0.0001), increased scar thickness (2.79±0.27 cm vs. 1.63±0.31 cm; p=0.01) and 
signiﬁcantly reduced expansion index (0.56±0.08 vs. 1.05±0.26; p<0.0001), as compared 
with controls. Serial echocardiography studies showed that alginate solution injection 
attenuated the progressive deterioration in LV fractional shortening, as compared with 
control (12±6% vs. 37±9%; p<0.05). Furthermore, while control animals developed 
restrictive LV ﬁlling pattern, as assessed by Doppler echocardiogram, diastolic function 
improved in alginate-treated hearts (E/A wave ratio of 1.73±0.09 for alginate vs. 3.34±0.5 
for control; p<0.0001).
Conclusions: Our work shows, for the ﬁrst time, that injection of in situ gelling solution of 
crossed-link alginate into an old scar tissue provides physical and biological scaffolding, 
and preserves LV systolic and diastolic function. Our work enables a minimally invasive, 
catheter-based, acellular option to repair old scar tissue and to prevent heart failure.
2:45 p.m.
820-6 Acute Vincristine Pretreatment Protects Adult Cardiac 
Myocytes From Oxidative Stress
Kanu Chatterjee, Jianqing Zhang, Norman Honbo, Rong Tao, Joel S. Karliner, UCSF, 
San Francisco, CA, NCIRE/VAMC, San Francisco, CA
Background: Vincristine, a vinca alkaloid, is a potent antitumor drug widely used in 
cancer chemotherapy and is also neuroprotective against ischemic damage. Aims: To 
determine the effects of vincristine pretreatment on the survival/viability of cultured adult 
mouse cardiac myocytes when exposed to chemical oxidative stress (H2O2). Methods: 
Cultured adult murine cardiac myocytes were pretreated with vincristine (30 uM, 1h) 
or vehicle, then exposed to H2O2 (30µM, 35 min). Trypan blue exclusion assay (TBE) 
measured myocyte survival (percent change relative to control). Viability was measured 
as the retention of healthy, trypan blue exluding rod-shaped myocytes (Rods)(percent 
TBE Rods relative to total TBE’s per dish). Phospho-Akt was measured by western 
blot. Results: Myocytes pretreated with vincristine were almost completely protected 
from chemical oxidative stress (96 + 6 % survival vs 53+ 7%, n=7, P<0.05). Vincristine 
pretreatment improved viability by 135% (61+5% vs 26+4%, n=8, P<0.05). A 6-fold 
increase in survival signal with vincristine cardioprotection was observed in preliminary 
western assays. Conclusions: Acute pretreatment by vincristine is cardioprotective as 
measured by increased survival, preservation of cardiac cell morphology and increased 
phospho-Akt in adult mouse cardiac myocytes exposed to H2O2. These ﬁndings may have 
clinical implications in protecting myocardial injury from oxidative stress.
3:00 p.m.
820-7 Inhibition of Protein Synthesis via mTOR Dependent 
Pathway Prevents Adverse Left Ventricular Remodeling 
and Reduces Infarct Size After Experimental Myocardial 
Infarction
Sebastian Münz, Pratima Malekar, Celine Johanssen, Sebastian Buss, Alexander 
Hansen, Rafﬁ Bekeredjian, Grigorios Korosoglou, Hugo A. Katus, Helmut F. Kuecherer, 
Stefan E. Hardt, University of Heidelberg, Heidelberg, Germany
Background: Attenuation of myocardial remodeling is a critical factor for improving the 
prognosis after myoardial infarction (MI). This chronic process comprises development 
of left ventricular dilatation and hypertrophy within the vital area of the myocardium. 
Rapamycin and analogous substances such as everolimus have an inhibitory effect on 
protein synthesis via inhibition of the FRAP/mTOR pathway. We speculated that inhibition 
of protein synthesis through mTOR dependent signaling might affect infarct size and 
attenuate left ventricular remodeling following MI.
Methods: Therefore, in this study we investigated the effect of everolimus - a rapamycin 
analogon - on left ventricular remodeling after MI in a rat model in vivo. Rats underwent MI 
by ligation of the left anterior descending artery and were followed up to four weeks after 
MI. Everolimus treatment was initiated immediately after MI.
Results: Untreated animals with MI (UT) displayed reduced ejection fraction and 
increased enddiastolic diameters as compared to sham-operated animals. As compared 
to UT oral treatment with everolimus (3 mg/kg/d) led to a decrease in end-diastolic 
diameter (11.0±1.1 mm vs. 9.2±1.3 mm, p<0.05) and to an increase in ejection fraction 
(67±6 % vs. 75±10 %, p<0.05). Mortality did not differ signiﬁcantly between the groups. 
Myocyte size measured in histological samples of the remote area was signiﬁcantly 
decreased by 33% in everolimus treated animals as compared to the NT group. In 
addition, there was a signiﬁcant reduction in infarct size in everolimus-treated animals 
(7.6±1.6% vs. 15.9±3.3%, p<0.05). Phosphorylation of p70S6-kinase and of 4EBP, which 
are key molecules of protein synthesis downstream of mTOR, was signiﬁcantly reduced 
due to inhibition of mTOR activity.
Conclusions: These data indicate for the ﬁrst time that targeting the FRAP/mTOR 
pathway constitutes a potential new strategy to limit infarct size and attenuate adverse left 
ventricular remodeling after MI.
3:15 p.m.
820-8 Low-dose Erythropoietin Treatment Preserves Cardiac 
Function and Mobilizes Endothelial Progenitor Cells in 
Rats With Ischemic Heart Failure
Erik Lipsic, Peter van der Meer, Pim van der Harst, B. Daan Westenbrink, Gideon J. du 
Marchie Sarvaas, Dirk J. van Veldhuisen, Regien G. Schoemaker, Wiek H. van Gilst, 
University Medical Center Groningen, Groningen, The Netherlands
Background: The hematopoietic hormone erythropoietin (EPO) is involved in postnatal 
neovascularization and was shown to enhance endothelial progenitor cells (EPCs) 
mobilization from bone marrow. We hypothesized that low-dose EPO treatment, not 
leading to hematocrit increase, would mobilize EPCs, increase capillarization and 
preserve cardiac function in a post-myocardial infarction (MI) heart failure.
Methods: Rats were either subjected to left coronary artery ligation or sham surgery. 
Rats with MI were left untreated (MI group) or long-acting EPO analogue darbepoetin 
treatment was started 3 weeks after MI in a low-dose (0.4 µg/kg/3 weeks, MI-EPO-low) or 
high-dose (40 µg/kg/3 weeks, MI-EPO-high). Echocardiography was used to measure the 
cardiac function during follow-up. After 9-weeks, hemodynamics, number of EPCs and 
capillary density were measured.
Results: Hematocrit increased in the MI-EPO-high, but not in MI-EPO-low group (p<0.01). 
Both high- and low-dose EPO treatment resulted in preservation of left ventricular systolic 
function during follow-up, and improved cardiac contractility (dP/dtmax) and relaxation (dP/
dtmin) at 9-weeks, compared to MI group (all p<0.05). In addition, in EPO-treated groups 
the number of circulating EPCs was signiﬁcantly increased (MI-EPO-high: 82 [66-147] 
and MI-EPO-low: 67 [55-107] vs. MI: 23 [19-33] cells/high-power ﬁeld; both p<0.01). This 
was associated with a 33% increase in capillary density in MI-EPO-high (p<0.01) and 
20% in MI-EPO-low (p<0.05), compared to MI group.
Conclusions: EPO treatment preserves cardiac function in post-MI heart failure, even in 
doses not affecting hematocrit level. This is associated with raised number of circulating 
EPCs and an increased capillary density.
ORAL CONTRIBUTIONS
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Cardiac Transplantation and Left 
Ventricular Assist: Clinical Outcomes
Monday, March 13, 2006, 4:00 p.m.-5:00 p.m.
Georgia World Congress Center, Room B314
4:00 p.m.
825-3 Increased Mortality With Post-operative Renal Failure 
After Cardiac Transplant
Soundos K. Moualla, Janet M. Boyle, Susana Arrigain, Sarah Worely, Muhammad Bakri, 
Jean-Pierre Yared, Randall C. Starling, Robert Heyka, Nicolas Smedira, Charuhas V. 
Thakar, Cleveland Clinic, Cleveland, OH, University of Cincinnati, Cincinnati, OH
Background: Renal failure (RF) after non-transplant cardiac surgery is a serious 
complication, with well known risk factors and consequences. RF after orthotopic 
cardiac transplant (OCT) is less well deﬁned. Our purpose is to identify risk factors and 
consequences of RF post OCT.
Methods: We studied 779 patients who had OCT at our institution between 1993 and 
2004. We excluded 16 patients for prior transplant, pre-operative dialysis, or insufﬁcient 
data. Post-operative RF was categorized into various classes: Class I, acute renal failure 
requiring dialysis (ARF-D), Class II, ≥50% decline in GFR (no dialysis), and Class III, 
< 50% decline in GFR. The outcomes included in-hospital ARF-D, in-hospital mortality, 
post-operative complications (cardiac, neurological, and infectious). Standard statistical 
methods were used.
Results: The overall mortality was 4.2%. The overall incidence of ARF-D was 5.8%. The 
mortality in the ARF-D groups was 50% vs. 1.4% in the other groups (P < 0.001). Post-
operative morbidity was signiﬁcantly higher in the ARF-D group compared to the other 
groups (P < 0.001), and was proportional to the severity of post-operative renal impairment 
(Table 1). Pre-operative characteristics, age, prior cardiac surgery, diabetes, albumin, 
hematocrit, creatinine, and bypass time, were independent risk factors for ARF-D.
Conclusions: In conclusion, RF post OCT is associated with signiﬁcant morbidity and 
mortality, and directly related to the severity of post-operative renal compromise.
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Correlation of outcomes with the various classes of renal impairment
Clinical 
Outcome
Class I ( ARF-
D) (n, 44)
Class II
(>=50% decline in 
GFR, no dialysis 
(n, 143)
Class III ( < 50% 
decline in GFR) 
(n, 576)
P Value
Death 50% ( 22/44) 2.7% (4/143) 1.04% (6/576) < 0.001
Cardiac 
Morbidity 43.2% (19/44) 9.7% (14/143) 1.7% (10/576) < 0.001
Neurological 
Morbidity 18.2% (8/44) 4.1% (6/143) 4.8% (28/576) < 0.001
Infectious 
Morbidity 54.4% (24/44) 16.1% (23/143) 1.04% (6/576) < 0.001
4:15 p.m.
825-4 The Impact of Patient Selection on Long-Term 
Outcomes of Left-ventricular Assist Device 
Implantation as Destination Therapy for End-Stage 
Heart Failure
K. Lietz, J. Long, A. G. Kfoury, M. S. Slaughter, M. A. Silver, C. A. Milano, J. Rogers, L. W. 
Miller, University of Minnesota, Minneapolis
Background: The REMATCH trial ﬁrst demonstrated that pt selection is very important 
to the success of left-ventricular assist device (LVAD) therapy as an alternative to 
transplantation, or Destination Therapy (DT). Candidate selection, however, requires 
further optimization to reduce the risk of complications and improve long-term survival.
Methods: Outcomes of the ﬁrst 195 recipients of HeartMate XVE as DT btw 11/01-5/05 
after completion of the REMATCH trial were evaluated using data obtained from the 
FDA mandated Thoratec DT Registry. Preoperative risk score was established to allow 
prospective stratiﬁcation of DT candidates.
Results: The majority of DT recipients were Caucasian males, older than 60 yrs, with 
end-stage heart failure due to ischemic cardiomyopathy. At implant the mean LVEF was 
17.7%, mean cardiac index 2.0+0.6 L/min/m2 and 74.5% of pts required inotropic support. 
The use of the HeartMate XVE was associated with longer pump durability, decreased 
incidence of complications and improved 2-yr survival from 29.4% in the REMATCH trial 
to 40.6% in post-REMATCH era. The long-term outcomes of DT, however, were largely 
determined by preoperative pt selection. Pts with severe functional impairment, markers 
of global cardiac dysfunction, end-organ damage or malnutrition were at the highest risk 
of mortality. When DT candidates were stratiﬁed by the cumulative risk score accounting 
for severity of these abnormalities, into low (n=41), moderate (n=51), high (n=53), very 
high (n=35) and extremely high (n=13) risk categories, the corresponding 2-yr survival 
decreased from 72.4%, 54.2%, 30.3% to 27.2% and 0%, respectively.
Conclusion: As safety and durability of the HeartMate XVE has improved, appropriate 
candidate selection has become one the most critical determinants of long-term success 
of DT. In the best suited candidates LVAD therapy was able to achieve 2-yr survival 
comparable to heart transplantation in recipients > 65 yrs, the target population for DT.
4:30 p.m.
825-5 Single Center Experience With the HeartMate II Left 
Ventricular Assist System
Reynolds M. Delgado, III, Branislav Radovancevic, Igor D. Gregoric, Tim J. Myers, Nanthini 
Palanichamy, Courtney Gemmato, O. H. Frazier, Texas Heart Institute, Houston, TX
Body: Axial ﬂow left ventricular assist systems (LVAS) offer potential advantages of 
simplicity and small size. These devices have only one moving part, no valves, and no 
vent or compliance chamber. We believe these unique features will lead to a high degree 
of reliability and enhanced patient acceptance of this technology. 
Methods: Fifteen patients supported by the HeartMate II LVAS as a bridge to heart 
transplant (10) or destination therapy (5) are included in this report. The 11 men and 
4 women had an average age of 40 yrs (range; 14-65 yrs). Eleven patients have non 
ischemic cardiomyopathy and 4 ischemic cardiomyopathy. Average LVAS support duration 
was 178 days (range; 6-693 days) and the cumulative duration was 2663 days. 
Results: Hemodynamic parameters were signiﬁcantly improved in all patients. When 
compared to baseline, the mean cardiac index increased from 1.78±0.27 L/min/m2 to 
3.9±0.8 L/min/m2 at 48 hours after implant. The pulmonary capillary wedge pressure 
decreased from 27.4±11 mmHg at baseline to 15.8±5.3 mmHg at 48 hours. At one 
month after implant, the mean LV diastolic dimension was 5.6 cm, compared to 6.7 cm 
at baseline. Support is ongoing in 12 patients with the longest at 693 days. One patient 
underwent successful transplant after 175 days of support. Two patients died during 
support; 1 at 6 days post implant of multi-organ failure, and the other died at 102 days 
following a cerebrovascular accident. One patient had his device exchanged after the 
pump driveline was fractured in a skateboarding accident. Three patients have received 
the HeartMate II after their HeartMate I device failed. These 4 pump exchange patients 
are doing well as outpatients. Thirteen of 15 patients were discharged from the hospital. 
Conclusion: These data indicate excellent results in this early single center experience. 
Good outcomes are conﬁrmed with high discharge rates and extended support times.
4:45 p.m.
825-6 Structural, Functional and Molecular Recovery of the 
Failing Canine Left Ventricle Following Short-Term 
Therapy with the Orqis Medical Cardiac Recovery System
Hani N. Sabbah, Robert Brewer, Sharad Rastogi, Sudhish Mishra, Robert C. Gupta, 
Michael S. Sabbah, Jeffrey Vlasic, Tony Viole, Marvin A. Konstam, Henry Ford Health 
System, Detroit, MI, Orqis Medical, Inc., Lake Forest, CA
Background: Acute (4 hours) therapy with the Cancion extracorporeal artery-to-artery 
Cardiac Recovery System (CRS) hemodynamically unloads the failing LV. We examined 
the effects of short-term therapy with the CRS on structural, functional and molecular 
recovery of the failing LV in 3 dogs with microembolization-induced heart failure (HF).
Methods: The CRS was implanted in a femoral-to-carotid ﬂow conﬁguration with the 
pump set at a constant ﬂow of ~ 400 ml/min. Dogs were maintained on therapy for 11 
to 18 days. LV end-diastolic (EDD) and end-systolic (ESD) dimensions, end-diastolic 
(EDV) and end-systolic (ESV) volumes and ejection fraction (EF) were measured before 
CRS implantation (PRE) and at end of therapy (POST). LV tissue obtained at POST was 
used to assess mRNA expression by RT-PCR and protein expression by Western blotting 
of the stretch response proteins (SRPs) p21ras and p38 MAPK and the sarcoplasmic 
reticulum protein SERCA-2. LV tissue from untreated HF dogs and normal dogs was 
used for comparison. 
Results: Compared to PRE, CRS decreased EDD (34±2 vs. 40±3 mm), ESD (27±3 vs. 
31±3 mm), EDV (53±3 vs. 59±3 ml), and ESV (31±3 vs. 39±3 ml) and increased EF (42±4 
vs. 33±2 %) at POST and was associated with normalization of SRPs and SERCA-2a 
(Table). 
Conclusions: In dogs with HF, short-term therapy with CRS results in structural, functional 
and molecular recovery of the failing LV. More studies are needed to determine the 
usefulness of the CRS as bridge to recovery and/or destination therapy in advanced HF.
 
mRNA and Protein Expression (densitometric units)
Normal HF-Untreated HF + CRS
mRNA Protein mRNA Protein mRNA Protein
p21ras 148 ± 11 590 ± 105 327 ± 7 1084 ± 102 180 ± 11 685 ± 75
p38 MAPK 217 ± 23 1035 ± 95 419 ± 50 1928 ± 135 257 ± 8 1103 ± 122
SERCA-2a 209 ± 4 1480 ± 165 126 ± 3 799 ± 65 171 ± 5 1303 ± 36
POSTER SESSION
1007 
Myocardial Function and Heart Failure:  
Basic Novel Therapies
Tuesday, March 14, 2006, 8:30 a.m.-Noon
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1007-47 Attenuation of LV Dysfunction by A PPAR-alpha 
Agonist in Hypertensive Rats is Associated With Down-
regulation of Redox-regulated Transcription Factors
Sahoko Ichihara, Yoshiji Yamada, Koji Obata, Kohzo Nagata, Akiko Noda, Gaku Ichihara, 
Hideo Izawa, Toyoaki Murohara, Mitsuhiro Yokota, Mie University, Tsu, Japan, Nagoya 
University Graduate School of Medicine, Nagoya, Japan
Background: Peroxisome proliferator-activated receptor-α (PPAR-α) is a key regulator of 
lipid and glucose metabolism and is implicated in inﬂammation. We investigated the effect 
of the PPAR-α activator fenoﬁbrate on the transition from compensated left ventricular 
(LV) hypertrophy to heart failure in Dahl salt-sensitive (DS) rats as well as the role of 
redox-regulated transcription factors in this transition.
Methods: DS rats were fed a high-salt diet and treated with either fenoﬁbrate (30 or 50 
mg/kg per day) or vehicle from 7 weeks of age.
Results: Fenoﬁbrate inhibited the development of compensated hypertensive LV 
hypertrophy, attenuated the LV relaxation abnormality and systolic dysfunction, and 
improved survival rate in the experimental animals. It also inhibited the up-regulation of 
the DNA binding activities and expression of the redox-regulated transcription factors 
NF-κB, AP-1, Egr-1, SP1, and Ets-1 induced in the left ventricle by the high-salt diet. 
Expression of target genes for these transcription factors, including those for adhesion 
molecules (VCAM-1, ICAM-1), cytokines (monocyte chemotactic protein-1), growth 
factors (transforming growth factor-β, platelet-derived growth factor B), and osteopontin, 
was also increased by the high-salt diet in a manner sensitive to treatment with fenoﬁbrate. 
Furthermore, the inﬁltration of macrophages and T lymphocytes into the left ventricle and 
the increase in the plasma concentration of C-reactive protein induced by the high-salt 
diet were inhibited by fenoﬁbrate.
Conclusions: The PPAR-α activator fenoﬁbrate attenuated the progression of heart 
failure and improved the survival rate in this rat model. These effects were associated with 
inhibition of the inﬂammatory response and of activation of redox-regulated transcription 
factors in the left ventricle.
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1007-48 Akt Overexpression Improves Cardiac Function and 
Ameliorates Heart Failure in Pressure Overload Animal 
Model Phosporilating Key Ca2+ Handling Protein
Paolo Gallo, Marco Santonastasi, Marcello Ceci, Cecilia Scimia, Germano Di Sciascio, 
Gianluigi Condorelli, Campus Bio-Medico University, Rome, Italy, San Raffaele 
Biomedical Science Park, Rome, Italy
Background: Cardiomyocytes (CMC) adapt to physical stress by increasing cell size 
while maintaining cell function, (physiological hypertrophy), in contrast to maladaptation, 
in which cell size and function do not increase accordingly. As shown previously, Akt 
overexpression increases CMC size and improves cardiac function in transgenic mice, 
increase inotropism and lusitropism at cellular level. Aim of this study is further investigate 
the role of Akt on Ca2+ metabolism and its effect on modulating contractility in a heart 
failure model “in vivo”
Methods: we performed Ca2+transient, CMC contraction and relaxation analisys and 
measurements of SRCa2+ uptake. Electrophoresis and immunoblotting were performed 
on tissue extracts from Akt-Tg and wild type (Wt) mouse hearts. Immunoprecipitation 
and kinase assay were performed on the SR fraction proteins from Wt or Akt ventricle 
extracts. For the effect in vivo, Wt and Akt mice underwent transverse aortic costriction 
(TAC) and echocardiographic study was performed at 1, 4, 8 and 12 weeks after TAC 
while hemodynamic study at 12 weeks before heart explantation
Results: Akt overexpression 1) phosphorylates two key Ca2+ handling proteins, 
phospholamban (PLB) and ryanodine receptor (RyR), in the respective Ca2+-calmodulin 
dependent kinase2δ (CAMK2) but not PKA-site; 2) increases IfCa2+ both in Akt and in Wt 
CMCs transduced with different active forms of Akt. We further proved that an active Akt 
mutant directed to the SR induces PLB phosphorylation and increase in the SRCa2+ uptake 
without inducing SERCA2 protein level upregulation and cell hypertrophy. The effects of 
Akt on cardiac contractility were evident in vivo compared to Wt (at 12 weeks TAC: FS%: 
34,9 vs 22,3, p<0.0002; Max dP/dT: 6599+1778 vs 3322+333 mmHg, p<0.02)
Conclusions: our study suggests a new mechanism through which Akt overexpression 
improves Ca2+ handling and CMC contractility. Akt can speciﬁcally phosphorylate PLB at 
Thr-17, the CAMK2δ site in physiological conditions, with not effect on PLB or RyR on 
PKA sites. In vivo data show that Akt decreases the negative long-term effects of TAC, 
ameliorating cardiac function in a heart failure animal model
1007-49 Chronic Therapy with Cardiac Contractility Modulation 
Electrical Signals Normalizes mRNA Expression of the 
Sodium-Calcium Exchanger and its Modulators GATA-4 
and FOG-2 in Dogs With Chronic Heart Failure
Sudhish Mishra, Ramesh C. Gupta, Sharad Rastogi, Makoto Imai, Omar Habib, Hani N. 
Sabbah, Henry Ford Health System, Detroit, MI
Background: The cardiac-speciﬁc sodium-calcium exchanger (NCX) is regulated by the 
transcription factor GATA-4 and its modulator FOG-2. The NCX is up-regulated in heart 
failure (HF), a maladaptation that contributes to worsening LV function. We showed that in 
dogs with microembolization-induced HF, chronic (3 months) therapy with non-excitatory 
cardiac contractility modulation (CCM) electrical signals delivered to LV muscle during 
the absolute refractory period leads to improved LV function. In this study, we examined 
the effects of chronic therapy with CCM in dogs with HF on mRNA expression of NCX, 
GATA-4 and FOG-2. 
Methods: RNA was extracted from LV tissue obtained from 7 CCM-treated ( 3 months) 
HF dogs, 7 untreated HF dogs and 6 normal (NL) dogs. mRNA expression for NCX, GATA-
4, FOG-2 and 18S, a housekeeping gene, was measured using reverse transcriptase 
polymerase chain reaction (RT-PCR) and bands obtained after gel electrophoresis were 
quantiﬁed in densitometeric units (du). 
Results: Data are shown in the table. There was no difference in expression of 18S 
among the 3 study groups. Compared to NL, expression of NCX and GATA-4 increased 
signiﬁcantly in untreated HF dogs while expression of FOG-2 decreased. CCM therapy 
normalized mRNA expression of NCX, GATA-4 and FOG-2. 
Conclusions: In dogs with HF, chronic CCM therapy normalizes NCX, GATA-4 and FOG-
2. Normalized expression of NCX and its regulators provides for a mechanism by which 
CCM therapy elicits improvement in function of the failing LV.
mRNA Expression of NCX, GATA-4, FOG-2 and 18S
Normal HF-Untreated HF+CCM
NCX mRNA (du) 30 ± 2 98 ± 14* 48 ± 4
GATA-4 mRNA (du) 103 ± 31 204 ± 19* 160 ± 26*^
FOG-2 mRNA (du) 4.8 ± 0.6 2.1 ± 0.1* 3.4 ± 0.3^
18S mRNA (du) 16.8 ± 0.3 17.1 ± 0.1 17.2 ± 0.3
*=p<0.05 vs. Normal; ^=p<0.05 vs. HF-Untreated
 
1007-50 Strain Related Alterations of the Phosphoinositide 3-
Kinase/Akt/BAD Survival Pathway
Tieluo Li, Ahmet Kilic, Jennifer R. Nash, Deyanira J. Prastein, Gary Schwartzbauer, 
Timothy DC Nolan, Zhongjun Wu, Bartley P. Grifﬁth, Universtiy of Maryland School of 
Medicine, Baltimore, MD
Background: Increased mechanical stress placed on the myocardium following 
myocardial infarction has been implicated in several stretch-activated signaling pathways. 
The purpose of this study is to identify the deterministic link between the degree of the 
PI3K/Akt/BAD survival pathway activation and the amount of regional myocardial strain 
in a large animal model.
Methods: Sixteen sonomicrometry transducers were placed into the mid-myocardium 
of the infarcted LV free wall to assess remodeling in an ovine model (n=7). Regional 
myocardial tissue eight weeks after infarction underwent Western blotting and 
phosphorimager quantiﬁcation for protein and was compared with normal, non-
instrumented sheep myocardium (n=3).
Results: The end systolic strain map showed dilatation of the infarct with a strain of 3.52 
% ± 1.89. The adjacent region showed shortening with a strain of -4.74 ± 1.75 (p < 0.05) 
and the remote region had a strain of -5.37 % ± 1.87 (p < 0.001). The relative abundance 
of protein is summarized (table). There is a general trend of the PI3K/Akt/BAD survival 
pathway activation associated with the strain change of the myocardium.
Conclusions: Regional myocardial strain may provide the driving impetus behind local 
cell survival in ischemic heart failure.
1007-51 Upregulation of Functional Cardiac Beta3-Adrenergic 
Receptors and Chronic Anthrax Lethal Toxin-Induced 
Progressive Cardiac Depression: Insights Into the 
Underlying Molecular Mechanism
Heng-Jie Cheng, Satoshi Masutani, Chun-Xian Zhang, Michael Cross, Michael F. Callahan, 
Che-Ping Cheng, Wake Forest University School of Medicine, Winston-Salem, NC
Background. Recent evidence suggests that cardiac injury related to anthrax lethal toxin 
(LeTx) may play a primary role in its lethality. However, the pathogenic LeTx-triggered 
events that cause heart failure (HF) are poorly understood. We tested the hypothesis 
that abnormalities in beta-adrenergic receptor (β-AR) signaling, including upregulation of 
cardiac β3-AR, may contribute to LeTx-induced progressive cardiac dysfunction and HF.
Methods. Fifteen CD-1 mice were divided into 3 groups: sham control (received saline, 
iv, n=5) and LeTx-treated mice (received a single bolus of LeTx: 3.0 mg/kg PA and 0.6 
mg/kg LF, iv, n=10). Post injection for 2 and 5 days, we assessed myocyte β1- and β3-AR 
expression and contractile and [Ca2+]i transient ([Ca
2+]iT) responses.
Results. Compared with controls, at 2 and 5 days post injection, the basal myocyte 
contraction and relaxation were progressively decreased more than 34% and 48% (dL/
dtmax, from 138.6 of control to 90.4 and 72.9 µm/s) and (dR/dtmax, from 95.8 to 53.7 and 46.0 
µm/s) with associated reduced peak systolic [Ca2+]iT (from 0.29 to 0.21 and 0.14) (p<0.01), 
respectively. After LeTx treament at 2 and 5 days, myocyte protein levels of β3-AR were 
increased 23% and 48% (from 0.21±0.03 of control to 0.26±0.04 and 0.31±0.02), while 
the protein levels of β1-AR decreased 43% and 72% (from 0.54±0.01 to 0.31±0.02 and 
0.15±0.02), respectively (p<0.05). Importantly, the contrast changes on myocyte β1- and 
β3-AR levels after LeTx were associated with altered myocyte responses to β-AR agonist 
stimulation. Compared with controls, in the post LeTx-treated myocytes at 2 and 5 days, 
superfusion of isoproterenol (10-8 M), a β-AR agonist, caused much less increases in dL/
dtmax (from 94% to 47 and 41%); by contrast, BRL-37344 (10
-8 M), a β3-AR agonist, produced 
signiﬁcantly greater decreases in dL/dtmax from 10.3 to 16.2 and 21.4%, respectively.
Conclusion. These data are the ﬁrst to show that LeTx produces progressive direct 
depression of cardiomyocyte contraction, relaxation, and [Ca2+]iT. LeTx causes upregulation 
of cardiac β3-AR, which contributes to the abnormal response of β-AR stimulation and 
may precede the development of LeTx-induced HF.
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1008-52 Do Simple Clinical and Echocardiographic  
Parameters Predict Long Term Responsiveness to 
Cardiac Resynchronization Therapy? Results From  
the CARE-HF Trial
Stefano Ghio, Nick Freemantle, A. Serio, G. Magrini, L. Scelsi, M. Pasotti, JGF Cleland, 
L. Tavazzi, CARE-HF Investigators, IRCCS Policlinico S. Matteo, Pavia, Italy
Background: Reﬁnement of selection criteria for the implantation of biventricular devices 
is crucial to improve cost-effectiveness of cardiac resynchronization therapy (CRT). The 
CARE-HF trial gives the opportunity to verify whether clinical criteria and the interventricular 
mechanical delay (IVMD), a dyssynchrony parameter easily measurable using conventional 
Doppler echocardiography, may predict long term responsiveness to CRT.
Methods: Echocardiographic examinations were performed at baseline and at 18 months 
in 735 patients enrolled in the CARE-HF trial and randomized 1:1 to CRT and control. 
Echocardiographic recordings were quantitatively analysed in a core laboratory. A long 
term responder to CRT was deﬁned as a patient who survived and whose end-systolic 
volume was reduced at the 18 month evaluation by more than twice the standard deviation 
of inter-observer variability in the core laboratory (40 mL).
Results: According to the above deﬁnition, the percentage of long term responders was 
49.2% in the CRT group as compared to 18.6% in the control group. In a multivariate 
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model which included age, sex, aetiology of heart failure (ischemic vs non ischemic), 
systolic blood pressure, end-diastolic and end-systolic volumes, ejection fraction, mitral 
regurgitation, left ventricular ﬁlling pattern, tricuspid annular plane excursion and IVMD, 
IVMD and etiology were signiﬁcantly predictive of response (p<0.001). The probability 
of being a responder increased linearly with the increase in IVMD in both ischemic and 
non ischemic patients with a fairly smooth slope but it was substantially lower in ischemic 
patients. For an IVMD of 20, 40 or 60 ms the calculated probability was respectively 52%, 
58% and 64% in non ischemic patients and 28%, 33% and 39% in ischemic patients.
Conclusions: In patients with non ischemic aetiology the probability of a positive 
response to CRT is never zero: low values of IVMD should therefore not be used to 
negate the beneﬁts of CRT in such patients. In ischemic patients, the probability of being 
a long term responder is lower and the risk of non response is therefore higher for low 
values of IVMD.
1008-53 Effect of Cardiac Resynchronization on the Incidence of 
Atrial Fibrillation in Patients with Severe Heart Failure
Uta C. Hoppe, Jaime Casares, Hans Eiskjaer, Arne Hagemenn, John G. Cleland, Nick 
Freemantle, Erland Erdmann, University of Cologne, Cologne, Germany
Background: Atrial ﬁbrillation/ﬂutter (AF) and heart failure often coexist. However, the 
effect of cardiac resynchronization therapy (CRT) on the incidence of AF and on the 
outcome of patients with new onset AF remains undeﬁned.
Methods: In CARE-HF 813 patients with moderate or severe heart failure were randomly 
assigned to pharmacological therapy alone or with the addition of CRT. The incidence of 
AF was assessed by adverse-event reporting and by electrocardiograms during follow-up 
and the impact of new onset AF on the outcome and efﬁcacy of CRT evaluated.
Results: By the end of the study AF had been documented in 66 patients in the CRT 
group, as compared with 58 patients who received medical therapy only (16.1 vs. 14.4%; 
hazard ratio, 1.05; 95% CI 0.73 to 1.50; P = 0.79). There was no difference in the time 
until the ﬁrst onset of AF between groups. Only history of AF, left atrial systolic area and 
NT-BNP levels were independently associated with a higher risk of developing AF across 
both groups (all p<0.05). In the entire population mortality was higher in patients who 
developed AF but was not an independent predictor (hazard ratio, 1.17; 95% CI 0.82 to 
1.67; P=0.37). In patients with new onset AF CRT signiﬁcantly reduced the risk for the 
combined primary end point of death from any cause or unplanned hospitalization for a 
major cardiovascular event (64% vs. 81%) and all predeﬁned secondary end points (i.e. 
all-cause mortality 24% vs. 38%), and improved ejection fraction (median at 18 months 
30.1% vs. 25.9%) and symptoms (no interaction between AF and CRT on all variables; 
all P > 0.2). Heart rate control in patients with new onset AF was better in the CRT group 
than in the medical therapy group (substantial interaction of AF and CRT at 18 months; 
P= 0.0003). In the CRT group the median percentage of ventricular pacing was similar in 
patients with new onset AF (99.1%) and without AF (99.9%).
Conclusions: While CRT could not prevent the induction of AF, CRT signiﬁcantly improved 
the outcome in patients with new onset AF. Therefore, CRT should not be withheld from 
patients at increased risk of subsequently developing AF.
1008-54 Feasibility and Short-Term Efﬁcacy of Percutaneous 
Mitral Annular Reduction for the Therapy of Mitral 
Regurgitation in Patients with Heart Failure
Stephen Duffy, Jacob Federman, Catherine Farrington, Meroula Richardson, David 
M. Kaye, Baker Heart Research Institute, Melbourne, Australia, Heart Centre, Alfred 
Hospital, Melbourne, Australia
Background: While functional mitral regurgitation (MR) commonly accompanies heart 
failure (HF) and contributes to HF progression, mitral repair in the setting of HF is not 
routinely practiced due to the attendant signiﬁcant morbidity and mortality. This limitation 
has fostered the development of percutaneous devices to reduce MR, and our group 
has recently reported the short- and long-term effectiveness of a percutaneous mitral 
annuloplasty device placed in the coronary sinus (Percutaneous Mitral Annuloplasty 
Device (PMAD), Cardiac Dimensions®, Inc., Kirkland, WA) in reducing MR in experimental 
animal models of heart failure with associated MR. In this study we performed a ‘ﬁrst in 
human’ study of temporary placement of the PMAD device. The aim of the study was to 
demonstrate the feasibility and safety of temporary deployment of this device in patients 
with functional MR in association with heart failure.
Methods: Five patients undergoing scheduled coronary angiography with heart failure 
(mean age was 52.2±8.8 [SD] years) and functional MR were recruited, and four had 
anatomy suitable for deployment of the device. Transthoracic echocardiography and 
coronary angiography were performed before, during and after temporary placement and 
tensioning of the PMAD in the coronary sinus via the right internal jugular vein.
Results: Temporary deployment of the device resulted in a signiﬁcant reduction in the 
mitral annular area from 35.5±4.7 mm2 to 32.2±4.6 mm2 (p=0.02) with evidence of a 
reduction in the MR color Doppler area from 98.3±43.6 mm2 to 83.3±35.1 mm2 (p=0.09). 
Temporary deployment of the PMAD demonstrated the overall feasibility and safety of 
permanent implantation, and evidence of temporary reduction in MR and a reduction in 
mitral annular area indicate promise for device effectiveness in chronic implantation.
Conclusions: This pilot study of a novel device for percutaneous treatment of functional 
MR has shown that temporary placement of this device in the coronary sinus/great 
cardiac vein of patients with heart failure and MR is feasible and safe.
1008-55 Biventricular Pacing Mode is Associated With a Higher 
Mortality Rate in Cardiac Resynchronization Therapy
Juergen Vogt, Barbara Lamp, Johannes Heintze, Lothar Faber, Bert Hansky, Anke 
Haering, Dieter Horstkotte, Department of Cardiology, Heart Center North Rhine-
Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany
Background: In randomized trials of cardiac resynchronization therapy (CRT), all 
patients (P) were paced biventricularly. Up to 30% did not improve. The aim of this study is 
to compare the outcome of P with atrio-left ventricular pacing versus biventricular mode.
Methods: All P underwent hemodynamic testing with respect to pacing mode, AV delay 
and optimal pacing site. Response was deﬁned as ≥ 10% pulse pressure (PP) increase. 
More than 3% PP increase between pacing modes discriminated best pacing mode. This 
mode was programmed during follow-up.
Results: Between 1999 and 2004, 349 P with sinus rhythm, QRS≥150 ms, NYHA class ≥ 
III received a CRT device. 91 P were on LV pacing only, 258 P on biventricular pacing in 
accordance with the test procedure. We found no signiﬁcant difference between the cohorts 
concerning gender, underlying disease and LV ejection fraction (24.7±7 and 24.5±7 %). 
During long-term FU, both cohorts improved signiﬁcantly in the prognostically important 
parameters (Table). But the analysis of serious adverse events, i.e. cardiac death, heart 
transplantation, or LV assist device, showed a worse outcome with biventricular pacing 
(17% (44P) versus 9% (8 P)). Mean follow-up was 24.4±17.2 versus 23.7±14 months.
Conclusions: Tailored left ventricular pacing is not inferior to tailored biventricular 
mode. Whether an adverse outcome of biventricular pacing mode is the consequence of 
asynchronous apical pacing of the right ventricle, has to be investigated further. 
LV only biventricular
baseline 6 months 9 months baseline 6 months 9 months
Patients (n) 91 77 60 258 202 175
Quality of life (score) 46±18 27±21* 27±20* 43.5±21.2 25.2±18.7* 26.4±16.7*
VO2peak (ml/min/kg) 12.6±2.7 14.9±3.8* 14.7±3.5* 13.2±3.1 15.7±4.0* 15.2±4.1*
LVEDD (mm) 79±10 74±11* 73±12* 77±11 71±12.8* 71±11.4*
*paired t-test p<0.0005
1008-56 Following Acute Myocardial Infarction, Myocardial 
Restraint With a Nitinol Wrap Reduces Left Ventricular 
Dyssynchrony
Mark Doyle, Diane A. Vido, June Yamrozik, Ronald Williams, Geetha Rayarao, James A. 
Magovern, Robert W. Biederman, Allegheny General Hospital, Pittsburgh, PA
Introduction A compliant Nitinol wrap (Paracor) placed around the heart following 
acute myocardial infarction (AMI) reduces left ventricular (LV) dilation and retards LV 
remodeling, but the effects on ventricular synchrony are not known.
Hypothesis We hypothesize that the degree of dyssynchrony post AMI is reduced only in 
the region actively constrained by the Nitinol wrap.
Methods Ten sheep (study group: 6, controls: 4) were imaged at baseline using 3D 
MRI (GE, Milwaukee, WI, CV/i 1.5T) to evaluate LV function. A proximal LAD myocardial 
infarction (MI) was created in all sheep. The study group received a Nitinol wrap placed 
over the ventricle, extending from the apex to the mid level. At 6 weeks post MI, the 
3D MRI evaluation was repeated. Contours outlining the epicardial and endocardial 
ventricular boundaries in the short axis view were analyzed to assess time to maximal 
systolic contraction for 16 circumferential regions equally spaced around the LV for each 
slice (>150 data points per heart). Excluded from analysis were: scar and regions not 
contracting ≥20%. The t test was used and the f-statistic calculated to assess the degree 
of dyssynchrony, with f<0.05 indicating signiﬁcance.
Results At baseline, there was no difference in time to end-systole between basal and 
mid ventricular regions within each group or between groups. When considering all 
sheep, the end-systolic time increased by an average of 35% from baseline to 6 weeks 
post MI (243+86 ms vs. 326+134 ms, p <0.001). Comparing baseline to post MI, the 
degree of dyssynchrony present in the mid ventricular region was almost a factor 2 
greater in controls vs. the wrap group (16% vs. 29%, f<0.05). Conversely, the degree of 
dyssynchrony for the unrestrained basal region markedly increased, and was equivalent 
for controls vs. the wrap group (99% vs. 107%, f=NS).
Conclusions A Nitinol wrap placed following AMI limits development of dyssynchrony 
only in the actively constrained region. Unconstrained regions experienced up to a six-
fold increase in dyssynchrony. These results indicate that a ventricular restraining device, 
with potential for minimally invasive placement, reduces dyssynchrony, possibly negating 
need for future resynchronization.
1008-57 Chronic Therapy with Selective Electric Vagus Nerve 
Stimulation Normalizes Plasma Concentration of Tissue 
Necrosis Factor-α, Interleukin-6 and B-Type Natriuretic 
Peptide in Dogs with Heart Failure
Ramesh C. Gupta, Makoto Imai, Alice J. Jiang, Mengjun Wang, Hani N. Sabbah, Henry 
Ford Health System, Detroit, MI
Background: Plasma concentration of the cytokines interlukin-6 (IL-6) and tumor necrosis 
factor-α (TNF-α), and of B-type natriuretic peptide is elevated in patients with heart failure 
(HF) and serve as biomarkers of worsening HF. We showed that chronic (3 months) therapy 
with selective electric Vagus nerve stimulation (VNS) (CardioFitTM, BioControl Medical, Ltd.), 
improves LV function and attenuates LV remodeling in dogs with microembolization-induced 
HF. This study examined the effects of chronic VNS therapy on plasma concentration of 
TNFα, IL-6, and n-terminal-proBNP (nt-proBNP) in the same dogs. 
Methods: Peripheral blood samples were collected asceptically in EDTA-treated tubes 
from 7 HF VNS-treated dogs, 6 sham-operated untreated HF dogs and 6 normal (NL) 
dogs. All blood samples were obtained from concious dogs at the end of 3 months 
of therapy or follow-up. TNFα, IL-6 and nt-proBNP were quantiﬁed in plasma using a 
colorimetric immunoassay kit speciﬁc for each of the 3 biomarkers and the results 
expressed as pg/ml. 
Results: Data are shown in the table. The levels of IL-6, TNFα, and NT-proBNP in plasma 
increased signiﬁcantly in untreated HF dogs compared to NL. Three months treatment 
with VNS normalized the levels of all three biomarkers. 
Conclusions: Chronic VNS therapy with CardioFitTM normalizes cytokines level and nt-
proBNP in plasma of dogs with HF. This ﬁnding is consistent with the observed improvement 
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in LV function and remodeling seen in dogs with HF after chronic VNS therapy.
IL-6, TNF , and nt-proBNP Plasma Levels (pg/ml)
NL HF-Untreated HF + VNS
TNFα 9 ± 1 59 ± 11* 14 ± 1**
IL-6 5 ± 1 47 ± 6* 16 ± 3**
nt-proBNP 230 ± 18 554 ± 84* 260 ± 24**
*=p<0.05 vs. NL; **=p<0.05 vs. HF-Untreated
 
1008-58 Which Parameter Is Best to Quantify Electromechanical 
Dyssynchrony for Predicting Cardiac Events in Patients 
With Advanced Heart Failure?
Goo-Yeong Cho, Min-Kyu Kim, Woo-Jung Park, Young-Jin Choi, Nam-Ho Lee, Kyung-
Soon Hong, Dong-Jin Oh, Chong-Yun Rhim, Hallym University, Seoul, South Korea
Background: Electromechanical dyssynchrony (Dsyn) is important risk factor of cardiac 
event in heart failure (HF). However there is no golden standard of Dsyn. We sought to 
identify which parameter of Dsyn is best for predicting cardiac events in advanced HF.
Methods: Patients (n = 153, age 65 ± 12) with HF (NYHA class ≥ 3, ejection fraction 
<35%) were followed serially. Doppler velocity imaging was performed using 4-basal and 
4-mid LV segments at apical 4 and 2 chamber to measure the time to peak systolic 
velocity from R wave on ECG (Ts). We measured maximal temporal difference of Ts 
(Ts-diff), standard deviation of Ts (Ts-SD), difference between basal septal and basal 
lateral (Ts-SL), and septal to posterior wall motion delay by M-mode (SPWMD) for 
intraventricular mechanical Dsyn and the difference between basal right ventricle and 
basal lateral (Ts-RVL) for interventricular Dsyn. Clinical events included readmission due 
to worsening of HF, transplantation, and cardiac death.
Results: During 37.1 ± 17.3 months follow-up, clinical events and death rate were 43.1 
and 23.5%. All Dsyn parameters were prolonged in events group. Of these, Ts-diff showed 
the greatest area under the curve (AUC) by ROC curve and was only independent 
predictor of cardiac events by multivariate Cox regression analysis (p < 0.001).
Conclusion: Of all electromechanical dyssynchrony parameters, Ts-diff is the best to 
quantify for predicting cardiac events in patients with advanced CHF.
Cardiac events
p-value
AUC (95% CI)
no yes All events Cardiac death
QRS duration 106.1 ± 2.2 119.1 ± 30.2 0.004 .63 (.54-.72) .58 (.48-.68)
SPWMD 126.8 ± 63.2 161.9 ± 74.2 0.003 .65 (.56-.74) .62 (.52-.72)
Ts-diff 79.7 ± 47.7 123.9 ± 58.7 < 0.001 .75 (.66-.83) .71 (.62-.81)
Ts-SD 31.4 ± 20.5 47.8 ± 22.9 < 0.001 .73 (.65-.81) .69 (.59-.79)
Ts-SL 46.5 ± 45.4 63.8 ± 48.8 0.027 .61 (.52-.70) .61 (.50-.71)
Ts-RVL 43.8 ± 43.7 72.4 ± 43.6 < 0.001 .70 (.62-.69) .66 (.56-.76)
1008-59 Should We Measure Both Electrical and Mechanical 
Dyssynchrony in Patients With Advanced Heart 
Failure? Learning From Long-Term Clinical Follow-Up
Goo-Yeong Cho, Min-Kyu Kim, Woo-Jung Park, Young-Jin Choi, Nam-Ho Lee, Kyung-
Soon Hong, Dong-Jin Oh, Chong-Yun Rhim, Hallym University, Seoul, South Korea
Background: Although both electrical and mechanical dyssynchrony (Dsyn) were poor 
prognostic factors in heart failure (HF), there is considerable discrepancy between two 
Dsyn. We performed a prospective analysis to identify that mechanical Dsyn had an 
additional beneﬁt for predicting cardiac events over electrical Dsyn in advanced HF.
Methods: One hundred ﬁfty three (age 65 ± 12) with HF (NYHA class ≥ 3, ejection 
fraction < 35%) were followed serially. Doppler velocity imaging was performed using 
4-basal and 4-mid LV segments at apical 4 and 2 chamber to measure the time to peak 
systolic velocity from R wave on ECG (Ts). The maximal temporal difference of Ts (Ts-
diff) was measured for mechanical Dsyn. Clinical events included readmission due to 
worsening of HF, transplantation, and cardiac death. The electrical and mechanical Dsyn 
was deﬁned as QRS duration > 120 msec and Ts-diff > 91 msec. According these criteria, 
we divided into 4 groups; group I = QRS ≤ 120 and Ts-diff ≤ 91, group II = QRS > 120 
and Ts-diff ≤ 91, group III = QRS ≤ 120 and Ts-diff > 91, group IV = QRS > 120 and 
Ts-diff > 91.
Results: During 37.1 ± 17.3 months (mo) follow-up, clinical events rate was 43.1% 
(37.0% in QRS duration ≤ 120 msec, 57.8% in QRS duration > 120 msec, p = 0.02) 
including cardiac death of 23.5%. By Kaplan-Meier analysis, mean event free survival 
time, event rate and cardiac death rate were 52.2 ± 2.7 mo (95% CI 47.0-57.5), 21.0%, 
and 9.7% in group I, 35.2 ± 5.0 mo (95% CI 25.3-45.1), 35.2%, and 17.7% in group II, 
28.6 ± 3.4 mo (95% CI 21.9-35.3), 58.7%, and 39.1% in group III, 24.5 ± 4.0 mo (95% CI 
17.6-33.1), 75%, and 32.1% in group IV.
Conclusion: Mechanical Dsyn is important risk factor in both with or without electrical 
Dsyn during long-term follow-up. Therefore, we should measure both QRS duration and 
mechanical dyssynchrony by echocardiography in all advanced HF.
1008-60 Successful Direct Left Atrial Pressure Monitoring and 
Fossal Pacing via an Implantable HEARTPOD Device in 
Animal Models
Saibal Kar, Aamer Jamali, Roderick Tung, Jeffrey Levisman, Fermin Tio, Michael 
Fishbein, James Whiting, Neil Eigler, Cedars-Sinai Medical Center, Los Angeles, CA
Background To evaluate the performance and healing of an implanted left atrial pressure 
(LAP) monitor in animal models. The feasibility of atrial pacing from the fossa ovalis was 
assessed.
Methods Farm pigs (n=16) and dogs (n=20) were implanted with HeartPOD systems 
comprised of a percutaneously placed transseptal left atrial pressure sensor and a 
subcutaneous telemetry coil, some (n=6) with pacing capabilities. Periodic ambulatory 
pressure recording was performed throughout survival. Animals were sacriﬁced from 
0 to 180 days. Pseudo-Valsalva (n=27) was performed to recalibrate the device (n=4). 
Explanted hearts with devices in situ were placed in a calibrated pressure chamber.
Results All 36 implants were successful and yielded high ﬁdelity LAP waveforms 
throughout survival duration. Valsalva tracked LAP with an error of 0.0±0.7 mmHg. At 
follow-up, resting HeartPOD LAP was equivalent to simultaneous catheter measurement 
(11.0±2.9 vs. 10.7±2.3 mmHg). Initial pressure drift was successfully corrected by 
non-invasive recalibration. The atrial surfaces were covered with nonthrombotic 
neoendocardium by 21 days and fully healed at 60 days. Transducer gain was not affected 
by tissue coverage (99.19±0.7%, n=6). Acute atrial pacing was successfully achieved 
in all pacing devices (threshold 0.8mV at 0.5 msec) . Preliminary pacing studies from 
the fossa ovalis have demonstrated decreased P wave duration compared to right atrial 
appendage pacing (60 vs. 101 msec) and improved hemodynamics (cardiac output 2.8 
vs. 1.5 l/min). Atrial pacing was feasible in all animals at 6 weeks.
Conclusions The HeartPOD device accurately measures LAP in animal models, and can 
be recalibrated noninvasively. Healing was rapid and did not affect transducer gain. Pacing 
via the lead is feasible and can potentially serve as an adjunct to rhythm management for 
heart failure patients. Human trials of this device have already begun.
1008-89 Long-Term Effect of Repeated Sequential VV 
Optimization in Patients with CRT-Therapy?
Burkhard J. Hügl, Anett Große, Zdravena Findeisen, Franziska Biedermann, Angela 
Germer, MarKus Jahnecke, Bernward Lauer, Christoph Geller, Zentral Klinik Bad Berka, 
Bad Berka, Germany
Background: Cardiac resynchronisation therapy (CRT) is well established as a treatment 
option in patients (pts) with severe heart failure. Biventricular devices offer the possibility 
to stimulate the right and left ventricle (VV) separately with a speciﬁc time delay. Aim of 
our study is to analyse the additional effect of a sequential VV-optimization over time 
trough invasive and non-invasive measurements in CRT-pts.
Method: In this prospective study pts with CRT-therapy (Heart failure, NYHA≥III, 
LBB>150ms, ejection fraction (EF) < 35%) were included. All pts received a CRT-device 
with the option of VV-optimization (Insync III or Insync III Marquis; Medtronic Inc.)
After one month without biventricular pacing (VVI 30) all pts received a baseline 
investigation with an invasive AV (60-150 ms) and VV (-40 to +40 ms) optimization using 
a micro tip pressure catheter (Millar, SPC790), which was placed in the left ventricle. 
Additional a non-invasive impedance-cardiographic measurement was performed to 
ﬁgure out the cardiac output (CO). These procedures were repeated after 3 months. The 
non-invasive measurement was done again after one year.
Results: 15 pts with CRT were included (age: 66±8 years; EF 23±7 %, 9 pts with DCM). 
Without stimulation we measured at baseline a CO of 4,2±1,3 l/min with a dp/dtmax of 
835±184 mmHg/s. With simultaneously biventricular stimulation and optimized AV-delay 
the CO increased to 5,3±1,5 l/min with a dp/dtmax. of 1021±214,4 mmHg/s (p<0,01). After 
optimization of the VV-time the dp/dtmax. increased additionally to 1090±127,8 mmHg/s 
with a CO of 5,9±1,8 l/min (p < 0,01).
After 3 months of CRT nearly the same results could be performed. (dp/dt max : 
915±114/951±129/1024±120 mmHg/s; CO: 4,4±1,1/4,7±1,2/5,5±1,2 l/min). But in 11/15 
pts the VV-interval was changed in relation to the baseline measurement. After one year 
the hemodynamic situation becomes more stable. In 3/11 pts a change of the VV-intervall 
was related to a signiﬁcant change of the cardic output (> 10%).
Conclusion: A sequential VV optimization improves the hemodynamic parameters 
besides AV-optimization in pts with CRT. A repeated optimization should be required to 
maintain optimal performance.
1008-90 Repeated Thermal Therapy Improves the Abnormality of 
Sympathetic Nervous System in Patients With Chronic 
Heart Failure
Yoshiyuki Ikeda, Masaaki Miyata, Takashi Kihara, Tsuyoshi Fukudome, Takuro Shinsato, 
Takuro Kubozono, Yutaka Otsuji, Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: In patients with chronic heart failure (CHF), the increased sympathetic 
nervous activity develops cardiac dysfunction. In addition, the prognosis of CHF is 
reported to be dependent on the plasma norepinephrine (NE) concentration. Therefore, 
improvement of the abnormality of sympathetic nervous activity may be a new target for 
the treatment of CHF. We developed the thermal therapy using 60 degree centigrade far 
infrared-ray dry sauna which was a different design from the traditional sauna. We reported 
that thermal therapy improves cardiac and vascular endothelial function in patients with 
CHF. The present study aims to investigate whether repeated thermal therapy improves 
sympathetic nervous activity in patients with CHF.
Methods: Thirty patients with CHF due to dilated cardiomyopathy were randomized into 
thermal therapy (n=20) or non-treated group (n=10). The patients in thermal therapy 
group took sauna once a day for 15 minutes and then was kept on bed rest with a blanket 
for 30 minutes, daily for 2 weeks. To analyze sympathetic nervous activity, we measured 
plasma concentration of NE and standard deviation of normal to normal intervals (SDNN) 
by 24-hour Holter ECG recordings. We performed echocardiography and chest X-ray, 
and measured the plasma level of brain natriuretic peptide (BNP). All examinations were 
performed before and after 2 weeks.
Results: Two-week thermal therapy improved left ventricular ejection fraction, 
cardiothoracic ratio of chest X-ray and BNP concentration. After 2-week thermal therapy, 
the plasma concentration of NE signiﬁcantly decreased and SDNN increased compared 
to those before treatment (NE: 485±158 to 321±148 pg/ml, P<0.001; SDNN: 113±8 to 
142±10 ms, P<0.01). Furthermore, the decrease of NE (∆NE) signiﬁcantly correlated with 
the increase of SDNN (∆SDNN) (r=0.92, P<0.005). It is suggesting that thermal therapy 
improves the abnormality of sympathetic nervous system. On the other hand, there were 
no signiﬁcant changes in those of non-treated group (NE: 414±42 to 455±84 pg/ml, 
SDNN: 111±10 to 112±11 ms).
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Conclusions: Repeated thermal therapy decreased sympathetic nervous activity and 
improved cardiac function in patients with CHF.
1008-91 Impedance Cardiography as a Predictor of Clinical 
Outcome in Heart Failure Patients
Jameson Wyatt, Brad Smith, Richard Krasuski, Autumn Dawn Gallbreath, Gregory L. 
Freeman, University of Texas Health Science Center, San Antonio, TX
Baseline: Impedance cardiography (ICG) allows noninvasive assessment of several 
cardiovascular parameters and has been proposed as a way to follow cardiac output in 
heart failure (HF). ICG can track acute drug-induced changes in hemodynamic status, 
but its reliability as a long term monitoring device is unknown. Whether ICG data reﬂect 
functional status or quality of life, and their ability to predict hospitalization and mortality 
in HF is unknown.
Methods: Standard ICG was performed at baseline and at 6 month intervals x3 using 
the BioZ (CardioDynamics, San Diego, CA) on 884 patients enrolled in the South Texas 
Disease Management Project. Physicians were blinded to ICG results and readings were 
not used to alter management.
Results: Patients were 70.5 ± 10.1 years old, 70% were men and 58.5% were NYHA 
Class II. 70.1% had systolic HF (ejection fraction 35±6%), with the remainder having 
echo-documented diastolic abnormalities. Baseline values for cardiac index (CI) did 
not correlate with 6-minute walk distance (6MW) or SF-36 scores. When normalized to 
stroke index (SI), there were very weak correlations with 6MW (p = 0.004, r2=.014) and 
SF-36 scores (p = 0.003, r2 =.012). No baseline ICG ﬁnding (CI, SI, and thoracic ﬂuid 
content (TFC)) was predictive for 30 day hospitalization or mortality. High TFC correlated 
with increased 180 day HF admission (p = 0.04) but not mortality. Fall in CI, SI, or TFC 
between 0 and 6 months was not associated with HF hospitalization or death, and did not 
correlate with SF-36 scores. Ranking the degree of fall (>10%, >25%, >50%) for CI and SI 
did not improve prediction of hospitalization. The area under the curve (AUC) for receiver-
operator curves (ROC) of baseline CI as a predictor of HF admission and death were 
0.524 and 0.556. ROC plots for change in CI also demonstrated no predictive relationship 
to CHF admission or death (AUC = 0.531 and 0.524).
Conclusions: ICG derived parameters correlate poorly with functional performance 
(6MW) and quality of life by SF-36, and are not predictive of heart failure hospitalization 
or death. Change in ICG parameters over 6 months is also not useful to predict these 
outcomes. Thus, ICG is not helpful in the long-term management of CHF.
1008-92 Signiﬁcant Relation of Corrected QT Dispersion to 
Improvement of Symptoms in Patients Who Received 
Cardiac Resynchronization Therapy
Kazuyoshi Hina, Cardiovascular Center Sakakibara Hospital, Okayama, Japan, 
Okayama University, Okayama, Japan
Background: Cardiac resynchronization therapy (CRT) has been introduced for 
treatment of patients with heart failure associated with prolonged QRS complexes. 
CRT is theoretically reasonable to affect repolarization as well as depolarization. Few 
studies, however, have examined the effects of CRT on repolarization. We studied the 
effects of CRT on corrected QT (QTc) dispersion in relation to symptomatic improvement. 
Methods: QTc dispersion was analyzed in 26 consecutive patients (64+/- 6years, 18men 
and 8women) who underwent CRT. CRT responder and non-responder were deﬁned as 
patients showing and not showing > 1 class NYHA symptomatic improvement 3 months 
after CRT, respectively. QTc interval, QRS width and QTc dispersion were measured 
automatically from digital data using an analyzing system (FDX-6521, Fukuda Denshi 
Co., Ltd., Tokyo, Japan) . Tissue Doppler imaging (TDI) was also examined. 
Results: CRT responders and non-responders were observed in 18 and 8 patients, 
respectively. CRT responder showed signiﬁcantly larger QTc dispersion than CRT non-
responder before CRT (111+/-27 vs 43+/-15 msec, p<0.01) and overlap values of QTc 
between CRT responders and CRT non-responders were small. Signiﬁcant decrease in 
QTc dispersion by CRT was observed in responders ( to 49+/-11 p<0.01). In contrast, 
QTc dispersion wan not decreased by CRT in non-respoder (43+/-15 to 33+/-10 msec, 
NS). The difference in QTc dispersion observed before CRT was thus abolished after 
CRT (49+/-11 vs 33+/-10 msec, NS). QRS width and QTc were shortened after CRT. 
There were, however, no signiﬁcant differences in QRS width or QTc between CRT 
responders and CRT non-responders before CRT. There were no differences in changes 
of QRS width or QTc after CRT between CRT responders and CRT non-responders. 
TDI did not show any signiﬁcant differences in asynchrony of wall motion between CRT 
responders and CRT non-responders before or after CRT. 
Conclusion: The present study clariﬁed that CRT responders showed signiﬁcantly larger 
QTc dispersion than CRT non-responders before CRT. These ﬁndings indicate that 
QTc dispersion may be clinically useful to distinguish CRT responders from CRT non-
responders before CRT.
1008-93 First Human Experience With a New Left Atrial Pressure 
Monitoring Device: Validation with Simultaneous 
Pulmonary Artery Occlusion Pressure in Subjects With 
Heart Failure
Jay L. Ritzema-Carter, Iain C. Melton, Ian G. Crozier, Saibal Kar, Neal Eigler, James 
Whiting, Henry Krum, William T. Abraham, Richard W. Troughton, Christchurch Hospital, 
Christchurch, New Zealand, The Alfred Hospital, Melbourne, Australia
Background: We describe the ﬁrst human experience with a permanent implantable 
direct left atrial pressure (LAP) monitoring device.
Methods: 8 male subjects with heart failure (LVEF 24 ± 11%, NYHA II-III) underwent 
device implantation. Via an 11 French right femoral vein sheath, the device was sited in 
the atrial septum by trans-septal puncture with ﬂuoroscopic guidance. Intra-cardiac echo 
(in 6) conﬁrmed deployment of the tip and distal anchors 1mm into the LA. Recordings 
were made of simultaneous mean direct LAP and mean pulmonary artery occlusion 
pressure (PAOP, Swan-Ganz catheter) at trans-septal puncture and of simultaneous 
PAOP and device LAP at implantation.
Results: Device implantation was successful in all patients, with no procedural 
complications. High ﬁdelity waveforms were obtained from all 8 devices. PAOP accurately 
approximated direct LAP. Mean PAOP was 17.5 ± 7.4 mmHg, mean direct LAP was 17 ± 
4.9 and mean device LAP was 17 ± 6.5. After 109±64 days, there are no device-related 
complications and all devices continue to record high-ﬁdelity LAP waveforms. At 3-month 
follow-up (5 patients) mean PAOP was 12.8 ± 4 and mean device LAP was 13 ± 3.
Figure: Direct LAP, device LAP and intra-cardiac electrogram at implantation in one subject.
Conclusions: A new LAP monitoring device was safely implanted in eight patients and 
accurately measured LAP at implantation and intermediate follow-up. This device could 
be used to accurately monitor and optimise treatment in heart failure patients.
1008-94 Greater Reduction in Mitral Regurgitation During 
Therapy Guided by Measured Filling Pressures
Sharon Reimold, Gudaye Tasissa, Michele A. Hamilton, Robert C. Bourge, Thomas 
G. DiSalvo, Uri Elkayam, James A. Hill, Lynne W. Stevenson, University of Texas 
Southwestern Medical Center, Dallas, TX, Brigham and Women’s Hospital, Boston, MA
Background. We investigated the impact of heart failure (HF) therapy on mitral 
regurgitation (MR) and left ventricular ﬁlling by analyzing echocardiograms from ESCAPE, 
a randomized trial of pulmonary artery catheter- (PAC) guided therapy versus clinical 
assessment (CLIN) in HF.
Methods. Echocardiograms were analyzed blindly and performed at randomization, 
discharge, and 3 months. MR was the primary prespeciﬁed physiologic endpoint. 
Variables measured were: left atrial area (LAA), MR color jet area, ratio of MR jet area to 
LAA (MR/LAA), early mitral inﬂow velocity (E), mitral deceleration time (Dec time), and 
ratio of pulmonary venous systolic to diastolic velocities (PV S/D). Changes in weight 
and jugular venous pressure were followed in all patients. Pulmonary capillary wedge 
pressure (target of 16 mm Hg) was measured during PAC-guided therapy.
Results. Means are shown with standard deviations. MR jet area was reduced in PAC 
compared with CLIN at discharge. Doppler evidence of decreased MR and decreased 
left heart ﬁlling pressures was supported by a decrease in early mitral inﬂow velocity, 
prolongation of mitral Dec time, and increase in PV S/D, which persisted at 3 months. By 
3 months, there was no difference between MR in the 2 groups.
Conclusions. Therapy to reduce ﬁlling pressures with PAC improves MR and related ﬁlling 
parameters more than CLIN during hospitalization. At 3 months, MR reduction was no different 
between groups, but trends for improved ﬁlling persisted after PAC-guided therapy. 
PAC CLIN
Baseline
DC
(change from 
baseline)
Baseline
DC
(change
from baseline)
P value*
Weight (kg) 86 (22) -4.0 (5.4) 86 (20) -3.2 (4.2) 0.10
PCWP (mm Hg) 25 (9.1) -7 (8.9) N/A N/A N/A
LAA (cm2) 30.4 (7.0) -0.72 (6.2) 31.1 (8.2) -0.20 (5.5) 0.54
MR jet (cm2) 9.4 (6.6) -2.1 (5.3) 10.0 (6.6) 0.25 (4.2) 0.005
MR/LAA 0.30 (0.18) -0.06 (0.18) 0.31 (0.18) 0.00 (0.13) 0.02
E (cm/sec) 101.4 (40.1) -8.3 (25.1) 96.7 (27.9) 6.2 (40.4) 0.009
Dec Time (msec) 140 (52) 20.0 (67) 147 (61) 7.0 (54) 0.26
PV S/D 0.47 (0.41) 0.24 (1.04) 0.52 (1.00) -0.25 (1.46) 0.15
*P values are for the differences between treatment arms for change from baseline to 
discharge
 
1008-95 Survival in Ischemic Cardiomyopathy: Medical Therapy 
is Superior to Revascularization in Patients With 
Limited Viability
Nowwar Mustafa, Irshad Alam, Waddah Maskoun, Judy Foltz, Jothiharan Mahenthiran, 
Masoor Kamalesh, Irmina Gradus-Pizlo, Harvey Feigenbaum, Stephen Sawada, Indiana 
University, Indianapolis, IN
Background: Assessing viability (viab) in coronary disease (CAD) and ventricular 
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dysfunction may be unnecessary based on results of prior studies showing that patients 
with limited viab still may beneﬁt from revascularization (revasc).
Methods: We studied the prognostic value of the extent of viab in matched groups of 
medically treated (medRx) (n = 127) and revasc (n = 121) patients with CAD and left 
ventricular dysfunction (mean ejection fraction 31% and 32%; respctively). 57% had 
symptoms of heart failure. Three vessel CAD was present in 82% of both groups. Based 
on low dose wall motion scores (WMS) patients were divided into three groups: extensive 
(WMS < 2.00), intermediate (WMS 2.00-2.49), and limited viab (WMS > 2.50). Patients 
were followed for cardiac death.
Results: Mean follow up was 4.0 years. Revasc improved ﬁve-year survival in patients 
with extensive viab (mean survival 4.4 in revasc versus 3.9 years in medRx; p = 0.01) 
and intermediate viab (4.2 in revasc versus 3.3 years in medRx; p = 0.04). In patients 
with limited viab there was a strong trend toward worse survival in revasc patients (2.5 
in revasc versus 3.8 years in medRx, p = 0.06). In patients with limited viab survival in 
medRx patients on beta-blockers was better than revasc patients (Figure, p = 0.01).
Conclusions: Patients with extensive and intermediate viability have improved survival 
with revasc but those with limited viability may have worse survival. Optimal medical 
therapy might be superior to revasc in patients with limited viability.
1008-96 The Incidence of Intraventricular Dyssynchrony in 
Patients With Dilated Cardiomyopathy With Narrow QRS 
Duration: Studied by Tissue Doppler and Strain Image
Young Soo Lee, Seong-Wook Han, Kee-Sik Kim, Chang-Wook Nam, Seung-Ho Hur, 
Yoon-Nyun Kim, Kwon-Bae Kim, DongSan Medical Center, Daegu, South Korea
Background: The cardiac resynchronization therapy (CRT) can improve the heart 
function in patients with heart failure with left bundle branch block. Recently, it has been 
pointed out that even patients with normal QRS may exhibit intraventricular dyssynchrony 
(IVD). The aim of this study was to evaluate the incidence of IVD in patients with dilated 
cardiomyopathy with narrow QRS by tissue Doppler and strain image.
Methods: We enrolled 22 non-ischemic dilated cardiomyopathy with narrow QRS (M:
F 17:5, 52.7±13.2). We measured the time from QRS onset to systolic peak in DTI and 
compression/expansion crossover point in the strain image at mid and basal segment 
of apical 4 and 2 chamber views. All data were corrected by heart rate. The IVD by DTI 
and strain image was deﬁned as > 100 msec and > 215 msec, respectively in difference 
between maximum and minimum at all segments. Also, after being corrected by heart 
rate, IVD by DTI and strain image was deﬁned as > 4.0 and > 6.5 msec, respectively. 
Results: The IVD by DTI in patients with narrow QRS was 41.9% (9/22), and 18.2 % 
(4/22) after correct by heart rate. However, IVD by strain image was 77.3%(17/22), and 
81.8%(18/22) after corrected by heart rate.
Conclusions: In our study, the incidence of IVD in patients with dilated cardiomyopathy 
with narrow QRS was similar by using DTI with other report, however by using strain 
image, the incidence was higher than expected.
Table 1
Mean ± SD Minimum Maximum
Ejection fraction (%) 28.0±6.9 18.0 39.0
QRS width (msec) 96.4±12.9 60.00 120.00
Heart rate (msec) 833.9±162.7 625.00 1176.47
IVD by DTI (msec) 91.2±22.8 50.57 126.41
IVD by DTI - corrected by HR (msec) 3.17±0.77 1.776 4.648
IVD by Strain image (msec) 246.3±57.7 153.00 359.69
IVD by Strain image - corrected by HR (msec) 8.61±2.04 5.009 13.378
1008-97 Mononuclear Bone Marrow Stem Cells Implant as 
an Alternative Treatment in Non-isquemic Dilated 
Cardiomyopathy
Jorge C. Trainini, Noemi E. Lago, Myriam Alvarez, Alejandra I. Christen, Eduardo 
Guevara, Jorge H. Mouras, Osvaldo H. Masoli, Jose L. Barisani, President Peron 
Hospital, Avellaneda, Argentina
Background: Cellular transplant strategies have been designed to treat patients with 
ischemic-necrotic cardiomyopathy; however, scarce information is available from patients 
with non-ischemic dilated cardiomyopathy. The aim of this work was to evaluate anatomic 
and functional improvements induced by mononuclear stem cells (MNSC) implant in 
patients (pt) with non-ischemic dilated cardiomyopathy (NIDC).
Methods: 8 pt were submitted to MNSC implant, 4 males, age 50±17 yrs, etiology of 
NIDC: idiopathic (5 pt), chagasic (2 pt) and lupus (1 pt). Cardiac catheterization showed 
no vessel disease. Echocardiographic evaluation of cardiac function and left ventricular 
diameters was obtained before and after each MNSC implant. Independent researchers 
performed blind evaluation of these studies. Bone marrow sample was obtained from 
iliac crest and processed to obtain MNSC. Enriched suspension of MNSC, diluted 
in autologous pt serum, was implanted via coronary arteries: 7.1±2.4 ml, containing 
2.6±1.13E+08 cells (95% viability, 0.85±0.36% CD34+). Medical treatment was not 
modiﬁed after MNSC implant. Results are shown as mean values and standard deviation. 
Statistical analysis included Student t test.
Results: No mortality or complications were observed at a follow-up of 295±37 days. 
Functional class (NYHA) improved from 2.5±0.8 to 1.4±0.5 (p<0.001), left ventricular 
ejection fraction increased from 18.3±7 to 26.4±10% (p<0.005) and left ventricular 
diastolic diameter showed a non-signiﬁcant decrease from 71±12 to 69±11 mm.
Conclusions: In these pts, MNSC implant via coronary arteries proved to be a feasible 
and safe alternative treatment for NIDC, showing a signiﬁcant improvement of clinical and 
functional parameters.
1008-98 A Novel, Simpliﬁed Two-Dimensional 
Echocardiographic Measure of Left Ventricular 
Dyssynergy Predicts Patient Response to Cardiac 
Resynchronization Therapy
Hind W. Rahmouni, Ted Plappert, Shumin Gao, Bettina B. Kuersten, Ed Chinchoy, 
Kathryn Hilpisch, Susan E. Wiegers, Martin St John Sutton, Hospital of the University of 
Pennsylvania, Philadelphia, PA
Background: Cardiac resynchronization therapy (CRT) is beneﬁcial for patients with 
severe, drug refractory systolic heart failure (HF) and evidence of ventricular dyssynchrony. 
However, an estimated 25 - 30% of patients do not improve following therapy. Direct 
measures of left ventricular (LV) dyssynchrony may better predict patient response than 
QRS duration alone. We assessed a novel echocardiographic screening parameter for the 
evaluation of left ventricular (LV) dyssynchrony.
Methods: Baseline echocardiograms from 45 patients randomly selected from the Multicenter 
In Sync Randomized Clinical Evaluation (MIRACLE) or MIRACLE ICD studies were 
retrospectively analyzed and clinical response determined at 6 months. All patients had EF ≤ 
35%, NYHA class II-IV HF and QRS ≥ 135mm. and were on optimal medical therapy. The time 
interval between the peak septal and peak lateral wall excursion from the two-dimensional 
short axis image at the level of the papillary muscles was quantiﬁed by counting the number of 
video frames between these two events and expressed in ms (1 frame= 33.33ms). Receiver 
operating characteristics (ROC) curves were constructed to display the best combination of 
sensitivity and speciﬁcity for each parameter measured. We deﬁned a positive response to 
CRT as a reduction of 13 points in the Minnesota Living With Heart Failure Questionnaire 
(QOL) ; improvement of 50 meters for the 6 minute hall walk (6MHW), increase of 25% of 
ejection fraction (EF) and a > 10% fall in end-systolic volume (ESV).
Results: The best threshold point was 200ms (6 frames). The AUC (Area Under the 
Curve), Sensitivity and Speciﬁcity are respectively: 0.90, 95.4%, 70.6% for QOL, 0.83, 
100%, 54% for 6MHW, 0.79, 94.1%, 64.6% for EF and 0.74, 72% 60% for ESV.
Conclusion: This new echo method of counting video frames between peak septal and 
peak lateral LV wall excursion had positive predictive value for response to CRT and 
has potential application in screening CRT candidates. Its value resides in its simplicity, 
time-effectiveness and universal availability over alternative methods including three-
dimensional echocardiography, tissue Doppler, strain rate imaging and tissue tracking.
1008-99 Kidney Transplantation Leads to Improved Left 
Ventricular Ejection Fraction in Patients with Systolic 
Dysfunction and End Stage Renal Failure Compared to 
Medical Management Alone
Sara Saberi, Jacob P. Deerhake, Todd M. Koelling, University of Michigan, Ann Arbor, MI
Background: Previous investigators have reported improved left ventricular ejection 
fraction (LVEF) in patients with end stage renal disease (ESRD) and left ventricular 
systolic dysfunction (LVSD) after kidney transplantation (KT). Whether this is due to the 
effects of KT or optimized medical management has not been investigated thoroughly.
Methods: We performed a case and control study of ESRD patients found to have LVSD 
by echocardiography (echo) on evaluation for KT from 1990-2000. Cases (18) underwent 
subsequent KT, while controls (18) remained on the KT waiting list. Both groups had repeat 
echo > 6 months later. Cases and controls were matched for age, gender, QRS interval, 
presence of CAD, and time from baseline echo. Changes in left atrial (LA) dimension, LV 
internal dimension in diastole and systole (LVIDD and LVIDS), and LVEF were compared.
Results: Baseline characteristics and medical therapy (age, presence of CAD, blood urea 
nitrogen, mean arterial pressure, ACE inhibitor use, beta blocker use, and digoxin use) for 
cases and controls did not differ signiﬁcantly. Comparison of the baseline and follow-up echo 
measurements are shown in the table below. Controlling for the baseline LVEF, cases were 
associated with higher LVEF on follow-up testing (beta 7.2, 95%CI 0.7 - 13.8, p = 0.03).
Conclusion: Patients with ESRD and LVSD have signiﬁcant improvement in LVEF after 
kidney transplantation compared to patients receiving medical therapy alone.
Control Group
n = 18
Transplanted Group
n = 18
Baseline Follow-up Change Baseline Follow-up Change p value †
LA (mm) 41 ± 8 43 ± 7 4 ± 6 44 ± 7 43 ± 6 -2 ± 7 0.029
LVIDd (mm) 52 ± 8 50 ± 11 1 ± 6 56 ± 8 51 ± 10* -5 ± 8 0.028
LVIDs (mm) 39 ± 10 37 ± 10 2 ± 8 47 ± 9 38 ± 12* -9 ± 9 0.009
LVEF (%) 32 ± 10 46 ± 12* 13 ± 14 26 ± 10 48 ± 12* 23 ± 12 0.037
* - p < 0.05 for follow-up vs baseline       † - cases vs controls
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1009-100 Can the Electrocardiogram Distinguish Stress 
(Tako-Tsubo) Cardiomyopathy from Acute Anterior 
Myocardial Infarction?
Scott W. Sharkey, Andrey G. Zenovich, John R. Lesser, Barry J. Maron, Minneapolis 
Heart Institute Foundation, Minneapolis, MN
Background: Stress-induced (tako-tsubo) cardiomyopathy (SCM) is a rapidly reversible form 
of left ventricular (LV) dysfunction triggered by psychological stress. However, because the 
clinical presentation of SCM often mimics that of acute anterior myocardial infarction (AMI), we 
investigated the possibility that the two conditions could be discriminated by the 12 lead ECG.
Methods: We studied 49 consecutive female patients with SCM (age 67±12 yrs) identiﬁed 
over 44 months. These patients were matched with 35 female patients (age 67±16 yrs) 
who presented, over the same time period, with ECG evidence of an anterior AMI, and 
underwent emergency reperfusion of the left anterior descending artery by percutaneous 
coronary intervention. ECG parameters were quantitatively analyzed in both groups at 
hospital admission and discharge.
Results:
ECG
(V2-6),
(mm)
Admission 
SCM
Admission 
AMI
Admission 
p-value
Discharge 
SCM
Discharge 
AMI
Discharge 
p-value
ST 
elevation 1.3 ± 1.5 3.6±2.3 <0.0001 1.3±1.5 3.6±2.3 <0.0001
R-wave 7.3±6.8 4.0±4.6 0.02 8.1±5.3 5.8±4.8 0.02
T-wave 2.6±4.2 5.3±4.0 0.003 -0.9±2.2 0.3±1.7 0.009
Sum 
Q/QS -15±16 -16±15 0.7 -12±14 -21±15 0.008
On admission, as well as discharge, ECGs in SCM differed from those of AMI by virtue 
of less marked ST-segment elevation, lower T-wave amplitude and greater precordial R-
wave amplitude. Q/QS-wave formation was more prominent in AMI, but only at discharge. 
Troponin T/I release was similar in SCM and AMI (2.6±5.4 ng/ml vs 3.5±4.6 ng/ml, 
respectively; p=0.4) but LV ejection fraction was lower in SCM patients (31±9 % vs. 42±12 
%, respectively; p<0.0001).
Conclusions: On admission, the ECG pattern in SCM differs importantly from that of 
anterior AMI. The ECG may be a useful adjunct for distinguishing SCM from the more 
common anterior AMI.
1009-101 Tako-tsubo -like Apical Ballooning Shape: What it 
Depends on?
Juan Benezet-Mazuecos, Borja Ibanez, Felipe Navarro, Antonio Pinero, Carlos G. 
Santos-Gallego, Pedro Marcos-Alberca, Javier Higueras, Jeronimo Farre, Fundacion 
Jimenez Diaz, Madrid, Spain
Background: Left ventricular (LV) akinesia in “tako-tsubo” syndrome is associated to a 
left anterior descending (LAD) with a long recurrent diaphragmatic segment. We have 
analyzed the morphology of the LV in 51 consecutive patients (PP)(29 men, age 66±14) 
diagnosed with AMI for single occlusion in the LAD, without other coronary obstructions, 
and treated with primary angioplasty.
Methods: We established the segment occluded and the relation between the recurrent 
segment and the total length of the LAD (LAD recurrence index [RI]). We identiﬁed 4 
patterns of LV akinesia:1)distal anterior wall, apex and distal diaphragmatic wall (“tako-
tsubo”-like)(45%),2)distal anterior wall and apex (“ballerina foot”-like)(31%),3)apex 
and distal diaphragmatic wall (12%),4)only apex (12%).(Fig). The occlusion was: 
proximal(22%), medium(55%), distal(23%).
Results: The LAD RI related with the LV pattern was:type 1 0,21±0,02;type 2 
0,06±0,04;type 3 0,20±0,04;and type 4 0,10±0,01, being the differences statistically 
signiﬁcant between type 1 and 2(P<.001), 1 and 4(P=.002), 3 and 2(P=.005), and 3 and 
4(P=.014). The occlusion was proximal or medium in types 1 and 2, and distal in 3 and 
4(P<.001 between 1+2 and 3+4).
Conclusions: “Tako-tsubo”-like akinesia was observed in 45% of PP with anterior AMI 
with a unique occlusion of the proximal or medium LAD. The development of this kind 
of akinesia depends exclusively of the segment occluded and the presence of a long 
wrapped LAD supplying the distal diaphragmatic LV wall.
1009-102 Transient Cardiac Apical Ballooning Syndrome: 
Prevalence and Clinical Implications of Right 
Ventricular Involvement
Ahmad A. Elesber, Abhiram Prasad, Kevin A. Bybee, Uma S. Valeti, Arashk Motiei, Amir 
Lerman, Krishnaswamy Chandrasekaran, Charanjit S. Rihal, Mayo Clinic, Rochester, MN
Background: Right ventricular (RV) dysfunction in patients with the transient left 
ventricular apical ballooning syndrome has not been previously reported. The aim of 
the study was to assess the prevalence and clinical signiﬁcance of RV in patients with 
transient left ventricular apical ballooning syndrome.
Methods: Thirty consecutive patients with the diagnosis of transient left ventricular apical 
ballooning syndrome were prospectively identiﬁed. Echocardiograms were retrospectively 
analyzed and included visual evaluation of RV function and regional RV wall motion 
abnormalities. Five patients also underwent evaluation by cardiac MRI.
Results: All patients were female (mean age: 71+12 years). Abnormal RV systolic 
function was present in 8 of the 25 patients in whom a transthoracic echocardiogram 
was performed at presentation. RV involvement was characterized by apical and mid-
RV systolic dysfunction with sparing of the basal segments. Twenty-two patients had 
a follow-up echocardiogram (median time to follow-up 43 days), and all demonstrated 
complete recovery of RV and left ventricular systolic function. Cardiac MRI conﬁrmed 
that RV involvement was limited to the apex and mid RV segments. Patients with RV 
involvement had a longer hospitalization (11+5 vs 7+4 days; p=0.033), higher incidence 
of severe heart failure (p=0.0016), need for mechanical ventilation (p=0.0003), and use 
of intra-aortic balloon pump for hemodynamic support (p=0.0071). The relationship 
between impaired RV function and the occurrence of severe heart failure (p=0.014), and 
the combined occurrence of severe heart failure, requirement for an intra-aortic balloon 
pump or cardiopulmonary resuscitation (p=0.0081) was independent of left ventricular 
ejection fraction.
Conclusion: Reversible impairment of RV function occurs in approximately one-third of 
patients with transient left ventricular apical ballooning syndrome, and has an important 
impact on heart failure severity, hemodynamic stability, and duration of hospitalization.
1009-103 The Variable Natural History of Idiopathic Dilated 
Cardiomyopathy
Kapil Parakh, Michelle M. Kittleson, Ilan S. Wittstein, Daniel P. Judge, Hunter C. 
Champion, Lili A. Barouch, Kenneth Baughman, Stuart D. Russell, Edward K. Kasper, 
Joshua M. Hare, Johns Hopkins Bayview Medical Center, Baltimore, MD, Johns Hopkins 
School of Medicine, Baltimore, MD
Background: Determining prognosis of patients with heart failure is a key part of patient 
management and clinical trial conduct, yet the assessment of long-term prognosis for 
individual patients is problematic and the relative value of traditional prognostic criteria 
remains unclear in the current era.
Methods: We investigated the ability of clinical, hemodynamic, and echocardiographic 
parameters to predict the long-term prognosis of individual patients in the modern setting 
in a large, representative, contemporary cohort of idiopathic dilated cardiomyopathy (IDCM) 
patients referred to Johns Hopkins from 1997 to 2004 for evaluation of cardiomyopathy. All 
patients underwent a history, review of medications used, physical examination, laboratory 
studies, echocardiogram, right heart catheterization, and endomyocardial biopsy at baseline.
Results: In 171 patients with IDCM followed for a median 3.5 years, there were 50 long-term 
event-free survivors (LTS) (median survival 6.4 years) and 34 patients died or underwent 
ventricular assist device placement or transplantation before 5 years (NLTS) (median time 
to event 1.83 years). Established risk factors (sex, race, presence of diabetes, serum 
creatinine, or serum sodium) and the use of accepted heart failure medications (angiotensin 
converting enzyme (ACE)-inhibitors inhibitors, angiotensin receptor blockers (ARB), and 
beta-blockers) were similar between groups. According to bootstrapped stepwise cox 
regression models, age, EF and NYHA class at baseline were the most predictive variables 
of survival. However, the positive predictive value of an EF<25% was 64% (95% CI 41% to 
79%) and of NYHA class>2 was 53% (95%CI 36% to 69%). A logistic model incorporating 
all three variables correctly classiﬁed only 65% of the patients as NLTS (area under the 
reciever operator curve (ROC) for the model was 0.72).
Conclusion: Although age, EF and NYHA class were independently associated with 
mortality, the ability of the clinical predictors to classify individual IDCM patients into broad 
prognostic categories was limited. These results suggest a paradigm shift in IDCM from a 
disease with a predictable outcome to one with a variable natural history.
1009-104 Cardiac Amyloidosis is Associated with a High 
Frequency of Intracardiac Thrombus Formation
Dali Feng, William D. Edwards, Krishnaswamy Chandrasekaran, Deborah Hughes, 
Morie A. Gertz, John A. Lust, Jae K. Oh, Kyle Klarich, Mayo Clinic, Rochester, MN
Background: Amyloidosis, especially primary type (AL), has a poor prognosis with 
frequent cardiac involvement. There are several case reports of intracardiac thrombus 
responsible for fatal embolism in patients with cardiac amyloidosis and sinus rhythm. 
However, it is unclear how frequently intracardiac thrombus is present in these patients.
Methods: We searched for cases of cardiac amyloidosis in the Tissue Registry at Mayo 
Clinic from 1998 to 2004. There were 97 hearts available for evaluation. Each heart 
sample was carefully examined to identify intracardiac thrombus. Chi-square test or an 
unpaired t-test was used to compare the differences between the 43 AL and 54 senile 
amyloidosis (AS) where appropriate.
Results: Intracardiac thrombus was found in 30 of the 97 hearts (31%) and included 49 
thrombi. Of these 30 hearts, 23 had thrombus in only one chamber while 5 had thrombus 
in 2 chambers and 2 in 3 chambers. Of the 49 thrombi, 28 were in the right atrium, 14 in 
the left atrium, 3 on coronary sinus valve, 1 in the right ventricle, and 1 in the left ventricle. 
AL patients had a signiﬁcantly higher frequency of intracardiac thrombus than AS even 
though AL patiets were younger and had a fewer AF (table).
Conclusions: There was a high frequency of intracardiac thrombosis in patients 
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with amyloidosis, especially the AL type. Early screening for intracardiac thrombosis 
and prophylactic anticoagulation may reduce morbidity and mortality associated with 
intracardiac thrombosis in patients with cardiac amyloidosis.
AL (n=43) AS (n=54) P value
Age (years) 61.0±1.9 82.8±1.6 <0.0001
Gender, % male 62.8 59.6 =0.50
Atrial ﬁbrillation (AF), % 17.1 39.6 <0.05
LVEF, % 48.0±3.3 51.1±3.4 =0.51
Intracardiac thrombosis, % 51.2 16.7 <0.001
POSTER SESSION
1010 
Cardiac Transplantation and Assist 
Devices:Coronary Vasculopathy
Tuesday, March 14, 2006, 8:30 a.m.-Noon
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1010-105 Coronary Blood Flow and Coronary Flow Reserve by 
Contrast-Enhanced Transthoracic Echocardiography 
Predict Long-Term Outcome in Heart Transplantation
Francesco Tona, Alida LP Caforio, Roberta Montisci, Antonio Gambino, Angelo 
Ramondo, Giuseppe Toscano, Massimo Ruscazio, Giuseppe Feltrin, Greta Dequal, 
Annalisa Angelini, Gino Gerosa, Sabino Iliceto, Cardiology, University of Padova, 
Padova, Italy, Cardiology, University of Cagliari, Cagliari, Italy
Background: Cardiac allograft vasculopathy (CAV) is a major obstacle to long-term graft 
survival. We assessed the validity of coronary ﬂow velocity analysis and coronary ﬂow 
reserve (CFR) by contrast-enhanced transthoracic echocardiography (CE-TTE) as a 
marker of long-term outcome after heart transplant (HT).
Methods: Deceleration time of diastolic ﬂow velocity (DDT) and CFR were measured in the 
left anterior descending coronary artery (LAD) by CE-TTE in 78 HT patients (pts) (65 M, aged 
50 ± 12 years at HT, follow up 8.1 ± 4.3 years). Coronary ﬂow velocity in the LAD was detected 
at rest and during adenosine infusion. CFR was obtained as the ratio of hyperaemic diastolic 
mean velocity (DMV) to resting DMV. Angiographies were analyzed using a qualitative grading 
system: grade I, normal angiogram; II, luminal irregularities, diameter reduction < 30%; III, 
stenosis < 50% and grade IV, stenosis ≥ 50% and/or diffuse narrowing of small vessels. CAV 
was deﬁned as angiographic changes ≥ grade II. Follow up was 18 ± 5 months. Combined 
endpoints were cardiac death, stent implant and heart failure.
Results: Pts with events had higher CAV incidence (p=0.002), higher CAV grade 
(p=0.003), shorter DDT (p=0.006) and lower CFR (p=0.006). A ROC derived DDT cutpoint 
≤ 840 ms (AUC 0.797, p=0.01), was 74% speciﬁc and 86% sensitive for predicting events, 
with positive (PPV) and negative predictive value (NPV) of 31% and 97% respectively 
(p=0.002). A CFR cutpoint of ≤ 2.6 (AUC 0.851, p=0.003) was 66% speciﬁc and 91% 
sensitive for predicting events, (PPV= 32%, NPV=97%) (p=0.001). Pts with CFR </= 2.6 
and pts with DDT </= 840 ms had a lower survival free from events (p=0.0003 and p=0.01, 
respectively). By Cox regression only a lower CFR predicts the risk of long-term cardiac 
events (OR 5.6, 95% CI 1.5-20.4, p=0.008).
Conclusions: CE-TTE assessment reveals that shorter DDT and lower CFR are reliable 
surrogate markers for subsequent events and that CFR is the main independent predictor 
of poor outcome in HT pts.
1010-106 Is Adenosine Pharmacologic Stress Testing Safe in 
Cardiac Transplant Patients?
Muhammad Arida, Chaﬁk Assal, Gino Tapia Zegarra, Enrique Garcia-Sayan, Mouaz 
Al-Mallah, Barbara Czerska, Karthik Ananthasubramaniam, Henry Ford Heart and 
Vascular Institute, Detroit, MI
Background: The safety proﬁle of Adenosine in Cardiac Transplant (CT) patients has 
been questioned due to increased incidence of high-grade atrioventricular (AV) block 
necessitating premature interruption of infusion in prior small reports. This phenomenon 
has been attributed to denervation supersensitivity of the sinus and AV node to adenosine. 
Since Adenosine Myocardial Perfusion Imaging (AMPI) is an accepted method for 
detection of coronary disease (CAD) we studied its safety in a large series CT patients.
Methods: A retrospective analysis of all CT patients who underwent AMPI between 
1997-2005. Baseline demographics, medications, AMPI electrocardiographic and stress 
variables were all recorded. Continuous variables were compared using standard t test 
and univariate and multivariate predictors for AV block were analyzed.
Results: Out of 350 cardiac transplant patients, 102 (21% females and 81% Caucasians) 
underwent AMPI. Mean age was 59 ±9 and the average interval from transplant to AMPI was 
8.5 ± 4.5 years. Overall, 21 patients (20%) experienced signiﬁcant sinus or high grade AV 
blocks. These events were transient and resolved after completion of infusion. The infusion 
was interrupted due to AV block in only 2 patients (1.9%). No long-term adverse events were 
noted in any patient. Multivariate regression analysis suggested baseline ﬁrst degree AV block 
and aspirin use being the only signiﬁcant predictors of signiﬁcant block with Adenosine.
Conclusion: Transient self-limiting high grade AV block during AMPI appears more 
common in CT patients than the general population (20% vs. 5%). These do not lead 
to premature test termination or long-term adverse sequelae. Hence AMPI appears 
a feasible and safe method to evaluate for graft CAD in CT patients. Slower infusion 
protocols or adjunctive low level exercise may decrease incidence of high-grade blocks. 
The predictive value of ﬁrst degree AV block for Adenosine induced high grade blocks 
needs further study.
1010-107 Coronary Hypersensitivity to Serotonin in Cardiac 
Transplant Recipients. Relation to Vessel Wall 
Morphology and Effect of Vitamin C
Nicolas Preumont, Olivier Pradier, Michel Goldman, Yvon Carpentier, Jean-Luc 
Vachiery, Martine Antoine, Guy Berkenboom, Cardiology Department, ERASME 
Hospital, ULB, Brussels, Belgium
Background: Coronary hypersensitivity to serotonin promotes platelet aggregation 
entailing the progression of the atherosclerotic process. This abnormality is a common 
ﬁnding in cardiac transplant recipients and may be triggered by reactive oxygen species 
(ROS) which play a main role in inﬂammatory process. Hence, we aimed determining 
the inﬂuence of intimal hyperplasia on this abnormality and its reversibility after acute 
supplementation with the superoxide anion scavenger, vitamin C.
Methods: Intracoronary (IC) injections of serotonin (5HT, 3 µg), bradykinin (Bk, 600 ng) and 
nitroglycerin (ISDN 200 µg) were performed in 21 cardiac transplant recipients (1 year post 
Tx) with normal coronary angiography; the 5HT injections were repeated after IC vitamin C 
supplementation (40 mg/min for 14 min). In the segments where 5HT effects were the most 
pronounced, the diameter changes were measured by quantitative angiography and the 
vessel wall morphology was studied by intravascular ultrasound (IVUS).
Results: The IVUS examination revealed moderate to severe intimal thickening (total 
area minus luminal area/ total area) in 9 patients (group 1): 25±2%, compatible with 
early stage of graft vasculopathy. In this group, the hypersensitivity to 5HT remained 
unchanged after IC vitamin C supplementation: from - 21±3% (% from baseline) to - 
25±3%; whereas in the other 12 patients with mild intimal thickening (9±1%; group 2), the 
hypersensitivity to 5HT was attenuated from -20±5% to -4±6% (P<0.01). In contrast, the 
responses to bradykinin and isosorbide dinitrate were similar in the 2 groups. In group 1, 
high sensitivity CRP and proinﬂammatory cytokines (IL-6 and IL-8) plasma levels were 
signiﬁcantly enhanced. For all the patients studied, the vitamin C effect on the response 
to 5HT was signiﬁcantly correlated with the intimal thickening.
Conclusion: At 1 year post-transplantation, the morphological changes, compatible 
with early stage of the graft vasculopathy, are accompanied by a hypersensitivity to 5HT 
unresponsive to vitamin C, despite a relatively preserved endothelial function (unaltered 
response to Bk).
ORAL CONTRIBUTIONS
837 
Prognosis
Tuesday, March 14, 2006, 9:00 a.m.-10:30 a.m.
Georgia World Congress Center, Room B402
9:00 a.m.
837-3 Trends in Survival Following a Diagnosis of Heart 
Failure
Paul A. Heidenreich, VA Palo Alto Health Care System, Palo Alto, CA, Stanford 
University, Stanford, CA
Background: Several life-prolonging therapies are now available for patients with heart 
failure. However, the impact on survival for patients with heart failure in the community 
is unclear.
Methods: We examined a random sample of Medicare outpatient and inpatient claims 
for patients following a diagnosis of heart failure between 1984 and 2001. Only patients 
with a new diagnosis (outpatient or inpatient with no encounters for heart failure in the 
prior 18 months) were included. Comorbidity diagnoses during prior and index encounters 
were combined into a modiﬁed Charleson score. Patient’s records were linked to create 
a longitudinal record for each patient. The primary outcome was death at 1 year following 
a diagnosis of heart failure.
Results: From 1988 to 2001 the mean age of the patients increased slightly from 79.7 to 
80.2, and the modiﬁed Charlson comorbidity score increased (worse comorbidity) from 
2.52 to 3.10 (all p < 0.0001). Despite the increase in age and comorbidiity, survival to 
one year improved from 66.7% in 1988 to 75.1% by 2000 and days of hospitalization 
for heart failure declined in the year following a diagnosis (9.2 to 5.9, all p < 0.0001) 
After adjustment for patient demographics and comorbidities, survival steadily improved 
throughout the 1990s (Figure, reference year 1987).
Conclusion: Survival for the U.S. elderly following a diagnosis for heart failure improved 
steadily from 1987 to 2000 despite the patients being older with more comorbidity.
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837-4 Changes in the 1-Year Survival After Hospital Discharge 
in Heart Failure Patients With Depressed Systolic 
Function in the Last Years. Had We Reached the Same 
in Men and Women?
Lilian Grigorian, Alfonso Varela Roman, Pilar Mazon Ramos, Jose Maria Garcia Acuña, 
Fernando Otero Raviña, Jose Ramon Gonzalez Juanatey, Hospital Clinico Universitario 
de Santiago de Compostela, Santiago de Compostela, Spain
Aims. To investigate whether changes in clinical characteristics and treatment strategies 
have had the same impact on the survival of male and female patients hospitalized 
with heart failure (HF) and depressed systolic function (D-SF). Method and Results. 
All patients hospitalized consecutively between 1991 and 2001 for HF in a cardiology 
department of a tertiary hospital were assessed and 668 patients with D-SF were 
selected for this analysis (69.5% males). The only signiﬁcant changes between periods 
before (period 1) and after (period 2) 2000 affected the prevalence of: third cardiac 
sound and digoxin prescription, which decreased, hyperlipidemia, coronariography 
performance, spironolactone and betablockers prescription, which increased, both in 
men and women. Additionally, in the male group an increase in angiotensin converting 
enzyme inhibitors prescription and decrease in the prevalence of atrial ﬁbrillation were 
detected. On the other hand, in the group of males the prevalence of all management 
strategies which have demonstrated to increase survival of HF patients was higher 
than in females in the period 2. Survival after 1-year of hospital discharge was clearly 
improved in men, whereas it remained unchanged among women (Figure). Conclusions. 
Lower adherence of physicians to HF treatment guidelines in women than in men has 
led to absence of prognostic improvement in the former group. There is a strong need to 
intensify the awareness of health care professionals in female patients.
9:30 a.m.
837-5 Predictors of Mortality After Discharge in Patients 
Hospitalized with Heart Failure: An Analysis from the 
Organized Program to Initiate Lifesaving Treatment in 
Hospitalized Patients with Heart Failure (OPTIMIZE-HF)
Christopher O’Connor, William T. Abraham, Nancy M. Albert, Robert Clare, Wendy 
Gattis Stough, Mihai Gheorghiade, Barry Greenberg, Clyde Yancy, James B. Young, 
Gregg C. Fonarow, OPTIMIZE-HF Investigators and Hospitals, Duke Clinical Research 
Institute, Durham, NC
Introduction: Patients with heart failure (HF) are at high risk for mortality in the early 
period after hospital discharge (DC).
Objectives: To develop a clinical model predictive of short-term mortality in a large, 
unselected, pt population discharged after HF hospitalization.
Methods: OPTIMIZE-HF is a registry/performance improvement program for pts 
hospitalized with HF. 60-90 day post-DC follow-up (f/u) data were prospectively 
collected in a pre-speciﬁed 10% sample. A total of 4,402 pts were included with 19 
potential predictor variables used in a stepwise Cox proportional hazard model for all-
cause mortality within the f/u period. Continuous variables that did not meet linearity 
assumptions were transformed. All signiﬁcant variables (P<.05) were entered into the 
multivariable analysis.
Results: Table 1 shows multivariable predictors of mortality. Factors predicting early post 
dc mortality include age, serum Cr, reactive airway disease, low systolic blood pressure, 
low serum sodium, and depression. Gender, CAD, and diabetes were not predictive. Use 
of statins and β-blockers at DC was associated with signiﬁcantly decreased mortality.
Conclusions: A substantial risk of mortality is present in the ﬁrst 60-90 days after DC for 
HF hospitalization. Several factors were identiﬁed that signal high risk patients. Increased 
efforts to provide optimal HF therapy, monitoring, and close follow-up to lower mortality 
are needed, particularly in HF patients with one or more of these risk factors.
Table 1: Some Predictors of Early Post-Discharge Mortality
Variable Hazard Ratio
95% Hazard 
Ratio Conﬁdence 
Limits
P Value Chi Square
Age (increasing by unit of 
decade) 1.22 1.11, 1.34 <0.0001 17.58
Reactive Airway Disease 1.58 1.17, 2.14 <0.0001 8.70
Depression 1.48 1.14, 1.93 0.0034 8.56
Admit SBP (decreasing 
units of 10 mmHg, <140) 1.18 1.10, 1.26 <0.0001 42.13
Admit Na (decreasing by 
units of 1 mEq/L, up to 
140 mEq/L)
1.03 1.01, 1.06 0.0066 7.38
Admit Cr (increasing by 
units of 1 mg/dL, up to 4 
mg/dL)
1.32 1.08, 1.6 0.0069 7.31
DC Cr (increasing by 
units of 1 mg/dL, up to 3 
mg/dL)
1.37 1.05, 1.77 0.0191 5.49
DC Statin 0.74 0.59, 0.94 0.0123 6.26
DC Beta-Blocker 0.76 0.61, 0.95 0.0137 6.07
9:45 a.m.
837-6 Short-Term and Long-Term Mortality With Nesiritide 
for Decompensated Heart Failure: A Meta-Analysis of 
Randomized Controlled Trials
Prasanna Kumar Venkatesh, Saurabh Kandpal, Janos Molnar, Rohit R. Arora, Chicago 
Medical School, Chicago, IL
Background: Nesiritide (recombinant human B-type natriuretic peptide) has been shown to 
provide symptomatic and hemodynamic improvement in decompensated heart failure (HF). 
A previous meta-analysis of 3 randomized controlled trials has suggested an increased 
short-term risk of death with nesiritide use. We performed a meta-analysis to evaluate the 
short-term and long-term risk of death with nesiritide use for decompensated HF.
Methods: Seven large randomized controlled non-mortality trials on nesiritide with 
available data on 30 day mortality were included. Data on 180 day mortality was available 
only in 4 trials. Mortality data in nesiritide and control arms were extracted from the 
selected trials and the nesiritide database (Scios Inc.).
Results: The pooled estimate of the relative risks (RR) for unadjusted 30 day and 180 day 
mortality revealed no signiﬁcant differences between the nesiritide and control arms [RR with 
95% conﬁdence interval (CI): 1.243 (0.798-1.935) and 1.002 (0.798-1.259)] respectively.
Conclusions: Unlike a previous analysis, our meta-analysis indicates that nesiritide is 
not associated with a higher 30 day or 180 day mortality. Further analysis of mortality 
adjusted for confounding variables like nesiritide dose, duration of infusion, concurrent 
use of inotropes, HF stage and arrhythmias may reveal subgroups in jeopardy. Large scale 
randomized controlled trials powered to evaluate mortality are required to conclusively 
address these ﬁndings.
Meta-Analysis showing the relative risk (RR) of 30-day and 180-day 
mortality with nesiritide use
Study 30-Day MortalityRR ( 95% CI)
180-Day Mortality
RR (95% CI)
Mills et al 0.392 (0.058-2.653)
Efﬁcacy 1.235 (0.250-6.104) 1.174 (0.561-2.456)
Comparative 1.407 (0.521-3.798) 0.879 (0.565-1.367)
PRECEDENT 0.611 (0.192-1.943) 0.736 (0.429-1.262)
VMAC 1.582 (0.785-3.191) 1.205 (0.861-1.686)
PROACTION 4.875 (0.578-41.10)
FUSION I 0.489 (0.070-3.401)
Pooled RR 1.243 (0.798-1.935) 1.002 (0.798-1.259)
10:00 a.m.
837-7 Clinical Outcomes by Baseline Left Ventricular Ejection 
Fraction in the African-American Heart Failure Trial
Jay N. Cohn, William Tam, Inder S. Anand, Manuel Worcel, Michael L. Sabolinski, Anne 
L. Taylor, University of Minnesota Medical School, Minneapolis, MN, NitroMed, Inc., 
Lexington, MA
Background: Fixed-dose combination of isosorbide dinitrate and hydralazine (ISDN/HYD) 
reduced the risk of all-cause mortality by 43% and reduced the risk of hospitalization for 
heart failure (HF) by 39% in black patients treated with standard therapy in the African-
American Heart Failure Trial (A-HeFT). Since little data exist for the relationship of left 
ventricular ejection fraction (LVEF) to outcomes in black patients, we examined the impact 
of LVEF on baseline characteristics and mortality and hospitalization.
Methods: Echocardiography was performed at baseline and at 6 months. Echos were 
analyzed by the same cardiologist in a core lab. Clinical outcomes were assessed 
separately in patients with > or ≤ mean baseline LVEF.
Results: 807 patients had baseline LVEF with a mean of 35±9%. At baseline, patients with 
LVEF ≤ 35% (mean 27.4%) had signiﬁcantly lower systolic and diastolic blood pressure, 
increased ischemic and decreased hypertensive HF etiology, higher BNP levels, greater 
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use of digoxin and aldosterone antagonists, and less use of beta blockers when compared 
to patients with baseline LVEF > 35% (mean 42.5%). In the placebo group, patients with 
baseline LVEF ≤ 35%, compared to those with baseline LVEF >35%, had much higher 
mortality (16.7% vs. 7.2%, p=0.004) and similar rate of ﬁrst hospitalization for HF (30.4% 
vs. 25.6%, p=0.28). In the low LVEF group (n=397) ISDN/HYD vs. placebo was associated 
with a reduced risk for mortality (HR 0.53, 95% CI 0.3-0.94, p=0.027) and trends for 
reduction in ﬁrst hospitalization for HF (HR 0.84, CI 0.58-1.22, p=0.36) and prolonged 
event-free survival (HR 0.82, CI 0.59-1.14, p=0.23). In the higher EF group (n=410) there 
was a favorable trend on mortality (HR 0.66, CI 0.3-1.5, p=0.30) but a signiﬁcant reduction 
in HF hospitalizations (HR 0.50, CI 0.32-0.79, p=0.002) and prolonged event-free survival 
(HR 0.52, CI 0.35-0.80, p=0.002).
Conclusion: Patients with LVEF ≤ 35% exhibit higher mortality which is greatly reduced 
by ISDN/HYD, whereas patients with LVEF > 35% respond to ISDN/HYD with a dramatic 
decrease in hospitalizations for HF. The drug combination is therefore effective in all black 
patients with HF regardless of the severity of LV remodeling.
10:15 a.m.
837-8 Outcomes by Gender in the African-American Heart 
Failure Trial (A-HeFT)
Anne L. Taylor, JoAnn Lindenfeld, Susan Ziesche, Mary Norine Walsh, Judith Mitchell, 
Kirkwood Adams, Manuel Worcel, Michael L. Sabolinski, S. William Tam, Jay N. Cohn, 
University of Minnesota Medical School, Minneapolis, MN
Background: Fixed-dose combined isosorbide dinitrate/hydralazine (I/H) signiﬁcantly 
reduced mortality, heart failure (HF) hospitalizations (HOS) and improved quality of life 
(QoL) in 1050 black patients with advanced HF. A-HeFT was unique in that 40% of the 
cohort were women. Baseline characteristics and outcomes by sex and treatment are 
compared.
Methods: Baseline characteristics and medications were compared between men and 
women by I/H and placebo treatment. Survival, time to ﬁrst HF HOS and event free 
survival were compared by sex and treatment.
Results: There were no differences by sex or treatment in baseline characteristics for 
age, diastolic blood pressure, or background medications. Women had slightly lower 
baseline hemoglobin, and creatinine and slightly higher BMI, diabetes prevalence, 
systolic blood pressure, and worse QoL scores. All cause mortality was lower in women 
than men but there was no signiﬁcant treatment interaction by sex. The primary composite 
score consisting of mortality, ﬁrst HF HOS and changes in QoL at 6 months was slightly 
better in women than men, but the magnitude of improvement by I/H was similar.
Men (n=630) Women (n=420)
Mortality HR=0.79 (95%CI 0.45, 1.4) p=0.38
HR=0.33 (95%CI 0.16, 0.71) 
p=0.003
First HF HOS HR=0.60 (95%CI 0.42, 0.86) p=0.005
HR=0.58 (95%CI 0.39, 0.86) 
p=0.007
Mortality or First HF 
HOS
HR=0.67 (95%CI 0.49, 0.92) 
p=0.013
HR=0.62 (95%CI 0.41, 0.96) 
p=0.029
Conclusion: Fixed dose I/H improved HF outcomes in both men and women in A-HeFT. 
I/H signiﬁcantly improved the primary composite score and event free survival as well as 
reduced the risk of ﬁrst HF HOS to similar extent in both sexes. I/H had a more pronounced 
mortality beneﬁt in women, but without a signiﬁcant treatment interaction by sex.
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1031-47 Angiotensin II Acutely Increases Diastolic Distensibility: 
A Protein Kinase C and Na+/H+ Exchanger-mediated 
Effect
Paulo M. Castro-Chaves, Pedro Pimentel-Nunes, Ricardo Fontes-Carvalho, Alexandre 
Lima-Carneiro, João B. Soares, Adelino Leite-Moreira, Serviço de Fisiologia, Faculdade 
de Medicina do Porto, Porto, Portugal
Background: Angiotensin II (AT-II) is a vasoactive octapeptide ubiquitous in the 
cardiovascular system. While its effects in myocardial contractility have been extensively 
studied, only recently an effect in acute diastolic properties was described. The increase 
in myocardial distensibility was dependent on AT-1 receptor stimulation in myocardial 
multicellular preparations with intact endothelium. Our aim in the present study was to 
clarify its underlying mechanisms.
Methods: Increasing doses of AT-II (10e-9 to 10e-5 M) were added to right papillary 
muscles of New Zealand white rabbits immersed in a modiﬁed Krebs solution (0.6 Hz, 
1.8 mM Ca2+, 35ºC) in baseline conditions (n=11) and in the presence of chelerythrine, 
a Protein Kinase C inhibitor (CHE, 10e-5M; n=8), or 5-(N-methyl-N-isobutyl)-amiloride, 
an inhibitor of Na+/H+ exchanger (MIA; 10e-6 M; n=10). Calculated parameters: resting 
tension, active tension (AT), peak rates of tension rise and decline (dT/dtmax and dT/
dtmin, respectively), muscle length (L) and peak shortening (PS). Results are presented 
as mean±SEM in % of baseline (p<0.05).
Results: In baseline conditions, AT-II induced a dose dependent positive inotropic effect 
and an increase in muscle length. At the maximal dose of 10e-5 M, AT-II increased 
43.3±6.25% AT, 58.6±9.6% dT/dtmax, 49.2±9.8% dT/dtmin, 35.8±4.4% PS and 
1.96±0.4% L. Restoring muscle length to the value it presented, before addition of AT-II, 
resulted in a decrease in resting tension of 46±4%. AT-II induced also a rightward shift 
and a decrease in the slope of passive length-tension relation. Effects of AT-II on resting 
tension and therefore on myocardial distensibility were attenuated by MIA (23±5%) and 
almost blunted by CHE (11±4%).
Conclusions: In the present work, AT-II decreased resting tension and rightward shifted 
the passive length-tension relation, indicating an increase in myocardial distensibility. The 
subcellular mechanisms involved in this AT-1 receptor dependent effect include activation 
of Protein Kinase C and Na+/H+ exchanger. These results further clarify the mechanisms 
by which AT-II may modulate diastolic function and the response to acute changes in 
ventricular ﬁlling.
1031-48 Direct and Acute Cardiotoxicity of Ultraﬁne Air 
Pollutants
Loren E. Wold, Boris Z. Simkhovich, Margaret A. Nordlie, Michael T. Kleinman, 
Constantinos Sioutas, Robert A. Kloner, Good Samaritan Hospital, Los Angeles, CA, 
University of California-Irvine, Irvine, CA
Background: Exposure to particulate air pollution is associated with increased pulmonary 
and cardiac morbidity and mortality. One major proposed mechanism is that ultraﬁne 
(<100 nm) particles (UP) cause release of oxygen radicals and cytotoxic mediators from 
the lungs that ultimately damage the cardiovascular system. However, since the UP can 
penetrate the lung and enter the vasculature, they could potentially mediate a direct toxic 
effect upon the cardiovasculature. We demonstrated that intravenous infusion of UP 
generated from diesel exhaust (UPDE) into living, anesthetized rats was arrhythmogenic 
and triggered premature ventricular beats. Intravenous infusion of UP did not preclude 
the involvement of other organs. Therefore to test the hypothesis that UP have a direct 
cardiotoxic effect, we studied their effects on isolated paced rat hearts perfused on a 
Langendorff apparatus.
Methods and Results: Baseline physiological parameters were measured, and UPDE 
(~100 µg) were administered into coronary arteries via the aortic root. Physiological 
parameters were remeasured at 60 min after particle infusion. UPDE decreased left 
ventricle end-systolic pressure (LVESP) by 39.1% and increased end-diastolic pressure 
(LVEDP) by 143.3 % (p<0.05 vs. the baseline). In addition, +dP/dt fell from 2712 mmHg/
sec to 931 mmHg/sec and -dP/dt decreased from 1537 to 553 mmHg/sec (p<0.05). 
Coronary ﬂow (CF) decreased by 31.7% in the UPDE group compared to 19.7% in the 
control group (p<0.05). In a second set of experiments, UP from diesel exhaust National 
Institute of Standards and Technology reference material (UPRM) and the soluble fraction 
(SF) in which particles were removed by ﬁltration were also studied. Paced hearts were 
perfused for 30 min with control (pure buffer) or buffers containing UPRM or SF. 30 min 
perfusion with UPRM decreased LVESP by 53.7%, +dP/dt by 57.9%, -dP/dt by 56.7% 
and CF by 67.3% compared to the control group (p<0.05). SF did not cause any effects 
on cardiac contractility and CF.
Conclusion: Our study suggests a new pathophysiologic mechanism in UP caused 
cardiac morbidity - i.e. their direct and acute cardiotoxic effects on left ventricle contractility 
and coronary ﬂow.
1031-49 The Functional Interaction Between CREB and C/EBPb 
Mediate beta AR Stimulation Induced IL-18 Binding 
Protein Expression in Cardiomyocytes
Bysani Chandrasekar, Srinivas Mummidi, Rick Derynck, Christoph F.A. Vogel, William C. 
Claycomb, David R. Murray, University of Texas Health Science Center, San Antonio, TX
Introduction: The crosstalk between sympathetic nervous system and proinﬂammatory 
cytokines plays a key role in the pathophysiology of congestive heart failure. IL-18, a 
proinﬂammatory cytokine, plays a causal role in this setting. The biological effects of IL-18 
are counteracted by IL-18 binding protein (IL-18BP), a natural inhibitor of IL-18. While 
b-AR stimulation mediated IL-18 induction has been reported, effects of b-AR stimulation 
on IL-18BP are not known.
Methods: Mouse HL-1 cardiomyocytes were treated with isoproterenol (ISO). Induction 
of IL-18BP expression was analyzed by Northern blotting, nuclear run-on, Actinomycin 
D pulse, Western blotting, and promoter-reporter assays. Possible signal transduction 
pathways involved in ISO mediated IL-18BP induction were also investigated.
Results: ISO upregulated IL-18BP mRNA and protein expression in b2-AR dependent 
manner. Expression levels were regulated mainly at the post-transcriptional level. To 
determine the mechanism of ISO induction of IL-18BP expression, we characterized the 
cis-regulatory region of mouse IL-18BP and determined the presence of several putative 
transcription factor-binding sites including CREB and C/EBPb binding motifs. ISO 
increased CREB phosphorylation (Ser 133), CREB DNA binding activity, and CRE-Luc 
activity. Similarly, ISO induced C/EBP activity and C/EBP-Luc activity. While ISO induced 
IL-18BP promoter-reporter activity, deletional constructs that lack these motifs were less 
responsive. Furthermore, mutations in CREB and C/EBPb, as compared to CREB or C/
EBP/b alone, signiﬁcantly attenuated ISO-induced IL-18BP expression. While expression 
of dnCREB or dnC/EBP attenuated ISO-mediated IL-18 BP expression, co-expression 
of dnCREB and dnC/EBPb signiﬁcantly inhibited ISO-mediated IL-18BP expression. In 
contrast, ectopic expression of CREB and C/EBPb induced IL-18BP promoter activity.
Conclusions These data provide the ﬁrst evidence that ISO induces IL-18BP expression 
in cardiomyocytes via a b2-AR and CREB-C/EBPb-dependent signaling. Similar events 
may occur in heart failure, a disease state characterized by sustained b-AR activation.
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1031-50 Down-regulation of Myocardial Fatty Acid Metabolism in 
Heart Failure Patients Is Dependent on Left Ventricular 
Chamber Size
Basil Dudar, Claudio Schuger, Krishnan Subramanian, Mathew Ebinger, William C. 
Stanley, Hani N. Sabbah, Henry Ford Hospital, Detroit, MI, Case Western Reserve 
University, Cleveland, OH
Background: Evidence from animal models of heart failure and from explanted hearts 
from patients suggests that the myocardium down-regulates myocardial free fatty acid 
(FFA) metabolism during advanced heart failure, but not during moderate severity disease. 
In this study we tested the hypothesis that the decrease in myocardial FFA metabolism in 
heart failure patients is dependent upon the degree of left ventricular (LV) chamber size.
Methods: 9 patients with advanced heart failure undergoing implantation of biventricular 
pacemakers were included; patients on inotropic therapy were excluded. The venous 
efﬂuent from the myocardium was sampled from a coronary sinus catheter, and the 
arterial inﬂuent was sampled from an arterial catheter. The transmyocardial extraction of 
plasma free fatty acids was calculated as the arterial - coronary sinus difference in FFA 
concentration. Left ventricular end diastolic diameter [LVEDD] (corrected for body surface 
area) was used as an index of ventricular remodeling.
Results: There was a signiﬁcant negative correlation between LVEDD and myocardial 
FFA extraction (see ﬁgure), suggesting that the down-regulation of myocardial FFA 
metabolism in human myocardium is dependent upon the extent of LV chamber 
enlargement. On the other hand, the relationship between FFA extraction and LV ejection 
fraction was not signiﬁcant (r=0.55, p=0.12).
Conclusion: Down-regulation of myocardial fatty acid metabolism in heart failure patients 
is dependent on LV chamber size.
1031-51 Role of Inducible NO in Sepsis Related Hemodynamic 
Impairment Assessed by High-frequency 
Echocardiography in a Murine Model
Massimiliano Guglielmi, Sergio Zanotti, Tracy Walker, Magali Zanotti, Bryan Foley, Felicitas 
A. Ross, Joseph E. Parrillo, Steven M. Hollenberg, UMDNJ/Cooper Hospital, Camden, NJ
Background: Overproduction of NO by inducible nitric oxide synthase (iNOS) in sepsis 
and septic shock has been implicated in vascular relaxation associated with refractory 
hypotension and in myocardial depression. We investigated the effect of NO on cardiac 
performance in septic mice.
Methods: 10 C57Bl/6 (WT) and 10 iNOS-knockout mice (KO) made septic by cecal 
ligation and puncture (CLP) were compared; 2 controls in each group had sham operation. 
After CLP animals had antibiotics (ceftriaxone 30mg/kg and clindamycin 25mg/kg q6hr) 
and aggressive resuscitation: 100mL/kg after surgery, 6 and 12 hr, then 35mL/kg q6hr. 
Animals were anesthetized brieﬂy with isoﬂurane and placed on a heated board with ECG 
leads. Cardiac performance was assessed every 3 hours for 24 hours with a 30Mhz scan-
head. Stroke Volume (SV, µL) was assessed by Doppler, Fractional Shortening (FS%) 
by M-mode in the short axis view at the papillary muscle level and Cardiac Output (CO, 
mL/min) was calculated as SV*HR.
Results: Even with aggressive ﬂuid resuscitation, CO was reduced at 6 hours (from 26±3 
to 18±5 (WT) and 26±3 to 18±6mL/min (KO), p<0.05 vs baseline and sham control, P=NS 
among groups) but increased at 12 and normalized by 24 hours (25±8 (WT), 22±10 (KO)). 
This was due to a reduction in SV (from 58±7 to 38±4 with recovery to 51±13 (WT), 
57±6 to 38±8 with recovery to 50±13µL (KO), P=NS among groups). HR did not change 
signiﬁcantly. FS however, was higher at 24 hr in KO, 48±11% vs WT, 35±11, p<0.001). 
LVEDD was decreased (3.2±0.5mm vs 3.8±0.3, p<0.01).
Conclusions:Early and aggressive ﬂuid resuscitation is mandatory to restore a 
normodynamic state in sepsis. Increased FS in iNOS-deﬁcent mice suggests that NO may 
be a myocardial depressant in sepsis: whether this serves to match the metabolic demand 
to supply is uncertain. In sepsis, capillary leakage and vasodilatation decreases ﬁlling 
pressure, so the LV must ﬁll at a lower pressure to maintain SV. Decreased diastolic ﬁlling in 
animals lacking iNOS suggests that NO may play an important lusitropic role as well.
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1032-52 Comparison of Ultraﬁltration to Nesiritide Therapy as a 
Treatment Modality for Decompensated Heart Failure
Syed Saghir, Cheryl Bartone, Raymond Barrows, Santosh Menon, Eugene Chung, The 
Christ Hospital, Cincinnati, OH, Ohio Heart and Vascular Center, Cincinnati, OH
BACKGROUND: Nesiritide (N) has been used extensively in addition to conventional 
treatment to treat symptoms of acute decompensated heart failure (HF). However, its 
safety has been brought to question by recent analyses suggesting increased likelihood 
of short-term renal dysfunction and death. Ultraﬁltration (UF): (Aquadex ﬂuid removal 
system 100, CHF Solutions, Inc.) has been developed to remove ﬂuid in a similar 
population of patients, through a relatively small venous access. We sought to compare 
these two methods of enhancing conventional treatment for acute HF in terms of renal 
function, weight loss, and clinical outcomes.
METHODS: We compared 21 hospitalized HF patients at our institution that underwent 
UF (Study group) with 21 HF patients who received N (Control). The control group was 
matched for age, sex, left ventricular ejection fraction, etiology of HF (ischemic or non-
ischemic) and renal function (creatinine (Cr) within 0.4 mg/dl). Analysis of variance was 
used to compare the two groups.
RESULTS: Results are shown in the table. 
UF
(n = 21)
N
(n = 21)
30 day HF 
readmission 1 (5.0%) 4 (19.0%)
In-Hospital Mortality 1 (4.8%) 0 (0.0)
Pre-treatment Post-treatment Pre-Treatment Post-Treatment
NYHA 3.5 ± 0.7 2.3 ± 0.7 3.1 ± 0.9 1.8 ± 0.7
Hematocrit 33.8 ± 5.1 34.0 ± 5.6 37.9 ± 8.2 35.5 ± 5.8
Na 135.8 ± 6.5 133.5 ± 7.3 * 136.1 ± 3.9 136.3 ± 4.1
K 4.2 ± 0.6 4.5 ± 0.6 4.3 ± 0.7 4.1 ± 0.5
BUN 54.8 ± 28.6 64.3 ± 35.2 * 38.0 ± 20.0 38.3 ± 22.1 †
Cr 2.0 ± 0.8 2.3 ± 1.1 * 1.6 ± 0.6 1.5 ± 0.7 †
BNP 1242.2 ± 1297.9
948.4 ± 
1105.4 1649 ± 1738.8 1274.6 ± 1129.2
Weight, lbs 231.0 ± 79.9 214.5 ± 74.3 * 201.4 ± 77.5 197.3 ± 80.2
Fluid Removed, Liters 7.5 ± 6.7 1.9 ± 4.7
Cr Increase > 0.5 7 (33.3%) 1 (4.8%)
Values ± standard deviation
* p<0.05 vs. pre-treatment value
† p<0.05 vs. post UF treatment value
UF group demonstrated more robust ﬂuid removal and weight loss but an increased BUN 
and Cr. However, there were more readmissions for HF in the N group. One patient in UF 
and none in N died in hospital.
CONCLUSION: In a clinical setting without a protocol driven algorithm for N use, UF appears 
to be more effective in decreasing volume, albeit with a greater increase in Cr and BUN.
1032-53 Beta Adrenergic Blockers Reduce the Risk of Mortality 
Associated with Elevated Troponin T in Patients with 
Acutely Decompensated Congestive Heart Failure
Rahul Sakhuja, Patrick Sluss, Elizabeth Lee-Lewandrowski, Kent B. Lewandrowski, 
James L. Januzzi, Massachusetts General Hospita, Boston, MA
Background: Troponin T (cTnT) elevation is common in patients with acute congestive 
heart failure (CHF) and is associated with adverse outcomes in such patients. It remains 
unclear what therapeutic options might be used to reduce the risk for death in those with 
acute CHF and elevated cTnT.
Methods Multivariate analyses of factors predictive of elevated TnT and factors predictive 
of survival at 60 days were performed to evaluate 209 subjects in the ProBNP Investigation 
of Dyspnea in the Emergency Department (PRIDE) study. The relationship of medication 
use to short-term mortality was evaluated. All analyses were adjusted for co-morbidities, 
including age, history of incident or prevalent CHF, arrhythmia, hypertension, ischemic 
and valvular disease and acute coronary syndrome during hospitalization.
Results: Of 209 subjects, 96 had levels of cTnT >0.01 ng/ml; only 7% had clinically 
evident ACS during their hospitalization. Independent predictors of an elevated cTnT in 
acute CHF included diabetes (odds ratio [OR]=3.76, 95% conﬁdence intervals [CI]=1.1-
12.8, p=0.03), creatinine clearance (OR=0.97, 95% CI=0.96-0.99, p=0.001), and ACS at 
presentation (OR=3.93, 95% CI=1.1-14.7, p=0.04). Between patients with and without 
elevated cTnT, there were no signiﬁcant differences in heart rate, hypotension, use of 
drug therapies such as beta blocker or angiotensin converting enzyme (ACE) inhibitors, 
or prevalence of sinus rhythm on admission. Among those with elevated cTnT in acute 
CHF, the use of beta blockers by hospital discharge was associated with signiﬁcantly 
improved survival at 60 days (OR=142.9; 95% CI=2.2-589.4, p=0.02). In contrast, the 
beneﬁts of beta blockers in reducing the risk of death in those without elevated cTnT in 
CHF were less clear (OR=0.75, 95% CI=0.1-5.81, p=0.790). Use of other therapeutic 
interventions such as ACE inhibitors did not appear to inﬂuence the risk for short-term 
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mortality in those with elevated cTnT.
Conclusions: In the setting of acute destabilized CHF, use of beta adrenergic blockade 
reduces the considerable short-term risk for death associated in those with elevated 
cTnT.
1032-54 Acute Heart Failure Asociated With Atrial Fibrillation: A 
Distinct Disorder and Not Just a Fast Pulse Rate?
Olga Milo-Cotter, Nir Uriel, G. Michael Felker, Eric J. Velazquez, Beth Weatherly, Joseph 
R. Rogers, Adrian Hernandez, Kirkwood F. Adams, Edo Kaluski, Zvi Vered, Christopher 
M. O’Connor, Gad Cotter, Assaf-Harofeh Medical Center, Zeriﬁn, Israel, Duke University 
Medical Center, Durham, NC
Background: Although atrial ﬁbrillation (Aﬁb) is reported in approximately 1/3 of acute heart 
failure (AHF) admissions, its independent role in AHF morbidity and mortality is debated.
Methods: During 3 consecutive months all admissions due to AHF (342 patients) to a city 
hospital providing the sole inpatient medical service to approximately 500,000 people were 
registered. Patients were followed through admission and for 6-months after discharge.
Results: Aﬁb was present at admission in 31% of the patients. Patients with Aﬁb at 
admission were older (78±9 vs 74±12, P=0.008), had lower incidence of DM (30% vs 
60%, p<0.001), ischemic heart disease (IHD) (60% vs 74%, p=0.012), previous MI (47% 
vs 62%, p=0.016), and presented with lower creatinine (1.3±0.5 vs 1.5±0.46, p= 0.038), 
higher glucose (130±55 vs 182±89, p<0.001) and lower cholesterol, triglicerides and % 
lymphocytes (16% vs 19%, p=0.007).
Aﬁb at admission was associated with (a smaller than expected) higher pulse rate (99±27 
vs 91±22, p=0.01) but with signiﬁcantly lower admission BP (152/83 vs 169/90, p=0.005).
Aﬁb at admission was not associated with an increased rate of recurrent heart failure either 
during admission (7 days) or at 6 months (42% vs 43%, p=0.86) and was not associated 
with a signiﬁcant difference in in-hospital mortality (4% vs 3%, p=0.67). Nevertheless, Aﬁb 
at admission was associated with increased 6-months mortality (17% vs 8%, p-0.03).
Interestingly, excluding patients with Aﬁb, in the overall cohort no correlation existed 
between heart rate and mortality in patients without Aﬁb at baseline suggesting that rapid 
heart rate per se may not be the cause for the increased long term adverse outcome 
observed in patients with Aﬁb.
Conclusions: Aﬁb at admission in patients with AHF is associated with a speciﬁc 
presentation including older age, lower BP, less DM, IHD and renal impairment. Aﬁb at 
admission is not associated with increased morbidity (recurrent HF) but is associated with 
increased long (but not short) term morality that probably cannot be accounted by the 
small difference in pulse rate at admission.
1032-55 The Effect of Pre-Admission Use of Angiotensin 
Converting Enzyme Inhibitor/Angiotensin II Receptor 
Blocker and/or Beta-Blocker Therapy on Hospital Acute 
Decompensated Heart Failure Hospital Mortality
Maria Rosa Costanzo, R. S. Johannes, Vikas Gupta, Mitchell Saltzberg, Sam Suri, Talat 
Ashraf, Midwest Heart Specialists, Naperville, IL
Background: Due to their long-term mortality beneﬁt demonstrated in clinical trials, 
practice guidelines recommend that patients without contraindications be treated with 
ACEI/ARB and beta-blocker (βB) therapy. However, it is not known if chronic use of ACEI/
ARB and/or βB therapy speciﬁcally inﬂuences hospital mortality of acute decompensated 
heart failure (ADHF) patients. This was investigated using data from the Acute 
Decompensated HEart Failure National REgistry (ADHERE).
Methods: The study population consisted of 99,963 cases from ADHERE, in which a 
diagnosis of heart failure (HF) was made before the 2nd hospital day and in which both 
the admission and discharge diagnosis was HF. The effect of ACEI/ARB, βB, and their 
combination prior to index admission on hospital mortality was evaluated after adjustment 
for covariates using multivariate regression.
Results: Overall all cause hospital mortality for the HF study population was 3.6%. 
All cause hospital morality was highest for patients on neither ACI/ARB or βB (4.8%), 
intermediate for patients on either ACEI/ARB (3.5%; OR=0.70; CI=0.63-0.77; p<0.001) or 
βB (3.9%; OR=0.71; CI=0.65-0.78; p<0.001), and lowest for patients on both ACEI/ARB 
and βB (2.4%; OR=0.49; CI=0.45-0.54; p<0.001).
Conclusions: This analysis demonstrates that therapy with ACEI/ARB, βB, or their 
combination not only increases the long-term survival of HF patients, but may also 
decrease hospital mortality when these patients are admitted with ADHF.
No βB On βB Total
No ACEI/ARB n=27,105 (27.1%)4.8% mort
n=49,146 (49.2%)
4.2% mort
n=47,364 (47.4%)
4.4% mort
On ACEI/ARB n=22,041 (22.0%)3.5% mort
n=30,558 (30.6%)
2.4% mort
n=52,599 (52.6%)
2.8% mort
Total n=49,146 (49.2%)4.2% mort
n=50,817 (50.8%)
3.0% mort
n=99,963
3.6% mort
 
1032-56 Failure to Use Percutaneous Coronary Intervention 
in Patients With an Acute Coronary Syndrome and 
Congestive Heart Failure. The Global Registry of Acute 
Coronary Events
Philippe Gabriel Steg, Frans Van de Werf, José López-Sendón, Joel M. Gore, Omar H. 
Dabbous, Laurent Feldman, Frederick A. Anderson, Álvaro Avezum, GRACE Investigators, 
Hôpital Bichat, Paris, France, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil
Background Patients (pts) with acute coronary syndromes (ACS) and congestive 
heart failure (CHF) have reduced survival. We analyzed the impact on outcomes of 
percutaneous coronary intervention (PCI) in pts with ACS and CHF.
Methods Data from 33,321 ACS pts without cardiogenic shock at admission were 
analyzed according to the presence of CHF (Killip II/III) at admission and the use of PCI 
during the index hospital stay (excl. transferred pts).
Results In pts +/- CHF, use of PCI was associated with lower risk characteristics (history 
of PAD, stroke, MI or CHF; all P<.0001). Pts who underwent PCI were younger, more 
often male, more often had ST elevation, and more often underwent angiography than 
those who did not (all P<.0001). In-hospital mortality was lower in pts who underwent PCI 
compared with those who did not (P<.0001). However, they were less likely to undergo 
CABG (P<.0001). This difference persisted after multivariable adjustment for baseline 
risk. PCI was done in 34% of pts -CHF vs 22% of those +CHF (P<.0001). Multivariable 
analysis demonstrated that PCI was associated with lower hospital mortality in pts -CHF but 
even more so in those +CHF (Fig). For 24,871 pts with 6-month follow-up, post-discharge 
mortality was 6.8% in CHF pts who had undergone PCI vs 12.4% for those who did not. PCI 
was an independent predictor of lower post-discharge mortality in pts with CHF (Fig).
Conclusion These results suggest underuse of PCI in ACS pts with CHF, and suggest 
that CHF pts are likely to derive the greatest beneﬁt from PCI.
1032-57 Rapid and Sustained Reductions of Plasma B-Type 
Natriuretic Peptide Concentrations in Patients with 
Acutely Decompensated Heart Failure Treated with 
Levosimendan: The REVIVE II Study
John R. Teerlink, Barry M. Massie, Wilson S. Colucci, James B. Young, Lloyd Fisher, 
Chris J. Garratt, Robert J. Padley, Toni Sarapohja, Bidan Huang, Milton Packer, on 
behalf of the REVIVE II Investigators, University of California, San Francisco, San 
Francisco, CA, University of Texas, Southwestern, Dallas, TX
Background: In heart failure patients, reductions in plasma B-type natriuretic peptide 
(BNP) concentrations have been associated with improved hemodynamic status, 
decreased myocardial wall stress, shorter hospital stays, less frequent rehospitalization 
and lower mortality. Levosimendan (Levo), a novel calcium sensitizer and K+-ATP channel 
opener, increases cardiac contractility and vasodilation without increasing myocardial 
oxygen demand. We hypothesized that Levo would signiﬁcantly reduce BNP in patients 
with acutely decompensated heart failure (ADHF).
Methods: REVIVE II was a multicenter, randomized, double-blind study that randomized 
600 ADHF patients to Levo or placebo in addition to standard therapy, including vasodilators 
and dobutamine. Plasma BNP levels were determined at baseline (prior to start of infusion), 
24 hours (end of infusion period), and 5 days after infusion was started.
Results: Levo reduced BNP levels by 55% at the end of infusion period (vs. 19% for 
placebo), an effect maintained at Day 5 (53% vs. 24%, respectively). The magnitude of 
BNP response between treatment groups at 24 hours was similar when nesiritide-treated 
patients were excluded or when stratiﬁed by etiology (ischemic/non-ischemic), baseline 
LVEF, or baseline serum creatinine.
Conclusions: Compared to placebo, treatment with levosimendan in ADHF patients 
resulted in a rapid and durable reduction in BNP levels indicative of decreased ﬁlling 
pressures and/ or myocardial wall stress.
Median [25th, 75th percentile] Plasma BNP Concentration
Treatment Group Time after Start of Infusion N Baseline Visit
% Change from 
Baseline
Kruskall-Wallis 
p-Value (Levo vs. 
Placebo)
Levosimendan At 24 hours 256 651 [291, 1260]
294 [110, 
572] -54.7 [-69.6,- 30.6] <0.001
At 5 days 212 701 [304, 980]
312 [118, 
609] -52.6 [-71.3, -22.8] <0.001
Placebo At 24 hours 252 639 [347, 1370]
560 [252, 
1180] -18.6 [-42.2, 9.9] --
At 5 days 210 649 [347, 1340]
489 [237, 
977] -24.2 [-49.7, 11.2] --
 
1032-58 Venous Thromboembolic Prophylaxis in Hospitalized 
Heart Failure Patients: Missing in Action?
W. Franklin Peacock, IV, Charles L. Emerman, Deborah Diercks, James Weber, Gregg 
C. Fonarow, The ADHERE® Scientiﬁc Advisory Committee and Investigators, The 
Cleveland Clinic, Cleveland, OH
Background: Venous thromboembolic (VTE) disease occurs in 15 to 40% of hospitalized 
CHF patients. Some recommend that hospitalized NYHA III or IV patients get VTE 
prophylaxis (VTEP). We describe usage and patient characteristics of VTEP during a 
HF hospitalization. 
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Methods: 155,073 ADHERE entries were evaluated. Exclusions were receiving 
coumadin or heparin, elevated troponin, cardiac catheterization, dialysis, or initial ICU 
admission. VTEP was deﬁned as low molecular weight or subq heparin any time during 
hospitalization, and IV vasoactives as any inotrope, inodilator, or vasodilator. Chi-square, 
ANOVA, and Wilcoxon tests were used in univariate analyses. 
Results: Entry criteria were met by 71,376; 21,847 (30.6%) received VTEP. VTEP 
patients were more often African American (28% vs. 21%) and admitted from the ED 
(83.6 vs. 79.0%), all p<0.0001. Other history items were similar, except edema which was 
more likely in VTEP patients (71 vs 66%, p< 0.0001).
Clinical Characteristics vs VTE prophylaxis status
Past Medical History Receiving VTE Prophylaxis
Not Receiving VTE 
Prophylaxis
Atrial Fibrillation 18.0% 19.4%
Coronary Artery Disease 54.3% 56.9%
Cardiac Valvular Disease 17.7% 19.7%
History of HF 74.2% 76.2%
Pacemaker 13.6% 15.7%
Peripheral Vascular Disease 16.9% 16.3%
Stroke 15.5% 15.5%
Diabetes 46.3% 44.6%
Mean EF 39.7% 39.2%
Patients receiving VTEP more often received an IV vasoactive agent (23 vs. 18%), ACEI 
(61 vs 54%), or beta-blocker (63 vs 58%) during their hospitalization and were more likely 
discharged on an ACEI (53 vs. 49%), or beta-blocker (57 vs. 54%), than the non-VTEP (all 
p=0.0001). VTEP patients were more often admitted to the ICU (4.8 vs 2.5%, p=<0.0001), 
and had longer median hospital stays (4.2 vs 3.8 days, p=0.0001). Mortality was similar 
between cohorts (3.0 vs 2.9%), p=0.690. 
Conclusions: Less than 1/3 of hospitalized HF patients receive VTE prophylaxis.
1032-59 Evolution of the Prognosis of Hospitalized Heart Failure 
Patients With Depressed and Normal Systolic Function 
Between 1991 and 2001.
Lilian Grigorian, Alfonso Varela Roman, Pilar Mazon Ramos, Jose Maria Garcia Acuña, 
Pedro Rigueiro Veloso, Jose Ramon Gonzalez-Juanatey, Hospital Clinico Universitario 
de Santiago de Compostela, Santiago de Compostela, Spain
Aims. To investigate changes of the survival of patients hospitalized with congestive heart 
failure (CHF) between 1991 and 2001, and whether those with normal left ventricular 
ejection fraction (LVEF ≥ 50%) differ in this respect from those with depressed LVEF.
Method and Results. In 1482 patients who had been admitted to the Cardiology Service 
of a tertiary Spanish hospital in the last 10 years with CHF, the prevalence of normal 
LVEF rose from 37% in the period 1991-1996 (period 1) to 47% in the period 2000-
2001 (period 3). The intensity of both diagnostic and therapeutic measures also increased 
during this 10-year period. The 1-year survival rate remained virtually unchanged in the 
whole group of patients, being 82%, 84% and 82% in periods 1, 2 (1997-1999) and 
3, respectively, even though the prognosis of patients with depressed LVEF (< 50%) 
improved signiﬁcantly, with 1-year survival rates of 76%, 77% and 84% in periods 1, 2 
and 3, respectively; the normal LVEF group had decreasing 1-year survival rates of 88%, 
86% and 81% in periods 1, 2 and 3, respectively, although the increased risk of death 
was not statistically signiﬁcant.
Conclusions. Although in our centre the death rate among hospitalized CHF patients 
with depressed LVEF during the ﬁrst year after discharge has tended to fall over the past 
10 years, application of current clinical guidelines has led to no such decrease for patients 
with normal LVEF.
 
1032-60 Changes in Renal Function During Hospitalization 
for Worsening Heart Failure Predict Postdischarge 
Survival: An OPTIME-CHF Analysis
Liviu Klein, Barry M. Massie, Jeffrey D. Leimberger, Christopher M. O’Connor, Ileana 
L. Pina, Kirkwood F. Adams, Jr., Robert M. Califf, Mihai Gheorghiade, Northwestern 
University, Chicago, IL
Background: The relationship between changes in renal function during hospitalization 
and post-discharge survival in patients (pts) hospitalized with worsening heart failure (HF) 
has not been well studied.
Methods: The OPTIME-CHF study randomized 949 pts hospitalized with worsening HF 
and systolic dysfunction to 48 - 72 hrs of iv milrinone or placebo in addition to standard 
therapy. The study enrolled pts who did not have a clinical indication for inotropes and 
excluded pts with renal failure. In this retrospective analysis, we investigated the relation 
between baseline values and changes in estimated glomerular ﬁltration rate (eGFR) 
and BUN and 60-day post-discharge mortality. Multivariable Cox proportional hazards 
analysis was used to examine these associations.
Results: Mean age was 65 yr, 66% were men and mean ejection fraction was 0.23. 
On admission, eGFR was 59 ± 24 ml/min/1.73 m2 and BUN was 32 ± 20 mg/dL. On 
average, there was no change in eGFR and a 5 mg/dL increase in BUN from admission 
to discharge. However, 17% of pts had >25% decrease in eGFR and 30% had >25% 
increase in BUN by discharge.
Lower admission eGFR was associated with higher 60-day mortality: 19 vs 10 vs 5 vs 4% 
(P<0.01, for comparison with the lowest quartile). Higher admission BUN was associated 
with increased 60-day mortality: 3 vs 5 vs 7 vs 22% (P<0.01, for comparison with the 
highest quartile).
Multivariable-adjusted Cox proportional hazards analysis showed that admission BUN 
was a stronger predictor of 60-day mortality than eGFR (chi-square 6.5 vs 1.8, for BUN 
and GFR, respectively). Admission BUN, when modeled linearly, predicted increased 60-
day mortality: BUN (per 5 mg/dL increase) had a HR of 1.09 (95% CI 1.03 - 1.15, P<0.01). 
In addition, more than 10 mg/dL increase in BUN during hospitalization was associated 
with worse 60-day survival: BUN (per 5 mg/dL increase above 10 mg/dL) had a HR of 1.08 
(95% CI 1.02 - 1.16, P<0.02).
Conclusions: More than 20% of pts admitted with worsening HF have worsening renal 
function during hospitalization. Admission BUN is a stronger predictor of post-discharge 
survival than eGFR. Higher admission BUN and increasing BUN during hospitalization 
are associated with increased post-discharge mortality.
1032-89 Death Causes in Hospitalized Heart Failure Patients 
With Preserved and Depressed Left Ventricular Systolic 
Function
Lilian Grigorian, Alfonso Varela Roman, Alejandro Virgos Lamela, Manuel Angel Bandin 
Dieguez, Milagros Pedreira Perez, Jose Ramon Gonzalez Juanatey, Hospital CLinico 
Universitario de Santiago de Compostela, Santiago de Compostela, Spain
Background: Heart failure (HF) with normal left ventricular systolic function (N-SF) is 
very prevalent and presents high mortality rates. However, causes of death in this group 
of patients are scarcely evaluated. Aim: to assess the mortality causes in HF patients 
with N-SF and compare them with those observed in group of patients with depressed 
systolic function (D-SF). 
Method and results: 912 patients consecutively hospitalized between 1998-2002 in 
a Cardiology Department with HF (mean age 71.2+11.5 years, 61% males, 50% with 
ischaemic cardiopathy, 60% hypertension, 28% diabetes, 44% with N-SF deﬁned by left 
ventricular ejection fraction > 50%) were followed-up for a mean time of 2.6+1.5 years. 
After this period 45% of patients were died. Assessment of death causes performed by 
end-point committee have shown that although sudden death was lightly more prevalent 
among D-SF group of patients (24.3% vs 20.0%) and death for vascular extracardiac 
causes more frequent in N-SF group (15.0% vs 11.2%), these differences did not reach 
statistical signiﬁcance. The main cause of death was due to refractory heart failure in 
both, N-SF and D-SF groups (41.3% and 39.3%, respectively). Similar proportion 
of patients in N-SF and D-SF groups was died as consequence of acute myocardial 
infarction (11.3% and 11.2%, respectively) and for non cardiovascular reasons (12.5% 
and 14.0%, respectively). 
Conclusion: Survival of hospitalized HF patients remains quite poor being the main causes 
of death refractory heart failure and sudden death. Despite different physiopathology of 
N-SF and D-SF types of HF both groups´ patients dies for the same reasons.
1032-90 The Effect of Intensity of Intravenous Diuretic Dosing 
on Occurrence of Worsening Renal Function in Patients 
Hospitalized With Acute Decompensated Heart Failure
Maria Rosa Costanzo, R. S. Johannes, Vikas Gupta, Mitchell Saltzberg, Sam Suri, Talat 
Ashraf, John Wigneswaran, Cardinal Health, Marlborough, MA, Scios, Inc, Freemont, CA
BACKGROUND: Effects of IV diuretic intensity on worsening renal function (WRF) in 
hospitalized ADHF patients is a critical issue for HF treatment and outcomes. However, 
data from prospective clinical trials are lacking. The effect of diuretic intensity was 
examined in patients treated with IV furosemide (FUR) in the ADHERE registry.
METHODS: The study population consisted of 99,963 cases with a diagnosis of heart 
failure (HF) at admission and discharge. Of these cases 24,497 patients were treated 
with IV FUR and no IV vasoactive agent and were included in this analysis. The total IV 
FUR dose in the ﬁrst 24 hours of use was examined at 3-levels; <80 mg (<50 percentile), 
80-160 mg (50-80 percentile) and >160 (>80 percentile). These cases were then stratiﬁed 
by baseline serum creatinine (<1.2, 1.3-2.0, 2.1-3.0, >3.0) for development of WRF. WRF 
is deﬁned as a >= 0.5 mg/dl rise in last serum creatinine (SCr, mg/dl) or requirement for 
new dialysis.
RESULTS: Of 24,497 ADHF cases exclusively treated with IV FUR, 48.5%, 36.8%, and 
14.7% of cases received <80 mg, 81-160 mg and >160 mg, respectively. Use of IV FUR 
>160 mg increased with increasing baseline SCr [<1.2 (11%), 1.3-2.0 (16.6%), 2.1-
3.0 (21.5%) and >3.0 (30.8%)]. At each baseline SCr group WRF rates increased with 
increasing diuretic intensity.
CONCLUSIONS: In patients admitted with ADHF a greater dosing intensity was 
associated with a higher occurrence of WRF. This needs to be further investigated in 
controlled clinical trials.
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re 1032-91 Sustained Improvement in Right Ventricular Function 
After Therapy to Reduce Congestion in the ESCAPE 
Trial
Sharon Reimold, Gudaye Tasissa, Teresa DeMarco, Gregg C. Fonarow, Maryl R. 
Johnson, Gail Peterson, Lynne W. Stevenson, University of Texas Southwestern Medical 
Center, Dallas, TX, Brigham and Women’s Hospital, Boston, MA
Background. To investigate the impact of heart failure therapy on right heart function, 
we analyzed echocardiograms from ESCAPE, a randomized trial of pulmonary artery 
catheter (PAC)-guided therapy versus clinical assessment in heart failure.
Methods. Echos were blindly analyzed and performed at randomization, discharge, and 3 
months. Variables prospectively speciﬁed included right atrial area, apical right ventricular 
(RV) diastolic area, fractional RV area change (100* [diastolic area-systolic area]/diastolic 
area), tricuspid regurgitant (TR)velocity, inferior vena cava (IVC) maximal dimensions, 
and pulsatility. Weight, jugular venous pressure (JVP), and right atrial pressure (PAC 
patients) were followed during therapy.
Results. Means are with standard deviations, except JVP assessed in ranges. Therapy 
was associated with decreased right heart ﬁlling pressures in the PAC group and estimated 
by JVP in both groups. Right atrial and RV size decreased; fractional RV area change 
improved. TR velocity was unchanged, IVC size decreased, IVC pulsatility increased 
consistent with decrease in right atrial ﬁlling pressures. At discharge, improvements were 
similar in both treatment groups except for greater decrease in IVC diameter in the PAC 
group. Improvements in echo-assessed right heart hemodynamics were sustained in both 
groups at 3 months.
Conclusions. Therapy to reduce ﬁlling pressures led to sustained improvement in IVC, 
right atrial, and RV size, and RV function.
 
PAC CLIN
Baseline
Discharge 
(change from 
baseline)
3-months 
(change from 
baseline)
Baseline
Discharge 
(change
from 
baseline)
3-months (change 
from baseline)
Weight (kg) 85.7(21.8) -4.2(5.7)* -1.7(7.0)* 85.6(20.3) -3.4(3.8)* -1.7(5.7)*
JVP (cm) 12.1(1.4) -5.4 12.5(1.4) -5.2
Right atrial pressure 13.3(8.8) -4.1(9.4)* N/A N/A N/A N/A
Right atrial area 
(cm2) 26.9(9.2) -2.0(6.8)* -2.3(7.6)* 27.3(8.7) -1.5(5.1)* -2.2(6.8)*
RVD (cm2) 24.9(6.9) -1.0(5.6) -2.1(5.8)* 25.6(7.4) -1.3(3.8)* -2.6(5.4)*
Fractional RV area 
change (%) 22.7(8.8) 3.1(8.2)* 4.3(14.4) 24.0(11.3) 0.8(7.1) 1.8(14.4)
IVC†
diameter, cm 2.2(0.7) -0.4(0.7)* -0.4(0.8)* 2.2(0.6) -0.2(0.5)* -0.4(0.6)*
% IVC pulsatility 31.9(20.9) 7.3(21.2)* 3.2(26.3) 28.5(21.6) 5.6(21.4)* 6.3(30.5)
*P<.05 baseline to discharge or to 3-mo changes. †P<.05 baseline to discharge change 
PAC vs. CLIN.
 
1032-92 Does African American or Caucasian Race Impact Use 
of B-Type Natriuretic Peptide and N-Terminal proBNP 
for Diagnosis of Decompensated Heart Failure and 
Predicting Mortality?
Robert H. Christenson, Stephen Seliger, Susan Maynard, Ruby C. Dunston, Show-Hong 
Duh, Strelitzia R. Tjon Kon Fat, Christopher deFilippi, University of Maryland School of 
Medicine, Baltimore, MD, Carolinas Medical Center, Charlotte, NC
Background: B-type Natriuretic Peptide (BNP) and N-terminal proBNP (NT-proBNP) 
are useful for diagnosis of decompensated heart failure (HF) and predicting outcomes. 
Differences in BNP and NT-proBNP between African Americans (AA) and Caucasians 
(C) are uncertain.
Methods: BNP and NT-proBNP were measured in consecutive AA (n=341) and C (n=546) 
patients. HF diagnosis was determined by a reviewer blinded to the measurements from 
clinical, risk factor and medication data abstracted from medical records. All cause 
mortality was followed for a median of 401 ([interquartile range] 330,480) days.
Results: HF was diagnosed in 55.5% (n=186) of the AA and 50.4% (n=275) of the C 
cohorts. The AA cohort was younger (median: 60 vs. 70 yrs; p<.001), had more hypertension 
(p<.001), and more diabetes (p<.004). The C cohort had more atrial ﬁbrillation (p<.003) and 
coronary artery disease (CAD) (p<.001). Diagnostic performance was: 
Biomarker Race C-Index Cutoff Sensitivity Speciﬁcity Accuracy
NT-proBNP C .724 838 pg/mL 83.3% 51.7% 67.6%
NT-proBNP AA .717 539 pg/mL 82.8% 55.5% 70.4%
BNP C .735 191 pg/mL 79.6% 59.0% 69.4%
BNP AA .718 199 pg/mL 76.3% 68.4% 72.7%
For HF diagnosis, the C-Index shows no difference between AA or C race and use of BNP 
(p=0.84) or NT-proBNP (p=0.64). Optimum cutoffs for the C cohort were higher for NT-
proBNP due to their advanced age. Biomarker association with mortality by AA or C race 
was examined after adjustment for age, gender, creatinine, hypertension, diabetes, CAD, 
prior HF and atrial ﬁbrillation. Resulting interaction terms for mortality were not signiﬁcant 
(BNP, 0.50; NT-proBNP, 0.60).
Conclusion: BNP and NT-proBNP performance for diagnosing HF and predicting all 
cause mortality does not differ between AA and C race.
1032-93 Impact of Increased Body Mass Index on Use of B-
Type Natriuretic Peptide and N-Terminal proBNP 
for Diagnosis of Decompensated Heart Failure and 
Prediction of All-Cause Mortality
Christopher deFilippi, Show-Hong Duh, Mandeep Mehra, Ruby C. Dunston, Stephen 
Seliger, Martin Engelhardt, Robert H. Christenson, University of Maryland School of 
Medicine, Baltimore, MD
Background: B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) 
measurements may be depressed in patients (pts) with increased body mass index (BMI). 
The impact of increased BMI on use of these biomarkers for diagnosis of decompensated 
heart failure (HF) and predicting outcomes is unknown.
Methods: BNP & NT-proBNP were measured in 665 pts with possible HF who had BMI 
determined. Pts were classiﬁed as obese (BMI >30 kg/m2), overweight (OWT; BMI 25-30 
kg/m2) and normal (BMI <25 kg/m2). HF diagnosis was adjudicated by a reviewer blinded 
to the biomarker results. All cause mortality was followed for a median of 401 ([interquartile 
range] 330,480) days. Receiver Operator Curve areas (AUC) were calculated for HF 
diagnosis and mortality.
Results: Of all pts, 41.6% were obese (n=267), 29.4% were OWT (n=189) and 29% had 
normal BMI (n=209). Data were: 
BNP NT-proBNP HF Diagnosis All Cause Mortality
HF pts, 
Number
Died, 
Number
Median,
Pg/mL
Median,
pg/mL BNP AUC NT-proBNP AUC BNP AUC NT-proBNP AUC
Obese 116 (51%) 59 (22%) 211 1153 0.721 0.710 0.720 0.746
OWT 102 (54%) 51 (27%) 373 2025 0.620 0.630 0.621 0.647
Normal 116 (56%) 82 (39%) 522 3084 0.777 0.766 0.648 0.715
Obese pts had lower mortality compared to normals (p<.0001) and lower BNP & NT-proBNP 
values compared to OWT or normals (p<.006). All AUCs were signiﬁcant for HF diagnosis 
(p<.003) and mortality (p<0.01). For predicting mortality in normals, NT-proBNP performed 
better than BNP (p=.004). Logistic regression showed that biomarkers remained signiﬁcant 
predictors of HF diagnosis and mortality after correction for age and GFR.
Conclusions: Obese pts have signiﬁcantly lower BNP & NT-proBNP values that may 
reﬂect the lower mortality in this cohort. BNP & NT-proBNP can be used in all BMI groups 
for HF diagnosis.
1032-94 Low Body Temperature at Hospital Discharge is a 
Marker of Poor Prognosis in Patients with Congestive 
Heart Failure
Amany Ahmed, Saeed Payvar, Ibrahim Aboshady, Shahzeb Munir, Hossein Eftekhari, 
Naushad Shaik, Douglas L. Mann, Samuel W. Casscells, Anita Deswal, Texas Heart 
Institute, Houston, TX
Background: Hospitalization for congestive heart failure (CHF) is associated with 
high post-discharge rates of readmission and mortality. We have previously shown that 
low body temperature at admission is a predictor of in-hospital mortality in CHF. We 
hypothesized that low body temperature at the time of discharge would predict death or 
CHF-related readmission in patients with CHF.
Methods: 500 patients’ medical records that were discharged after a CHF admission 
to the VA Medical Center, Houston, TX, were reviewed. Body temperature as well as 
demographic, clinical, comorbidity and laboratory data at the time of discharge were 
extracted by electronic chart review. Outcomes included all-cause mortality, readmission 
for CHF and a combined end-point of CHF readmission or death. Temperature (T) at 
discharge was entered into models in quartiles deﬁned as ≥ 98.6 (Q1), 98.0- 98.5 (Q2), 
97.4- 97.9 (Q3) and < 97.4 °F (Q4).
Results: Patients had a mean age of 68 + 10 years. Within 6 months of discharge, 90 
(18%) were readmitted for CHF and 79 (15.8 %) died. In patients in Q4 (T < 97.4), 26% 
died compared with 10% for patients in Q1 (T ≥ 98.6), 11% in Q2 (T 98.0-98.6), and 
19% in Q3 (T 97.4-98.0), (p=0.8). After adjustment for age, systolic blood pressure and 
elevated blood urea nitrogen (BUN >30 mg/dL), body T in the lowest quartile, Q4 (T 
<97.4) was associated with mortality (hazard ratio 2.3, 95% CI 1-5, p= 0.03) compared 
to Q1. In addition, patients in Q3 showed a trend for higher mortality compared to Q1 
(hazard ratio 1.8, 95% CI 0.8-4.2). Readmission for CHF within 6 months occurred in 18% 
patients in Q4 compared with 19% in Q1, 19% in Q2 and 25% in Q3. Combined CHF 
readmission or death within 6 months after discharge occurred in 38% patients in Q4 
compared with 27%, 26%, and 37% in other groups, respectively.
Conclusions: Low body temperature at discharge was an independent predictor of 6-
month mortality after a HF admission. Further studies are needed to better understand 
the pathophysiology of low body temperature in HF.
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1032-95 A Simple Multi-biomarker Model Does Not Predict 
Outcomes Better Than Single Biomarkers in Heart 
Failure
Amandeep S. Dhaliwal, Qiang E. Zhang, Anita Deswal, Allison M. Pritchett, Douglas L. 
Mann, Biykem Bozkurt, Michael E. DeBakey Veterans Affairs Medical Center, Houston, 
TX, Baylor College of Medicine, Houston, TX
Background: The validity of single biomarkers to predict outcomes in heart failure (HF) is 
well known. However, the role of a multi-marker strategy is not well established.
Methods: Retrospective chart reviews were performed in 383 patients with HF 
admissions from 4/2002 to 6/ 2004. Receiver operating curves (ROCs) were constructed 
for each biomarker for prediction of a combined end point (EP) of re-admission for HF 
or all cause mortality at 90, 180 and 360 days adjusted for age, NYHA class,CAD and 
chronic renal insufﬁciency. Biomarkers with the highest predictive value were combined 
into a multi-marker strategy, and the new multimarker ROCs were compared to individual 
biomarker ROCs.
Results: The mean age of study patients was 69±11, 99% were male, 61% had ischemic 
cardiomyopathy, 85 % had NYHA class II or III HF. Admission B-type natriuretic peptide 
(BNP) was 970 ± 402 mg/dL. BNP was the most predictive biomarker for the combined 
end point, followed by BUN and peak Troponin I (TnI). A multi-marker model combining 
the best 3 single biomarkers; BNP, BUN and peak TnI for EP revealed a non-signiﬁcant 
improvement in predictive value over BNP alone (90days ROC area (AUC): 0.65 vs 0.62, 
180days 0.68 vs 0.64, 360days 0.67 vs 0.65, p = ns).
Conclusions: In our study population, a simple multimarker strategy combining the 3 
best single biomarkers; BNP, BUN and TnI, was not superior to BNP alone in predicting 
outcomes in HF. New models with different biomarkers, symptoms, signs or comorbidities 
may better predict outcomes in HF.
1032-96 BNP Guided Care by a Heart Failure Specialist in 
Addition to Home-Based Nurse Care in Patients With 
Chronic Heart Failure: A Three-Arm, Prospective, 
Randomized Study
Rudolf Berger, Deddo Moertl, Martin Huelsmann, Roozbeh Ahmadi, Richard Pacher, 
Medical University of Vienna, Vienna, Austria
Background: Heart failure is associated with a high rate of rehospitalization and a poor 
prognosis. BNP-guided management (BGM) and home-based nurse care (HNC) improve 
outcome in chronic heart failure patients. We investigated whether BGM by a heart failure 
specialist in combination with HNC improves outcome compared to HNC alone or usual 
care (UC) for decompensated heart failure patients after discharge.
Methods: Patients hospitalized with cardiac decompensation were randomized to BGM, 
HNC, or UC. HNC included 2 consultations of a heart failure specialist 10 days and 2 
months after discharge for recommending medical optimization and care by a specialized 
heart failure nurse including 4 home visits and telephone contact. In addition to this care 
BGM included repeated follow-up visits in a heart failure clinic in patients with an Nt-BNP 
level above 2200pg/ml at discharge.
Results: Of 441 eligible patients 278 patients were randomly assigned in 8 Viennese 
hospitals. Groups differed signiﬁcantly in reaching the combined endpoint death or 
rehospitalisation due to cardiac decompensation after an observation period between 
10 and 24 months (p=0.03). In the intention-to-treat analysis, signiﬁcantly more patients 
in the UC group reached the combined endpoint compared to patients in the BGC group 
(p=0.007). In a per-protocol analysis, an additional difference was detected between the 
BGM and HBC group (p=0.03) and between the HBC and UC group (p=0.04).
Conclusions: BGM is superior to HBC alone in heart failure patients who were 
hospitalized due to cardiac decompensation.
1032-97 Hemoglobin and N-Terminal Pro-brain Natriuretic 
Peptide: Independent and Synergistic Predictors of 
Mortality in Patients With Acute Heart Failure
Aaron L. Baggish, Roland van Kimmenade, Antoni Bayes-Genis, Mark Davis, John 
G. Lainchbury, Chris Frampton, Yigal Pinto, A. Mark Richards, James L. Januzzi, 
Massachusetts General Hospital, Boston, MA
Background: Hemoglobin and NT-proBNP are both independent predictors of mortality 
in patients with chronic heart failure (HF). Their predictive power for mortality in the setting 
of acute HF is undeﬁned and no studies have examined their use in combination.
Methods: In an international prospective cohort design, we evaluated the relationships 
between hemoglobin, NT-proBNP, and 60-day mortality in 690 patients with acute HF. 
Results: The median hemoglobin for the entire cohort was 13.0 g/dL (interquartile range 
11.6-14.3). WHO criteria for anemia (hemoglobin <13.0g/dL [male] / <12.0g/dL [female]) were 
fulﬁlled by 44% (n=305) of the cohort. The 60-day mortality rate for anemic patients was 
16.4% versus a rate of 8.8% in non-anemic patients (p<0.001). Anemia was an independent 
predictor of short-term mortality (OR= 1.72, 95% CI=1.05-2.80, p=0.03), as was an NT-
proBNP concentration in excess of 5180 pg/ml (OR=2.32, 95% CI= 1.36-3.94 p=0.002). 
Consideration of four risk groups revealed 60-day mortality rates as depicted in table 1.
Conclusions: Anemia is common among patients with acute HF and independently 
predicts short-term mortality. Integrated use of hemoglobin and NT-proBNP provides 
powerful additive prognostic information and is superior to the use of either in isolation.
 
Risk Group 60 day mortality OR 95% CI p value
low NT-proBNP/non-anemic (n=220) 5.0% Referent
low NT-proBNP/anemic (n=152) 9.2% 1.93 0.85-4.36 0.12
high NT-proBNP/non-anemic (n=165) 13.9% 3.07 1.45-6.50 0.003
high NT-proBNP/anemic (n=153) 23.5% 5.84 2.87-11.89 <0.001
 
1032-98 Continuous Brain Natriuretic Peptide Infusion 
Preserves Systolic Function After Myocardial Ischemia 
and Prevents Ventricular Remodeling in Conscious 
Dogs
Isaac George, Yanping Cheng, Geng-Hua Yi, Brad Morrow, Jordan Muraskin, Christian 
Soneru, Mehmet C. Oz, Andrew A. Protter, Zhihe Li, Jie Wang, Columbia University 
College of Physicians and Surgeons, New York, NY
Background: Brain natriuretic peptide (BNP) is an established ﬁrst line therapy in acutely 
decompensated chronic heart failure (HF), but its efﬁcacy in preventing left ventricular 
(LV) remodeling after acute myocardial injury is unknown. The goal of this study is to test 
if BNP attenuates the progression of HF following sustained ischemic insults.
Methods: Dogs were chronically instrumented for hemodynamics. Ischemia was created 
by daily coronary embolization (Embo) (2.5 x 104 beads/day) for 3 wks; concurrently, BNP 
(100 ng/kg/min) (n=6) or vehicle (n=6) was continuously infused via a left atrial catheter 
for 3 wks, beginning 60 minutes after the ﬁrst Embo. Hemodynamics, LV pressure-volume 
analysis, and echocardiography were performed in an awake state at baseline, 3 wks 
after Embo/BNP infusion and 4 wks after stopping Embo/BNP infusion.
Results: Systolic function was preserved throughout BNP administration and maintained 
after discontinuation. Cardiac dimensions were signiﬁcantly reduced, and ejection fraction 
was maintained in treated dogs versus vehicle group. No signiﬁcant change in diastolic 
function was seen.
Conclusion: Treatment with continuous infusion BNP preserves LV geometry, improves 
systolic function, and prevents the progression of systolic HF after acute and persistent 
ischemic injury. The results suggest a clinical beneﬁt of BNP after acute myocardial 
ischemia, and further research to clarify its therapeutic potential in patients with acute 
ischemia is warranted.
 
Hemodynamics and Echocardiography (Vehicle n=6, BNP n=6)
Baseline 3 wks Embo/BNP 4 wks post-Embo/BNP
LV EDP (mmHg)
Vehicle 12.8 ± 1.8 20.4 ± 1.3 18.3 ± 0.9
BNP 11.3 ± 1.7 17.5 ± 2.9 17.6 ± 2.7
LV dP/dt (mmHg/s)
Vehicle 2818 ± 125 2068 ± 95 2042 ± 54
BNP 2889 ± 79 2417 ± 96 * 2462 ± 147 *
LV EF (%)
Vehicle 58 ± 1 44 ± 1 46 ± 2
BNP 60 ± 1 51 ± 1* 53 ± 2 *
LV EDD (cm)
Vehicle 4.43 ± 0.14 4.60 ± 0.17 4.76 ± 0.17
BNP 4.20 ± 0.13 4.20 ± 0.19 * 4.27 ± 0.12*
Ees (mmHg/ml)
Vehicle 2.16 ± 0.29 1.41 ± 0.16 1.78 ± 0.29
BNP 3.37 ± 0.71 3.76 ± 1.01* 2.61 ± 0.40
α (ml-1)
Vehicle 0.028 ± 0.010 0.0177 ± 0.004 0.037 ± 0.010
BNP 0.052 ± 0.015 0.038 ± 0.009 0.035 ± 0.0.005
* p <0.05 vs NS
Embo-Coronary Embolization, Vehicle-0.9% Normal Saline, BNP-Brain Natriuretic 
Peptide, LV-Left Ventricular, EF-Ejection Fraction, EDD-End Diastolic Diameter, Ees-Left 
Ventricular Elastance, α-Passive Myocardial Stiffness Constant
 
1032-99 Beta1-Adrenergic cAMP Signaling Is Uncoupled 
After Acute Treatment of Anthrax Lethal Toxin in 
Cardiomyocytes in Normal Rats
Heng-Jie Cheng, Chun-Xian Zhang, Satoshi Masutani, Michael Cross, Michael F. 
Callahan, Arthur E. Frankel, Che-Ping Cheng, Wake Forest University School of Medicine, 
Winston-Salem, NC
Background. Our recent in vivo study has shown that anthrax lethal toxin (LeTx) causes time-
dependent progressive depression of left ventricular (LV) contractility. LeTx-induced abnormal 
cardiac response to β-adrenergic receptor (AR) stimulation may contribute to this effect.
Methods. We examined acute exposure of LeTx caused alterations of myocyte β1- 
and β3-AR expression and myocyte basal contraction and relaxation and responses 
to isoproterenol (ISO), a β-AR agonist, and colforsin (COLF), a cAMP activator. 
Cardiomyocytes were isolated from 8 adult normal rats incubated for 6 hours in study 
buffer without and with LeTx (10 nM PA and 1 nM LF).
Result. Compared with controls, LeTx treatment caused no signiﬁcant changes on basal 
myocyte contraction and relaxation. Myocyte β1-AR (0.47±0.04 vs 0.46±0.02) and β3-AR 
(0.21±0.02 vs 0.23±0.02) protein levels also remained relatively unchanged. In controls, 
superfusion with ISO (10-8 M) caused about 46% increase in cell percent shortening (SA, 
14.5 vs 10.0%) and 83% and 44% increases in peak velocity shortening (dL/dtmax, 270.0 
vs 147.7 µm/s) and relengthening (dR/dtmax, 172.2 vs 119.6 µm/s), respectively. However, 
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after LeTx treatment, myocyte positive inotropic functional response to β-AR stimulation 
was signiﬁcantly decreased. In LeTx-treated myocytes, ISO produced signiﬁcantly less 
increases in SA (25%, 9.9 vs 12.3%), dL/dtmax (29%, 130.5 vs 183.6 µm/s) and dR/dtmax 
(32.4%, 87.5 vs 115.8 µm/s). In contrast, superfusion of COLF (10-6 M) caused similar 
increases in SA (43.1 vs 43.7%), dL/dtmax (77.4 vs 83.2% ) and dR/dtmax (35.2 vs 30.8%). 
In addition, compared with normal controls, LeTx-treated myocyte contractile responses 
to zinterol (ZIN, 10-5 M), a highly selective β2-AR agonist, and BRL-37,344 (BRL, 10-8 M), 
a selective β3-AR agonist, were also unaffected.
Conclusion. Acute treatment of LeTx causes cardiac myocyte β1-AR uncoupling from 
cAMP-mediated signaling and impairs myocyte responses to β-adrenergic stimulation. 
These results suggest that the early changes in cardiac β-AR signal transduction system 
may mediate the connection between the acute and chronic cardiac action of LeTx.
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1033-100 Strain Imaging Can Differentiate Constriction From 
Restriction
Grace Casaclang-Verzosa, Chinami Miyazaki, Rick A. Nishimura, Fletcher A. Miller, Raul 
E. Espinosa, Jae K. Oh, Mayo Clinic, Rochester, MN
Background: Early diastolic mitral annulus velocity by tissue Doppler imaging (TDI) is 
helpful in differentiating restrictive cardiomyopathy (RCM) from constrictive pericarditis 
(CP). However, mitral annulus systolic velocity has been observed to be reduced similarly 
in both conditions. Since strain (S) and strain rate (SR) of left ventricular myocardium have 
not been compared between RCM and CP, we sought to determine whether S and SR are 
able to differentiate RCM from CP.
Methods: TDI, S and SR imaging were performed prospectively in 3 groups (age matched 
normal control, constriction, and cardiac amyloidosis) with 10 patients in each group. 
TDI, S, and SR values were obtained from the inferior interventricular septum and the 
lateral left ventricular free wall at the base and mid-portion in all patients from an apical 
4-chamber view.
Results: Systolic TDI velocity of the septum and the lateral wall were similarly reduced in 
CP and amyloid (septum 4.1 vs. 4.9 p=.2; 2.5 vs.3.5 p=.09; lateral 5 vs. 5 p=.98; 3.1 vs. 2.7 
p=.75). Likewise, early diastolic velocity was decreased in amyloid (-4.2 vs. -6.4 p=.03) 
but not in CP (-7.1 vs. -6.4 p=.6). SR and S were preserved in CP but were signiﬁcantly 
reduced in cardiac amyloid (S, -8.5 vs. -22.2 p=.0001; SR, systole, -.6 vs. -1.2 p=.02, SR 
diastole, .8 vs. 1.7 p=.01).
Conclusion: Diastolic TDI, S and SR were signiﬁcantly different between CP and RCM. 
The ﬁndings suggest that SRI can be clinically useful in differentiating the 2 conditions.
Table 1. TVI, SR and S values of 3 groups. 
Amyloid Normal CP
Mean SD Mean SD Mean SD P
Age yrs 61.5 12 56 8 58 15 .7
EF % 58 12 67 4 61 9 .14
TDI
Systole
IVS base 4.9 1.1 6 1.1 4.1 1.2 .0087
IVS mid 3.5 1.1 4 1.3 2.5 1 .03
Lat base 5 2.1 9.9 12.6 5 1.9 .37
Lat mid 2.7 2.8 3.4 1.3 3.1 1.2 .75
Diastole
IVS base -4.2 1.6 -6.4 1.9 -7.1 3.3 .08
IVS mid -3.6 1.5 -5.4 1.5 -6 2.2 .04
Lat base -6.4 2.2 -6.3 2.3 -7.8 2.3 .3
Lat mid -5.4 1.8 -3.4 2.1 -5.5 1.7 .08
SR
Systole
IVS base -.6 .5 -1.2 .15 -1.3 .45 .005
IVS mid -1.1 .4 -1.3 .4 -1.4 .63 .45
Lat base -1.6 1 -1.9 .9 -1.5 1.4 .79
Lat mid -1.1 .4 -1.1 .5 -1.6 .9 .3
Diastole
IVS base .8 .5 1.7 .6 2 .9 .007
IVS mid 1.1 .7 1.3 .4 1.5 .9 .47
Lat base 1.3 1.5 2.4 .3 1.3 1.9 .34
Lat mid 1.4 .8 1.3 .4 2.4 .6 .01
Strain
IVS base -8.5 5 -22.2 2.5 -18.5 6.4 <.0001
IVS mid -11 15 -22.5 5.3 -16.8 14.6 .24
Lat base -18 13 -28 7.6 -18 8.4 .1
Lat mid -12.6 9 .17 5.5 -17 9.9 .5
 
1033-101 Urgent Coronary Angiography Is Frequently Performed 
in Patients With Acute Pericarditis and ST Elevation
Cristina Olalla, Farouk Mookadam, Grace Casaclang-Verzosa, Henry H. Ting, Charanjit 
S. Rihal, Jae K. Oh, Mayo Clinic, Rochester, MN
Background: Diffuse concave upward ST segment elevation is a characteristic 
electrocardiographic (ECG) manifestation of acute pericarditis (AP), but may lead to 
emergent coronary angiography (CA) or thrombolysis since it may be difﬁcult to be 
differentiated from an acute coronary event. We aimed to study early management of 
patients with acute pericarditis with and without ST segment elevation.
Methods: One hundred eighty two patients (age 49 ± 17 years; 62% male) from the Mayo 
Clinic database with the ﬁnal diagnosis of acute pericarditis based on serology and/or 
clinical manifestation were identiﬁed and their acute management (within 24 hours) was 
reviewed. Fifteen patients were excluded from analysis because of inconclusive ECG 
ﬁndings. The remaining 167 patients were stratiﬁed by ECG into 2 groups: Group 1= 
without ST elevation; and Group 2 = with ST elevation.
Results: Eighty (48%) patients (Group 1) had normal or ST segment depression and 87 
(52%) patients (Group 2) had ST segment elevation. There were no differences in age, 
gender, and ethnicity between groups. Friction rub (23.8 % vs 8%; p = 0.005), jugular venous 
distension (18.8% vs. 7%; p = 0.02), and pulsus paradoxus (5% vs. 0%; p = 0.03) were more 
frequent in Group 1. Urgent coronary angiography to rule out acute myocardial infarction 
(AMI) was performed in 18.4% of patients in Group 2 and 6% received thrombolysis. No 
Group 1 patient received angiography or thrombolysis. The administration of ASA, nitrates, 
anti-thrombin, beta-blockers was also higher in Group 2. Pericardial effusion (34.6% 
vs. 12.6%; p < 0.01), evolution to cardiac tamponade (13.8% vs 3.4%; p = 0.02), and 
pericardiocentesis (16.3% vs 5.7%; p < 0.01) were more frequent in Group 1.
Conclusions: Emergent Coronary Angiography and thrombolysis were frequently 
(24.4%) performed in patients with Acute Pericarditis presenting with ST elevation. This 
is most likely related to the difﬁculty in differentiating AP from AMI, and our increased 
awareness of importance of acute reperfusion therapy in patients with STEMI.
1033-102 Microbiologic Trends of Purulent Pericarditis: A Single 
Center Experience from 1994 to 2004
Yinguang Sun, Floranne Wilson, Lawrence Sinak, Kenton Zehr, Imad Tleyjeh, 
Mohammed Shazli, Farouk Mookadam, Mayo Clinic, Rochester, MN, Ruijin Hospital, 
SJTU, Shanghai, People’s Republic of China
Background: The microbiological spectrum of purulent pericarditis continues to evolve. 
However, there is a paucity of data within the last 10 years examining the microbiology, 
clinical characteristics, and management of purulent pericarditis.
Methods: A retrospective chart review was performed at the Mayo Clinic in Olmsted 
County, Minnesota involving patients (n=2309) with evidence of gross pus or microscopic 
purulence in pericardial ﬂuid from January 1994 to December 2004. One hundred and 
thirty eight cases had positive cultures (n=135) and/or Gram stain (n=95).
Results: The mean age was 53 ± 18 years (range 14 days - 83 years). Males comprised 
74% of the patient population. Causative organisms were propionibacterium species (38%), 
staphylococcal species (37%), Corynebacterium (11%), streptococcal species (7.3%), 
Enterococcus (3%), Escherichia coli (2.3%), Actinomyces sp (2.1%) and pseudomonal 
species (2.1%). The clinical circumstances associated with purulent pericarditis were 
the following: unknown (38%), immunocompromised (22%), post-cardiovascular surgery 
(18%), other (13%). pneumonia (5%), connective tissue disease (4%). The mortality 
rate in the medically and surgically-treated group was 23% (intravenous antibiotics and 
pericardiocentesis/pericardectomy) versus 77% in the medically-treated group (p<0.0001).
Conclusions: The common causative organisms were the propionibacterium species and 
the coagulase-negative staphylococcal species. Predisposing factors for the development 
of purulent pericarditis include an immunocompromised health status as well as post-
cardiovascular surgery. Patients undergoing both medical and surgical management of 
purulent pericarditis demonstrated lower mortality rates. Additionally, patients treated 
with non-steroidal anti-inﬂammatory drugs (NSAIDs) appeared to fare better than those 
patients who were not treated with NSAIDs.
1033-103 MRI for Diagnosis of Myocarditis by Global and Delayed 
Enhancement Techniques: Added Value to Diagnose 
Unsuspected Coronary Disease
Umaima Fatima, Pal Maurovich-Horvat, Pal Maurovich-Horvat, Ricardo Cury, Christian 
Witzke, Udo Hoffmann, Suhny Abbara, Thomas J. Brady, Igor F. Palacios, Godtfred 
Holmvang, Massachusetts General Hospital, Boston, MA
Objective: To compare two imaging techniques in patients referred for cardiac MRI with 
a high clinical suspicion of myocarditis.
Methods: We studied 29 consecutive patients (15 men, mean age 49 + 18 yrs) with 
suspected myocarditis referred for cardiac MRI between March 2003 and May 2005. All 
patients were hospitalized with symptoms of new onset chest pain (n = 21), dyspnea (n = 
8), heart failure (n = 11), fever (n = 10), ECG changes consistent with myocarditis (n = 19) 
and elevation of cardiac enzymes (n = 21). Obstructive coronary disease that could account 
for patient’s symptoms, had been excluded by coronary angiography (n=26) or by a nuclear 
stress perfusion scan (n=3). The MRI scan was performed within 2 weeks of symptom onset 
in 22 patients and after 2 weeks in 7 patients. In each MRI study, the global myocardial 
enhancement relative to the skeletal muscle was calculated by the method of Fredrich et al 
from T1 weighted spin-echo images acquired before and after administration of 0.1 mmol/
kg Gadolinium(Gd-DTPA). This was followed by myocardial delayed enhancement (MDE) 
imaging 10-15 min after additional administration of 0.1 mmol/kg of Gd-DTPA.
Results: In 7 of 29 patients the MDE images demonstrated a typical sub-endocardial 
enhancement pattern of non-transmural myocardial infarction, establishing coronary 
disease as the basis for these patient’s clinical syndrome. Of the remaining 22 patients, 
18(82%) had MRI evidence of myocarditis. 17 patients (77%) were positive by global 
relative enhancement (GRE), 8(36%) were positive by MDE and 7 patients(32%) had 
MRI evidence of myocarditis by both techniques. Only one myocarditis case (5%) was 
detected by MDE alone. 7 of the 8 cases detected by MDE occurred in the acute group of 
22 patients studied within 2 weeks of symptom onset.
Conclusions: The GRE method has approximately twice the sensitivity for detecting 
myocarditis. MDE detected only one additional case which may be insensitive to diffuse 
myocardial involvement, but has an important added value for detecting unrecognized 
coronary disease. The two techniques are complementary and should both be part of the 
MRI evaluation of myocarditis.
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1033-104 Augmented Nitric Oxide Release in the Coronary 
Circulation Parallels Myocardial Metabolic Stress in 
Patients with Dilated Cardiomyopathy
Danilo Neglia, Paolo Marraccini, Cecilia Vecoli, Alberto De Caterina, Amalia Gastaldelli, 
Demetrio Ciociaro, Andrea Natali, Emilia Bramanti, Cristina Vassalle, Cristina Prontera, 
Renata Barsacchi, Fabio Recchia, Antonio L’Abbate, William Stanley, Istituto di 
Fisiologia Clinica CNR, Pisa, Italy, Scuola Superiore S. Anna, Pisa, Italy
Background: Several in vivo and ex vivo studies indicate that nitric oxide (NO) may have 
an important role in the regulation of myocardial glucose (Glu) and free fatty acids (FFA) 
metabolism, and may be involved in the pathogenesis of cardiac dysfunction. The aim of 
this study was to evaluate the potential association of cardiac release of NO metabolites 
(NOx) and stress induced changes in myocardial metabolism in a clinical model of cardiac 
dysfunction.
Methods: In 6 patients with Dilated Cardiomyopathy (DCM), arterial - coronary venous 
blood samples were obtained at baseline (Bas), during atrial pacing up to 130 bpm (Pac) 
and at post-pacing recovery (Rec) during cardiac catheterization. NOx release, lactate 
uptake (L-Up), release (L-Rel), net-balance (L-NetB) (as measured with a continuous 
infusion of 13C-lactate), FFA uptake (FFA-Up) and Glu uptake (Glu-Up) were determined.
Results: During pacing stress, augmented cardiac release of NOx was paralleled by 
increased FFA-Up without signiﬁcant changes in elevated baseline Glu-Up. Moreover, 
augmented L-Rel was associated with sustained increase of GSSG/GSHtotal ratio in 
the coronary sinus consistently with elevated glycolitic ﬂux and oxidative stress in the 
myocardium during pacing (See Table).
Conclusions: These results suggest that in the clinical condition of DCM cardiac 
production of NO may be involved in regulating myocardial metabolism and participating 
to oxidative damage as in the experimental setting.
#=p<0.05 versus Bas;$=p<0.05 versus Bas and Rec
NOx Release 
(nmol/min)
L-Rel (µmol/
min)
L-Up (µmol/
min)
L-NetB (µmol/
min)
FFA-Up (µmol/
min)
Glu-Up(µmol/
min)
Bas 236±287 16±11 63±21 38±20 1.1±0.7 28±15
Pac 2190±1922# 33±14$ 67±36 35±25 2.5±1.6# 23±19
Rec 794±962 12±10 48±24 33±18 1.4±0.7 22±15
POSTER SESSION
1034 
Cardiac Transplantation and Assist 
Devices: Basic and Clinical
Tuesday, March 14, 2006, 12:30 p.m.-4:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 1:30 p.m.-2:30 p.m.
1034-105 Metoprolol Rescues Depressed Myocardial Contractility 
in Chronically Unloaded Hearts
Hideo Kanemitsu, Hiroshi Tsuneyoshi, Masaki Tsukashita, Takeshi Nishina, Tadashi 
Ikeda, Masashi Komeda, Kyoto University, Kyoto, Japan
Background: Chronic mechanical unloading of the heart is reported to cause depression 
of myocardial contractile function, which may disturb functional recovery with LV-assist 
device. Although chronic β-blocker therapy has been shown to improve LV function 
in patients with heart failure, the effects of β-blockers during LV unloading are still 
unknown.
Methods: We investigated the effects of Metoprolol on the unloaded LV by using the 
heterotopic heart transplantation in isogenic rats as a model of LV unloading. After 
transplantation, rats were randomized into two groups (n=15, each): Meto-group was 
administrated with 24mg/kg/day of Metoprolol for 4 weeks, Control-group was given 
normal-saline. Results: Heart rate of the host hearts decreased in Meto-group. Papillary 
muscles were isolated and stimulated. The developed tension (DT) and inotropic 
response to isoproterenol (Iso) improved in Meto-group. The mRNA expressions of 
BNP, Phospholamban (PLB), and MHC-isoform in LV myocardium signiﬁcantly improved 
in Meto-group. The ratio of SERCA2a to PLB (SERCA2a/PLB) mRNA was increased 
(p<0.01) and β2-adrenergic receptor (AR) mRNA expression was enhanced in Meto-
group unloaded heart. Conclusions: During chronic LV unloading, the myocardial 
contractile function was depressed, but metoprolol maintained its function as shown by 
improved myocardial contraction, β-adrenergic response, and gene expressions of BNP, 
PLB, and βMHC.
Control 
Host-Heart
Control 
Unloaded-
Heart
Metoprolol 
Host-Heart
Metoprolol 
Unloaded-Heart
Papillary muscle 
developed tension(DT,g) 0.19±0.03 0.13±0.01 0.21±0.04 0.19±0.01
†
Maximal increase of DT 
with Iso(%) 156±4 109±4* 140±9 125±5
†
BNP mRNA 0.78±0.12 1.63±0.18* 0.91±0.09 1.15±0.11†
α-MHC mRNA 0.33±0.04 0.34±0.02 0.30±0.03 0.31±0.03
β-MHC mRNA 0.31±0.05 2.42±0.38* 0.33±0.04 1.97±0.14†
SERCA2a mRNA 0.25±0.03 0.24±0.02 0.29±0.03 0.30±0.03
PLB mRNA 0.33±0.04 0.66±0.07* 0.33±0.04 0.45±0.03†
β1-AR mRNA 0.21±0.04 0.37±0.06* 0.21±0.02 0.48±0.05
β2-AR mRNA 0.15±0.04 0.26±0.03* 0.20±0.03 0.38±0.03†
*p<0.05 vs. Control host-heart, †p<0.05 vs. Control unloaded-heart
1034-106 Risk Factors for the Development of Coronary Artery 
Disease After Cardiac Transplantation. An Intravascular 
Ultrasound Study
Koji Tanaka, Haiyan Li, Krishnan Rangarajan, Jesse W. Currier, Lawrence A. Yeatman, 
Jon A. Kobashigawa, Jonathan M. Tobis, University of Calfornia, Los Angeles, Center for 
Health Sciences, Los Angeles, CA
Background: The role of speciﬁc risk factors in the development of cardiac allograft vasculopathy 
(CAV) of heart transplant patients remains unclear. This study evaluated the association between 
risk factors and identiﬁcation of CAV using intravascular ultrasound imaging.
Methods: Intravascular ultrasound examinations at baseline and 1year after transplantation 
were performed in 167 patients. The greatest change in maximal intimal thickness (MIT) 
from baseline to 1year was obtained for each matched site. The development of CAV 
was deﬁned as an increase in MIT ≥0.5mm. The incidence of 26 risk factors potentially 
affecting the development of CAV was analyzed.
Results: There were signiﬁcant differences in trigriceride level, use of azathioprine 
(AZA), use of statins at follow-up, donor age, and grade 3A rejections in patients who 
developed CAV (n=28) versus those who did not (n=139). Using multivariate analysis, 
hypertriglyceridemia, older donor age, use of AZA and not using statins were independent 
predictors for the development of vasculopathy (p<0.05). Classiﬁcation and regression 
tree (CART) analysis identiﬁed the levels of variables that predict the highest likelihood 
of developing CAV: 1) TG>500mg/dl, 2) Donor age>36years, 3) ischemic time>5hrs, and 
4) BMI>41.6.
Conclusions: The use of statins is effective for preventing vasculopathy. A high 
triglyceride level, perhaps as a manifestation of the metabolic syndrome, during the ﬁrst 
year post transplant is associated with early vasculopathy. Older donors, longer ischemic 
time, use of AZA, and higher BMI also predispose patients to develop vasculopathy.
1034-107 Post-transplant Ischemic Injury Is Associated With 
Increased AlloMap Gene Expression Score
Mohamad H. Yamani, Rene E. Rodriguez, Daniel J. Cook, David Pelegrin, Karen Kiefer, 
Phyllis J. Colosimo, Lingmei Zhou, David O. Taylor, Robert Hobbs, Dianna Sendrey, 
Jay Wohlgemuth, Nicholas Smedira, Randall C. Starling, Cleveland Clinic Foundation, 
Cleveland, OH, XDX Inc., South San Francisco, CA
Background: The AlloMap gene expression test is used for the non-invasive detection 
of rejection and quiescence in heart transplant recipients. However, the impact of early 
post-transplant ischemic injury on subsequent AlloMap gene expression analysis has not 
been evaluated before.
Methods: Sixty seven heart transplant recipients, mean age 53 years, were evaluated 
at a mean 34 months post transplant. AlloMap score was determined on the same day 
of heart biopsies. Nineteen patients had evidence of early post-transplant ischemic 
injury (Injury group). These were compared to the remaining 48 patients, Control group. 
Post-transplant ischemic injury is deﬁned as extensive myocardial necrosis, organizing 
necrosis, or ﬁbrosis within two weeks of cardiac transplantation. Coronary vasculopathy 
was conﬁrmed by angiography that was performed annually. Left ventricular ejection 
fraction was determined within 3 ± 3.6 months of the AlloMap score.
Results: The Injury group had a longer mean followup duration (40.0 versus 31.3 months, 
P=0.056) compared with controls. There was a signiﬁcant correlation of AlloMap score 
with time period following transplantation (r=0.30, P=0.01). Multiple regression model 
with a backward selection method was used to adjust for the time factor and account 
for potential baseline confounders (including steroid dose). Early post-transplant 
ischemic injury was still associated with signiﬁcant increased long-term AlloMap score 
compared with controls (31.5±4.6 versus 26±6.2, P<0.01). AlloMap score greater than 
30 was observed in 31% and 63% of Control and Injury groups, respectively (P=0.016). 
Further, the Injury group had worse transplant vasculopathy (KM 5-year freedom from 
vasculopathy: 34% versus 52%, P=0.015), and lower mean left ventricular ejection 
fraction (54% versus 59%, P=0.033) than Controls.
Conclusions: Post-transplant ischemic injury may inﬂuence the results of AlloMap gene 
expression analysis, probably related to increased transplant vasculopathy in the injury 
group. Prospective larger studies are required to evaluate the inﬂuence of early post-
transplant ischemic injury on AlloMap gene expression analysis.
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851 
Arrhythmias and Dyssynchrony
Tuesday, March 14, 2006, 2:00 p.m.-3:30 p.m.
Georgia World Congress Center, Room B206
2:00 p.m.
851-3 Right Ventricular Dysfunction and Adverse Outcome in 
Patients Receiving Cardiac Resynchronization Therapy
Michael E. Field, Scott D. Solomon, Eldrin F. Lewis, Daniel Kramer, Kenneth L. 
Baughman, Lynne W. Stevenson, Usha B. Tedrow, Brigham and Women’s Hospital, 
Boston, MA
Background: While cardiac resynchronization therapy (CRT) improves symptoms and 
reduces mortality in patients with advanced heart failure and left ventricular (LV) systolic 
dysfunction, up to a third of patients do not respond. Coexistent right ventricular (RV) 
dysfunction, which is not speciﬁcally addressed by CRT, may play a role in outcome in 
this population.
Methods: The RV myocardial performance index (RVMPI), a simple, Doppler-derived 
measurement of RV function, was measured on 77 pre-implantation echocardiograms 
from consecutive patients undergoing CRT. RVMPI was calculated as: (RV isovolumic 
contraction time + RV isovolumic relaxation time) / pulmonic ejection time. The 
relationship between RVMPI and the endpoint of death, transplant or ventricular assist 
device placement was evaluated.
Results: The mean age of the cohort was 65±12 years, with an ischemic etiology in 
47%, NYHA Class III-IV in 89%, a mean LV ejection fraction of 21±8%, and mean QRS 
duration of 170±36 ms. The endpoint occurred in 28 patients (36%) during a median 
follow-up of 21 months. The RVMPI was normally distributed with a mean of 0.76 ± 
0.36. RVMPI was higher, indicating worse RV function, among patients who reached the 
endpoint compared with those who did not (0.96 vs. 0.62, p<0.001). The highest tercile 
of RVMPI was associated with a 3.3 fold increased risk of the endpoint (95% CI 1.3-8.5). 
Analyzed as a continuous variable, each 0.1 unit increase in RVMPI was associated with 
a 15% increased risk of the endpoint (95% CI 8%-24%). RVMPI remained signiﬁcant 
after adjusting for other clinical variables, including age, renal insufﬁciency, RV systolic 
pressure, and tricuspid regurgitation.
Conclusions: In patients undergoing CRT, pre-implantation RV function, as assessed by 
RVMPI, is associated with adverse outcome. These data support further investigation of 
the role of RV dysfunction in predicting response to CRT.
2:15 p.m.
851-4 Increasing QRS Duration During Antihypertensive 
Therapy is Associated With an Increased Incidence of 
New-Onset Congestive Heart Failure: The LIFE Study
Peter M. Okin, Richard B. Devereux, Katherine E. Harris, Sverker Jern, Sverre E. 
Kjeldsen, Jonathan M. Edelman, Björn Dahlöf, for the LIFE Study Investigators, Cornell 
Medical Center, New York, NY
Background: Although prolonged QRS duration (QRSd) has been associated with left 
ventricular (LV) dyssynchrony and dysfunction and with the presence of congestive heart 
failure (CHF) in cross-sectional studies, whether increasing QRSd over time is associated 
with an increased incidence of new-onset CHF has not been examined.
Methods: QRSd was evaluated over time in 8945 hypertensive patients without CHF at 
baseline in the LIFE study. Patients were treated with losartan- or atenolol-based regimens 
and followed with serial ECGs at 6 months and then yearly until death or study end. QRSd 
was measured to the nearest 4 ms and was considered abnormal if >110 ms.
Results: After mean follow-up of 4.7±1.1 years, new-onset CHF occurred in 262 patients 
(2.9%). Patients who developed CHF had higher mean QRSd at baseline (109±22 vs 
101±18 ms), were more likely to have a QRSd 110 >110 ms at baseline (39.4 vs 21.1%) 
and at last follow-up (49.8 vs 24.2%), and had a greater increase in QRSd between 
baseline and last in-study measurement (6±17 vs 2±12 ms) (all p<0.001). In univariate 
Cox analyses in which QRSd over the course of the study was entered as a time-varying 
covariate, in-treatment persistence or development of a QRSd >110 ms was associated 
with a 153% increased risk of developing CHF (HR 2.53, 95% CI 2.00-3.20). After 
adjusting for treatment effect, baseline differences in risk factors for CHF, baseline and 
in-treatment systolic and diastolic pressure, baseline severity of LV hypertrophy (LVH) 
by Cornell product and Sokolow-Lyon voltage, in-treatment Sokolow-Lyon voltage and 
Cornell voltage, and for the possible separate predictive value of a left bundle branch 
block at baseline, persistence or development of a QRSd >110 ms remained associated 
with a 65% increased risk of new-onset CHF (HR 1.65, 95% CI 1.17-2.33).
Conclusions: Persistence or development of a QRSd >110 ms during antihypertensive 
therapy is associated with an increased likelihood of new-onset CHF, independent of 
blood pressure lowering, treatment modality and regression of ECG LVH in patients with 
essential hypertension. These ﬁndings suggest that serial assessment of QRSd over time 
can be used to track the risk of CHF in hypertensive patients.
2:30 p.m.
851-5 Intra-Left Ventricular Contractile Dyssynchrony Is 
Independently Associated with Diastolic Heart Failure 
in Medically Controlled Hypertensive Patients
Yi-Chih Wang, Jen-Yu Wang, Ling-Ping Lai, Juey-Jen Hwang, Lung-Chun Lin, Chia-Ti 
Tsai, Chuen-Den Tseng, Jiunn-Lee Lin, National Taiwan University Hospital, Taipei, 
Taiwan,ROC
Background: The presence of intra-left ventricular contractile dyssynchrony (IVCD) is an 
independent predictor of long-term cardiovascular events in patients (pts) with systolic 
heart failure (SHF). However, its role in diastolic HF (DHF) remains largely unknown.
Methods: We hypothesized that IVCD is critical in hypertensive pts presented with DHF. 
Echocardiography coupled with tissue Doppler imaging (TDI) was studied in 68 medically 
well-controlled hypertensive pts (36 men and 32 women, mean aged 64±12 years) with 
preserved (≥50%) left ventricular ejection fraction (LVEF) and no active ischemia. Among 
them, 21 pts with exertional dyspnea (NYHA class II-III), diastolic dysfunction (E/A<1 or 
E deceleration time >250 m/sec), and elevated N-terminal pro-brain natriuretic peptide 
(>100 pg/ml) were classiﬁed as DHF group. Between pts in DHF (21 pts) and non-DHF 
groups (47 pts), we compared their clinical features, echocardiographic parameters, 
inter-V contraction delay (time difference between the QRS onset to the onset of the 
pulmonary and aortic ﬂow), and IVCD index (SD-Ts12: standard deviation of the time 
difference between the QRS onset to the peak systolic velocity of the 6-basal and 6-mid 
LV segments).
Results: In univariate analyses, the coexistent systemic diseases, choice of anti-
hypertensive agents, LV wall thickness and chamber size, and inter-V delay were similar 
in both groups. However, pts in DHF group were older (71±8 vs 61±12 y/o, p<0.001) 
and had more female (14/21 vs 18/47, p=0.03), smaller mitral annular early diastolic 
velocity (7.1±2.4 vs 9.2±3.3 cm/s, p=0.01), larger SD-Ts12 (57.2±24.5 vs 32±21.5 msec, 
p<0.001), and borderline longer isovolumic relaxation time (108±23 vs 97±25 msec, 
p=0.08). Multivariate logistic regression analysis revealed that only SD-Ts12 remained 
independently (p=0.022) associated with DHF. Hypertensive pts with SD-Ts12≥35 msec 
would be at greater risk to have DHF (odds ratio=5.0, 95% CI=1.1-22.8, p<0.04) than 
those with more synchronized LV contraction (SD-Ts12<35 msec).
Conclusions: IVCD, addressed more often in SHF, is a crucial contributor to the 
development of clinical DHF in medically controlled hypertensive pts with preserved LVEF.
2:45 p.m.
851-6 The Long-Term Cost-Effectiveness of Cardiac 
Resynchronization Therapy With or Without an 
Implantable Cardioverter-Deﬁbrillator: Model Based 
Analyses Based on Results From the CArdiac 
REsynchronization In Heart Failure Trial
Nick Freemantle, Guiqing Yao, Melanie J. Calvert, John G.F. Cleland, Stirling Bryan, 
University of Birmingham, Birmingham, United Kingdom, University of Hull, Kingston 
upon Hull, United Kingdom
Background: Cardiac Resynchronisation Therapy (CRT-P) is an effective treatment for 
patients with heart failure and cardiac dyssynchrony when moderate or severe symptoms 
persist despite pharmacological therapy. Addition of an implantable cardioverter-deﬁbrillator 
(ICD) function may further reduce the risk of sudden death. We assessed the cost-effectiveness 
of CRT-P and CRT-ICD compared to medical therapy on incremental cost per life year and 
quality adjusted life year (QALY) using data from two contemporary clinical trials.
Methods: A Markov model with Monte Carlo simulation to assess costs, life years and 
QALYs associated with CRT (± ICD) and medical therapy in patients with heart failure 
and cardiac dyssynchrony was developed, based on a UK healthcare perspective. Model 
parameter estimates, including NYHA class distribution and transitions, associated 
health utilities, rates and cause of hospitalization and death and were estimated from 
individual patient data from the CARE-HF trial that enrolled patients between January 
2001 and March 2003. Patients who were thought to require an ICD according to the then 
current evidence were excluded from study. The additional beneﬁt on survival of an ICD 
was based on results from SCD-HeFT. The base case analysis was based on 100,000 
simulations over 6 years.
Results: The incremental cost-effectiveness ratio of CRT compared with medical therapy 
was $7,745 (95% CI $7,262 to $8,257) per life year, and $6,353 (95% CI $6,020 to 
$6,689) per QALY. The incremental cost-effectiveness ratio of CRT-ICD compared with 
medical therapy was $32,574 (95% CI $31,462 to $33,699) per life year, and $27,065 
(95% CI $26,454 to $27,695) per QALY. Data on the incremental cost-effectiveness of 
adding an ICD to CRT in patients at different risks of sudden death will be presented.
Conclusions: Long-term treatment with CRT-P or CRT-ICD appears cost-effective 
compared to medical therapy. Compared to CRT-P, CRT-ICD may be cost-effective in 
patients with an increase in the risk of sudden death.
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851-7 Patients With Severely Reduced Ejection Fractions and 
Atrial Fibrillation Have No Beneﬁt from Rhythm Control: 
An Analysis of the AFFIRM Study
Ronald S. Freudenberger, Alan C. Wilson, John B. Kostis, Robert Wood Johnson 
Medical School, New Brunswick, NJ
Background: Optimal treatment for patients with atrial ﬁbrillation (AF) and signiﬁcantly 
reduced ejection fraction (EF) is poorly deﬁned. It is unclear if sinus rhythm (SR) is more 
important in those with signiﬁcantly reduced EF. AFFIRM compared 2 treatment strategies: 
1) attempts to maintain SR, principally with antiarrhythmic drugs-rhythm control (RY) and 
2) allowing AF to persist or recur while controlling the ventricular rate -rate control (RC). 
AFFIRM found that more patients in RY than in RC were hospitalized, and had more 
adverse drug effects with no effect on mortality. Analysis of subgroups above or below 
50% EF found no difference.
Methods: We analyzed patients with EF <50 by subgroups; 40-49%, 30-39% and < 30%. 
Outcome measures were 1) mortality 2) hospitalization 3) a change in New York Heart 
Association class. Patients with a documented EF by echocardiography were included 
in the analysis. 
HF
(EF category)
Death
n/n (%)
Hospitalization
n/n (%)
Change in NYHA Class 
mean±SD
Rate Rhythm Rate Rhythm Rate Rhythm
Mild (40-49%) 38/192 (20%)42/200 (21%)
116/192 (60%)
140/200 (70%)
0.06±0.9
0.08±0.9
Moderate (30-
39%)
p=0.72
(Chi-
square 
test)
p=0.04
(Chi-
square 
test)
p=0.81
(Wilcoxon 
test)
25/107 (24%)
29/134 (22%)
72/107 (67%)
92/134 (69%)
0.19±1.0
-0.02±1.2
Severe (<30%)
p=0.74 p=0.82 P=0.15
30/81 (37%)
33/74 (44%)
51/81 (63%)
51/74 (69%)
0.13±1.1
0.09±1.2
p=0.39 p=0.44 p=0.81
Results: There was no signiﬁcant improvement in RY with regard to mortality, 
hospitalization and change in NYHA class. There were more hospitalizations in RY with 
mild dysfunction (p=.04). In addition we analyzed change in NYHA class by ﬁnal rhythm 
status rather than randomized group assignment, since some patients randomized to 
RY may not have achieved RY and some in RC may have converted to SR and found no 
signiﬁcant change in functional capacity.
Conclusions: In patients with decreased EF, regardless of the severity, there is no beneﬁt 
of a RY strategy with regard to death, hospitalization and NYHA class.
3:15 p.m.
851-8 Is Cardiac Resynchronisation Therapy Effective in 
Patients With Less Severe Symptoms?
John G. Cleland, Melanie J. Calvert, Nick Freemantle, Luigi Tavazzi, Erland Erdmann, 
Lukas Kappenberger, Jean-Claude Daubert, Daniel Gras, University of Hull, Kingston 
upon Hull, United Kingdom
Background: : It is uncertain whether cardiac resynchronisation therapy (CRT) is 
effective in patients with mild symptoms of heart failure.
Methods: Patients with New York Heart Association (NYHA) class III/IV heart failure 
(physician-reported), LVEF <35% and evidence of cardiac dyssynchrony were enrolled 
in CARE-HF. Patients rated themselves by NYHA class, EuroHeart Failure Survey 
questionnaire (EHFSQ) and Euroqol EQ-5D. The effects of CRT on the primary end point 
of the main study (death or unplanned hospitalisation for a major cardiovascular event), 
of the extension study (mortality) and NYHA class at 18 months (death/transplant ranked 
as V) were assessed according to baseline patient-reported symptom severity. Analyses 
were conducted by intention to treat.
Results:Of 813 patients, 175 (22%) rated themselves NYHA I/II and 608 (75%) III/IV. 
NYHA I/II patients had similar LVEF (26%) but lower NT pro-BNP (mean difference -
1156pg/ml, 95% CI -2129 to -184) compared to NYHAIII/IV patients. 399 (50%) patients 
felt that breathlessness greatly limited normal activity (score 4 or 5) and 229 (29%) rated 
their health as poor/very poor (score 5 or 6) on the EHFSQ. The effect of CRT on all 
three endpoints was similar regardless of baseline symptom severity. Patients with EQ-5D 
score >median (better quality of life) had a smaller beneﬁt from CRT in terms of mortality 
and NYHA class at 18 months. 
P for interaction
*0.01 ~ 0.02
Primary endpoint - 
main study
HR (95% CI)
Death
HR (95% CI)
NYHA I/II at 18 m
OR (95% CI)
NYHA I/II 0.69 (0.44 to 1.09) 0.89 (0.51 to 1.6) 2.2 (1.1 to 4.6)
NYHA III/IV 0.62 (0.49 to 0.78) 0.53 (0.39 to 0.70) 3.5 (2.4 to 5.1)
EHFS SOB <4 0.64 (0.47 to 0.89) 0.66 (0.44 to 0.98) 3.0 (1.9 to 4.9)
EHFS SOB >4 0.64 (0.49 to 0.84) 0.54 (0.39 to 0.76) 3.1 (2.0 to 4.7)
EHFS Health <5 0.65 (0.50 to 0.84) 0.66 (0.48 to 0.92) 2.7 (1.8 to 3.9)
EHFS Health >5 0.60 (0.43 to 0.86) 0.49 (0.32 to 0.75) 4.5 (2.2 to 8.9)
EQ5D > median 0.78 (0.57 to 1.06) 0.87 (0.59 to 1.29)* 2.2 (1.4 to 3.6)~
EQ5D < median 0.51 (0.38 to 0.69) 0.43 (0.30 to 0.63) 4.8 (2.9 to 8.0)
Conclusions: The effect of CRT on long-term morbidity and mortality is similar regardless 
of symptom severity in CARE-HF.
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